0000719135-23-000027.txt : 20230511 0000719135-23-000027.hdr.sgml : 20230511 20230511150623 ACCESSION NUMBER: 0000719135-23-000027 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 66 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230511 DATE AS OF CHANGE: 20230511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Apyx Medical Corp CENTRAL INDEX KEY: 0000719135 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 112644611 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-31885 FILM NUMBER: 23910484 BUSINESS ADDRESS: STREET 1: 5115 ULMERTON ROAD CITY: CLEARWATER STATE: FL ZIP: 33760 BUSINESS PHONE: 7273842323 MAIL ADDRESS: STREET 1: 5115 ULMERTON ROAD CITY: CLEARWATER STATE: FL ZIP: 33760 FORMER COMPANY: FORMER CONFORMED NAME: BOVIE MEDICAL Corp DATE OF NAME CHANGE: 20150319 FORMER COMPANY: FORMER CONFORMED NAME: BOVIE MEDICAL CORP DATE OF NAME CHANGE: 19990216 FORMER COMPANY: FORMER CONFORMED NAME: AN CON GENETICS INC DATE OF NAME CHANGE: 19920703 10-Q 1 apyx-20230331.htm 10-Q apyx-20230331
0000719135FALSEDecember 31Q1202300007191352023-01-012023-03-3100007191352023-05-10xbrli:shares00007191352023-03-31iso4217:USD00007191352022-12-31iso4217:USDxbrli:shares00007191352022-01-012022-03-310000719135us-gaap:CommonStockMember2021-12-310000719135us-gaap:AdditionalPaidInCapitalMember2021-12-310000719135us-gaap:RetainedEarningsMember2021-12-310000719135us-gaap:NoncontrollingInterestMember2021-12-3100007191352021-12-310000719135us-gaap:CommonStockMember2022-01-012022-03-310000719135us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310000719135us-gaap:RetainedEarningsMember2022-01-012022-03-310000719135us-gaap:NoncontrollingInterestMember2022-01-012022-03-310000719135us-gaap:CommonStockMember2022-03-310000719135us-gaap:AdditionalPaidInCapitalMember2022-03-310000719135us-gaap:RetainedEarningsMember2022-03-310000719135us-gaap:NoncontrollingInterestMember2022-03-3100007191352022-03-310000719135us-gaap:CommonStockMember2022-12-310000719135us-gaap:AdditionalPaidInCapitalMember2022-12-310000719135us-gaap:RetainedEarningsMember2022-12-310000719135us-gaap:NoncontrollingInterestMember2022-12-310000719135us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000719135us-gaap:RetainedEarningsMember2023-01-012023-03-310000719135us-gaap:NoncontrollingInterestMember2023-01-012023-03-310000719135us-gaap:CommonStockMember2023-03-310000719135us-gaap:AdditionalPaidInCapitalMember2023-03-310000719135us-gaap:RetainedEarningsMember2023-03-310000719135us-gaap:NoncontrollingInterestMember2023-03-3100007191352018-01-012018-12-3100007191352022-01-012022-12-3100007191352023-02-170000719135apyx:ShelfRegistrationMember2022-11-222022-11-220000719135apyx:AtTheMarketFacilityMember2022-11-222022-11-220000719135us-gaap:LineOfCreditMemberapyx:CreditAgreementMember2023-02-170000719135us-gaap:LineOfCreditMemberapyx:CreditAgreementMemberus-gaap:SecuredDebtMember2023-02-170000719135us-gaap:LineOfCreditMemberapyx:CreditAgreementMemberapyx:DebtInstrumentCovenantTrancheOneMemberus-gaap:SecuredDebtMember2023-02-170000719135us-gaap:LineOfCreditMemberapyx:CreditAgreementMemberus-gaap:SecuredDebtMemberapyx:DebtInstrumentCovenantTrancheTwoMember2023-02-170000719135us-gaap:LineOfCreditMemberapyx:CreditAgreementMemberus-gaap:SecuredDebtMemberapyx:DebtInstrumentCovenantTrancheThreeMember2023-02-170000719135us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberapyx:CreditAgreementMember2023-02-1700007191352023-03-142023-03-1400007191352023-01-012023-01-3100007191352023-01-092023-01-09xbrli:pure0000719135us-gaap:LandMember2023-03-310000719135us-gaap:LandMember2022-12-310000719135us-gaap:BuildingAndBuildingImprovementsMember2023-03-310000719135us-gaap:BuildingAndBuildingImprovementsMember2022-12-310000719135us-gaap:MachineryAndEquipmentMember2023-03-310000719135us-gaap:MachineryAndEquipmentMember2022-12-310000719135us-gaap:FurnitureAndFixturesMember2023-03-310000719135us-gaap:FurnitureAndFixturesMember2022-12-310000719135apyx:ComputerEquipmentAndSoftwareMember2023-03-310000719135apyx:ComputerEquipmentAndSoftwareMember2022-12-310000719135us-gaap:LeaseholdImprovementsMember2023-03-310000719135us-gaap:LeaseholdImprovementsMember2022-12-310000719135apyx:MoldsMember2023-03-310000719135apyx:MoldsMember2022-12-310000719135us-gaap:SubsequentEventMember2023-05-082023-05-080000719135apyx:AdjustedTermSecuredOvernightFinancingRateSOFRMemberus-gaap:LineOfCreditMemberapyx:CreditAgreementMemberus-gaap:SecuredDebtMember2023-02-172023-02-170000719135us-gaap:LineOfCreditMemberapyx:CreditAgreementMemberus-gaap:SecuredDebtMember2023-02-172023-02-17apyx:monthlyPayment0000719135us-gaap:LineOfCreditMemberapyx:CreditAgreementMemberus-gaap:SecuredDebtMemberapyx:DebtInstrumentPrepaymentPeriodOneMember2023-02-172023-02-170000719135apyx:DebtInstrumentPrepaymentPeriodTwoMemberus-gaap:LineOfCreditMemberapyx:CreditAgreementMemberus-gaap:SecuredDebtMember2023-02-172023-02-170000719135us-gaap:LineOfCreditMemberapyx:CreditAgreementMemberus-gaap:SecuredDebtMemberapyx:DebtInstrumentPrepaymentPeriodThreeMember2023-02-172023-02-170000719135us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberapyx:CreditAgreementMemberapyx:DebtInstrumentTerminationPeriodOneMember2023-02-170000719135us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberapyx:CreditAgreementMemberapyx:DebtInstrumentTerminationPeriodOneMember2023-02-172023-02-170000719135apyx:AdjustedTermSecuredOvernightFinancingRateSOFRMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberapyx:CreditAgreementMember2023-02-172023-02-170000719135us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberapyx:CreditAgreementMember2023-02-172023-02-170000719135us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberapyx:DebtInstrumentTerminationPeriodTwoMemberapyx:CreditAgreementMember2023-02-172023-02-170000719135apyx:DebtInstrumentTerminationPeriodThreeMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberapyx:CreditAgreementMember2023-02-172023-02-1700007191352023-02-172023-02-170000719135us-gaap:LineOfCreditMemberapyx:CreditAgreementMember2023-02-172023-02-170000719135us-gaap:LineOfCreditMemberapyx:CreditAgreementMemberus-gaap:SecuredDebtMember2023-01-012023-03-310000719135us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberapyx:CreditAgreementMember2023-01-012023-03-310000719135us-gaap:LineOfCreditMemberus-gaap:LineOfCreditMember2023-03-310000719135apyx:ChineseSupplierMember2019-12-3100007191352019-12-3100007191352021-01-012021-12-3100007191352020-01-012020-12-310000719135us-gaap:CorporateJointVentureMember2022-12-310000719135us-gaap:CorporateJointVentureMember2021-12-310000719135us-gaap:CorporateJointVentureMember2023-01-012023-03-310000719135us-gaap:CorporateJointVentureMember2022-01-012022-03-310000719135us-gaap:CorporateJointVentureMember2023-03-310000719135us-gaap:CorporateJointVentureMember2022-03-310000719135us-gaap:EmployeeStockOptionMember2023-01-012023-03-310000719135us-gaap:EmployeeStockOptionMember2022-01-012022-03-310000719135us-gaap:WarrantMember2023-01-012023-03-310000719135us-gaap:WarrantMember2022-01-012022-03-310000719135srt:MinimumMember2021-12-310000719135srt:MaximumMember2021-12-310000719135srt:MinimumMemberapyx:SuitAgainstGoodwinAndSimbMember2022-12-310000719135srt:MaximumMemberapyx:SuitAgainstGoodwinAndSimbMember2022-12-310000719135apyx:SuitAgainstGoodwinAndSimbMember2022-12-310000719135apyx:SuitsFiledIn2022Member2022-01-012022-12-31apyx:lease0000719135apyx:SuitsFiledIn2022Membersrt:MinimumMember2023-03-310000719135srt:MaximumMemberapyx:SuitsFiledIn2022Member2023-03-310000719135apyx:SuitsFiledIn2022Member2023-03-310000719135us-gaap:CoVenturerMember2023-01-012023-03-310000719135us-gaap:CoVenturerMember2022-01-012022-03-310000719135us-gaap:CoVenturerMember2023-03-310000719135us-gaap:CoVenturerMember2022-12-31apyx:segment0000719135us-gaap:OperatingSegmentsMemberapyx:AdvancedEnergyMember2023-01-012023-03-310000719135apyx:OEMMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000719135us-gaap:CorporateNonSegmentMember2023-01-012023-03-310000719135us-gaap:OperatingSegmentsMemberapyx:AdvancedEnergyMember2022-01-012022-03-310000719135apyx:OEMMemberus-gaap:OperatingSegmentsMember2022-01-012022-03-310000719135us-gaap:CorporateNonSegmentMember2022-01-012022-03-310000719135country:US2023-01-012023-03-310000719135country:US2022-01-012022-03-310000719135us-gaap:NonUsMember2023-01-012023-03-310000719135us-gaap:NonUsMember2022-01-012022-03-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended
March 31, 2023
or
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____ to _____
Commission File Number: 0-12183
apyxmedicallogotagline.jpg
APYX MEDICAL CORPORATION
(Exact name of registrant as specified in its charter)
Delaware11-2644611
(State or other jurisdiction of
incorporation or organization)		(I.R.S. Employer
Identification No.)
5115 Ulmerton Road, Clearwater, FL 33760
(Address of principal executive offices, zip code)
(727) 384-2323
(Registrant’s telephone number)
Securities Registered Pursuant to Section 12 (b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Common StockAPYXNasdaq Global Select Market

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes: ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes: ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☐
Accelerated filer
☐
Non-accelerated filer☒Smaller reporting company☒
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes: ☐ No ☒

As of May 10, 2023, 34,597,822 shares of the registrant’s $0.001 par value common stock were outstanding.

APYX MEDICAL CORPORATION
INDEX TO QUARTERLY REPORT ON FORM 10-Q
For the quarterly period ended March 31, 2023

Page
Part I.
Item 1.
Condensed Consolidated Financial Statements (Unaudited)
Condensed Consolidated Balance Sheets at March 31, 2023 and December 31, 2022
Condensed Consolidated Statements of Operations for the three months ended March 31, 2023 and 2022
Condensed Consolidated Statements of Changes in Equity for the three months ended March 31, 2023 and 2022
Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2023 and 2022
Item 2.
Item 3.
Item 4.
Part II.
Item 1.
Item 1A.
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.
1
PART I.     Financial Information

ITEM 1. Condensed Consolidated Financial Statements

APYX MEDICAL CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)
March 31, 2023
(Unaudited)
December 31, 2022
ASSETS
Current assets:
Cash and cash equivalents$16,255 $10,192 
   Trade accounts receivable, net of allowance of $359 and $668
9,966 10,602 
Income tax receivables7,752 7,545 
Other receivables417 99 
Inventories, net of provision for obsolescence of $428 and $457
10,946 11,797 
Assets held for sale4,569 — 
Prepaid expenses and other current assets2,779 2,737 
Total current assets52,684 42,972 
Property and equipment, net2,109 6,761 
Operating lease right-of-use assets646 710 
Finance lease right-of-use assets106 115 
Other assets1,239 1,217 
Total assets$56,784 $51,775 
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable$1,905 $2,669 
Accrued expenses and other current liabilities7,626 8,928 
Current portion of operating lease liabilities184 216 
Current portion of finance lease liabilities33 37 
Term loan, net8,778 — 
Total current liabilities18,526 11,850 
Long-term operating lease liabilities448 470 
Long-term finance lease liabilities68 73 
Long-term contract liabilities1,343 1,408 
Other liabilities185 181 
Total liabilities20,570 13,982 
EQUITY
Preferred Stock, $0.001 par value; 10,000,000 shares authorized; 0 issued and outstanding as of March 31, 2023 and December 31, 2022
— — 
Common stock, $0.001 par value; 75,000,000 shares authorized; 34,597,822 issued and outstanding as of March 31, 2023 and December 31, 2022
35 35 
Additional paid-in capital75,235 73,282 
Accumulated deficit(39,218)(35,735)
Total stockholders' equity36,05237,582
Non-controlling interest 162 211 
Total equity36,214 37,793 
Total liabilities and equity$56,784 $51,775 
The accompanying notes are an integral part of the condensed consolidated financial statements.
2
APYX MEDICAL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except per share data)
Three Months Ended
March 31,
20232022
Sales$12,142 $12,493 
Cost of sales4,569 4,274 
Gross profit7,573 8,219 
Other costs and expenses:
Research and development1,121 1,158 
Professional services1,740 2,286 
Salaries and related costs5,068 5,181 
Selling, general and administrative5,255 5,465 
Total other costs and expenses13,184 14,090 
Loss from operations(5,611)(5,871)
Interest income51 2 
Interest expense(234)(8)
Other loss, net(5)(21)
Total other loss, net(188)(27)
Loss before income taxes(5,799)(5,898)
Income tax (benefit) expense(2,267)70 
Net loss(3,532)(5,968)
   Net loss attributable to non-controlling interest(49)(23)
Net loss attributable to stockholders$(3,483)$(5,945)
Loss per share:
Basic and diluted$(0.10)$(0.17)

The accompanying notes are an integral part of the condensed consolidated financial statements.
3
APYX MEDICAL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(Unaudited)
(In thousands)
Three Months Ended March 31, 2023 and 2022
Common StockAdditional Paid-In Capital Accumulated DeficitNon-controlling InterestTotal Equity
SharesPar Value
Balance at December 31, 202134,410 $34 $66,221 $(12,551)$305 $54,009 
Shares issued on stock options exercises for cash24 — 152 — —152 
Stock based compensation— — 1,650 — —1,650 
Shares issued on net settlement of stock options19 — — — —— 
Net loss— — — (5,945)(23)(5,968)
Balance at March 31, 202234,453 $34 $68,023 $(18,496)$282 $49,843 
Balance at December 31, 202234,598 $35 $73,282 $(35,735)$211 $37,793 
Stock based compensation— — 1,367 — —1,367 
Proceeds received from issuance of warrants— — 586 — —586 
Net loss— — — (3,483)(49)(3,532)
Balance at March 31, 202334,598 $35 $75,235 $(39,218)$162 $36,214 
 
The accompanying notes are an integral part of the condensed consolidated financial statements.
4
APYX MEDICAL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)
Three Months Ended March 31,
20232022
Cash flows from operating activities
Net loss$(3,532)$(5,968)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization203 225 
Provision for inventory obsolescence— 85 
Loss on disposal of property and equipment— 26 
Stock based compensation1,367 1,650 
Provision for allowance for doubtful accounts(142)140 
Non-cash interest expense67 — 
Changes in operating assets and liabilities:
Trade receivables837 475 
Prepaid expenses and other assets858 649 
Income tax receivables(207)— 
Inventories879 (371)
Accounts payable(776)(51)
Accrued expenses and other liabilities(1,435)(1,378)
Net cash used in operating activities(1,881)(4,518)
Cash flows from investing activities
Purchases of property and equipment(110)(279)
Net cash used in investing activities(110)(279)
Cash flows from financing activities
Proceeds from stock option exercises— 152 
Proceeds from term loan9,289 — 
Payment of debt issuance costs(1,754)— 
Proceeds from issuance of warrants586 — 
Repayment of finance lease liabilities(9)(54)
Net cash provided by financing activities8,112 98 
Effect of exchange rates on cash(58)63 
Net change in cash and cash equivalents6,063 (4,636)
Cash and cash equivalents, beginning of period10,192 30,870 
Cash and cash equivalents, end of period$16,255 $26,234 
Cash paid for:
Interest$1 $8 
Income taxes125 — 

The accompanying notes are an integral part of the condensed consolidated financial statements.
5
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

NOTE 1.     BASIS OF PRESENTATION

Apyx Medical Corporation (“Company”, “Apyx”, “it” and similar terms) was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 5115 Ulmerton Road, Clearwater, FL 33760.

The Company is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Technology products marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion® and J-Plasma® offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers.

As part of its plan to accelerate and fully fund the development of its advanced energy business, with a focus in the cosmetic surgery market, the Company sold its Core business in 2018 for gross proceeds of $97 million. These proceeds were used to launch broad marketing and sales initiatives which resulted in rapid sales growth through December 31, 2021 and into the first quarter of 2022. This planned growth in the business was accompanied by scaled operations, including procurement of components, expanded manufacturing capacity to turn those materials into saleable inventory, additional discretionary expenditures, including increased global participation at trade shows, additional employee trainings, user meetings, increased travel and entertainment expenses, more expansive research and development projects, and additional headcount to support those activities. Additionally, the Company had, and still has, some significant non-recurring discretionary expenditures associated with completing its multi-year marketing initiatives related to its dermal resurfacing and skin laxity clearances.

On March 14, 2022, the U.S. Food and Drug Administration (“FDA”) posted a Medical Device Safety Communication (“Safety Communication”). The FDA warned against the use of Renuvion/J-Plasma for procedures intended to improve the appearance of the skin through dermal resurfacing (a procedure on the skin to treat wrinkles) or skin contraction (a procedure under the skin that can be performed either alone or in combination with liposuction to achieve skin effects, such as “tightening”). At that time, the Renuvion/J-Plasma device system was FDA cleared for general use of cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures. The use of the device had not been determined to be safe or effective for any aesthetic skin procedures (procedures intended to improve the appearance of the skin). Following the Safety Communication, the Company experienced slowed demand for the adoption of its Helium Plasma Technology.

On May 26, 2022, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion® Dermal Handpiece for certain dermal resurfacing procedures, specifically, for the treatment of moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick Skin Types I, II or III.

On June 2, 2022, the FDA updated the Safety Communication to inform consumers and healthcare providers about the new 510(k) clearance for the Renuvion® device system for certain dermal resurfacing procedures.

On July 18, 2022, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for use in subcutaneous dermatological and aesthetic procedures to improve the appearance of lax (loose) skin in the neck and submental (under the chin) region.

On July 21, 2022, the FDA updated the Safety Communication to inform consumers and healthcare providers about the clearance for the Renuvion® APR handpieces for use under the skin in certain procedures intended to improve the appearance of loose skin.

On February 27, 2023, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. Soft tissue includes subcutaneous tissue.

On April 28, 2023, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring.

On May 10, 2023, the FDA updated the Safety Communication to inform consumers and healthcare providers about the clearance for the Renuvion® APR handpiece for use under the skin in certain procedures intended to improve the appearance of the skin, including for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring.

6
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)

Management believes that the May 10, 2023 FDA update to the Safety Communication addresses the issues set forth in the original Safety Communication from March 14, 2022. While no assurances can be provided, management believes that receiving these additional clearances and the corresponding updates to the Safety Communication since March 14, 2022 should mitigate the financial effects of the Safety Communication in future periods.

The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue in operation one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business.

Pursuant to the requirements of the Financial Accounting Standards Board’s Accounting Standards Codification (“ASC”) Topic 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for one year from the date these unaudited condensed consolidated financial statements are issued. This evaluation does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented or are not within control of the Company as of the date the unaudited condensed consolidated financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued.

While sales were continuing to grow into the first quarter of 2022 prior to the FDA Safety Communication, over the last few years, exclusive of the Company’s sale of the Core business segment to Symmetry Surgical during 2018, the Company has incurred recurring net losses and cash outflows from operations and the Company anticipates that losses will continue in the near term. During the year ended December 31, 2022, the Company incurred an operating loss of $23.6 million and used $20.3 million of cash in operations. During the three months ended March 31, 2023, the Company incurred an operating loss of $5.6 million and used $1.9 million of cash in operations. As of March 31, 2023, the Company had cash and cash equivalents of $16.3 million, of which the Company must maintain $10.0 million under its Credit Agreement. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements.

In an effort to alleviate these conditions, the Company pursued various funding solutions in order to improve liquidity.

On November 22, 2022, the Company filed a shelf registration statement providing it the ability to register securities in the aggregate amount up to $100 million. The shelf registration included an embedded ATM facility for up to $40 million. To date, the Company has not utilized this facility.

On February 17, 2023, the Company entered into a Credit, Security and Guaranty Agreement (the “Credit Agreement”) with MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time.

The Credit Agreement provides for an up to $35 million facility, consisting of senior secured term loans and a secured revolving facility. The Credit Agreement provides for senior secured term loans of up to $25 million, comprised of (i) an initial tranche of $10 million, (ii) a second tranche of $5 million, and (iii) a third tranche of $10 million. The secured revolving facility provides for loans in an aggregate principal amount of up to $10 million, subject to a borrowing base equal to certain percentages of the Company’s eligible accounts receivable and inventory, as determined in accordance with the terms of the Credit Agreement.

For a more in depth description of the terms of the Credit Agreement, see Note 6.

On February 27, 2023, the Company’s Board of Directors approved a plan to sell and leaseback the Company’s real property located in Clearwater, FL. On March 14, 2023, the Company entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with VK Acquisitions VI, LLC (the “Purchaser”), for the sale of the Company’s facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the “Property”) for a purchase price
7
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)

of $7,650,000. On May 8, 2023, the Company closed on the Purchase Agreement and concurrently executed a 10-year agreement to leaseback the underlying Property from the Purchaser.

For a more in depth description of the terms of the Purchase Agreement, see Note 4.

During January 2023, the Company was notified that the IRS examination process of our 2018, 2019 and 2020 tax returns was complete and that the Company’s tax refunds were approved for approximately $0.2 million more than the amount recorded in the Company’s Consolidated Balance Sheet at December 31, 2022. As of the date of this report, the Company is awaiting receipt of the tax refunds.

The Company also continues to re-assess its operating expenditures and cost structure to be commensurate with expected levels of revenue and management has the ability to reduce or delay expenditures to enhance and preserve liquidity. Management has already reduced some operating expenditures, including a reduction-in-force on January 9, 2023, that reduced the Company’s U.S. headcount by 14%.

Management believes that the actions already taken, and additional actions that it intends to take to manage operating expenditures, will enable the Company to meet its obligations and its debt covenants for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements. As a result, management believes its plans alleviate substantial doubt about the Company’s ability to continue as a going concern. These unaudited condensed consolidated financial statements do not include any adjustments relating to the carrying amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern.

NOTE 2.     RECENT ACCOUNTING PRONOUNCEMENTS

In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments—Credit Losses (Topic 326). The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company adopted the new standard on January 1, 2023 and its impact was not material to the Company.

No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.
8
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)

NOTE 3.     INVENTORIES

Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours.

Inventories consisted of the following:
(In thousands)March 31,
2023		December 31,
2022
Raw materials$4,388 $4,979 
Work in process2,331 2,160 
Finished goods 4,655 5,115 
Gross inventories11,374 12,254 
Less: provision for obsolescence(428)(457)
Inventories, net$10,946 $11,797 

NOTE 4.     ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT

(In thousands)March 31, 2023
(Unaudited)		December 31,
2022
Land$— $1,600 
Building and improvements16 4,426 
Machinery and equipment2,472 2,613 
Furniture and fixtures213 211 
Computer equipment and software1,230 1,420 
Leasehold improvements178 178 
Molds847 847 
Total property, plant and equipment4,956 11,295 
Less: accumulated depreciation and amortization(3,387)(5,041)
Property and equipment in service1,569 6,254 
Construction in progress540 507 
Property and equipment, net$2,109 $6,761 
Assets held for sale$4,569 $— 

In an effort to improve liquidity and the balance sheet condition of the Company, management has been exploring options to leverage the Company’s unencumbered real property. On February 27, 2023, the Company’s Board of Directors approved a plan to sell and leaseback the Company's real property located in Clearwater, FL.

On March 14, 2023, the Company entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with VK Acquisitions VI, LLC (the “Purchaser”), for the sale of the Company’s facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the “Property”) for a purchase price of $7,650,000.
9
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)


In accordance with the requirements of ASC Topic 360, Property, Plant, and Equipment, the Company has determined that the real property to be sold meets the requirements to be presented as held for sale. Accordingly, the Company has presented the associated assets as held for sale in the accompanying unaudited condensed consolidated balance sheet and the table above at March 31, 2023.

In accordance with the terms of the Purchase Agreement, upon the closing of the sale of the Property, the Company will enter into a Single Tenant Industrial Building Lease (the “Lease”) with the Purchaser, pursuant to which the Property will be leased back to the Company. The Lease will have an initial term of ten (10) years commencing from the closing (the “Initial Term”), and a renewal term of five (5) years, exercisable at the Company’s option. The annual fixed rent will be $619,500 for the first year of the Initial Term, and will be subject to a 4% escalation every year thereafter through the Initial Term. Rent will be reset to the current market rate should the Company exercise the renewal option. The Lease provides for a 3% management fee on rent payments throughout the Initial Term and optional renewal term.

The Lease is a triple net lease, pursuant to which all costs, expenses, and obligations relating to the Property, including, repair and maintenance charges, utility charges, real estate taxes or other taxes that may be imposed that relate to the Property, shall be paid by the Company. In addition, the Lease contains other customary terms and provisions generally contained within leases of this type.

On May 8, 2023, the Company closed on the Purchase Agreement and concurrently executed a 10-year agreement to leaseback the underlying Property from the Purchaser. The Company received net cash proceeds of approximately $6,600,000, after withholding the security deposit equal to one years rent, taxes, first months rent, expenses, and fees. The Company anticipates that the net cash proceeds will be used to strengthen its balance sheet and provide working capital to its operations.

NOTE 5.     ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

Accrued expenses and other current liabilities consisted of the following:
(in thousands)March 31,
2023		December 31,
2022
Accrued payroll$848 $563 
Accrued bonuses570 — 
Accrued commissions790 847 
Accrued product warranties368 391 
Accrued product liability claim insurance deductibles1,794 1,825 
Accrued professional fees and legal related contingent liabilities924 901 
Short-term contract liabilities1,053 853 
Joint and several payroll liability345 345 
Uncertain tax positions— 2,079 
Sales tax payable211 245 
Other accrued expenses and current liabilities723 879 
Total accrued expenses and other current liabilities$7,626 $8,928 

During April 2023, the Company was relieved of the remainder of its joint and several payroll liability due to the lapse of the statute of limitations on the liability.


NOTE 6.     CREDIT AGREEMENT

On February 17, 2023, the Company entered into a Credit, Security and Guaranty Agreement (the “Credit Agreement”), by and among the Company (as borrower) and Apyx China Holding Corp., the Company’s wholly-owned subsidiary (as guarantor), and MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time (collectively “MidCap”).

10
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)

The Credit Agreement provides for an up to $35 million facility, consisting of senior secured term loans and a secured revolving facility. The Credit Agreement provides for senior secured term loans of up to $25 million, comprised of (i) an initial tranche of $10 million, (ii) a second tranche of $5 million, and (iii) a third tranche of $10 million. The secured revolving facility provides for loans in an aggregate principal amount of up to $10 million, subject to a borrowing base equal to percentages of eligible accounts receivable and inventory determined in accordance with the Credit Agreement. The Credit Agreement matures on February 1, 2028.

Term Loans

The initial tranche of $10 million was fully funded on February 17, 2023 less transaction costs. Subject to certain terms and conditions of the Credit Agreement, the second tranche would be available between June 30, 2023 and December 31, 2023 and the third tranche would be available between January 1, 2024 and September 30, 2024, respectively. The Company’s ability to access these additional tranches is conditioned upon, among other things, the achievement of certain minimum revenue targets.

Each term loan bears interest at a floating rate reset monthly based on an adjusted one month SOFR plus 0.1%, subject to a floor of 2.5%, plus 7.35% calculated on a 360 day basis (12.1% at March 31, 2023). Interest is payable monthly in arrears on the first day of each month.

The first twenty-four (24) months of the term loans constitute an interest-only period (with a possible twelve (12) month extension). Subsequent to the interest-only period, the outstanding principal amount of the term loans is repayable in thirty-six (36) equal monthly payments (or twenty-four (24) with the extension). All remaining outstanding principal, together with all accrued and unpaid interest, is due at maturity on February 1, 2028. The term loans may be voluntarily prepaid in full, or in part, at any time, subject to terms and conditions set forth in the Credit Agreement. Additionally, the term loans are subject to mandatory prepayment fees, pursuant to the terms of the Credit Agreement. Prepayments of the term loans are subject to fees of 3%, 2%, and 1% of the prepayment amounts made during the first year, second year, and thereafter, respectively. At the time of the final payment of the term loans, the Company is also obligated to pay an exit fee of 4% of the total amount funded thereunder. The exit fee is being accreted over the life of the Credit Agreement utilizing the effective interest method.

As the Credit Agreement contains a subjective acceleration clause and the Company has experienced recurring losses, outstanding borrowings have been presented as a current liability in the accompanying condensed consolidated balance sheet at March 31, 2023.

Revolving Facility

The Company may borrow, repay and reborrow under the revolving facility until February 1, 2028, at which time the facility will terminate and all outstanding amounts thereunder, including all accrued and unpaid interest, must be repaid. Borrowings are limited to the lesser of the Company’s borrowing base and the revolving commitment of $10,000,000.

In connection with the revolving facility, the Company is required to maintain a lockbox account for the benefit of MidCap. Funds deposited into the lockbox account will be swept daily to MidCap and applied to outstanding borrowings under the revolving agreement 5 days after the receipt of the funds by MidCap. Any balances in excess of the revolving borrowings will be promptly returned to the Company.

Loans made under the revolving facility bear interest at a floating rate based on an adjusted one month SOFR plus 0.1%, subject to a floor of 2.5%, plus 4.00% calculated on a 360 day basis (8.8% at March 31, 2023). The Company is obligated to pay a fee equal to 0.5% per annum on the outstanding balance of the revolving loans and the average unused portion of the available revolving commitments, respectively. Additionally, if the revolving facility is terminated or reduced before maturity, the Company is subject to a deferred origination fee. Terminations and reductions of the commitments are subject to fees of 3%, 2%, and 1% of the terminated or reduced commitments during the first year, second year, and thereafter, respectively. The Company is also required to maintain a minimum balance of 30% of the lesser of the borrowing base or $10 million under the revolving facility. If the average outstanding balance for a month is less than the minimum balance, the Company will pay a minimum balance fee for the difference between the minimum balance and the average outstanding balance for the month at the highest rate for the revolving loans during the month. For such loans, interest and fees are payable monthly on the first day of each month.

As of March 31, 2023, the Company has drawn no amounts on the revolving facility. As of March 31, 2023, the Company had approximately $5,700,000 available to be drawn on the revolving facility. As the Credit Agreement contains a subjective acceleration clause and the Company is required to maintain a lockbox, any amounts drawn on the revolving facility will be presented as a current liability in the consolidated financial statements.

11
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)

Collateral

The obligations of the Company under the Credit Agreement are secured by first priority liens on substantially all of its assets.

Covenants

The Credit Agreement contains customary affirmative and negative covenants, including covenants limiting the ability of the Company and its subsidiaries, among other things, to incur debt, grant liens, make distributions, enter certain restrictive agreements, pay or modify subordinated debt, dispose of assets, make investments and acquisitions, enter into certain transactions with affiliates, and undergo certain fundamental changes, in each case, subject to limitations and exceptions.

The Credit Agreement also requires the Company to satisfy certain financial covenants, including minimum trailing twelve (12) month net revenue targets relating to its Advanced Energy segment (tested quarterly), with year-end targets of $49 million, $60 million and $70 million for 2023, 2024, and 2025, respectively. Additionally, the Company must maintain a balance of $10 million in cash and cash equivalents during the duration of the Credit Agreement’s term.

As of March 31, 2023, the Company was in compliance with the financial covenants contained within the Credit Agreement.

Events of Default

The Credit Agreement also contains customary Events of Default that include, among other things, certain payment defaults, cross defaults to certain other contracts and indebtedness, covenant defaults, inaccuracy of representations and warranties, bankruptcy and insolvency defaults, judgment defaults, change of control defaults, defaults related to the failure to remain registered with the Securities and Exchange Commission and listed for trading on the Nasdaq Stock Market, and any material adverse change.

Upon the occurrence and during the continuance of an Event of Default under the Credit Agreement, the respective administrative agent, if requested by the respective lenders, may, among other things, (i) suspend or terminate commitments, as well as obligations of the relevant administrative agent and lenders, (ii) declare all outstanding obligations under the agreement (including principal and accrued and unpaid interest) immediately due and payable, and (iii) exercise the other rights and remedies provided for under the agreement. The Credit Agreement provides that, under certain circumstances, a default interest rate will apply on all obligations under such agreement during the existence of an Event of Default, at a per annum rate equal to 2% in excess of the applicable interest rate.

The Company bifurcated a derivative liability related to the potential acceleration triggered upon an event of default (contingent put option) and the supplemental interest upon an event of default features of the Credit Agreement. The bifurcated derivative is de minimis to the Company's unaudited condensed consolidated financial statements.

Issuance of Warrants

In connection with the Company’s obligations under the Credit Agreement, the Company issued to a statutory trust of MidCap Financial warrants to purchase up to 250,000 shares of its common stock, par value $0.001, with an exercise price of $3.40 per share.

The warrants have a 10 year term and can be exercised by issuing payment to the Company for the number of warrants exercised or exercised net by surrendering warrants with an intrinsic value equal to the cumulative exercise price of the warrants being exercised.

The Company determined that these warrants meet the criteria for equity classification and included the proceeds allocated to the warrants, on a relative fair value basis, as a debt discount and additional paid-in capital in the accompanying condensed consolidated financial statements.

Debt Issuance Costs

In connection with entering into the Credit Agreement, the Company incurred debt issuance costs of approximately $1.8 million, comprised primarily of commissions paid to the financial advisor. These costs were allocated to the issued and unissued term loans and the revolving facility. The costs allocated to the issued term loan will be amortized using the effective interest method over the life of the loan. The costs allocated to the unissued term loans have been deferred and will be amortized over the life of the term loans starting at the issuance date. If these loans are not issued, the Company will recognize
12
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)

the deferred costs at the point that the Company's rights to borrow on the term loans expires. The costs allocated to the revolving facility will be recognized on a straight-line basis over the term of the Credit Agreement.

The costs allocated to the issued term loan have been presented as a reduction of the term loan in the accompanying unaudited condensed consolidated balance sheet. The costs allocated to the unissued term loans and the revolving facility have been presented in prepaid expenses and other current assets in the accompanying unaudited condensed consolidated balance sheet.

Included in interest expense for the three months ended March 31, 2023 are $17,000 and $37,000, respectively, of amortization of the debt issuance costs and amortization of the debt discounts including accretion of the exit fee on the term loan. Included in interest expense for the three months ended March 31, 2023 are $12,000 and $1,000, respectively, of amortization of the debt issuance costs and amortization of the debt discount on the revolving facility.

The Company’s term loan, net consists of the following at March 31, 2023:

(In thousands)March 31, 2023
Term loan$10,000 
Unamortized debt issuance costs(485)
Unamortized debt discount, including accretion of exit fee(737)
Term loan, net$8,778 

As of March 31, 2023, principal repayments on the term loan are as follows:

(In thousands)
2023$— 
2024— 
20252,778 
20263,333 
20273,333 
Thereafter556 
Total repayments$10,000 

NOTE 7.     INTEREST IN JOINT VENTURE INVESTMENT

In 2019, the Company executed a joint venture agreement with its Chinese supplier (“China JV”) whereby the Company has a 51% interest. The China JV has been consolidated in these condensed consolidated financial statements. The agreement required the Company to make capital contributions into the newly formed entity of approximately $357,000, of which approximately $203,000 and $154,000, respectively, were contributed during the years ended December 31, 2021 and 2020. As of the date of these condensed consolidated financial statements, the joint venture has not commenced principal operations.

Changes in the Company’s ownership investment in the China JV were as follows:

Three Months Ended March 31,
(In thousands)20232022
Beginning interest in China JV$219 $317 
Net loss attributable to Apyx(51)(23)
Ending interest in China JV$168 $294 

13
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)

NOTE 8.     EARNINGS (LOSS) PER SHARE

Basic earnings (loss) per share (“basic EPS”) is computed by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period. Diluted earnings (loss) per share (“diluted EPS”) gives effect to all dilutive potential shares outstanding. As the Company is in a net loss position for all periods presented, all potential shares outstanding are anti-dilutive. The following table provides the computation of basic and diluted loss per share.
Three Months Ended
March 31,
(in thousands, except per share data)20232022
Numerator:
Net loss attributable to stockholders$(3,483)$(5,945)
Denominator:
Weighted average shares outstanding - basic and diluted
34,598 34,429 
Loss per share:
Basic and diluted$(0.10)$(0.17)
Anti-dilutive instruments excluded from diluted loss per common share:
Options7,783 6,796 
Warrants250 — 

14
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)

NOTE 9.     STOCK-BASED COMPENSATION

Under the Company's stock option plans, the Board of Directors may grant restricted stock and options to purchase common shares to the Company's employees, officers, directors and consultants. The Company accounts for stock options in accordance with FASB ASC Topic 718, Compensation - Stock Compensation, with stock-based compensation expense recognized over the vesting period based on the grant date fair value utilizing the Black Scholes model, which includes a number of estimates that affect the grant date fair value and the amount of expense to recognize.

The Company recognized approximately $1,367,000 in stock-based compensation expense for the three months ended March 31, 2023, as compared with $1,650,000 for the three months ended March 31, 2022.

Stock option activity is summarized as follows:
Number of optionsWeighted average exercise price
Outstanding at December 31, 2022
6,520,444 $7.12 
Granted1,408,865 2.50 
Exercised— — 
Canceled and forfeited(146,164)8.08 
Outstanding at March 31, 2023
7,783,145 $6.27 

The Company allows stock option holders to exercise stock-based awards by surrendering stock-based awards with an intrinsic value equal to the cumulative exercise price of the stock-based awards being exercised, referred to as net settlements. These surrenders are included in stock options exercised in the options rollforward above. For the three months ended March 31, 2022, we received 22,654 options as payment in the exercise of 19,013 options. There were no such exercises for the three months ended March 31, 2023.

Common shares required to be issued upon the exercise of stock options would be issued from authorized and unissued shares. The Company calculated the grant date fair value of options granted in 2023 (“2023 Grants”) utilizing a Black Scholes model.
2023 Grants
Strike price$2.50
Risk-free rate3.6%
Expected dividend yield—
Expected volatility85.8%
Expected term (in years)6

NOTE 10.     INCOME TAXES

Income tax (benefit) expense was approximately $(2,267,000) and $70,000 with effective tax rates of 39.1% and (1.2)% for the three months ended March 31, 2023 and 2022, respectively. For the three months ended March 31, 2023, the effective rate differs from the statutory rate primarily due to the reversal of the Company’s liability for uncertain tax positions, including accrued interest and penalties of approximately $2.1 million which were sustained upon the completion in January 2023 of the IRS examination of our 2018 through 2020 income tax returns, partially offset by a valuation allowance on the net operating loss (“NOL”) and net deferred tax assets generated during the period. For the three months ended March 31, 2022, the effective rate differs from the statutory rate primarily due to the full valuation allowance recorded on the NOL generated during the period, combined with interest and penalties on uncertain tax positions.



15
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)

NOTE 11.     COMMITMENTS AND CONTINGENCIES

Litigation

The medical device industry is characterized by frequent claims and litigation, and the Company may become subject to various claims, lawsuits and proceedings in the ordinary course of our business. Such claims may include claims by current or former employees, distributors and competitors, claims concerning the marketing and promotion of our products and product liability claims.

The Company is involved in a number of legal actions relating to the use of our Helium Plasma technology. The outcomes of these legal actions are not within the Company’s control and may not be known for prolonged periods of time. It believes that such claims are adequately covered by insurance; however, in the case of one of the Company’s carriers, the Company is in a dispute regarding the total level of coverage available. Notwithstanding the foregoing, in the opinion of management, the Company has meritorious defenses, and such claims are not expected, individually or in the aggregate, to result in a material, adverse effect on its financial condition, results of operations and cash flows. However, in the event that damages exceed the aggregate coverage limits of the Company’s policies or if its insurance carriers disclaim coverage, management believes it is possible that costs associated with these claims could have a material adverse impact on the consolidated financial condition, results of operations and cash flows.

The Company accrues a liability in its consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded, actual results may differ from these estimates.

During December 2021, the Company provided notice of contract termination to an international distributor of the Company. In March 2022, the Company received a letter from the former distributor citing improper contract termination and alleging damages. While the matter is still in the early stages, management has determined that a loss is probable and that a range of estimated losses is approximately $250,000 to $1,000,000. The Company recorded an estimated loss of $250,000 related to the matter during 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.

As previously disclosed with the U.S. Securities and Exchange Commission on the Company’s Current Report on Form 8-K filed June 7, 2022, on June 6, 2022, a complaint (the “Hattaway Complaint”) was filed in the United States District Court for the Middle District of Florida by plaintiff William E. Hattaway, individually and on behalf of all others similarly situated against the Company, Charles D. Goodwin (“Goodwin”), the Company’s President and Chief Executive Officer and a member of the Company’s Board of Directors, and Tara Semb (“Semb”), the Company’s Chief Financial Officer, Treasurer and Secretary, alleging violations by the Company, Goodwin and Semb of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, primarily related to certain public statements and disclosures concerning the off-label usage of certain of the Company’s Advanced Energy products and the impact such usage would have on the Company’s business, operations and prospects. The Hattaway Complaint seeks an unspecified amount of damages.

Although the ultimate outcome of this matter cannot be determined with certainty, the Company believes that the allegations stated in the Hattaway Complaint are without merit. The Company, Goodwin and Semb intend to defend themselves vigorously in the suit. In the opinion of management, such claims are adequately covered by insurance, however, in the event that damages exceed the aggregate coverage limits of our policy or if our insurance carriers disclaim coverage, we believe it is possible that costs associated with this claim could have a material adverse impact on our consolidated results of operations, financial position or cash flows. While the matter is still in the early stages, management has determined that a loss is probable and that a range of estimated losses is approximately $475,000 to $2,500,000. The Company recorded an estimated loss of $475,000 related to the matter during 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.

During 2022, the Company was notified of certain procedures alleged to have been performed by the same physician and which are currently the subject of two related products liability cases within the courts. Subsequent to year end, the Company was notified by its insurance carriers that all or most of the ten individual plaintiff’s allegations could be subject to separate
16
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)

deductibles notwithstanding the commonality of each underlying occurrence. The Company has determined that a loss is probable and that a range of estimated losses is approximately $1,450,000 to $2,400,000. The Company recorded an estimated loss of $1,450,000 related to the matters during 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.

On March 1, 2023, Shiva Stein as plaintiff filed a derivative complaint in the Court of Chancery of the State of Delaware, captioned Stein v. Makrides, et al., C.A. No. 2023-0239-MTZ (the “Stein Suit”) against individual members of the Company’s board of directors and naming the Company as a nominal defendant, primarily concerning the facts at issue in a previously disclosed federal securities class action lawsuit filed in 2019 and settled in 2020, captioned Pritchard v. Apyx Medical Corporation, et al., Case No. 8:19-cv-00919 (M.D. Fla.) (the “Pritchard Case”). The Stein Suit seeks unspecified damages alleged to have resulted from purported breaches of fiduciary duty, unjust enrichment and related claims based on the same set of allegedly misleading statements and material omissions described in the settled Pritchard Case, which concerned the 2018-2019 clinical study conducted by the Company to evaluate the safety and efficacy of its J-Plasma technology for dermal resurfacing. The Company believes that the claims are subject to procedural and substantive defenses, anticipates defense and indemnity coverage to be made available by the relevant insurer, and expects the individual defendants to defend all of the allegations vigorously. The outcome of the action is not within the Company’s control and may not be known for a prolonged period of time. In the opinion of management, neither the alleged claims against the individual defendants nor the defense thereof are expected to result in a material, adverse effect on the Company’s financial condition, results of operations and cash flows.

Purchase Commitments

At March 31, 2023, the Company had purchase commitments totaling approximately $4.0 million, substantially all of which is expected to be purchased within the next twelve months.

17
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)

NOTE 12.     RELATED PARTY TRANSACTIONS

Several relatives of Nikolay Shilev, Apyx Bulgaria’s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev’s spouse, is an employee of the Company working in the accounting department. Svetoslav Shilev, Mr. Shilev’s son, is a quality manager in the quality assurance department.

The partner in the Company's China JV is also a supplier to the Company. For the three months ended March 31, 2023 and 2022, the Company made purchases from this supplier of approximately $44,000 and $124,000, respectively. At March 31, 2023 and December 31, 2022, respectively, the Company had net payables to and receivables from this supplier approximately $2,000 and $8,000, respectively.

NOTE 13.     GEOGRAPHIC AND SEGMENT INFORMATION

Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, the Company also considers the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to its chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment, accordingly, the Company has not presented a measure of assets by segment.

The Company's reportable segments are disclosed as principally organized and managed as two operating segments: Advanced Energy and OEM. "Corporate & Other" includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.

Summarized financial information with respect to reportable segments is as follows:
18
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)

Three Months Ended March 31, 2023
(In thousands)Advanced EnergyOEMCorporate & OtherTotal
Sales$9,690 $2,452 $— $12,142 
Income (loss) from operations(1,326)851 (5,136)(5,611)
Interest income— — 51 51 
Interest expense— — (234)(234)
Other loss, net— — (5)(5)
Income tax benefit— — (2,267)(2,267)

Three Months Ended March 31, 2022
(In thousands)Advanced EnergyOEMCorporate & OtherTotal
Sales$10,814 $1,679 $— $12,493 
Income (loss) from operations(1,339)317 (4,849)(5,871)
Interest income— — 2 2 
Interest expense— — (8)(8)
Other loss, net— — (21)(21)
Income tax expense— — 70 70 

International sales represented approximately 26.9% of total revenues for the three months ended March 31, 2023, as compared with approximately 39.6% of total revenues for the three months ended March 31, 2022.

Revenue by geographic region, based on the customer's “ship to” location on the invoice, are as follows:
Three Months Ended
March 31,
(In thousands)20232022
Sales by Domestic and International
Domestic$8,871 $7,548 
International3,271 4,945 
Total$12,142 $12,493 

19
APYX MEDICAL CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS


ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis in conjunction with our financial statements and related notes contained elsewhere in this report. This discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors discussed in this report and those discussed in other documents we file with the SEC. In light of these risks, uncertainties and assumptions, readers are cautioned not to place undue reliance on such forward-looking statements. These forward-looking statements represent beliefs and assumptions as of the date of this report. While we may elect to update forward-looking statements and at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. Past performance does not guarantee future results.

Executive Level Overview

We are an advanced energy technology company with a passion for elevating people’s lives through innovative products, including our Helium Plasma Technology products marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion® and J-Plasma® offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. We also leverage our deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers.

As part of our plan to accelerate and fully fund the development of our advanced energy business, with a focus in the cosmetic surgery market, we sold our Core business in 2018 for gross proceeds of $97 million. These proceeds were used to launch broad marketing and sales initiatives which resulted in rapid sales growth through December 31, 2021 and into the first quarter of 2022. This planned growth in the business was accompanied by scaled operations, including procurement of components, expanded manufacturing capacity to turn those materials into saleable inventory, additional discretionary expenditures, including increased global participation at trade shows, additional employee trainings, user meetings, increased travel and entertainment expenses, more expansive research and development projects, and additional headcount to support those activities. Additionally, we had and still have, some significant non-recurring discretionary expenditures associated with completing our multi-year marketing initiatives related to our dermal resurfacing and skin laxity clearances.

On March 14, 2022, the U.S. Food and Drug Administration (“FDA”) posted a Medical Device Safety Communication (“Safety Communication”). The FDA warned against the use of Renuvion/J-Plasma for procedures intended to improve the appearance of the skin through dermal resurfacing (a procedure on the skin to treat wrinkles) or skin contraction (a procedure under the skin that can be performed either alone or in combination with liposuction to achieve skin effects, such as “tightening”). At that time, the Renuvion/J-Plasma device system was FDA cleared for general use of cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures. The use of the device had not been determined to be safe or effective for any aesthetic skin procedures (procedures intended to improve the appearance of the skin). Following the Safety Communication, we experienced slowed demand for the adoption of its Helium Plasma Technology.

On May 26, 2022, we announced that we received 510(k) clearance from the FDA for the use of the Renuvion® Dermal Handpiece for certain dermal resurfacing procedures, specifically, for the treatment of moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick Skin Types I, II or III.

On June 2, 2022, the FDA updated the Safety Communication to inform consumers and healthcare providers about the new 510(k) clearance for the Renuvion® device system for certain dermal resurfacing procedures.

On July 18, 2022, we announced that we received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for use in subcutaneous dermatological and aesthetic procedures to improve the appearance of lax (loose) skin in the neck and submental (under the chin) region.

On July 21, 2022, the FDA updated the Safety Communication to inform consumers and healthcare providers about the clearance for the Renuvion® APR handpieces for use under the skin in certain procedures intended to improve the appearance of loose skin.

On February 27, 2023, we announced that we received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. Soft tissue includes subcutaneous tissue.

20
APYX MEDICAL CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued

On April 28, 2023, we announced that we received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring.

On May 10, 2023, the FDA updated the Safety Communication to inform consumers and healthcare providers about the clearance for the Renuvion® APR handpiece for use under the skin in certain procedures intended to improve the appearance of the skin, including for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring.

We believe that the May 10, 2023 FDA update to the Safety Communication addresses the issues set forth in the original Safety Communication from March 14, 2022. While no assurances can be provided, we believe that receiving these additional clearances and the corresponding updates to the Safety Communication since March 14, 2022 should mitigate the financial effects of the Safety Communication in future periods.

While sales were continuing to grow into the first quarter of 2022 prior to the FDA Safety Communication, over the last few years, exclusive of our sale of the Core business segment to Symmetry Surgical during 2018, we have incurred recurring net losses and cash outflows from operations and we anticipate that losses will continue in the near term. During the year ended December 31, 2022, the we incurred an operating loss of $23.6 million and used $20.3 million of cash in operations. During the three months ended March 31, 2023, the we incurred an operating loss of $5.6 million and used $1.9 million of cash in operations. As of March 31, 2023, the we had cash and cash equivalents of $16.3 million, of which we must maintain $10.0 million under our Credit Agreement. These conditions raise substantial doubt about our ability to continue as a going concern for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements.

In an effort to alleviate these conditions, we pursued various funding solutions in order to improve liquidity.

On November 22, 2022, the we filed a shelf registration statement providing us the ability to register securities in the aggregate amount up to $100 million. The shelf registration included an embedded ATM facility for up to $40 million. To date, we have not utilized this facility.

On February 17, 2023, we entered into a Credit, Security and Guaranty Agreement (the “Credit Agreement”) with MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time.

The Credit Agreement provides for an up to $35 million facility, consisting of senior secured term loans and a secured revolving facility. The Credit Agreement provides for senior secured term loans of up to $25 million, comprised of (i) an initial tranche of $10 million, (ii) a second tranche of $5 million, and (iii) a third tranche of $10 million. The secured revolving facility provides for loans in an aggregate principal amount of up to $10 million, subject to a borrowing base equal to certain percentages of the Company’s eligible accounts receivable and inventory, as determined in accordance with the terms of the Credit Agreement.

For a more in depth description of the terms of the Credit Agreement, see Note 6 of Notes to Condensed Consolidated Financial Statements in Item 1 of this report on Form 10-Q.

On February 27, 2023, our Board of Directors approved a plan to sell and leaseback the our real property located in Clearwater, FL. On March 14, 2023, we entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with VK Acquisitions VI, LLC (the “Purchaser”), for the sale of our facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the “Property”) for a purchase price of $7,650,000. The Purchase Agreement is subject to the satisfactory completion of due diligence by the Purchaser. On May 8, 2023, we closed on the Purchase Agreement and concurrently executed a 10-year agreement to leaseback the underlying Property from the Purchaser.

For a more in depth description of the terms of the Purchase Agreement, see Note 4 of Notes to Condensed Consolidated Financial Statements in Item 1 of this report on Form 10-Q.

During January 2023, we were notified that the IRS examination process of our 2018, 2019 and 2020 tax returns was complete and that the our tax refunds were approved for approximately $0.2 million more than the amount recorded in the Company’s Consolidated Balance Sheet at December 31, 2022. As of the date of this report, we are awaiting receipt of the tax refunds.

21
APYX MEDICAL CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued

We also continue to re-assess our operating expenditures and cost structure to be commensurate with our expected levels of revenue and we have the ability to reduce or delay expenditures to enhance and preserve liquidity. We have already reduced some operating expenditures, including a reduction-in-force on January 9, 2023, that reduced our U.S. headcount by 14%.

We believe that the actions already taken, and additional actions that we intend to take to manage operating expenditures, will enable us to meet our obligations and our debt covenants for a period of at least one year from the date of issuance of our audited consolidated financial statements. As a result, we believe our plans alleviate substantial doubt about our ability to continue as a going concern. Our audited financial statements do not include any adjustments relating to the carrying amounts and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern.

We continue to drive sales in our Advanced Energy business by increasing the adoption and utilization of our handpieces by surgeons in the U.S. and fulfilling demand from distributors in our international markets. Management estimates that our products have been sold in more than 60 countries. As of March 31, 2023, we had a direct sales force of 35 field-based selling professionals and utilized 3 independent sales agencies. We also had 4 sales managers. This selling organization is focused on the use of Renuvion® in the cosmetic surgery market, supported by our global medical affairs team. This global team of clinical support specialists focuses on supporting our users to ensure optimal outcomes for their patients. In addition, we have invested in training programs and marketing-related activities to support accelerated adoption of Renuvion® into physicians’ practices.

In regards to our operating segments, our results are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, we also consider the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to our chief operating decision maker for operating and administrative activities, availability of discrete financial information, and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment and, accordingly, we have not presented a measure of assets by reportable segment.

Our reportable segments are disclosed as principally organized and managed as two operating segments: Advanced Energy and OEM. "Corporate & Other" includes certain unallocated corporate and administrative costs which are not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, and all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.

In response to the global supply chain instability and inflationary cost increases, we continue to take action to minimize, as much as possible, any potential adverse impacts by working closely with our suppliers to closely monitor the availability of raw material components (i.e. semiconductors and plastics), lead times, and freight carrier availability. We expect global supply chain instability will continue to have an impact on our business, but to date that has not been material to our financial performance. The consequences of the pandemic, global supply chain instability and inflationary cost increases and their adverse impact to the global economy, continue to evolve. Accordingly, the significance of the future impact to our business and financial statements remains subject to significant uncertainty.

We strongly encourage investors to visit our website: www.apyxmedical.com to view the most current news and to review our filings with the Securities and Exchange Commission.

Results of Operations

Sales
22
APYX MEDICAL CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued

Three Months Ended
March 31,
(In thousands)20232022Change
Sales by Reportable Segment
Advanced Energy$9,690 $10,814 (10.4)%
OEM2,452 1,679 46.0 %
Total$12,142 $12,493 (2.8)%
Sales by Domestic and International
Domestic$8,871 $7,548 17.5 %
International3,271 4,945 (33.9)%
Total$12,142 $12,493 (2.8)%

Total revenue decreased by 2.8%, or approximately $0.4 million, for the three months ended March 31, 2023 when compared with the three months ended March 31, 2022. Advanced Energy segment sales decreased 10.4%, or approximately $1.1 million, for the three months ended March 31, 2023 when compared with the three months ended March 31, 2022. The Advanced Energy sales decrease was driven by decreases in adoption of our generator technology in international markets and in global utilization based demand for our handpieces following the FDA Safety Communication on March 14, 2022. These decreases were partially offset by domestic customers, who upgraded their generator to our new Apyx One Console, which we launched in January 2023.

OEM segment sales increased 46.0%, or approximately $0.8 million, for the three months ended March 31, 2023 when compared with the three months ended March 31, 2022. The increase in OEM sales was due to increases in sales volume to existing customers as well as incremental new sales upon the commencement of the supply arrangement related to the completion of the development portion of some of our OEM development agreements.

International sales represented approximately 26.9% of total revenues for the three months ended March 31, 2023, as compared with 39.6% of total revenues for the same prior year period. Management estimates our products have been sold in more than 60 countries through local dealers coordinated by sales and marketing personnel through our facilities in Clearwater, Florida and Sofia, Bulgaria.

Gross Profit
Three Months Ended
March 31,
(In thousands)20232022Change
Cost of sales$4,569 $4,274 6.9 %
Percentage of sales37.6 %34.2 %
Gross profit$7,573 $8,219 (7.9)%
Percentage of sales62.4 %65.8 %
Gross profit for the three months ended March 31, 2023, decreased 7.9% to $7.6 million, compared to $8.2 million for the same period in the prior year. Gross margin for the three months ended March 31, 2023, was 62.4%, compared to 65.8% for the same period in 2021.

The decrease in gross profit margins for the three months ended March 31, 2023 from the prior year period is primarily attributable to changes in the sales mix between our two segments, with our OEM segment comprising a higher percentage of total sales and product mix within our Advanced Energy segment. These decreases were partially offset by geographic mix within our Advanced Energy segment, with domestic sales comprising a higher percentage of total sales.

Other Costs and Expenses
23
APYX MEDICAL CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued

Research and development
Three Months Ended
March 31,
(In thousands)20232022Change
Research and development expense$1,121 $1,158 (3.2)%
Percentage of sales9.2 %9.3 %

Research and development expenses decreased 3.2% for the three months ended March 31, 2023, primarily due to lower spending on our two investigational device exemption (IDE) clinical studies and other product development initiatives ($0.1 million). This decrease was partially offset by increased labor and benefit costs from the same period in the prior year ($0.1 million).

Professional services
Three Months Ended
March 31,
(In thousands)20232022Change
Professional services expense$1,740 $2,286 (23.9)%
Percentage of sales14.3 %18.3 %

Professional services expense decreased 23.9% for the three months ended March 31, 2023 as compared to the same period in the prior year, primarily attributable to decreases in legal expenses ($0.3 million), physician consulting fees ($0.2 million) and accounting and audit fees ($0.1 million).

Salaries and related costs
Three Months Ended
March 31,
(In thousands)20232022Change
Salaries and related expenses$5,068 $5,181 (2.2)%
Percentage of sales41.7 %41.5 %

During the three months ended March 31, 2023, salaries and related expenses decreased 2.2%, primarily driven by lower stock based compensation expense ($0.2 million). This increase was partially offset by higher compensation and benefits ($0.1 million) as compared to the same period in the prior year.

Selling, general and administrative expenses
Three Months Ended
March 31,
(In thousands)20232022Change
SG&A expense$5,255 $5,465 (3.8)%
Percentage of sales43.3 %43.7 %

During the three months ended March 31, 2023, selling, general and administrative expense decreased 3.8%, primarily driven by decreased advertising expense, including trade show fees and related costs ($0.5 million), lower bad debt expenses ($0.3 million) and employee training and other meeting expenses ($0.2 million). These decreases were partially offset by increases in travel and entertainment expense ($0.5 million) and insurance expense ($0.3 million).

24
APYX MEDICAL CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued

Interest Income (Expense)
Three Months Ended
March 31,
(In thousands)20232022
Interest income$51 $2 
Percentage of sales0.4 %— %
Interest expense(234)(8)
Percentage of sales(1.9)%(0.1)%

Interest income increased approximately $0.1 million for the three months ended March 31, 2023, compared with same period in the prior year. This increase is due to higher yields on our investments in money market funds and U.S. Treasury securities included in cash, cash equivalents and restricted cash, partially offset by a lower average balance.

Interest expense increased approximately $0.2 million for the three months ended March 31, 2023, compared with same period in the prior year. This increase is due to cash and noncash interest expense on the Credit Agreement executed on February 17, 2023.

Income Taxes
Three Months Ended
March 31,
(In thousands)20232022
Income tax (benefit) expense$(2,267)$70 
Effective tax rate39.1 %(1.2)%

Our income tax (benefit) expense was approximately $(2,267,000) and $70,000 with effective tax rates of 39.1% and (1.2)% for the three months ended March 31, 2023 and 2022, respectively. For the three months ended March 31, 2023, the effective rate differs from the statutory rate primarily due to the reversal of our liability for uncertain tax positions, including accrued interest and penalties, of approximately $2.1 million which were sustained upon the completion in January 2023 of the IRS examination of our 2018 through 2020 income tax returns, partially offset by a valuation allowance on our NOL and net deferred tax assets generated during the period. For the three months ended March 31, 2022, the effective rate differs from the statutory rate primarily due to the full valuation allowance recorded on the NOL generated during the period, combined with interest and penalties on uncertain tax positions.

Liquidity and Capital Resources

At March 31, 2023, we had approximately $16.3 million in cash, cash equivalents and restricted cash as compared to approximately $10.2 million in cash and cash equivalents at December 31, 2022. Our working capital at March 31, 2023 was approximately $34.2 million compared with $31.1 million at December 31, 2022. The increase in working capital at March 31, 2023 was primarily due to the reclassification of assets held for sale from long term assets to current assets in March 2023 and the reversal of our liability for uncertain tax positions upon the completion in January 2023 of the IRS examination of our 2018, 2019 and 2020 income tax returns. This increase was partially offset by the net loss incurred by the Company in the first quarter of 2023, excluding non-cash activity, comprised primarily of stock-based compensation.

For the three months ended March 31, 2023, net cash used in operating activities was approximately $1.9 million, which principally funded our loss from operations of $5.6 million, compared with net cash used in operating activities of approximately $4.5 million in 2022. As discussed in the Executive Level Overview, our operating loss, cash used in operations and current cash and cash equivalents balance of $16.3 million, of which we must maintain $10.0 million under our Credit Agreement, raise substantial doubt about our ability to continue as a going concern for a period of at least one year from the date of issuance of our unaudited condensed consolidated financial statements.

In an effort to alleviate these conditions, we pursued various funding solutions in order to improve liquidity.

25
APYX MEDICAL CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued

On November 22, 2022, the we filed a shelf registration statement providing us the ability to register securities in the aggregate amount up to $100 million. The shelf registration included an embedded ATM facility for up to $40 million. To date, we have not utilized this facility.

On February 17, 2023, we entered into a Credit, Security and Guaranty Agreement (the “Credit Agreement”) with MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time.

The Credit Agreement provides for an up to $35 million facility, consisting of senior secured term loans and a secured revolving facility. The Credit Agreement provides for senior secured term loans of up to $25 million, comprised of (i) an initial tranche of $10 million, (ii) a second tranche of $5 million, and (iii) a third tranche of $10 million. The secured revolving facility provides for loans in an aggregate principal amount of up to $10 million, subject to a borrowing base equal to certain percentages of the Company’s eligible accounts receivable and inventory, as determined in accordance with the terms of the Credit Agreement.

For a more in depth description of the terms of the Credit Agreement, see Note 6 of Notes to Condensed Consolidated Financial Statements in Item 1 of this report on Form 10-Q.

On February 27, 2023, our Board of Directors approved a plan to sell and leaseback the our real property located in Clearwater, FL. On March 14, 2023, we entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with VK Acquisitions VI, LLC (the “Purchaser”), for the sale of our facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the “Property”) for a purchase price of $7,650,000. On May 8, 2023, we closed on the Purchase Agreement and concurrently executed a 10-year agreement to leaseback the underlying Property from the Purchaser.

For a more in depth description of the terms of the Purchase Agreement, see Note 4 of Notes to Condensed Consolidated Financial Statements in Item 1 of this report on Form 10-Q.

During January 2023, we were notified that the IRS examination process of our 2018, 2019 and 2020 tax returns was complete and that the Company's tax refunds were approved for approximately $0.2 million more than the amount recorded in the Company's Consolidated Balance Sheet at December 31, 2022. As of the date of this report, we are awaiting receipt of the tax refunds.

We also continue to re-assess our operating expenditures and cost structure to be commensurate with our expected levels of revenue and we have the ability to reduce or delay expenditures to enhance and preserve liquidity. We have already reduced some operating expenditures, including a reduction-in-force on January 9, 2023, that reduced our U.S. headcount by 14%.

We believe that the actions already taken, and additional actions that we intend to take to manage operating expenditures, will enable us to meet our obligations and our debt covenants for a period of at least one year from the date of issuance of our audited consolidated financial statements. As a result, we believe our plans alleviate substantial doubt about our ability to continue as a going concern. Our audited financial statements do not include any adjustments relating to the carrying amounts and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern.

Net cash used in investing activities for the three months ended March 31, 2023 and 2022, were $0.1 million and $0.3 million, respectively, related to purchases of property and equipment.

Net cash provided by financing activities for the three months ended March 31, 2023 was $8.1 million related to proceeds received upon the execution of the Credit Agreement ($9.9 million) less debt issuance costs incurred in the transaction ($1.8 million).

At March 31, 2023, our borrowing availability under the revolving facility was approximately $5.7 million.

At March 31, 2023, we had purchase commitments for inventories totaling approximately $4.0 million, substantially all of which is expected to be purchased by the end of 2023.

26
APYX MEDICAL CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued

Critical Accounting Estimates

In preparing the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP), we have adopted various accounting policies. Our most significant accounting policies are disclosed in Note 2 to the consolidated financial statements included in our 2022 Form 10-K, filed with the SEC on March 16, 2023.

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Our estimates and assumptions, including those related to inventories, intangible assets, property, plant and equipment, legal proceedings, research and development, warranty obligations, product liability, sales returns and discounts, stock-based compensation and income taxes are updated as appropriate, which in most cases is at least quarterly. We base our estimates on historical experience, or various assumptions that are believed to be reasonable under the circumstances and the results form the basis for making judgments about the reported values of assets, liabilities, revenues and expenses. Actual results may materially differ from these estimates.

Estimates are considered to be critical if they meet both of the following criteria: (1) the estimate requires assumptions about material matters that are uncertain at the time the accounting estimates are made and (2) other materially different estimates could have been reasonably made or material changes in the estimates are reasonably likely to occur from period to period. Our critical accounting estimates include the following:

Stock-Based Compensation

Under our stock option plans, options to purchase common shares of the Company may be granted to employees, officers and directors of the Company by the Board of Directors. We account for stock options in accordance with FASB ASC Topic 718-10, Compensation-Stock Compensation, with compensation expense recognized over the vesting period. Options are valued using the Black-Scholes model, which includes a number of estimates that affect the amount of our expense. We have determined that the most critical of these estimates are the estimates of expected life and volatility used in the calculations.

Expected life

For employee stock-based compensation awards, we estimate the expected life of awards utilizing the SEC's simplified method. We utilize this method, as we have not historically granted stock-based compensation awards to employees in sufficient volumes to determine a reasonable estimate of the life of awards. For awards granted to non-employees, we calculate expected life using a combination of past exercise behavior, the contractual term and expected remaining exercise behavior.

Volatility

We determine the volatility by utilizing the historical volatility of our stock over the period of the awards expected life. The SEC allows us to include periods in excess of the useful life if we determine that they provide a more reasonable basis for the volatility of our stock. Additionally, ASC 718-10 allows us to exclude periods from the volatility if they pertain to events or circumstances that in our judgment are specific to us and if the event or transaction is not reasonably expected to occur again during the expected term of the awards. We have not included any additional periods, nor disregarded any periods, in calculating our volatility.

Accounts Receivable Allowance

We maintain a reserve for uncollectible accounts receivable. When evaluating the adequacy of the allowance for doubtful accounts, we analyze historical bad debt experience, the composition of outstanding receivables by customer class, and the age of outstanding balances, and we make estimates in connection with establishing the allowance for doubtful accounts, including the expected impacts of changes in the operating environment and other trends. Changes in estimates are reflected in the period they are made. If the financial condition of our customers deteriorates, resulting in an inability to make payments, additional allowances may be required.
27
APYX MEDICAL CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued

Inventory Obsolescence Allowance

We maintain a reserve for excess and obsolete inventory resulting from the potential inability to sell our products at prices in excess of current carrying costs. The markets in which we operate are highly competitive, with new products and surgical procedures introduced on an ongoing basis. Such marketplace changes may cause our products to become obsolete. We make estimates regarding the future recoverability of the costs of these products and record a provision for excess and obsolete inventories based on historical experience and expected future trends. If actual product life cycles, product demand or acceptance of new product introductions are less favorable than projected by management, additional inventory write-downs may be required, which would unfavorably affect future operating results.

Litigation Contingencies

In accordance with authoritative guidance, we record a liability in our consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded; actual results may differ from these estimates.

Income Taxes

The provision for income taxes includes federal, foreign, state and local income taxes currently payable and those deferred because of temporary differences between the financial statement and tax bases of assets and liabilities. Deferred tax assets or liabilities are computed based on the difference between the financial statement and income tax bases of assets and liabilities using enacted marginal tax rates. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. Deferred income tax expenses or credits are based on the changes in the asset or liability from period to period.

As a result of historical losses and our expectation to continue to generate losses in the near future, we recorded a valuation allowance on our net deferred tax assets. Exclusive of the carryback provisions of the CARES Act and the associated income tax benefit recognized in 2020, we do not anticipate recording an income tax benefit related to our deferred tax assets. We will reassess the realization of deferred tax assets each reporting period and will be able to reduce the valuation allowance to the extent our results of operations improve, and it becomes more likely than not that the deferred tax assets will be realized. As Management has not fully determined the timing of when it will generate taxable income in the U.S., we continued to record a valuation allowance on the net deferred tax assets balance as of March 31, 2023.

We assess the financial statement impact of an uncertain tax position taken or expected to be taken on an income tax return at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized in the financial statements unless it is more likely than not of being sustained.

Inflation

The consequences of the pandemic, global supply chain instability and inflationary cost increases and their adverse impact to the global economy, continue to evolve. Accordingly, the significance of the future impact to our business and financial statements remains subject to significant uncertainty. Inflation has not, to date, materially impacted our operations or financial performance. However, as these trends continue for raw materials, freight, and labor costs, our future financial performance could be adversely impacted.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements at this time.

Recent Accounting Pronouncements


28
APYX MEDICAL CORPORATION
ITEM 3. Quantitative and Qualitative Disclosures about Market Risk

Not applicable.

29
APYX MEDICAL CORPORATION
ITEM 4. Controls and Procedures

Disclosure Controls and Procedures

Our management has established and maintains disclosure controls and procedures that are designed to ensure that the information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Management carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of March 31, 2023, the Company's disclosure controls and procedures were effective.

Changes in Internal Control Over Financial Reporting

In February 2023, we entered into a Credit, Security and Guaranty Agreement ("Credit Agreement"). We are in the process of developing new control activities around the accounting for the Credit Agreement, including the review and compliance with debt covenants. There were no other changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the period covered by the Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
30
APYX MEDICAL CORPORATION
PART II.     Other Information

ITEM 1. Legal Proceedings



31
APYX MEDICAL CORPORATION
ITEM 1A. Risk factors

There have been no material changes to the risk factors described under Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022.


32
APYX MEDICAL CORPORATION
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

ITEM 3. Defaults Upon Senior Securities

None.

ITEM 4. Mine Safety Disclosures

Not Applicable.

ITEM 5. Other Information

On May 8, 2023, Apyx Medical Corporation (the “Company”) closed the previously announced sale and leaseback of its facility located at 5115 Ulmerton Road, Clearwater, Florida, with VK Acquisitions VI, LLC for a purchase price of $7,650,000. Following the closing, the Company received net cash proceeds of approximately $6,600,000 after withholding the security deposit equal to one years rent, taxes, first months rent, expenses and fees.
33
APYX MEDICAL CORPORATION
ITEM 6. Exhibits
3.1
3.2
3.3
Certificate of Amendment of the Certificate of Incorporation of the Registrant (Incorporated by reference to Exhibit 3.5 to the Registrant’s Quarterly Report on Form 10-Q filed on November 3, 2017)
3.4
Certificate of Elimination (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on May 3, 2018)
3.5
Certificate of Amendment of the Certificate of Incorporation of the Registrant (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on December 28, 2018)
31.1*
31.2*
32.1*
32.2*
101.INS**XBRL Instance Document
101.SCH**XBRL Taxonomy Extension Schema Document
101.CAL**XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF**XBRL Taxonomy Extension Definition Linkbase Document
101.LAB**XBRL Taxonomy Extension Label Linkbase Document
101.PRE**XBRL Taxonomy Extension Label Presentation Document

* Filed herewith.

** XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended and otherwise is not subject to liability under these sections.

34
APYX MEDICAL CORPORATION
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Apyx Medical Corporation
Date: May 11, 2023By:/s/ Charles D. Goodwin II
Charles D. Goodwin II
President, Chief Executive Officer and Director
(Principal Executive Officer)
Date: May 11, 2023By:/s/ Tara Semb
Tara Semb
Chief Financial Officer,
Treasurer and Secretary
(Principal Financial Officer)

35
 EX-31.1 2 a2023q110-kexhibit311.htm EX-31.1 Document
EXHIBIT 31.1

Certificate Pursuant to Section 302
of Sarbanes – Oxley Act of 2002
CERTIFICATION OF CEO

I, Charles D Goodwin II, the Registrant's Chief Executive Officer, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Apyx Medical Corporation;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected or is reasonably likely to materially affect the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.
Date: May 11, 2023By:/s/ Charles D. Goodwin II
Charles D. Goodwin II
President and Chief Executive Officer

 EX-31.2 3 a2023q110-kexhibit312.htm EX-31.2 Document
EXHIBIT 31.2

Certificate Pursuant to Section 302
of Sarbanes – Oxley Act of 2002
CERTIFICATION OF CFO

I, Tara Semb, the Registrant's Chief Financial Officer, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Apyx Medical Corporation;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected or is reasonably likely to materially affect the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.
Date: May 11, 2023By:/s/ Tara Semb
Tara Semb
Chief Financial Officer, Treasurer and Secretary


 EX-32.1 4 a2023q110-qexhibit321.htm EX-32.1 Document
EXHIBIT 32.1
Certificate Pursuant to 18 U.S.C Section 1350, as adopted pursuant to
Section 906 of Sarbanes – Oxley Act of 2002
CERTIFICATION OF CEO

In connection with the quarterly report on Form 10-Q of Apyx Medical Corporation (the "Company") for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned Chief Executive Officer certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: May 11, 2023By:/s/ Charles D. Goodwin II
Charles D. Goodwin II
President and Chief Executive Officer




 EX-32.2 5 a2023q110-kexhibit322.htm EX-32.2 Document
EXHIBIT 32.2
Certificate Pursuant to 18 U.S.C Section 1350, as adopted pursuant to
Section 906 of Sarbanes – Oxley Act of 2002
CERTIFICATION OF CFO

In connection with the quarterly report on Form 10-Q of Apyx Medical Corporation (the "Company") for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned Chief Financial Officer certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: May 11, 2023By:/s/ Tara Semb
Tara Semb
Chief Financial Officer, Treasurer and Secretary


 EX-101.SCH 6 apyx-20230331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000007 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - INVENTORIES link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - CREDIT AGREEMENT link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - EARNINGS (LOSS) PER SHARE link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - BASIS OF PRESENTATION (Policies) link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - INVENTORIES (Tables) link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - BASIS OF PRESENTATION (Details) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - INVENTORIES (Details) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT - Schedule of Assets Held-for-Sale (Details) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - CREDIT AGREEMENT - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - CREDIT AGREEMENT - Schedule Of Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - CREDIT AGREEMENT - Schedule of Long-Term Debt Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT - Rollforward of Joint Venture (Details) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - EARNINGS (LOSS) PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - STOCK-BASED COMPENSATION - Summary of Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - STOCK-BASED COMPENSATION - Fair Value Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - RELATED PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 apyx-20230331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 apyx-20230331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 apyx-20230331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Net loss Net loss Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Related Party Transactions [Abstract] Related Party Transactions [Abstract] Provision for allowance for doubtful accounts Accounts Receivable, Credit Loss Expense (Reversal) Term loan Term loan, net Long-Term Debt, Gross Entity Address, Postal Zip Code Entity Address, Postal Zip Code Finance lease right-of-use assets Finance Lease, Right-of-Use Asset, after Accumulated Amortization Interest income Interest income Interest Income, Operating Property, Plant and Equipment [Abstract] Debt Instrument, Prepayment Period One Debt Instrument, Prepayment Period One [Member] Debt Instrument, Prepayment Period One Preferred stock, outstanding (in shares) Preferred Stock, Shares Outstanding 2025 Long-Term Debt, Maturity, Year Two Debt Instrument [Axis] Debt Instrument [Axis] Total property, plant and equipment Property, Plant and Equipment, Gross Debt Instrument, Covenant, Tranche One Debt Instrument, Covenant, Tranche One [Member] Debt Instrument, Covenant, Tranche One Credit facility Line of Credit Facility, Maximum Borrowing Capacity Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Stock swaps (in shares) Stock Issued During Period, Shares, Stock Swaps Stock Issued During Period, Shares, Stock Swaps Additional paid-in capital Additional Paid in Capital Number of plaintiffs Loss Contingency, Number of Plaintiffs Variable rate Debt Instrument, Basis Spread on Variable Rate Statistical Measurement [Domain] Statistical Measurement [Domain] Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Sale leaseback, management fee on rent payment Sale Leaseback, Management Fee On Rent Payment Sale Leaseback, Management Fee On Rent Payment Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] OEM OEM [Member] Lockbox account, funds to be applied to borrowings Debt Instrument, Lockbox Account, Funds To Be Applied To Borrowings Debt Instrument, Lockbox Account, Funds To Be Applied To Borrowings Income taxes Income Taxes Paid Net loss attributable to stockholders Net Income (Loss) Attributable to Parent Thereafter Long-Term Debt, Maturity, After Year Four Long-Term Debt, Maturity, After Year Four Proceeds from stock option exercises Proceeds From Stock Options Exercised And Warrants Exercised Proceeds From Stock Options Exercised And Warrants Exercised Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Anti-dilutive instruments (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Schedule of Maturities of Long-Term Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Equity Component [Domain] Equity Component [Domain] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Earnings Per Share Reconciliation [Abstract] Earnings Per Share Reconciliation [Abstract] Secured Debt Secured Debt [Member] Ownership [Axis] Ownership [Axis] Estimate of possible loss Loss Contingency, Estimate of Possible Loss Related Party [Domain] Related Party [Domain] Denominator: Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] Debt Instrument, Covenants [Axis] Debt Instrument, Covenants [Axis] Debt Instrument, Covenants Cash paid for: Supplemental Cash Flow Information [Abstract] Number of operating segments Number of Operating Segments Noncontrolling Interest [Abstract] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Borrowing base, minimum balance Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Amount Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Amount Net cash used in operating activities Net cash used in cash operations Net Cash Provided by (Used in) Operating Activities Current portion of operating lease liabilities Operating Lease, Liability, Current Related Party Transaction [Domain] Related Party Transaction [Domain] Proceeds from the disposition of Core business Proceeds from Divestiture of Businesses Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Other costs and expenses: Costs and Expenses [Abstract] Total liabilities Liabilities Geographical [Axis] Geographical [Axis] Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Sale leaseback, term of lease Sale Leaseback, Term Of Lease Sale Leaseback, Term Of Lease Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Revolving Credit Facility Revolving Credit Facility [Member] Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Accounting Standards Update and Change in Accounting Principle [Abstract] Accounting Standards Update and Change in Accounting Principle [Abstract] Preferred stock, issued (in shares) Preferred Stock, Shares Issued Document Type Document Type Weighted average exercise price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Canceled and forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Segments [Axis] Segments [Axis] CREDIT AGREEMENT Debt Disclosure [Text Block] Entity Shell Company Entity Shell Company Annual fee Debt Instrument, Annual Fee, Percent Debt Instrument, Annual Fee, Percent Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities Debt Instrument, Prepayment Period Three Debt Instrument, Prepayment Period Three [Member] Debt Instrument, Prepayment Period Three At-The-Market Facility At-The-Market Facility [Member] At-The-Market Facility 2026 Long-Term Debt, Maturity, Year Three Consolidation Items [Domain] Consolidation Items [Domain] Subsequent Event Subsequent Event [Member] Document Period End Date Document Period End Date Accrued payroll Accrued Salaries, Current Accrued product warranties Product Warranty Accrual, Current Property and equipment in service Property, Plant And Equipment, In Service Property, Plant And Equipment, In Service Total assets Assets Default, applicable interest rate Debt Instrument, Default, Applicable Interest Rate Debt Instrument, Default, Applicable Interest Rate Debt Disclosure [Abstract] Debt Disclosure [Abstract] Loss per share: Earnings Per Share [Abstract] Sales tax payable Sales and Excise Tax Payable, Current Antidilutive Securities [Axis] Antidilutive Securities [Axis] Debt Instrument, Prepayment Period [Domain] Debt Instrument, Prepayment Period [Domain] Debt Instrument, Prepayment Period [Domain] Schedule of Accounts Payable and Accrued Liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Beginning balance (in shares) Ending balance (in shares) Shares, Issued Term loan, net Long-Term Debt, Current Maturities Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Line of Credit Line of Credit [Member] Debt Instrument, Covenant, Tranche Three Debt Instrument, Covenant, Tranche Three [Member] Debt Instrument, Covenant, Tranche Three Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest EQUITY Stockholders' Equity Attributable to Parent [Abstract] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Segments [Domain] Segments [Domain] Amortization of debt discounts Amortization of Debt Issuance Costs and Discounts EARNINGS (LOSS) PER SHARE Earnings Per Share [Text Block] INTEREST IN JOINT VENTURE INVESTMENT Noncontrolling Interest Disclosure [Text Block] Schedule of option fair value assumptions Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Long-term finance lease liabilities Finance Lease, Liability, Noncurrent Accrued commissions Accrued Sales Commission, Current Credit Agreement Credit Agreement [Member] Credit Agreement Securities registered, new issues Securities Registered, New Issues Securities Registered, New Issues Related Party Transaction [Line Items] Related Party Transaction [Line Items] Warrants Class of Warrant or Right, Number of Securities Called by Warrants or Rights Uncertain tax positions Uncertain Tax Positions Liability Uncertain Tax Positions Liability Income tax receivables Income Taxes Receivable, Current Finished goods Inventory, Finished Goods, Gross Borrowing base, minimum balance Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Percent Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Percent Gross profit Gross Profit Sale leaseback. annual rent payment Sale Leaseback. Annual Rent Payment Sale Leaseback. Annual Rent Payment Entity Registrant Name Entity Registrant Name Shares issued on net settlement of stock options (in shares) Stock swap to acquire options, Shares Stock swap to acquire options shares. Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Other accrued expenses and current liabilities Other Accrued Expenses And Liabilities, Current Other Accrued Expenses And Liabilities, Current Sale leaseback, net cash proceeds Sale Leaseback, Net Cash Proceeds Sale Leaseback, Net Cash Proceeds Entity Address, City or Town Entity Address, City or Town Total equity Beginning balance Ending balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Minimum Minimum [Member] Non-controlling interest Beginning interest in China JV Ending interest in China JV Stockholders' Equity Attributable to Noncontrolling Interest Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Trading Symbol Trading Symbol Entity File Number Entity File Number Long-term contract liabilities Contract with Customer, Liability, Noncurrent Research and development Research and Development Expense Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Accrued product liability claim insurance deductibles Accrued Insurance, Current Debt Instrument, Termination Period [Axis] Debt Instrument, Termination Period [Axis] Debt Instrument, Termination Period Raw materials Inventory, Raw Materials, Gross Accounts payable Increase (Decrease) in Accounts Payable INCOME TAXES Income Tax Disclosure [Text Block] Due to related parties Due to Related Parties Advanced Energy Advanced Energy [Member] Advanced Energy [Member] Credit Facility [Domain] Credit Facility [Domain] Warrants, exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Interest Interest Paid, Excluding Capitalized Interest, Operating Activities Basic (in dollars per share) Earnings Per Share, Basic Assets held for sale Assets Held-for-sale, Not Part of Disposal Group, Current Security deposit equal to annual rent Sale Leaseback, Security Deposit Equal To Annual Rent Sale Leaseback, Security Deposit Equal To Annual Rent Construction in progress Construction in Progress, Gross Purchase agreement Sale Leaseback, Purchase Agreement Sale Leaseback, Purchase Agreement Corporate & Other Corporate, Non-Segment [Member] Twelve month net revenue target, year one Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year One Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year One Inventories Inventory, Policy [Policy Text Block] Total stockholders' equity Stockholders' Equity Attributable to Parent Ownership [Domain] Ownership [Domain] Entity Interactive Data Current Entity Interactive Data Current Noncontrolling Interest [Line Items] Noncontrolling Interest [Line Items] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Twelve month net revenue target, year two Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Two Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Two Accumulated Deficit Retained Earnings [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Common Stock Common Stock [Member] Number of reportable segments Number of Reportable Segments Statement [Table] Statement [Table] Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Document Quarterly Report Document Quarterly Report Furniture and fixtures Furniture and Fixtures [Member] Current assets: Assets, Current [Abstract] Long-term operating lease liabilities Operating Lease, Liability, Noncurrent Statistical Measurement [Axis] Statistical Measurement [Axis] Chinese Supplier Chinese Supplier [Member] Chinese Supplier Molds Molds [Member] Molds Related Party Transaction [Axis] Related Party Transaction [Axis] Leasehold improvements Leasehold Improvements [Member] Accumulated deficit Retained Earnings (Accumulated Deficit) Trade accounts receivable, net of allowance of $359 and $668 Accounts Receivable, after Allowance for Credit Loss, Current Equity Components [Axis] Equity Components [Axis] Litigation Case [Domain] Litigation Case [Domain] RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Statement [Line Items] Statement [Line Items] Warrants term Warrants and Rights Outstanding, Term Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward] Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward] Variable Rate [Domain] Variable Rate [Domain] Selling, general and administrative Selling, General and Administrative Expense RECENT ACCOUNTING PRONOUNCEMENTS Accounting Standards Update and Change in Accounting Principle [Text Block] Loss Contingencies [Table] Loss Contingencies [Table] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Salaries and related costs Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold Document Transition Report Document Transition Report Local Phone Number Local Phone Number Summary of stock options and stock awards Share-Based Payment Arrangement, Option, Activity [Table Text Block] Loss from operations Loss from operations Income (loss) from operations Operating Income (Loss) Inventories Increase (Decrease) in Inventories Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Debt Instrument, Termination Period One Debt Instrument, Termination Period One [Member] Debt Instrument, Termination Period One Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Debt Instrument, Covenant, Tranche Two Debt Instrument, Covenant, Tranche Two [Member] Debt Instrument, Covenant, Tranche Two Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Gross inventories Inventory, Gross Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Contributions from non-controlling interest Noncontrolling Interest, Increase from Subsidiary Equity Issuance Number of monthly payments Debt Instrument, Number Of Monthly Payments Debt Instrument, Number Of Monthly Payments Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Income tax (benefit) expense Income tax expense (benefit) Income tax (benefit) expense Income Tax Expense (Benefit) Geographical [Domain] Geographical [Domain] Debt Instrument, Covenants [Domain] Debt Instrument, Covenants [Domain] Debt Instrument, Covenants [Domain] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Income Statement [Abstract] Income Statement [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Additional Paid-In Capital Additional Paid-in Capital [Member] Document Fiscal Period Focus Document Fiscal Period Focus Loss per share: Earnings Per Share, Basic [Abstract] Twelve month net revenue target, year three Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Three Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Three Cost of sales Cost of Goods and Services Sold Weighted average shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Accumulated depreciation and amortization Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Schedule of inventory Schedule of Inventory, Current [Table Text Block] International sales, percent of total revenue Total Revenue, Percent Total Revenue, Percent Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Debt Instrument, Termination Period Two Debt Instrument, Termination Period Two [Member] Debt Instrument, Termination Period Two Loss Contingencies [Line Items] Loss Contingencies [Line Items] Building and improvements Building and Building Improvements [Member] Debt issuance costs Debt Issuance Costs, Gross Common stock, $0.001 par value; 75,000,000 shares authorized; 34,597,822 issued and outstanding as of March 31, 2023 and December 31, 2022 Common Stock, Value, Issued Cash and cash equivalents balance Debt Instrument, Covenant, Cash And Cash Equivalents Balance Debt Instrument, Covenant, Cash And Cash Equivalents Balance Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Other loss, net Other income (loss), net Other Operating Income (Expense), Net Operating Segments Operating Segments [Member] Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Accrued bonuses Accrued Bonuses, Current Net loss attributable to non-controlling interest Net loss attributable to Apyx Net Income (Loss) Attributable to Noncontrolling Interest COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Proceeds received from issuance of warrants Adjustments to Additional Paid in Capital, Warrant Issued Current liabilities: Liabilities, Current [Abstract] Net loss attributable to stockholders, basic Net Income (Loss) Available to Common Stockholders, Basic Proceeds from term loan Proceeds from Issuance of Long-Term Debt Common stock, shares issued (in shares) Common Stock, Shares, Issued Adjusted Term Secured Overnight Financing Rate (SOFR) Adjusted Term Secured Overnight Financing Rate (SOFR) [Member] Adjusted Term Secured Overnight Financing Rate (SOFR) Short-term contract liabilities Contract with Customer, Liability, Current Debt Instrument, Prepayment Period [Axis] Debt Instrument, Prepayment Period [Axis] Debt Instrument, Prepayment Period Current portion of finance lease liabilities Finance Lease, Liability, Current Interest rate floor Debt Instrument, Interest Rate Floor, Percent Debt Instrument, Interest Rate Floor, Percent Amendment Flag Amendment Flag Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Professional services Professional Fees Mortgage loan, principal amount Debt Instrument, Face Amount New claims filed Loss Contingency, New Claims Filed, Number Litigation Case [Axis] Litigation Case [Axis] Schedule of reporting information by segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Entity Current Reporting Status Entity Current Reporting Status Other assets Other Assets, Noncurrent Computer equipment and software Computer Equipment And Software [Member] Computer Equipment And Software Purchases from related party Related Party Transaction, Purchases from Related Party Depreciation and amortization Depreciation, Depletion and Amortization Repayment of finance lease liabilities Repayment of Finance Lease Liabilities Repayment of Finance Lease Liabilities Outstanding, beginning of period (in shares) Outstanding, end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Effect of exchange rates on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Interest rate floor spread Debt Instrument, Interest Rate Floor Spread Adjustment, Percent Debt Instrument, Interest Rate Floor Spread Adjustment, Percent Inventories, provision for obsolescence Provision For Obsolescence, Inventory Provision For Obsolescence, Inventory Options Share-Based Payment Arrangement, Option [Member] Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Shares issued on stock options exercises for cash Stock Issued During Period, Value, Stock Options Exercised Term loan, net Long-Term Debt Total other loss, net Other Nonoperating Income (Expense) Common stock, shares authorized (in shares) Common Stock, Shares Authorized Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Corporate Joint Venture Corporate Joint Venture [Member] Exit fee Debt Instrument, Exit Fee Debt Instrument, Exit Fee Total other costs and expenses Operating Expenses Maximum Maximum [Member] Debt Instrument, Termination Period [Domain] Debt Instrument, Termination Period [Domain] Debt Instrument, Termination Period [Domain] Schedule of revenue by geographic area Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Work in process Inventory, Work in Process, Gross Total current assets Assets, Current Prepayment fee Debt Instrument, Prepayment Fee, Percent Debt Instrument, Prepayment Fee, Percent Entity Small Business Entity Small Business Income tax receivables Income tax receivables Increase (Decrease) in Income Taxes Receivable Number of options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT Property, Plant and Equipment Disclosure [Text Block] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Trade receivables Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security BASIS OF PRESENTATION Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Ownership interest Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Payables and Accruals [Abstract] Payables and Accruals [Abstract] Termination fees Debt Instrument, Termination Fees Debt Instrument, Termination Fees Debt Instrument [Line Items] Debt Instrument [Line Items] Shares issued on stock options exercises for cash (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Payment of debt issuance costs Payments of Debt Issuance Costs GEOGRAPHIC AND SEGMENT INFORMATION Segment Reporting Disclosure [Text Block] Share based compensation Share-Based Payment Arrangement [Policy Text Block] Noncontrolling Interest [Table] Noncontrolling Interest [Table] LIABILITIES AND EQUITY Liabilities and Equity [Abstract] Granted (in dollars per share) Strike price (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Canceled and forfeited (in dollars per shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 2023 Long-Term Debt, Maturity, Remainder of Fiscal Year Inventories, net of provision for obsolescence of $428 and $457 Inventories, net Inventory, Net Accounts payable Accounts Payable, Current Unamortized debt discount, including accretion of exit fee Debt Instrument, Unamortized Discount 2027 Long-Term Debt, Maturity, Year Four Warrants Warrant [Member] Entity Filer Category Entity Filer Category Weighted average shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Domestic UNITED STATES Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Costs accrued Loss Contingency Accrual Period of interest only Debt Instrument, Period Of Interest Only Debt Instrument, Period Of Interest Only Stock based compensation Share-Based Payment Arrangement, Expense Security Exchange Name Security Exchange Name Outstanding, beginning of period (in dollars per share) Outstanding, end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Preferred Stock, $0.001 par value; 10,000,000 shares authorized; 0 issued and outstanding as of March 31, 2023 and December 31, 2022 Preferred Stock, Value, Issued Non-cash interest expense Increase (Decrease) in Interest Payable, Net Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Sales Revenue from Contract with Customer, Excluding Assessed Tax Cover [Abstract] Cover [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] STOCK-BASED COMPENSATION Share-Based Payment Arrangement [Text Block] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Allowance for doubtful accounts receivable Accounts Receivable, Allowance for Credit Loss Segment Reporting [Abstract] Segment Reporting [Abstract] Non-controlling Interest Noncontrolling Interest [Member] Risk-free rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Joint and several payroll liability Joint And Several Payroll Liability Joint And Several Payroll Liability Total liabilities and equity Liabilities and Equity Suits Filed in 2022 Suits Filed in 2022 [Member] Suits Filed in 2022 Amortization of debt issuance costs Amortization of Debt Issuance Costs Related Party [Axis] Related Party [Axis] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Land Land [Member] Anti-dilutive instruments excluded from diluted loss per common share: Earnings Per Share, Diluted [Abstract] International Non-US [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Current Fiscal Year End Date Current Fiscal Year End Date Accrued interest and penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accounts Payable and Accrued Liabilities Disclosure [Text Block] Net loss attributable to stockholders, diluted Net Income (Loss) Available to Common Stockholders, Diluted Diluted (in dollars per share) Earnings Per Share, Diluted Sale of Stock [Domain] Sale of Stock [Domain] Loss on disposal of property and equipment Gain (Loss) on Disposition of Property Plant Equipment Co-venturer Co-venturer [Member] Stock based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Consolidation Items [Axis] Consolidation Items [Axis] Total current liabilities Liabilities, Current Schedule of China Joint Venture Noncontrolling Interest [Table Text Block] Noncontrolling Interest Due from related parties Due from Related Parties Suit Against Goodwin And Simb Suit Against Goodwin And Simb [Member] Suit Against Goodwin And Simb Required capital contribution Noncontrolling Interest, Required Capital Contribution Noncontrolling Interest, Required Capital Contribution Entity Address, Address Line One Entity Address, Address Line One Sale leaseback, annual rent increase Sale Leaseback, Annual Rent Increase Sale Leaseback, Annual Rent Increase Remaining borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity Debt Instrument, Termination Period Three Debt Instrument, Termination Period Three [Member] Debt Instrument, Termination Period Three Interest expense Interest Expense Sale leaseback, renewal term Sale Leaseback, Renewal Term Sale Leaseback, Renewal Term Credit Facility [Axis] Credit Facility [Axis] Less: provision for obsolescence Inventory Valuation Reserves INVENTORIES Inventory Disclosure [Text Block] Schedule of Long-Term Debt Instruments Schedule of Long-Term Debt Instruments [Table Text Block] Machinery and equipment Machinery and Equipment [Member] Proceeds from issuance of warrants Proceeds from Issuance of Warrants Other receivables Other Receivables, Net, Current Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Entity Tax Identification Number Entity Tax Identification Number Unamortized debt issuance costs Unamortized Debt Issuance Expense Stock swaps equity instruments received (in shares) Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received Shelf Registration Shelf Registration [Member] Shelf Registration Accrued expenses and other current liabilities Total accrued expenses and other current liabilities Accrued Liabilities and Other Liabilities, Current Accrued Liabilities and Other Liabilities, Current Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] City Area Code City Area Code Accrued professional fees and legal related contingent liabilities Accrued Professional Fees, Current ASSETS Assets [Abstract] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Purchase obligation Purchase Obligation Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Sale of Stock [Axis] Sale of Stock [Axis] Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] 2024 Long-Term Debt, Maturity, Year One Stock based compensation Share-Based Payment Arrangement, Noncash Expense Variable Rate [Axis] Variable Rate [Axis] Other liabilities Other Liabilities, Noncurrent Number of monthly payments, extension Debt Instrument, Number Of Monthly Payments, Extension Debt Instrument, Number Of Monthly Payments, Extension Provision for inventory obsolescence Provision For Inventory Obsolescence Provision For Inventory Obsolescence Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Basic and diluted earnings (loss) per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Extension period Debt Instrument, Extension Period Debt Instrument, Extension Period Debt Instrument, Prepayment Period Two Debt Instrument, Prepayment Period Two [Member] Debt Instrument, Prepayment Period Two Number of positions eliminated Restructuring and Related Cost, Number of Positions Eliminated, Period Percent EX-101.PRE 10 apyx-20230331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 apyx-20230331_g1.jpg begin 644 apyx-20230331_g1.jpg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end XML 12 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover - shares
 3 Months Ended
Mar. 31, 2023
May 10, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2023  
Document Transition Report false  
Entity File Number 0-12183  
Entity Registrant Name APYX MEDICAL CORPORATION  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 11-2644611  
Entity Address, Address Line One 5115 Ulmerton Road,  
Entity Address, City or Town Clearwater  
Entity Address, State or Province FL  
Entity Address, Postal Zip Code 33760  
City Area Code 727  
Local Phone Number 384-2323  
Title of 12(b) Security Common Stock  
Trading Symbol APYX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   34,597,822
Entity Central Index Key 0000719135  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2023  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 16,255 $ 10,192
Trade accounts receivable, net of allowance of $359 and $668 9,966 10,602
Income tax receivables 7,752 7,545
Other receivables 417 99
Inventories, net of provision for obsolescence of $428 and $457 10,946 11,797
Assets held for sale 4,569 0
Prepaid expenses and other current assets 2,779 2,737
Total current assets 52,684 42,972
Property and equipment, net 2,109 6,761
Operating lease right-of-use assets 646 710
Finance lease right-of-use assets 106 115
Other assets 1,239 1,217
Total assets 56,784 51,775
Current liabilities:    
Accounts payable 1,905 2,669
Accrued expenses and other current liabilities 7,626 8,928
Current portion of operating lease liabilities 184 216
Current portion of finance lease liabilities 33 37
Term loan, net 8,778 0
Total current liabilities 18,526 11,850
Long-term operating lease liabilities 448 470
Long-term finance lease liabilities 68 73
Long-term contract liabilities 1,343 1,408
Other liabilities 185 181
Total liabilities 20,570 13,982
EQUITY    
Preferred Stock, $0.001 par value; 10,000,000 shares authorized; 0 issued and outstanding as of March 31, 2023 and December 31, 2022 0 0
Common stock, $0.001 par value; 75,000,000 shares authorized; 34,597,822 issued and outstanding as of March 31, 2023 and December 31, 2022 35 35
Additional paid-in capital 75,235 73,282
Accumulated deficit (39,218) (35,735)
Total stockholders' equity 36,052 37,582
Non-controlling interest 162 211
Total equity 36,214 37,793
Total liabilities and equity $ 56,784 $ 51,775
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts receivable $ 359 $ 668
Inventories, provision for obsolescence 428 457
Accumulated depreciation and amortization $ 3,387 $ 5,041
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, authorized (in shares) 10,000,000 10,000,000
Preferred stock, outstanding (in shares) 0 0
Preferred stock, issued (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 75,000,000 75,000,000
Common stock, shares issued (in shares) 34,597,822  
Common stock, shares outstanding (in shares) 34,597,822  
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]    
Sales $ 12,142 $ 12,493
Cost of sales 4,569 4,274
Gross profit 7,573 8,219
Other costs and expenses:    
Research and development 1,121 1,158
Professional services 1,740 2,286
Salaries and related costs 5,068 5,181
Selling, general and administrative 5,255 5,465
Total other costs and expenses 13,184 14,090
Loss from operations (5,611) (5,871)
Interest income 51 2
Interest expense (234) (8)
Other loss, net (5) (21)
Total other loss, net (188) (27)
Loss before income taxes (5,799) (5,898)
Income tax (benefit) expense (2,267) 70
Net loss (3,532) (5,968)
Net loss attributable to non-controlling interest (49) (23)
Net loss attributable to stockholders $ (3,483) $ (5,945)
Loss per share:    
Basic (in dollars per share) $ (0.10) $ (0.17)
Diluted (in dollars per share) $ (0.10) $ (0.17)
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Non-controlling Interest
Beginning balance (in shares) at Dec. 31, 2021   34,410      
Beginning balance at Dec. 31, 2021 $ 54,009 $ 34 $ 66,221 $ (12,551) $ 305
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Shares issued on stock options exercises for cash (in shares)   24      
Shares issued on stock options exercises for cash 152   152    
Stock based compensation 1,650   1,650    
Shares issued on net settlement of stock options (in shares)   19      
Net loss (5,968)     (5,945) (23)
Ending balance (in shares) at Mar. 31, 2022   34,453      
Ending balance at Mar. 31, 2022 49,843 $ 34 68,023 (18,496) 282
Beginning balance (in shares) at Dec. 31, 2022   34,598      
Beginning balance at Dec. 31, 2022 37,793 $ 35 73,282 (35,735) 211
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock based compensation 1,367   1,367    
Proceeds received from issuance of warrants 586   586    
Net loss (3,532)     (3,483) (49)
Ending balance (in shares) at Mar. 31, 2023   34,598      
Ending balance at Mar. 31, 2023 $ 36,214 $ 35 $ 75,235 $ (39,218) $ 162
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Jan. 31, 2023
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Cash flows from operating activities        
Net loss   $ (3,532) $ (5,968)  
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation and amortization   203 225  
Provision for inventory obsolescence   0 85  
Loss on disposal of property and equipment   0 26  
Stock based compensation   1,367 1,650  
Provision for allowance for doubtful accounts   (142) 140  
Non-cash interest expense   67 0  
Changes in operating assets and liabilities:        
Trade receivables   837 475  
Prepaid expenses and other assets   858 649  
Income tax receivables $ (200) (207) 0  
Inventories   879 (371)  
Accounts payable   (776) (51)  
Accrued expenses and other liabilities   (1,435) (1,378)  
Net cash used in operating activities   (1,881) (4,518) $ (20,300)
Cash flows from investing activities        
Purchases of property and equipment   (110) (279)  
Net cash used in investing activities   (110) (279)  
Cash flows from financing activities        
Proceeds from stock option exercises   0 152  
Proceeds from term loan   9,289 0  
Payment of debt issuance costs   (1,754) 0  
Proceeds from issuance of warrants   586 0  
Repayment of finance lease liabilities   (9) (54)  
Net cash provided by financing activities   8,112 98  
Effect of exchange rates on cash   (58) 63  
Net change in cash and cash equivalents   6,063 (4,636)  
Cash and cash equivalents, beginning of period $ 10,192 10,192 30,870 30,870
Cash and cash equivalents, end of period   16,255 26,234 $ 10,192
Cash paid for:        
Interest   1 8  
Income taxes   $ 125 $ 0  
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.23.1
BASIS OF PRESENTATION
 3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BASIS OF PRESENTATION BASIS OF PRESENTATION
Apyx Medical Corporation (“Company”, “Apyx”, “it” and similar terms) was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 5115 Ulmerton Road, Clearwater, FL 33760.

The Company is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Technology products marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion® and J-Plasma® offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers.

As part of its plan to accelerate and fully fund the development of its advanced energy business, with a focus in the cosmetic surgery market, the Company sold its Core business in 2018 for gross proceeds of $97 million. These proceeds were used to launch broad marketing and sales initiatives which resulted in rapid sales growth through December 31, 2021 and into the first quarter of 2022. This planned growth in the business was accompanied by scaled operations, including procurement of components, expanded manufacturing capacity to turn those materials into saleable inventory, additional discretionary expenditures, including increased global participation at trade shows, additional employee trainings, user meetings, increased travel and entertainment expenses, more expansive research and development projects, and additional headcount to support those activities. Additionally, the Company had, and still has, some significant non-recurring discretionary expenditures associated with completing its multi-year marketing initiatives related to its dermal resurfacing and skin laxity clearances.

On March 14, 2022, the U.S. Food and Drug Administration (“FDA”) posted a Medical Device Safety Communication (“Safety Communication”). The FDA warned against the use of Renuvion/J-Plasma for procedures intended to improve the appearance of the skin through dermal resurfacing (a procedure on the skin to treat wrinkles) or skin contraction (a procedure under the skin that can be performed either alone or in combination with liposuction to achieve skin effects, such as “tightening”). At that time, the Renuvion/J-Plasma device system was FDA cleared for general use of cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures. The use of the device had not been determined to be safe or effective for any aesthetic skin procedures (procedures intended to improve the appearance of the skin). Following the Safety Communication, the Company experienced slowed demand for the adoption of its Helium Plasma Technology.

On May 26, 2022, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion® Dermal Handpiece for certain dermal resurfacing procedures, specifically, for the treatment of moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick Skin Types I, II or III.

On June 2, 2022, the FDA updated the Safety Communication to inform consumers and healthcare providers about the new 510(k) clearance for the Renuvion® device system for certain dermal resurfacing procedures.

On July 18, 2022, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for use in subcutaneous dermatological and aesthetic procedures to improve the appearance of lax (loose) skin in the neck and submental (under the chin) region.

On July 21, 2022, the FDA updated the Safety Communication to inform consumers and healthcare providers about the clearance for the Renuvion® APR handpieces for use under the skin in certain procedures intended to improve the appearance of loose skin.

On February 27, 2023, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. Soft tissue includes subcutaneous tissue.

On April 28, 2023, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring.

On May 10, 2023, the FDA updated the Safety Communication to inform consumers and healthcare providers about the clearance for the Renuvion® APR handpiece for use under the skin in certain procedures intended to improve the appearance of the skin, including for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring.
Management believes that the May 10, 2023 FDA update to the Safety Communication addresses the issues set forth in the original Safety Communication from March 14, 2022. While no assurances can be provided, management believes that receiving these additional clearances and the corresponding updates to the Safety Communication since March 14, 2022 should mitigate the financial effects of the Safety Communication in future periods.

The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue in operation one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business.

Pursuant to the requirements of the Financial Accounting Standards Board’s Accounting Standards Codification (“ASC”) Topic 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for one year from the date these unaudited condensed consolidated financial statements are issued. This evaluation does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented or are not within control of the Company as of the date the unaudited condensed consolidated financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued.

While sales were continuing to grow into the first quarter of 2022 prior to the FDA Safety Communication, over the last few years, exclusive of the Company’s sale of the Core business segment to Symmetry Surgical during 2018, the Company has incurred recurring net losses and cash outflows from operations and the Company anticipates that losses will continue in the near term. During the year ended December 31, 2022, the Company incurred an operating loss of $23.6 million and used $20.3 million of cash in operations. During the three months ended March 31, 2023, the Company incurred an operating loss of $5.6 million and used $1.9 million of cash in operations. As of March 31, 2023, the Company had cash and cash equivalents of $16.3 million, of which the Company must maintain $10.0 million under its Credit Agreement. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements.

In an effort to alleviate these conditions, the Company pursued various funding solutions in order to improve liquidity.

On November 22, 2022, the Company filed a shelf registration statement providing it the ability to register securities in the aggregate amount up to $100 million. The shelf registration included an embedded ATM facility for up to $40 million. To date, the Company has not utilized this facility.

On February 17, 2023, the Company entered into a Credit, Security and Guaranty Agreement (the “Credit Agreement”) with MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time.

The Credit Agreement provides for an up to $35 million facility, consisting of senior secured term loans and a secured revolving facility. The Credit Agreement provides for senior secured term loans of up to $25 million, comprised of (i) an initial tranche of $10 million, (ii) a second tranche of $5 million, and (iii) a third tranche of $10 million. The secured revolving facility provides for loans in an aggregate principal amount of up to $10 million, subject to a borrowing base equal to certain percentages of the Company’s eligible accounts receivable and inventory, as determined in accordance with the terms of the Credit Agreement.

For a more in depth description of the terms of the Credit Agreement, see Note 6.

On February 27, 2023, the Company’s Board of Directors approved a plan to sell and leaseback the Company’s real property located in Clearwater, FL. On March 14, 2023, the Company entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with VK Acquisitions VI, LLC (the “Purchaser”), for the sale of the Company’s facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the “Property”) for a purchase price
of $7,650,000. On May 8, 2023, the Company closed on the Purchase Agreement and concurrently executed a 10-year agreement to leaseback the underlying Property from the Purchaser.

For a more in depth description of the terms of the Purchase Agreement, see Note 4.

During January 2023, the Company was notified that the IRS examination process of our 2018, 2019 and 2020 tax returns was complete and that the Company’s tax refunds were approved for approximately $0.2 million more than the amount recorded in the Company’s Consolidated Balance Sheet at December 31, 2022. As of the date of this report, the Company is awaiting receipt of the tax refunds.

The Company also continues to re-assess its operating expenditures and cost structure to be commensurate with expected levels of revenue and management has the ability to reduce or delay expenditures to enhance and preserve liquidity. Management has already reduced some operating expenditures, including a reduction-in-force on January 9, 2023, that reduced the Company’s U.S. headcount by 14%.

Management believes that the actions already taken, and additional actions that it intends to take to manage operating expenditures, will enable the Company to meet its obligations and its debt covenants for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements. As a result, management believes its plans alleviate substantial doubt about the Company’s ability to continue as a going concern. These unaudited condensed consolidated financial statements do not include any adjustments relating to the carrying amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.23.1
RECENT ACCOUNTING PRONOUNCEMENTS
 3 Months Ended
Mar. 31, 2023
Accounting Standards Update and Change in Accounting Principle [Abstract]  
RECENT ACCOUNTING PRONOUNCEMENTS RECENT ACCOUNTING PRONOUNCEMENTS
In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments—Credit Losses (Topic 326). The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company adopted the new standard on January 1, 2023 and its impact was not material to the Company.

No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.23.1
INVENTORIES
 3 Months Ended
Mar. 31, 2023
Inventory Disclosure [Abstract]  
INVENTORIES INVENTORIES
Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours.

Inventories consisted of the following:
(In thousands)March 31,
2023		December 31,
2022
Raw materials$4,388 $4,979 
Work in process2,331 2,160 
Finished goods 4,655 5,115 
Gross inventories11,374 12,254 
Less: provision for obsolescence(428)(457)
Inventories, net$10,946 $11,797 
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.23.1
ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT
 3 Months Ended
Mar. 31, 2023
Property, Plant and Equipment [Abstract]  
ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT
(In thousands)March 31, 2023
(Unaudited)		December 31,
2022
Land$— $1,600 
Building and improvements16 4,426 
Machinery and equipment2,472 2,613 
Furniture and fixtures213 211 
Computer equipment and software1,230 1,420 
Leasehold improvements178 178 
Molds847 847 
Total property, plant and equipment4,956 11,295 
Less: accumulated depreciation and amortization(3,387)(5,041)
Property and equipment in service1,569 6,254 
Construction in progress540 507 
Property and equipment, net$2,109 $6,761 
Assets held for sale$4,569 $— 

In an effort to improve liquidity and the balance sheet condition of the Company, management has been exploring options to leverage the Company’s unencumbered real property. On February 27, 2023, the Company’s Board of Directors approved a plan to sell and leaseback the Company's real property located in Clearwater, FL.

On March 14, 2023, the Company entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with VK Acquisitions VI, LLC (the “Purchaser”), for the sale of the Company’s facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the “Property”) for a purchase price of $7,650,000.
In accordance with the requirements of ASC Topic 360, Property, Plant, and Equipment, the Company has determined that the real property to be sold meets the requirements to be presented as held for sale. Accordingly, the Company has presented the associated assets as held for sale in the accompanying unaudited condensed consolidated balance sheet and the table above at March 31, 2023.

In accordance with the terms of the Purchase Agreement, upon the closing of the sale of the Property, the Company will enter into a Single Tenant Industrial Building Lease (the “Lease”) with the Purchaser, pursuant to which the Property will be leased back to the Company. The Lease will have an initial term of ten (10) years commencing from the closing (the “Initial Term”), and a renewal term of five (5) years, exercisable at the Company’s option. The annual fixed rent will be $619,500 for the first year of the Initial Term, and will be subject to a 4% escalation every year thereafter through the Initial Term. Rent will be reset to the current market rate should the Company exercise the renewal option. The Lease provides for a 3% management fee on rent payments throughout the Initial Term and optional renewal term.

The Lease is a triple net lease, pursuant to which all costs, expenses, and obligations relating to the Property, including, repair and maintenance charges, utility charges, real estate taxes or other taxes that may be imposed that relate to the Property, shall be paid by the Company. In addition, the Lease contains other customary terms and provisions generally contained within leases of this type.
On May 8, 2023, the Company closed on the Purchase Agreement and concurrently executed a 10-year agreement to leaseback the underlying Property from the Purchaser. The Company received net cash proceeds of approximately $6,600,000, after withholding the security deposit equal to one years rent, taxes, first months rent, expenses, and fees. The Company anticipates that the net cash proceeds will be used to strengthen its balance sheet and provide working capital to its operations.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.23.1
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
 3 Months Ended
Mar. 31, 2023
Payables and Accruals [Abstract]  
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
Accrued expenses and other current liabilities consisted of the following:
(in thousands)March 31,
2023		December 31,
2022
Accrued payroll$848 $563 
Accrued bonuses570 — 
Accrued commissions790 847 
Accrued product warranties368 391 
Accrued product liability claim insurance deductibles1,794 1,825 
Accrued professional fees and legal related contingent liabilities924 901 
Short-term contract liabilities1,053 853 
Joint and several payroll liability345 345 
Uncertain tax positions— 2,079 
Sales tax payable211 245 
Other accrued expenses and current liabilities723 879 
Total accrued expenses and other current liabilities$7,626 $8,928 
During April 2023, the Company was relieved of the remainder of its joint and several payroll liability due to the lapse of the statute of limitations on the liability.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.23.1
CREDIT AGREEMENT
 3 Months Ended
Mar. 31, 2023
Debt Disclosure [Abstract]  
CREDIT AGREEMENT CREDIT AGREEMENTOn February 17, 2023, the Company entered into a Credit, Security and Guaranty Agreement (the “Credit Agreement”), by and among the Company (as borrower) and Apyx China Holding Corp., the Company’s wholly-owned subsidiary (as guarantor), and MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time (collectively “MidCap”).
The Credit Agreement provides for an up to $35 million facility, consisting of senior secured term loans and a secured revolving facility. The Credit Agreement provides for senior secured term loans of up to $25 million, comprised of (i) an initial tranche of $10 million, (ii) a second tranche of $5 million, and (iii) a third tranche of $10 million. The secured revolving facility provides for loans in an aggregate principal amount of up to $10 million, subject to a borrowing base equal to percentages of eligible accounts receivable and inventory determined in accordance with the Credit Agreement. The Credit Agreement matures on February 1, 2028.

Term Loans

The initial tranche of $10 million was fully funded on February 17, 2023 less transaction costs. Subject to certain terms and conditions of the Credit Agreement, the second tranche would be available between June 30, 2023 and December 31, 2023 and the third tranche would be available between January 1, 2024 and September 30, 2024, respectively. The Company’s ability to access these additional tranches is conditioned upon, among other things, the achievement of certain minimum revenue targets.

Each term loan bears interest at a floating rate reset monthly based on an adjusted one month SOFR plus 0.1%, subject to a floor of 2.5%, plus 7.35% calculated on a 360 day basis (12.1% at March 31, 2023). Interest is payable monthly in arrears on the first day of each month.

The first twenty-four (24) months of the term loans constitute an interest-only period (with a possible twelve (12) month extension). Subsequent to the interest-only period, the outstanding principal amount of the term loans is repayable in thirty-six (36) equal monthly payments (or twenty-four (24) with the extension). All remaining outstanding principal, together with all accrued and unpaid interest, is due at maturity on February 1, 2028. The term loans may be voluntarily prepaid in full, or in part, at any time, subject to terms and conditions set forth in the Credit Agreement. Additionally, the term loans are subject to mandatory prepayment fees, pursuant to the terms of the Credit Agreement. Prepayments of the term loans are subject to fees of 3%, 2%, and 1% of the prepayment amounts made during the first year, second year, and thereafter, respectively. At the time of the final payment of the term loans, the Company is also obligated to pay an exit fee of 4% of the total amount funded thereunder. The exit fee is being accreted over the life of the Credit Agreement utilizing the effective interest method.

As the Credit Agreement contains a subjective acceleration clause and the Company has experienced recurring losses, outstanding borrowings have been presented as a current liability in the accompanying condensed consolidated balance sheet at March 31, 2023.

Revolving Facility

The Company may borrow, repay and reborrow under the revolving facility until February 1, 2028, at which time the facility will terminate and all outstanding amounts thereunder, including all accrued and unpaid interest, must be repaid. Borrowings are limited to the lesser of the Company’s borrowing base and the revolving commitment of $10,000,000.

In connection with the revolving facility, the Company is required to maintain a lockbox account for the benefit of MidCap. Funds deposited into the lockbox account will be swept daily to MidCap and applied to outstanding borrowings under the revolving agreement 5 days after the receipt of the funds by MidCap. Any balances in excess of the revolving borrowings will be promptly returned to the Company.

Loans made under the revolving facility bear interest at a floating rate based on an adjusted one month SOFR plus 0.1%, subject to a floor of 2.5%, plus 4.00% calculated on a 360 day basis (8.8% at March 31, 2023). The Company is obligated to pay a fee equal to 0.5% per annum on the outstanding balance of the revolving loans and the average unused portion of the available revolving commitments, respectively. Additionally, if the revolving facility is terminated or reduced before maturity, the Company is subject to a deferred origination fee. Terminations and reductions of the commitments are subject to fees of 3%, 2%, and 1% of the terminated or reduced commitments during the first year, second year, and thereafter, respectively. The Company is also required to maintain a minimum balance of 30% of the lesser of the borrowing base or $10 million under the revolving facility. If the average outstanding balance for a month is less than the minimum balance, the Company will pay a minimum balance fee for the difference between the minimum balance and the average outstanding balance for the month at the highest rate for the revolving loans during the month. For such loans, interest and fees are payable monthly on the first day of each month.

As of March 31, 2023, the Company has drawn no amounts on the revolving facility. As of March 31, 2023, the Company had approximately $5,700,000 available to be drawn on the revolving facility. As the Credit Agreement contains a subjective acceleration clause and the Company is required to maintain a lockbox, any amounts drawn on the revolving facility will be presented as a current liability in the consolidated financial statements.
Collateral

The obligations of the Company under the Credit Agreement are secured by first priority liens on substantially all of its assets.

Covenants

The Credit Agreement contains customary affirmative and negative covenants, including covenants limiting the ability of the Company and its subsidiaries, among other things, to incur debt, grant liens, make distributions, enter certain restrictive agreements, pay or modify subordinated debt, dispose of assets, make investments and acquisitions, enter into certain transactions with affiliates, and undergo certain fundamental changes, in each case, subject to limitations and exceptions.

The Credit Agreement also requires the Company to satisfy certain financial covenants, including minimum trailing twelve (12) month net revenue targets relating to its Advanced Energy segment (tested quarterly), with year-end targets of $49 million, $60 million and $70 million for 2023, 2024, and 2025, respectively. Additionally, the Company must maintain a balance of $10 million in cash and cash equivalents during the duration of the Credit Agreement’s term.

As of March 31, 2023, the Company was in compliance with the financial covenants contained within the Credit Agreement.

Events of Default

The Credit Agreement also contains customary Events of Default that include, among other things, certain payment defaults, cross defaults to certain other contracts and indebtedness, covenant defaults, inaccuracy of representations and warranties, bankruptcy and insolvency defaults, judgment defaults, change of control defaults, defaults related to the failure to remain registered with the Securities and Exchange Commission and listed for trading on the Nasdaq Stock Market, and any material adverse change.

Upon the occurrence and during the continuance of an Event of Default under the Credit Agreement, the respective administrative agent, if requested by the respective lenders, may, among other things, (i) suspend or terminate commitments, as well as obligations of the relevant administrative agent and lenders, (ii) declare all outstanding obligations under the agreement (including principal and accrued and unpaid interest) immediately due and payable, and (iii) exercise the other rights and remedies provided for under the agreement. The Credit Agreement provides that, under certain circumstances, a default interest rate will apply on all obligations under such agreement during the existence of an Event of Default, at a per annum rate equal to 2% in excess of the applicable interest rate.

The Company bifurcated a derivative liability related to the potential acceleration triggered upon an event of default (contingent put option) and the supplemental interest upon an event of default features of the Credit Agreement. The bifurcated derivative is de minimis to the Company's unaudited condensed consolidated financial statements.

Issuance of Warrants

In connection with the Company’s obligations under the Credit Agreement, the Company issued to a statutory trust of MidCap Financial warrants to purchase up to 250,000 shares of its common stock, par value $0.001, with an exercise price of $3.40 per share.

The warrants have a 10 year term and can be exercised by issuing payment to the Company for the number of warrants exercised or exercised net by surrendering warrants with an intrinsic value equal to the cumulative exercise price of the warrants being exercised.

The Company determined that these warrants meet the criteria for equity classification and included the proceeds allocated to the warrants, on a relative fair value basis, as a debt discount and additional paid-in capital in the accompanying condensed consolidated financial statements.

Debt Issuance Costs

In connection with entering into the Credit Agreement, the Company incurred debt issuance costs of approximately $1.8 million, comprised primarily of commissions paid to the financial advisor. These costs were allocated to the issued and unissued term loans and the revolving facility. The costs allocated to the issued term loan will be amortized using the effective interest method over the life of the loan. The costs allocated to the unissued term loans have been deferred and will be amortized over the life of the term loans starting at the issuance date. If these loans are not issued, the Company will recognize
the deferred costs at the point that the Company's rights to borrow on the term loans expires. The costs allocated to the revolving facility will be recognized on a straight-line basis over the term of the Credit Agreement.

The costs allocated to the issued term loan have been presented as a reduction of the term loan in the accompanying unaudited condensed consolidated balance sheet. The costs allocated to the unissued term loans and the revolving facility have been presented in prepaid expenses and other current assets in the accompanying unaudited condensed consolidated balance sheet.

Included in interest expense for the three months ended March 31, 2023 are $17,000 and $37,000, respectively, of amortization of the debt issuance costs and amortization of the debt discounts including accretion of the exit fee on the term loan. Included in interest expense for the three months ended March 31, 2023 are $12,000 and $1,000, respectively, of amortization of the debt issuance costs and amortization of the debt discount on the revolving facility.

The Company’s term loan, net consists of the following at March 31, 2023:

(In thousands)March 31, 2023
Term loan$10,000 
Unamortized debt issuance costs(485)
Unamortized debt discount, including accretion of exit fee(737)
Term loan, net$8,778 

As of March 31, 2023, principal repayments on the term loan are as follows:

(In thousands)
2023$— 
2024— 
20252,778 
20263,333 
20273,333 
Thereafter556 
Total repayments$10,000 
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.23.1
INTEREST IN JOINT VENTURE INVESTMENT
 3 Months Ended
Mar. 31, 2023
Noncontrolling Interest [Abstract]  
INTEREST IN JOINT VENTURE INVESTMENT INTEREST IN JOINT VENTURE INVESTMENT
In 2019, the Company executed a joint venture agreement with its Chinese supplier (“China JV”) whereby the Company has a 51% interest. The China JV has been consolidated in these condensed consolidated financial statements. The agreement required the Company to make capital contributions into the newly formed entity of approximately $357,000, of which approximately $203,000 and $154,000, respectively, were contributed during the years ended December 31, 2021 and 2020. As of the date of these condensed consolidated financial statements, the joint venture has not commenced principal operations.

Changes in the Company’s ownership investment in the China JV were as follows:

Three Months Ended March 31,
(In thousands)20232022
Beginning interest in China JV$219 $317 
Net loss attributable to Apyx(51)(23)
Ending interest in China JV$168 $294 
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.23.1
EARNINGS (LOSS) PER SHARE
 3 Months Ended
Mar. 31, 2023
Earnings Per Share [Abstract]  
EARNINGS (LOSS) PER SHARE EARNINGS (LOSS) PER SHARE
Basic earnings (loss) per share (“basic EPS”) is computed by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period. Diluted earnings (loss) per share (“diluted EPS”) gives effect to all dilutive potential shares outstanding. As the Company is in a net loss position for all periods presented, all potential shares outstanding are anti-dilutive. The following table provides the computation of basic and diluted loss per share.
Three Months Ended
March 31,
(in thousands, except per share data)20232022
Numerator:
Net loss attributable to stockholders$(3,483)$(5,945)
Denominator:
Weighted average shares outstanding - basic and diluted
34,598 34,429 
Loss per share:
Basic and diluted$(0.10)$(0.17)
Anti-dilutive instruments excluded from diluted loss per common share:
Options7,783 6,796 
Warrants250 — 
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.23.1
STOCK-BASED COMPENSATION
 3 Months Ended
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION
Under the Company's stock option plans, the Board of Directors may grant restricted stock and options to purchase common shares to the Company's employees, officers, directors and consultants. The Company accounts for stock options in accordance with FASB ASC Topic 718, Compensation - Stock Compensation, with stock-based compensation expense recognized over the vesting period based on the grant date fair value utilizing the Black Scholes model, which includes a number of estimates that affect the grant date fair value and the amount of expense to recognize.

The Company recognized approximately $1,367,000 in stock-based compensation expense for the three months ended March 31, 2023, as compared with $1,650,000 for the three months ended March 31, 2022.

Stock option activity is summarized as follows:
Number of optionsWeighted average exercise price
Outstanding at December 31, 2022
6,520,444 $7.12 
Granted1,408,865 2.50 
Exercised— — 
Canceled and forfeited(146,164)8.08 
Outstanding at March 31, 2023
7,783,145 $6.27 

The Company allows stock option holders to exercise stock-based awards by surrendering stock-based awards with an intrinsic value equal to the cumulative exercise price of the stock-based awards being exercised, referred to as net settlements. These surrenders are included in stock options exercised in the options rollforward above. For the three months ended March 31, 2022, we received 22,654 options as payment in the exercise of 19,013 options. There were no such exercises for the three months ended March 31, 2023.

Common shares required to be issued upon the exercise of stock options would be issued from authorized and unissued shares. The Company calculated the grant date fair value of options granted in 2023 (“2023 Grants”) utilizing a Black Scholes model.
2023 Grants
Strike price$2.50
Risk-free rate3.6%
Expected dividend yield—
Expected volatility85.8%
Expected term (in years)6
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.23.1
INCOME TAXES
 3 Months Ended
Mar. 31, 2023
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES Income tax (benefit) expense was approximately $(2,267,000) and $70,000 with effective tax rates of 39.1% and (1.2)% for the three months ended March 31, 2023 and 2022, respectively. For the three months ended March 31, 2023, the effective rate differs from the statutory rate primarily due to the reversal of the Company’s liability for uncertain tax positions, including accrued interest and penalties of approximately $2.1 million which were sustained upon the completion in January 2023 of the IRS examination of our 2018 through 2020 income tax returns, partially offset by a valuation allowance on the net operating loss (“NOL”) and net deferred tax assets generated during the period. For the three months ended March 31, 2022, the effective rate differs from the statutory rate primarily due to the full valuation allowance recorded on the NOL generated during the period, combined with interest and penalties on uncertain tax positions.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES
 3 Months Ended
Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
Litigation

The medical device industry is characterized by frequent claims and litigation, and the Company may become subject to various claims, lawsuits and proceedings in the ordinary course of our business. Such claims may include claims by current or former employees, distributors and competitors, claims concerning the marketing and promotion of our products and product liability claims.

The Company is involved in a number of legal actions relating to the use of our Helium Plasma technology. The outcomes of these legal actions are not within the Company’s control and may not be known for prolonged periods of time. It believes that such claims are adequately covered by insurance; however, in the case of one of the Company’s carriers, the Company is in a dispute regarding the total level of coverage available. Notwithstanding the foregoing, in the opinion of management, the Company has meritorious defenses, and such claims are not expected, individually or in the aggregate, to result in a material, adverse effect on its financial condition, results of operations and cash flows. However, in the event that damages exceed the aggregate coverage limits of the Company’s policies or if its insurance carriers disclaim coverage, management believes it is possible that costs associated with these claims could have a material adverse impact on the consolidated financial condition, results of operations and cash flows.

The Company accrues a liability in its consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded, actual results may differ from these estimates.

During December 2021, the Company provided notice of contract termination to an international distributor of the Company. In March 2022, the Company received a letter from the former distributor citing improper contract termination and alleging damages. While the matter is still in the early stages, management has determined that a loss is probable and that a range of estimated losses is approximately $250,000 to $1,000,000. The Company recorded an estimated loss of $250,000 related to the matter during 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.

As previously disclosed with the U.S. Securities and Exchange Commission on the Company’s Current Report on Form 8-K filed June 7, 2022, on June 6, 2022, a complaint (the “Hattaway Complaint”) was filed in the United States District Court for the Middle District of Florida by plaintiff William E. Hattaway, individually and on behalf of all others similarly situated against the Company, Charles D. Goodwin (“Goodwin”), the Company’s President and Chief Executive Officer and a member of the Company’s Board of Directors, and Tara Semb (“Semb”), the Company’s Chief Financial Officer, Treasurer and Secretary, alleging violations by the Company, Goodwin and Semb of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, primarily related to certain public statements and disclosures concerning the off-label usage of certain of the Company’s Advanced Energy products and the impact such usage would have on the Company’s business, operations and prospects. The Hattaway Complaint seeks an unspecified amount of damages.

Although the ultimate outcome of this matter cannot be determined with certainty, the Company believes that the allegations stated in the Hattaway Complaint are without merit. The Company, Goodwin and Semb intend to defend themselves vigorously in the suit. In the opinion of management, such claims are adequately covered by insurance, however, in the event that damages exceed the aggregate coverage limits of our policy or if our insurance carriers disclaim coverage, we believe it is possible that costs associated with this claim could have a material adverse impact on our consolidated results of operations, financial position or cash flows. While the matter is still in the early stages, management has determined that a loss is probable and that a range of estimated losses is approximately $475,000 to $2,500,000. The Company recorded an estimated loss of $475,000 related to the matter during 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.

During 2022, the Company was notified of certain procedures alleged to have been performed by the same physician and which are currently the subject of two related products liability cases within the courts. Subsequent to year end, the Company was notified by its insurance carriers that all or most of the ten individual plaintiff’s allegations could be subject to separate
deductibles notwithstanding the commonality of each underlying occurrence. The Company has determined that a loss is probable and that a range of estimated losses is approximately $1,450,000 to $2,400,000. The Company recorded an estimated loss of $1,450,000 related to the matters during 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.

On March 1, 2023, Shiva Stein as plaintiff filed a derivative complaint in the Court of Chancery of the State of Delaware, captioned Stein v. Makrides, et al., C.A. No. 2023-0239-MTZ (the “Stein Suit”) against individual members of the Company’s board of directors and naming the Company as a nominal defendant, primarily concerning the facts at issue in a previously disclosed federal securities class action lawsuit filed in 2019 and settled in 2020, captioned Pritchard v. Apyx Medical Corporation, et al., Case No. 8:19-cv-00919 (M.D. Fla.) (the “Pritchard Case”). The Stein Suit seeks unspecified damages alleged to have resulted from purported breaches of fiduciary duty, unjust enrichment and related claims based on the same set of allegedly misleading statements and material omissions described in the settled Pritchard Case, which concerned the 2018-2019 clinical study conducted by the Company to evaluate the safety and efficacy of its J-Plasma technology for dermal resurfacing. The Company believes that the claims are subject to procedural and substantive defenses, anticipates defense and indemnity coverage to be made available by the relevant insurer, and expects the individual defendants to defend all of the allegations vigorously. The outcome of the action is not within the Company’s control and may not be known for a prolonged period of time. In the opinion of management, neither the alleged claims against the individual defendants nor the defense thereof are expected to result in a material, adverse effect on the Company’s financial condition, results of operations and cash flows.

Purchase Commitments

At March 31, 2023, the Company had purchase commitments totaling approximately $4.0 million, substantially all of which is expected to be purchased within the next twelve months.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.23.1
RELATED PARTY TRANSACTIONS
 3 Months Ended
Mar. 31, 2023
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS
Several relatives of Nikolay Shilev, Apyx Bulgaria’s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev’s spouse, is an employee of the Company working in the accounting department. Svetoslav Shilev, Mr. Shilev’s son, is a quality manager in the quality assurance department.

The partner in the Company's China JV is also a supplier to the Company. For the three months ended March 31, 2023 and 2022, the Company made purchases from this supplier of approximately $44,000 and $124,000, respectively. At March 31, 2023 and December 31, 2022, respectively, the Company had net payables to and receivables from this supplier approximately $2,000 and $8,000, respectively.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.23.1
GEOGRAPHIC AND SEGMENT INFORMATION
 3 Months Ended
Mar. 31, 2023
Segment Reporting [Abstract]  
GEOGRAPHIC AND SEGMENT INFORMATION GEOGRAPHIC AND SEGMENT INFORMATION
Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, the Company also considers the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to its chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment, accordingly, the Company has not presented a measure of assets by segment.

The Company's reportable segments are disclosed as principally organized and managed as two operating segments: Advanced Energy and OEM. "Corporate & Other" includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.

Summarized financial information with respect to reportable segments is as follows:
Three Months Ended March 31, 2023
(In thousands)Advanced EnergyOEMCorporate & OtherTotal
Sales$9,690 $2,452 $— $12,142 
Income (loss) from operations(1,326)851 (5,136)(5,611)
Interest income— — 51 51 
Interest expense— — (234)(234)
Other loss, net— — (5)(5)
Income tax benefit— — (2,267)(2,267)

Three Months Ended March 31, 2022
(In thousands)Advanced EnergyOEMCorporate & OtherTotal
Sales$10,814 $1,679 $— $12,493 
Income (loss) from operations(1,339)317 (4,849)(5,871)
Interest income— — 2 2 
Interest expense— — (8)(8)
Other loss, net— — (21)(21)
Income tax expense— — 70 70 

International sales represented approximately 26.9% of total revenues for the three months ended March 31, 2023, as compared with approximately 39.6% of total revenues for the three months ended March 31, 2022.

Revenue by geographic region, based on the customer's “ship to” location on the invoice, are as follows:
Three Months Ended
March 31,
(In thousands)20232022
Sales by Domestic and International
Domestic$8,871 $7,548 
International3,271 4,945 
Total$12,142 $12,493 
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.23.1
BASIS OF PRESENTATION (Policies)
 3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Recent Accounting Pronouncements
In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments—Credit Losses (Topic 326). The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company adopted the new standard on January 1, 2023 and its impact was not material to the Company.

No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.
Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours.
Share based compensation Under the Company's stock option plans, the Board of Directors may grant restricted stock and options to purchase common shares to the Company's employees, officers, directors and consultants. The Company accounts for stock options in accordance with FASB ASC Topic 718, Compensation - Stock Compensation, with stock-based compensation expense recognized over the vesting period based on the grant date fair value utilizing the Black Scholes model, which includes a number of estimates that affect the grant date fair value and the amount of expense to recognize.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.23.1
INVENTORIES (Tables)
 3 Months Ended
Mar. 31, 2023
Inventory Disclosure [Abstract]  
Schedule of inventory
Inventories consisted of the following:
(In thousands)March 31,
2023		December 31,
2022
Raw materials$4,388 $4,979 
Work in process2,331 2,160 
Finished goods 4,655 5,115 
Gross inventories11,374 12,254 
Less: provision for obsolescence(428)(457)
Inventories, net$10,946 $11,797 
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.23.1
ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT (Tables)
 3 Months Ended
Mar. 31, 2023
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment
(In thousands)March 31, 2023
(Unaudited)		December 31,
2022
Land$— $1,600 
Building and improvements16 4,426 
Machinery and equipment2,472 2,613 
Furniture and fixtures213 211 
Computer equipment and software1,230 1,420 
Leasehold improvements178 178 
Molds847 847 
Total property, plant and equipment4,956 11,295 
Less: accumulated depreciation and amortization(3,387)(5,041)
Property and equipment in service1,569 6,254 
Construction in progress540 507 
Property and equipment, net$2,109 $6,761 
Assets held for sale$4,569 $— 
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.23.1
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)
 3 Months Ended
Mar. 31, 2023
Payables and Accruals [Abstract]  
Schedule of Accounts Payable and Accrued Liabilities
Accrued expenses and other current liabilities consisted of the following:
(in thousands)March 31,
2023		December 31,
2022
Accrued payroll$848 $563 
Accrued bonuses570 — 
Accrued commissions790 847 
Accrued product warranties368 391 
Accrued product liability claim insurance deductibles1,794 1,825 
Accrued professional fees and legal related contingent liabilities924 901 
Short-term contract liabilities1,053 853 
Joint and several payroll liability345 345 
Uncertain tax positions— 2,079 
Sales tax payable211 245 
Other accrued expenses and current liabilities723 879 
Total accrued expenses and other current liabilities$7,626 $8,928 
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Debt (Tables)
 3 Months Ended
Mar. 31, 2023
Debt Disclosure [Abstract]  
Schedule of Long-Term Debt Instruments
The Company’s term loan, net consists of the following at March 31, 2023:

(In thousands)March 31, 2023
Term loan$10,000 
Unamortized debt issuance costs(485)
Unamortized debt discount, including accretion of exit fee(737)
Term loan, net$8,778 
Schedule of Maturities of Long-Term Debt
As of March 31, 2023, principal repayments on the term loan are as follows:

(In thousands)
2023$— 
2024— 
20252,778 
20263,333 
20273,333 
Thereafter556 
Total repayments$10,000 
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.23.1
INTEREST IN JOINT VENTURE INVESTMENT (Tables)
 3 Months Ended
Mar. 31, 2023
Noncontrolling Interest [Abstract]  
Schedule of China Joint Venture
Changes in the Company’s ownership investment in the China JV were as follows:

Three Months Ended March 31,
(In thousands)20232022
Beginning interest in China JV$219 $317 
Net loss attributable to Apyx(51)(23)
Ending interest in China JV$168 $294 
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.23.1
EARNINGS (LOSS) PER SHARE (Tables)
 3 Months Ended
Mar. 31, 2023
Earnings Per Share [Abstract]  
Basic and diluted earnings (loss) per share The following table provides the computation of basic and diluted loss per share.
Three Months Ended
March 31,
(in thousands, except per share data)20232022
Numerator:
Net loss attributable to stockholders$(3,483)$(5,945)
Denominator:
Weighted average shares outstanding - basic and diluted
34,598 34,429 
Loss per share:
Basic and diluted$(0.10)$(0.17)
Anti-dilutive instruments excluded from diluted loss per common share:
Options7,783 6,796 
Warrants250 — 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.23.1
STOCK-BASED COMPENSATION (Tables)
 3 Months Ended
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Summary of stock options and stock awards
Stock option activity is summarized as follows:
Number of optionsWeighted average exercise price
Outstanding at December 31, 2022
6,520,444 $7.12 
Granted1,408,865 2.50 
Exercised— — 
Canceled and forfeited(146,164)8.08 
Outstanding at March 31, 2023
7,783,145 $6.27 
Schedule of option fair value assumptions The Company calculated the grant date fair value of options granted in 2023 (“2023 Grants”) utilizing a Black Scholes model.
2023 Grants
Strike price$2.50
Risk-free rate3.6%
Expected dividend yield—
Expected volatility85.8%
Expected term (in years)6
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.23.1
GEOGRAPHIC AND SEGMENT INFORMATION (Tables)
 3 Months Ended
Mar. 31, 2023
Segment Reporting [Abstract]  
Schedule of reporting information by segment Summarized financial information with respect to reportable segments is as follows:
Three Months Ended March 31, 2023
(In thousands)Advanced EnergyOEMCorporate & OtherTotal
Sales$9,690 $2,452 $— $12,142 
Income (loss) from operations(1,326)851 (5,136)(5,611)
Interest income— — 51 51 
Interest expense— — (234)(234)
Other loss, net— — (5)(5)
Income tax benefit— — (2,267)(2,267)

Three Months Ended March 31, 2022
(In thousands)Advanced EnergyOEMCorporate & OtherTotal
Sales$10,814 $1,679 $— $12,493 
Income (loss) from operations(1,339)317 (4,849)(5,871)
Interest income— — 2 2 
Interest expense— — (8)(8)
Other loss, net— — (21)(21)
Income tax expense— — 70 70 
Schedule of revenue by geographic area
Revenue by geographic region, based on the customer's “ship to” location on the invoice, are as follows:
Three Months Ended
March 31,
(In thousands)20232022
Sales by Domestic and International
Domestic$8,871 $7,548 
International3,271 4,945 
Total$12,142 $12,493 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.23.1
BASIS OF PRESENTATION (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Mar. 14, 2023
Jan. 09, 2023
Nov. 22, 2022
Jan. 31, 2023
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Dec. 31, 2018
Feb. 17, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                  
Proceeds from the disposition of Core business               $ 97,000  
Loss from operations         $ 5,611 $ 5,871 $ 23,600    
Net cash used in cash operations         1,881 4,518 20,300    
Cash and cash equivalents         16,255   $ 10,192    
Cash and cash equivalents balance                 $ 10,000
Number of positions eliminated   14.00%              
Purchase agreement $ 7,650                
Income tax receivables       $ 200 $ 207 $ 0      
Credit Agreement | Line of Credit                  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                  
Credit facility                 35,000
Credit Agreement | Line of Credit | Secured Debt                  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                  
Mortgage loan, principal amount                 25,000
Credit Agreement | Line of Credit | Secured Debt | Debt Instrument, Covenant, Tranche One                  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                  
Mortgage loan, principal amount                 10,000
Credit Agreement | Line of Credit | Secured Debt | Debt Instrument, Covenant, Tranche Two                  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                  
Mortgage loan, principal amount                 5,000
Credit Agreement | Line of Credit | Secured Debt | Debt Instrument, Covenant, Tranche Three                  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                  
Mortgage loan, principal amount                 10,000
Credit Agreement | Line of Credit | Revolving Credit Facility                  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                  
Credit facility                 $ 10,000
At-The-Market Facility                  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                  
Securities registered, new issues     $ 40,000            
Shelf Registration                  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                  
Securities registered, new issues     $ 100,000            
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.23.1
INVENTORIES (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Inventory Disclosure [Abstract]    
Raw materials $ 4,388 $ 4,979
Work in process 2,331 2,160
Finished goods 4,655 5,115
Gross inventories 11,374 12,254
Less: provision for obsolescence (428) (457)
Inventories, net $ 10,946 $ 11,797
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.23.1
ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT - Schedule of Assets Held-for-Sale (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Total property, plant and equipment $ 4,956 $ 11,295
Less: accumulated depreciation and amortization (3,387) (5,041)
Property and equipment in service 1,569 6,254
Construction in progress 540 507
Property and equipment, net 2,109 6,761
Assets held for sale 4,569 0
Land    
Property, Plant and Equipment [Line Items]    
Total property, plant and equipment 0 1,600
Building and improvements    
Property, Plant and Equipment [Line Items]    
Total property, plant and equipment 16 4,426
Machinery and equipment    
Property, Plant and Equipment [Line Items]    
Total property, plant and equipment 2,472 2,613
Furniture and fixtures    
Property, Plant and Equipment [Line Items]    
Total property, plant and equipment 213 211
Computer equipment and software    
Property, Plant and Equipment [Line Items]    
Total property, plant and equipment 1,230 1,420
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Total property, plant and equipment 178 178
Molds    
Property, Plant and Equipment [Line Items]    
Total property, plant and equipment $ 847 $ 847
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.23.1
ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT - Narrative (Details) - USD ($)
May 08, 2023
Mar. 14, 2023
Property, Plant and Equipment [Line Items]    
Purchase agreement   $ 7,650,000
Sale leaseback, term of lease   10 years
Sale leaseback, renewal term   5 years
Sale leaseback. annual rent payment   $ 619,500
Sale leaseback, annual rent increase   4.00%
Sale leaseback, management fee on rent payment   3.00%
Subsequent Event    
Property, Plant and Equipment [Line Items]    
Sale leaseback, term of lease 10 years  
Sale leaseback, net cash proceeds $ 6,600,000  
Security deposit equal to annual rent 1 year  
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.23.1
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Payables and Accruals [Abstract]    
Accrued payroll $ 848 $ 563
Accrued bonuses 570 0
Accrued commissions 790 847
Accrued product warranties 368 391
Accrued product liability claim insurance deductibles 1,794 1,825
Accrued professional fees and legal related contingent liabilities 924 901
Short-term contract liabilities 1,053 853
Joint and several payroll liability 345 345
Uncertain tax positions 0 2,079
Sales tax payable 211 245
Other accrued expenses and current liabilities 723 879
Total accrued expenses and other current liabilities $ 7,626 $ 8,928
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.23.1
CREDIT AGREEMENT - Narrative (Details)
$ / shares in Units, $ in Thousands
 3 Months Ended
Feb. 17, 2023
USD ($)
monthlyPayment
$ / shares
shares
Mar. 31, 2023
USD ($)
$ / shares
Dec. 31, 2022
$ / shares
Debt Instrument [Line Items]      
Twelve month net revenue target, year one $ 49,000    
Twelve month net revenue target, year two 60,000    
Twelve month net revenue target, year three 70,000    
Cash and cash equivalents balance $ 10,000    
Warrants | shares 250,000    
Common stock, par value (in dollars per share) | $ / shares $ 0.001 $ 0.001 $ 0.001
Warrants, exercise price (in dollars per share) | $ / shares $ 3.40    
Warrants term 10 years    
Debt issuance costs $ 1,800    
Line of Credit | Credit Agreement      
Debt Instrument [Line Items]      
Credit facility $ 35,000    
Default, applicable interest rate 2.00%    
Line of Credit | Credit Agreement | Secured Debt      
Debt Instrument [Line Items]      
Mortgage loan, principal amount $ 25,000    
Interest rate floor 2.50%    
Interest rate floor spread 7.35%    
Period of interest only 24 months    
Extension period 12 months    
Number of monthly payments | monthlyPayment 36    
Number of monthly payments, extension | monthlyPayment 24    
Exit fee 4.00%    
Amortization of debt issuance costs   $ 17  
Amortization of debt discounts   37  
Line of Credit | Credit Agreement | Secured Debt | Debt Instrument, Prepayment Period One      
Debt Instrument [Line Items]      
Prepayment fee 3.00%    
Line of Credit | Credit Agreement | Secured Debt | Debt Instrument, Prepayment Period Three      
Debt Instrument [Line Items]      
Prepayment fee 1.00%    
Line of Credit | Credit Agreement | Secured Debt | Debt Instrument, Prepayment Period Two      
Debt Instrument [Line Items]      
Prepayment fee 2.00%    
Line of Credit | Credit Agreement | Secured Debt | Adjusted Term Secured Overnight Financing Rate (SOFR)      
Debt Instrument [Line Items]      
Variable rate 0.10%    
Line of Credit | Credit Agreement | Secured Debt | Debt Instrument, Covenant, Tranche One      
Debt Instrument [Line Items]      
Mortgage loan, principal amount $ 10,000    
Effective interest rate 12.10%    
Line of Credit | Credit Agreement | Secured Debt | Debt Instrument, Covenant, Tranche Two      
Debt Instrument [Line Items]      
Mortgage loan, principal amount $ 5,000    
Line of Credit | Credit Agreement | Secured Debt | Debt Instrument, Covenant, Tranche Three      
Debt Instrument [Line Items]      
Mortgage loan, principal amount 10,000    
Line of Credit | Credit Agreement | Revolving Credit Facility      
Debt Instrument [Line Items]      
Credit facility $ 10,000    
Interest rate floor 2.50%    
Interest rate floor spread 4.00%    
Annual fee 0.50%    
Remaining borrowing capacity $ 5,700    
Amortization of debt issuance costs   12  
Amortization of debt discounts   $ 1  
Line of Credit | Credit Agreement | Revolving Credit Facility | Debt Instrument, Termination Period One      
Debt Instrument [Line Items]      
Effective interest rate 8.80%    
Borrowing base, minimum balance $ 10,000    
Lockbox account, funds to be applied to borrowings 5 days    
Termination fees 3.00%    
Borrowing base, minimum balance 30.00%    
Line of Credit | Credit Agreement | Revolving Credit Facility | Debt Instrument, Termination Period Two      
Debt Instrument [Line Items]      
Termination fees 2.00%    
Line of Credit | Credit Agreement | Revolving Credit Facility | Debt Instrument, Termination Period Three      
Debt Instrument [Line Items]      
Termination fees 1.00%    
Line of Credit | Credit Agreement | Revolving Credit Facility | Adjusted Term Secured Overnight Financing Rate (SOFR)      
Debt Instrument [Line Items]      
Variable rate 0.10%    
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.23.1
CREDIT AGREEMENT - Schedule Of Long-Term Debt (Details)
$ in Thousands
Mar. 31, 2023
USD ($)
Debt Instrument [Line Items]  
Term loan $ 10,000
Unamortized debt issuance costs (485)
Unamortized debt discount, including accretion of exit fee (737)
Term loan, net 8,778
Line of Credit | Line of Credit  
Debt Instrument [Line Items]  
Term loan $ 10,000
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.23.1
CREDIT AGREEMENT - Schedule of Long-Term Debt Maturities (Details)
$ in Thousands
Mar. 31, 2023
USD ($)
Debt Disclosure [Abstract]  
2023 $ 0
2024 0
2025 2,778
2026 3,333
2027 3,333
Thereafter 556
Term loan, net $ 10,000
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.23.1
INTEREST IN JOINT VENTURE INVESTMENT - Narrative (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Noncontrolling Interest [Line Items]      
Required capital contribution     $ 357
Contributions from non-controlling interest $ 203 $ 154  
Chinese Supplier      
Noncontrolling Interest [Line Items]      
Ownership interest     51.00%
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.23.1
INTEREST IN JOINT VENTURE INVESTMENT - Rollforward of Joint Venture (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]    
Beginning interest in China JV $ 211  
Net loss attributable to Apyx (49) $ (23)
Ending interest in China JV 162  
Corporate Joint Venture    
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]    
Beginning interest in China JV 219 317
Net loss attributable to Apyx (51) (23)
Ending interest in China JV $ 168 $ 294
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.23.1
EARNINGS (LOSS) PER SHARE (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Earnings Per Share Reconciliation [Abstract]    
Net loss attributable to stockholders, basic $ (3,483) $ (5,945)
Net loss attributable to stockholders, diluted $ (3,483) $ (5,945)
Denominator:    
Weighted average shares outstanding - basic (in shares) 34,598 34,429
Weighted average shares outstanding - diluted (in shares) 34,598 34,429
Loss per share:    
Basic (in dollars per share) $ (0.10) $ (0.17)
Diluted (in dollars per share) $ (0.10) $ (0.17)
Options    
Anti-dilutive instruments excluded from diluted loss per common share:    
Anti-dilutive instruments (in shares) 7,783 6,796
Warrants    
Anti-dilutive instruments excluded from diluted loss per common share:    
Anti-dilutive instruments (in shares) 250 0
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.23.1
STOCK-BASED COMPENSATION - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]    
Stock based compensation $ 1,367 $ 1,650
Stock swaps equity instruments received (in shares) 22,654  
Stock swaps (in shares) 19,013  
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.23.1
STOCK-BASED COMPENSATION - Summary of Stock Options (Details)
 3 Months Ended
Mar. 31, 2023
$ / shares
shares
Number of options  
Outstanding, beginning of period (in shares) | shares 6,520,444
Granted (in shares) | shares 1,408,865
Exercised (in shares) | shares 0
Canceled and forfeited (in shares) | shares (146,164)
Outstanding, end of period (in shares) | shares 7,783,145
Weighted average exercise price  
Outstanding, beginning of period (in dollars per share) | $ / shares $ 7.12
Granted (in dollars per share) | $ / shares 2.50
Exercised (in dollars per share) | $ / shares 0
Canceled and forfeited (in dollars per shares) | $ / shares 8.08
Outstanding, end of period (in dollars per share) | $ / shares $ 6.27
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.23.1
STOCK-BASED COMPENSATION - Fair Value Assumptions (Details)
 3 Months Ended
Mar. 31, 2023
$ / shares
Share-Based Payment Arrangement [Abstract]  
Strike price (in dollars per share) $ 2.50
Risk-free rate 3.60%
Expected dividend yield 0.00%
Expected volatility 85.80%
Expected term (in years) 6 years
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.23.1
INCOME TAXES (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Tax Disclosure [Abstract]    
Income tax expense (benefit) $ (2,267) $ 70
Effective income tax rate 39.10% (1.20%)
Accrued interest and penalties $ 2,100  
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
USD ($)
lease
Mar. 31, 2023
USD ($)
Dec. 31, 2021
USD ($)
Loss Contingencies [Line Items]      
Costs accrued   $ 250  
Purchase obligation   4,000  
Suit Against Goodwin And Simb      
Loss Contingencies [Line Items]      
Costs accrued $ 475    
Suits Filed in 2022      
Loss Contingencies [Line Items]      
Costs accrued   1,450  
New claims filed | lease 2    
Number of plaintiffs | lease 10    
Minimum      
Loss Contingencies [Line Items]      
Estimate of possible loss     $ 250
Minimum | Suit Against Goodwin And Simb      
Loss Contingencies [Line Items]      
Estimate of possible loss $ 475    
Minimum | Suits Filed in 2022      
Loss Contingencies [Line Items]      
Estimate of possible loss   1,450  
Maximum      
Loss Contingencies [Line Items]      
Estimate of possible loss     $ 1,000
Maximum | Suit Against Goodwin And Simb      
Loss Contingencies [Line Items]      
Estimate of possible loss $ 2,500    
Maximum | Suits Filed in 2022      
Loss Contingencies [Line Items]      
Estimate of possible loss   $ 2,400  
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.23.1
RELATED PARTY TRANSACTIONS (Details) - Co-venturer - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Related Party Transaction [Line Items]      
Purchases from related party $ 44 $ 124  
Due to related parties $ 2    
Due from related parties     $ (8)
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.23.1
GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details) - segment
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Segment Reporting [Abstract]    
Number of reportable segments 2  
Number of operating segments 2  
International sales, percent of total revenue 26.90% 39.60%
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.23.1
GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Segment Reporting Information [Line Items]      
Sales $ 12,142 $ 12,493  
Income (loss) from operations (5,611) (5,871) $ (23,600)
Interest income 51 2  
Interest expense (234) (8)  
Other income (loss), net (5) (21)  
Income tax (benefit) expense (2,267) 70  
Operating Segments | Advanced Energy      
Segment Reporting Information [Line Items]      
Sales 9,690 10,814  
Income (loss) from operations (1,326) (1,339)  
Interest income 0 0  
Interest expense 0 0  
Other income (loss), net 0 0  
Income tax (benefit) expense 0 0  
Operating Segments | OEM      
Segment Reporting Information [Line Items]      
Sales 2,452 1,679  
Income (loss) from operations 851 317  
Interest income 0 0  
Interest expense 0 0  
Other income (loss), net 0 0  
Income tax (benefit) expense 0 0  
Corporate & Other      
Segment Reporting Information [Line Items]      
Sales 0 0  
Income (loss) from operations (5,136) (4,849)  
Interest income 51 2  
Interest expense (234) (8)  
Other income (loss), net (5) (21)  
Income tax (benefit) expense $ (2,267) $ 70  
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.23.1
GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Segment Reporting Information [Line Items]    
Sales $ 12,142 $ 12,493
Domestic    
Segment Reporting Information [Line Items]    
Sales 8,871 7,548
International    
Segment Reporting Information [Line Items]    
Sales $ 3,271 $ 4,945
XML 60 apyx-20230331_htm.xml IDEA: XBRL DOCUMENT 0000719135 2023-01-01 2023-03-31 0000719135 2023-05-10 0000719135 2023-03-31 0000719135 2022-12-31 0000719135 2022-01-01 2022-03-31 0000719135 us-gaap:CommonStockMember 2021-12-31 0000719135 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000719135 us-gaap:RetainedEarningsMember 2021-12-31 0000719135 us-gaap:NoncontrollingInterestMember 2021-12-31 0000719135 2021-12-31 0000719135 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000719135 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000719135 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000719135 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0000719135 us-gaap:CommonStockMember 2022-03-31 0000719135 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000719135 us-gaap:RetainedEarningsMember 2022-03-31 0000719135 us-gaap:NoncontrollingInterestMember 2022-03-31 0000719135 2022-03-31 0000719135 us-gaap:CommonStockMember 2022-12-31 0000719135 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000719135 us-gaap:RetainedEarningsMember 2022-12-31 0000719135 us-gaap:NoncontrollingInterestMember 2022-12-31 0000719135 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000719135 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000719135 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0000719135 us-gaap:CommonStockMember 2023-03-31 0000719135 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000719135 us-gaap:RetainedEarningsMember 2023-03-31 0000719135 us-gaap:NoncontrollingInterestMember 2023-03-31 0000719135 2018-01-01 2018-12-31 0000719135 2022-01-01 2022-12-31 0000719135 2023-02-17 0000719135 apyx:ShelfRegistrationMember 2022-11-22 2022-11-22 0000719135 apyx:AtTheMarketFacilityMember 2022-11-22 2022-11-22 0000719135 apyx:CreditAgreementMember us-gaap:LineOfCreditMember 2023-02-17 0000719135 us-gaap:SecuredDebtMember apyx:CreditAgreementMember us-gaap:LineOfCreditMember 2023-02-17 0000719135 apyx:DebtInstrumentCovenantTrancheOneMember us-gaap:SecuredDebtMember apyx:CreditAgreementMember us-gaap:LineOfCreditMember 2023-02-17 0000719135 apyx:DebtInstrumentCovenantTrancheTwoMember us-gaap:SecuredDebtMember apyx:CreditAgreementMember us-gaap:LineOfCreditMember 2023-02-17 0000719135 apyx:DebtInstrumentCovenantTrancheThreeMember us-gaap:SecuredDebtMember apyx:CreditAgreementMember us-gaap:LineOfCreditMember 2023-02-17 0000719135 us-gaap:RevolvingCreditFacilityMember apyx:CreditAgreementMember us-gaap:LineOfCreditMember 2023-02-17 0000719135 2023-03-14 2023-03-14 0000719135 2023-01-01 2023-01-31 0000719135 2023-01-09 2023-01-09 0000719135 us-gaap:LandMember 2023-03-31 0000719135 us-gaap:LandMember 2022-12-31 0000719135 us-gaap:BuildingAndBuildingImprovementsMember 2023-03-31 0000719135 us-gaap:BuildingAndBuildingImprovementsMember 2022-12-31 0000719135 us-gaap:MachineryAndEquipmentMember 2023-03-31 0000719135 us-gaap:MachineryAndEquipmentMember 2022-12-31 0000719135 us-gaap:FurnitureAndFixturesMember 2023-03-31 0000719135 us-gaap:FurnitureAndFixturesMember 2022-12-31 0000719135 apyx:ComputerEquipmentAndSoftwareMember 2023-03-31 0000719135 apyx:ComputerEquipmentAndSoftwareMember 2022-12-31 0000719135 us-gaap:LeaseholdImprovementsMember 2023-03-31 0000719135 us-gaap:LeaseholdImprovementsMember 2022-12-31 0000719135 apyx:MoldsMember 2023-03-31 0000719135 apyx:MoldsMember 2022-12-31 0000719135 us-gaap:SubsequentEventMember 2023-05-08 2023-05-08 0000719135 us-gaap:SecuredDebtMember apyx:CreditAgreementMember us-gaap:LineOfCreditMember apyx:AdjustedTermSecuredOvernightFinancingRateSOFRMember 2023-02-17 2023-02-17 0000719135 us-gaap:SecuredDebtMember apyx:CreditAgreementMember us-gaap:LineOfCreditMember 2023-02-17 2023-02-17 0000719135 apyx:DebtInstrumentPrepaymentPeriodOneMember us-gaap:SecuredDebtMember apyx:CreditAgreementMember us-gaap:LineOfCreditMember 2023-02-17 2023-02-17 0000719135 apyx:DebtInstrumentPrepaymentPeriodTwoMember us-gaap:SecuredDebtMember apyx:CreditAgreementMember us-gaap:LineOfCreditMember 2023-02-17 2023-02-17 0000719135 apyx:DebtInstrumentPrepaymentPeriodThreeMember us-gaap:SecuredDebtMember apyx:CreditAgreementMember us-gaap:LineOfCreditMember 2023-02-17 2023-02-17 0000719135 apyx:DebtInstrumentTerminationPeriodOneMember us-gaap:RevolvingCreditFacilityMember apyx:CreditAgreementMember us-gaap:LineOfCreditMember 2023-02-17 0000719135 apyx:DebtInstrumentTerminationPeriodOneMember us-gaap:RevolvingCreditFacilityMember apyx:CreditAgreementMember us-gaap:LineOfCreditMember 2023-02-17 2023-02-17 0000719135 us-gaap:RevolvingCreditFacilityMember apyx:CreditAgreementMember us-gaap:LineOfCreditMember apyx:AdjustedTermSecuredOvernightFinancingRateSOFRMember 2023-02-17 2023-02-17 0000719135 us-gaap:RevolvingCreditFacilityMember apyx:CreditAgreementMember us-gaap:LineOfCreditMember 2023-02-17 2023-02-17 0000719135 apyx:DebtInstrumentTerminationPeriodTwoMember us-gaap:RevolvingCreditFacilityMember apyx:CreditAgreementMember us-gaap:LineOfCreditMember 2023-02-17 2023-02-17 0000719135 apyx:DebtInstrumentTerminationPeriodThreeMember us-gaap:RevolvingCreditFacilityMember apyx:CreditAgreementMember us-gaap:LineOfCreditMember 2023-02-17 2023-02-17 0000719135 2023-02-17 2023-02-17 0000719135 apyx:CreditAgreementMember us-gaap:LineOfCreditMember 2023-02-17 2023-02-17 0000719135 us-gaap:SecuredDebtMember apyx:CreditAgreementMember us-gaap:LineOfCreditMember 2023-01-01 2023-03-31 0000719135 us-gaap:RevolvingCreditFacilityMember apyx:CreditAgreementMember us-gaap:LineOfCreditMember 2023-01-01 2023-03-31 0000719135 us-gaap:LineOfCreditMember us-gaap:LineOfCreditMember 2023-03-31 0000719135 apyx:ChineseSupplierMember 2019-12-31 0000719135 2019-12-31 0000719135 2021-01-01 2021-12-31 0000719135 2020-01-01 2020-12-31 0000719135 us-gaap:CorporateJointVentureMember 2022-12-31 0000719135 us-gaap:CorporateJointVentureMember 2021-12-31 0000719135 us-gaap:CorporateJointVentureMember 2023-01-01 2023-03-31 0000719135 us-gaap:CorporateJointVentureMember 2022-01-01 2022-03-31 0000719135 us-gaap:CorporateJointVentureMember 2023-03-31 0000719135 us-gaap:CorporateJointVentureMember 2022-03-31 0000719135 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0000719135 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0000719135 us-gaap:WarrantMember 2023-01-01 2023-03-31 0000719135 us-gaap:WarrantMember 2022-01-01 2022-03-31 0000719135 srt:MinimumMember 2021-12-31 0000719135 srt:MaximumMember 2021-12-31 0000719135 apyx:SuitAgainstGoodwinAndSimbMember srt:MinimumMember 2022-12-31 0000719135 apyx:SuitAgainstGoodwinAndSimbMember srt:MaximumMember 2022-12-31 0000719135 apyx:SuitAgainstGoodwinAndSimbMember 2022-12-31 0000719135 apyx:SuitsFiledIn2022Member 2022-01-01 2022-12-31 0000719135 apyx:SuitsFiledIn2022Member srt:MinimumMember 2023-03-31 0000719135 apyx:SuitsFiledIn2022Member srt:MaximumMember 2023-03-31 0000719135 apyx:SuitsFiledIn2022Member 2023-03-31 0000719135 us-gaap:CoVenturerMember 2023-01-01 2023-03-31 0000719135 us-gaap:CoVenturerMember 2022-01-01 2022-03-31 0000719135 us-gaap:CoVenturerMember 2023-03-31 0000719135 us-gaap:CoVenturerMember 2022-12-31 0000719135 us-gaap:OperatingSegmentsMember apyx:AdvancedEnergyMember 2023-01-01 2023-03-31 0000719135 us-gaap:OperatingSegmentsMember apyx:OEMMember 2023-01-01 2023-03-31 0000719135 us-gaap:CorporateNonSegmentMember 2023-01-01 2023-03-31 0000719135 us-gaap:OperatingSegmentsMember apyx:AdvancedEnergyMember 2022-01-01 2022-03-31 0000719135 us-gaap:OperatingSegmentsMember apyx:OEMMember 2022-01-01 2022-03-31 0000719135 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-03-31 0000719135 country:US 2023-01-01 2023-03-31 0000719135 country:US 2022-01-01 2022-03-31 0000719135 us-gaap:NonUsMember 2023-01-01 2023-03-31 0000719135 us-gaap:NonUsMember 2022-01-01 2022-03-31 shares iso4217:USD iso4217:USD shares pure apyx:monthlyPayment apyx:lease apyx:segment 0000719135 false --12-31 Q1 2023 10-Q true 2023-03-31 false 0-12183 APYX MEDICAL CORPORATION DE 11-2644611 5115 Ulmerton Road, Clearwater FL 33760 727 384-2323 Common Stock APYX NASDAQ Yes Yes Non-accelerated Filer true false false 34597822 16255000 10192000 359000 668000 9966000 10602000 7752000 7545000 417000 99000 428000 457000 10946000 11797000 4569000 0 2779000 2737000 52684000 42972000 2109000 6761000 646000 710000 106000 115000 1239000 1217000 56784000 51775000 1905000 2669000 7626000 8928000 184000 216000 33000 37000 8778000 0 18526000 11850000 448000 470000 68000 73000 1343000 1408000 185000 181000 20570000 13982000 0.001 0.001 10000000 10000000 0 0 0 0 0 0 0.001 0.001 75000000 75000000 34597822 34597822 35000 35000 75235000 73282000 -39218000 -35735000 36052000 37582000 162000 211000 36214000 37793000 56784000 51775000 12142000 12493000 4569000 4274000 7573000 8219000 1121000 1158000 1740000 2286000 5068000 5181000 5255000 5465000 13184000 14090000 -5611000 -5871000 51000 2000 234000 8000 -5000 -21000 -188000 -27000 -5799000 -5898000 -2267000 70000 -3532000 -5968000 -49000 -23000 -3483000 -5945000 -0.10 -0.10 -0.17 -0.17 34410000 34000 66221000 -12551000 305000 54009000 24000 152000 152000 1650000 1650000 19000 -5945000 -23000 -5968000 34453000 34000 68023000 -18496000 282000 49843000 34598000 35000 73282000 -35735000 211000 37793000 1367000 1367000 586000 586000 -3483000 -49000 -3532000 34598000 35000 75235000 -39218000 162000 36214000 -3532000 -5968000 203000 225000 0 85000 0 -26000 1367000 1650000 -142000 140000 67000 0 -837000 -475000 -858000 -649000 207000 0 -879000 371000 -776000 -51000 -1435000 -1378000 -1881000 -4518000 110000 279000 -110000 -279000 0 152000 9289000 0 1754000 0 586000 0 9000 54000 8112000 98000 -58000 63000 6063000 -4636000 10192000 30870000 16255000 26234000 1000 8000 125000 0 BASIS OF PRESENTATION<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apyx Medical Corporation (“Company”, “Apyx”, “it” and similar terms) was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 5115 Ulmerton Road, Clearwater, FL 33760.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Technology products marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion® and J-Plasma® offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of its plan to accelerate and fully fund the development of its advanced energy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">business, with a focus in the cosmetic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">surgery market, the Company sold its Core business in 2018 for gross proceeds of $97 million.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These proceeds were used to launch broad marketing and sales initiatives which resulted in rapid sales growth through December 31, 2021 and into the first quarter of 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This planned growth in the business was accompanied by scaled operations, including procurement of components, expanded manufacturing capacity to turn those materials into saleable inventory, additional discretionary expenditures, including increased global participation at trade shows, additional employee trainings, user meetings, increased travel and entertainment expenses, more expansive research and development projects, and additional headcount to support those activities. Additionally, the Company had, and still has, some significant non-recurring discretionary expenditures associated with completing its multi-year marketing initiatives related to its dermal resurfacing and skin laxity clearances. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 14, 2022, the U.S. Food and Drug Administration (“FDA”) posted a Medical Device Safety Communication (“Safety Communication”). The FDA warned against the use of Renuvion/J-Plasma for procedures intended to improve the appearance of the skin through dermal resurfacing (a procedure on the skin to treat wrinkles) or skin contraction (a procedure under the skin that can be performed either alone or in combination with liposuction to achieve skin effects, such as “tightening”). At that time, the Renuvion/J-Plasma device system was FDA cleared for general use of cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures. The use of the device had not been determined to be safe or effective for any aesthetic skin procedures (procedures intended to improve the appearance of the skin). Following the Safety Communication, the Company experienced slowed demand for the adoption of its Helium Plasma Technology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 26, 2022, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion® Dermal Handpiece for certain dermal resurfacing procedures, specifically, for the treatment of moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick Skin Types I, II or III. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 2, 2022, the FDA updated the Safety Communication to inform consumers and healthcare providers about the new 510(k) clearance for the Renuvion® device system for certain dermal resurfacing procedures. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 18, 2022, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for use in subcutaneous dermatological and aesthetic procedures to improve the appearance of lax (loose) skin in the neck and submental (under the chin) region. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 21, 2022, the FDA updated the Safety Communication to inform consumers and healthcare providers about the clearance for the Renuvion® APR handpieces for use under the skin in certain procedures intended to improve the appearance of loose skin. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 27, 2023, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. Soft tissue includes subcutaneous tissue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 28, 2023, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 10, 2023, the FDA updated the Safety Communication to inform consumers and healthcare providers about the clearance for the Renuvion® APR handpiece for use under the skin in certain procedures intended to improve the appearance of the skin, including for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Management believes that the May 10, 2023 FDA update to the Safety Communication addresses the issues set forth in the original Safety Communication from March 14, 2022. While no assurances can be provided, management believes that receiving these additional clearances and the corresponding updates to the Safety Communication since March 14, 2022 should mitigate the financial effects of the Safety Communication in future periods.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue in operation one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Financial Accounting Standards Board’s Accounting Standards Codification (“ASC”) Topic 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for one year from the date these unaudited condensed consolidated financial statements are issued. This evaluation does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented or are not within control of the Company as of the date the unaudited condensed consolidated financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While sales were continuing to grow into the first quarter of 2022 prior to the FDA Safety Communication, over the last few years, exclusive of the Company’s sale of the Core business segment to Symmetry Surgical during 2018, the Company has incurred recurring net losses and cash outflows from operations and the Company anticipates that losses will continue in the near term. During the year ended December 31, 2022, the Company incurred an operating loss of $23.6 million and used $20.3 million of cash in operations. During the three months ended March 31, 2023, the Company incurred an operating loss of $5.6 million and used $1.9 million of cash in operations. As of March 31, 2023, the Company had cash and cash equivalents of $16.3 million, of which the Company must maintain $10.0 million under its Credit Agreement. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In an effort to alleviate these conditions, the Company pursued various funding solutions in order to improve liquidity. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 22, 2022, the Company filed a shelf registration statement providing it the ability to register securities in the aggregate amount up to $100 million. The shelf registration included an embedded ATM facility for up to $40 million. To date, the Company has not utilized this facility.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2023, the Company entered into a Credit, Security and Guaranty Agreement (the “Credit Agreement”) with MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement provides for an up to $35 million facility, consisting of senior secured term loans and a secured revolving facility. The Credit Agreement provides for senior secured term loans of up to $25 million, comprised of (i) an initial tranche of $10 million, (ii) a second tranche of $5 million, and (iii) a third tranche of $10 million. The secured revolving facility provides for loans in an aggregate principal amount of up to $10 million, subject to a borrowing base equal to certain percentages of the Company’s eligible accounts receivable and inventory, as determined in accordance with the terms of the Credit Agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a more in depth description of the terms of the Credit Agreement, see Note 6.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2023, the Company’s Board of Directors approved a plan to sell and leaseback the Company’s real property located in Clearwater, FL. On March 14, 2023, the Company entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with VK Acquisitions VI, LLC (the “Purchaser”), for the sale of the Company’s facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the “Property”) for a purchase price </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $7,650,000. On May 8, 2023, the Company closed on the Purchase Agreement and concurrently executed a 10-year agreement to leaseback the underlying Property from the Purchaser. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For a more in depth description of the terms of the Purchase Agreement, see Note 4.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During January 2023, the Company was notified that the IRS examination process of our 2018, 2019 and 2020 tax returns was complete and that the Company’s tax refunds were approved for approximately $0.2 million more than the amount recorded in the Company’s Consolidated Balance Sheet at December 31, 2022. As of the date of this report, the Company is awaiting receipt of the tax refunds. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also continues to re-assess its operating expenditures and cost structure to be commensurate with expected levels of revenue and management has the ability to reduce or delay expenditures to enhance and preserve liquidity. Management has already reduced some operating expenditures, including a reduction-in-force on January 9, 2023, that reduced the Company’s U.S. headcount by 14%. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Management believes that the actions already taken, and additional actions that it intends to take to manage operating expenditures, will enable the Company to meet its obligations and its debt covenants for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements. As a result, management believes its plans alleviate substantial doubt about the Company’s ability to continue as a going concern. These unaudited condensed consolidated financial statements do not include any adjustments relating to the carrying amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern.</span></div> 97000000 -23600000 -20300000 -5600000 -1900000 16300000 10000000 100000000 100000000 40000000 40000000 35000000 25000000 10000000 5000000 10000000 10000000 7650000 200000 0.14 RECENT ACCOUNTING PRONOUNCEMENTS <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments—Credit Losses (Topic 326).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company adopted the new standard on January 1, 2023 and its impact was not material to the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments—Credit Losses (Topic 326).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company adopted the new standard on January 1, 2023 and its impact was not material to the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.</span></div> INVENTORIES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,388 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,979 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,331 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,655 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross inventories</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,374 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,254 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: provision for obsolescence</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(428)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(457)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,946 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,797 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,388 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,979 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,331 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,655 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross inventories</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,374 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,254 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: provision for obsolescence</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(428)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(457)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,946 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,797 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 4388000 4979000 2331000 2160000 4655000 5115000 11374000 12254000 428000 457000 10946000 11797000 ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023<br/>(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,426 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,472 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,613 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,230 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,420 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,956 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,295 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,387)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,041)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment in service</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,569 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,254 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,109 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,761 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets held for sale</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,569 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to improve liquidity and the balance sheet condition of the Company, management has been exploring options to leverage the Company’s unencumbered real property. On February 27, 2023, the Company’s Board of Directors approved a plan to sell and leaseback the Company's real property located in Clearwater, FL. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 14, 2023, the Company entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with VK Acquisitions VI, LLC (the “Purchaser”), for the sale of the Company’s facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the “Property”) for a purchase price of $7,650,000. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In accordance with the requirements of ASC Topic 360,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Property, Plant, and Equipment, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the Company has determined that the real property to be sold meets the requirements to be presented as held for sale. Accordingly, the Company has presented the associated assets as held for sale in the accompanying unaudited condensed consolidated balance sheet and the table above at March 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In accordance with the terms of the Purchase Agreement, upon the closing of the sale of the Property, the Company will enter into a Single Tenant Industrial Building Lease (the “Lease”) with the Purchaser, pursuant to which the Property will be leased back to the Company. The Lease will have an initial term of ten (10) years commencing from the closing (the “Initial Term”), and a renewal term of five (5) years, exercisable at the Company’s option. The annual fixed rent will be $619,500 for the first year of the Initial Term, and will be subject to a 4% escalation every year thereafter through the Initial Term. Rent will be reset to the current market rate should the Company exercise the renewal option. The Lease provides for a 3% management fee on rent payments throughout the Initial Term and optional renewal term. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Lease is a triple net lease, pursuant to which all costs, expenses, and obligations relating to the Property, including, repair and maintenance charges, utility charges, real estate taxes or other taxes that may be imposed that relate to the Property, shall be paid by the Company. In addition, the Lease contains other customary terms and provisions generally contained within leases of this type.</span></div>On May 8, 2023, the Company closed on the Purchase Agreement and concurrently executed a 10-year agreement to leaseback the underlying Property from the Purchaser. The Company received net cash proceeds of approximately $6,600,000, after withholding the security deposit equal to one years rent, taxes, first months rent, expenses, and fees. The Company anticipates that the net cash proceeds will be used to strengthen its balance sheet and provide working capital to its operations. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023<br/>(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,426 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,472 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,613 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,230 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,420 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,956 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,295 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,387)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,041)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment in service</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,569 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,254 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,109 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,761 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets held for sale</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,569 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 0 1600000 16000 4426000 2472000 2613000 213000 211000 1230000 1420000 178000 178000 847000 847000 4956000 11295000 3387000 5041000 1569000 6254000 540000 507000 2109000 6761000 4569000 0 7650000 P10Y P5Y 619500 0.04 0.03 P10Y 6600000 P1Y ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonuses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued commissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product warranties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product liability claim insurance deductibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,794 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,825 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees and legal related contingent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">901 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,053 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joint and several payroll liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,079 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales tax payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses and current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,626 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,928 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>During April 2023, the Company was relieved of the remainder of its joint and several payroll liability due to the lapse of the statute of limitations on the liability. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonuses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued commissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product warranties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product liability claim insurance deductibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,794 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,825 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees and legal related contingent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">901 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,053 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joint and several payroll liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,079 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales tax payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses and current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,626 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,928 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 848000 563000 570000 0 790000 847000 368000 391000 1794000 1825000 924000 901000 1053000 853000 345000 345000 0 2079000 211000 245000 723000 879000 7626000 8928000 CREDIT AGREEMENTOn February 17, 2023, the Company entered into a Credit, Security and Guaranty Agreement (the “Credit Agreement”), by and among the Company (as borrower) and Apyx China Holding Corp., the Company’s wholly-owned subsidiary (as guarantor), and MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time (collectively “MidCap”).<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Credit Agreement provides for an up to $35 million facility, consisting of senior secured term loans and a secured revolving facility. The Credit Agreement provides for senior secured term loans of up to $25 million, comprised of (i) an initial tranche of $10 million, (ii) a second tranche of $5 million, and (iii) a third tranche of $10 million. The secured revolving facility provides for loans in an aggregate principal amount of up to $10 million, subject to a borrowing base equal to percentages of eligible accounts receivable and inventory determined in accordance with the Credit Agreement. The Credit Agreement matures on February 1, 2028.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline">Term Loans</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The initial tranche of $10 million was fully funded on February 17, 2023 less transaction costs. Subject to certain terms and conditions of the Credit Agreement, the second tranche would be available between June 30, 2023 and December 31, 2023 and the third tranche would be available between January 1, 2024 and September 30, 2024, respectively. The Company’s ability to access these additional tranches is conditioned upon, among other things, the achievement of certain minimum revenue targets. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Each term loan bears interest at a floating rate reset monthly based on an adjusted one month SOFR plus 0.1%, subject to a floor of 2.5%, plus 7.35% calculated on a 360 day basis (12.1% at March 31, 2023). Interest is payable monthly in arrears on the first day of each month.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The first twenty-four (24) months of the term loans constitute an interest-only period (with a possible twelve (12) month extension). Subsequent to the interest-only period, the outstanding principal amount of the term loans is repayable in thirty-six (36) equal monthly payments (or twenty-four (24) with the extension). All remaining outstanding principal, together with all accrued and unpaid interest, is due at maturity on February 1, 2028. The term loans may be voluntarily prepaid in full, or in part, at any time, subject to terms and conditions set forth in the Credit Agreement. Additionally, the term loans are subject to mandatory prepayment fees, pursuant to the terms of the Credit Agreement. Prepayments of the term loans are subject to fees of 3%, 2%, and 1% of the prepayment amounts made during the first year, second year, and thereafter, respectively. At the time of the final payment of the term loans, the Company is also obligated to pay an exit fee of 4% of the total amount funded thereunder. The exit fee is being accreted over the life of the Credit Agreement utilizing the effective interest method. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As the Credit Agreement contains a subjective acceleration clause and the Company has experienced recurring losses, outstanding borrowings have been presented as a current liability in the accompanying condensed consolidated balance sheet at March 31, 2023.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline">Revolving Facility</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company may borrow, repay and reborrow under the revolving facility until February 1, 2028, at which time the facility will terminate and all outstanding amounts thereunder, including all accrued and unpaid interest, must be repaid. Borrowings are limited to the lesser of the Company’s borrowing base and the revolving commitment of $10,000,000. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the revolving facility, the Company is required to maintain a lockbox account for the benefit of MidCap. Funds deposited into the lockbox account will be swept daily to MidCap and applied to outstanding borrowings under the revolving agreement 5 days after the receipt of the funds by MidCap. Any balances in excess of the revolving borrowings will be promptly returned to the Company. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Loans made under the revolving facility bear interest at a floating rate based on an adjusted one month SOFR plus 0.1%, subject to a floor of 2.5%, plus 4.00% calculated on a 360 day basis (8.8% at March 31, 2023). The Company is obligated to pay a fee equal to 0.5% per annum on the outstanding balance of the revolving loans and the average unused portion of the available revolving commitments, respectively. Additionally, if the revolving facility is terminated or reduced before maturity, the Company is subject to a deferred origination fee. Terminations and reductions of the commitments are subject to fees of 3%, 2%, and 1% of the terminated or reduced commitments during the first year, second year, and thereafter, respectively. The Company is also required to maintain a minimum balance of 30% of the lesser of the borrowing base or $10 million under the revolving facility. If the average outstanding balance for a month is less than the minimum balance, the Company will pay a minimum balance fee for the difference between the minimum balance and the average outstanding balance for the month at the highest rate for the revolving loans during the month. For such loans, interest and fees are payable monthly on the first day of each month. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of March 31, 2023, the Company has drawn no amounts on the revolving facility. As of March 31, 2023, the Company had approximately $5,700,000 available to be drawn on the revolving facility. As the Credit Agreement contains a subjective acceleration clause and the Company is required to maintain a lockbox, any amounts drawn on the revolving facility will be presented as a current liability in the consolidated financial statements. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline">Collateral</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The obligations of the Company under the Credit Agreement are secured by first priority liens on substantially all of its assets.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline">Covenants</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Credit Agreement contains customary affirmative and negative covenants, including covenants limiting the ability of the Company and its subsidiaries, among other things, to incur debt, grant liens, make distributions, enter certain restrictive agreements, pay or modify subordinated debt, dispose of assets, make investments and acquisitions, enter into certain transactions with affiliates, and undergo certain fundamental changes, in each case, subject to limitations and exceptions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Credit Agreement also requires the Company to satisfy certain financial covenants, including minimum trailing twelve (12) month net revenue targets relating to its Advanced Energy segment (tested quarterly), with year-end targets of $49 million, $60 million and $70 million for 2023, 2024, and 2025, respectively. Additionally, the Company must maintain a balance of $10 million in cash and cash equivalents during the duration of the Credit Agreement’s term.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March 31, 2023, the Company was in compliance with the financial covenants contained within the Credit Agreement.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline">Events of Default</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Credit Agreement also contains customary Events of Default</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">that include, among other things, certain payment defaults, cross defaults to certain other contracts and indebtedness, covenant defaults, inaccuracy of representations and warranties, bankruptcy and insolvency defaults, judgment defaults, change of control defaults, defaults related to the failure to remain registered with the Securities and Exchange Commission and listed for trading on the Nasdaq Stock Market, and any material adverse change.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Upon the occurrence and during the continuance of an Event of Default under the Credit Agreement, the respective administrative agent, if requested by the respective lenders, may, among other things, (i) suspend or terminate commitments, as well as obligations of the relevant administrative agent and lenders, (ii) declare all outstanding obligations under the agreement (including principal and accrued and unpaid interest) immediately due and payable, and (iii) exercise the other rights and remedies provided for under the agreement. The Credit Agreement provides that, under certain circumstances, a default interest rate will apply on all obligations under such agreement during the existence of an Event of Default, at a per annum rate equal to 2% in excess of the applicable interest rate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company bifurcated a derivative liability related to the potential acceleration triggered upon an event of default (contingent put option) and the supplemental interest upon an event of default features of the Credit Agreement. The bifurcated derivative is de minimis to the Company's unaudited condensed consolidated financial statements. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline">Issuance of Warrants</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the Company’s obligations under the Credit Agreement, the Company issued to a statutory trust of MidCap Financial warrants to purchase up to 250,000 shares of its common stock, par value $0.001, with an exercise price of $3.40 per share.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The warrants have a 10 year term and can be exercised by issuing payment to the Company for the number of warrants exercised or exercised net by surrendering warrants with an intrinsic value equal to the cumulative exercise price of the warrants being exercised.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company determined that these warrants meet the criteria for equity classification and included the proceeds allocated to the warrants, on a relative fair value basis, as a debt discount and additional paid-in capital in the accompanying condensed consolidated financial statements. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline">Debt Issuance Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with entering into the Credit Agreement, the Company incurred debt issuance costs of approximately $1.8 million, comprised primarily of commissions paid to the financial advisor. These costs were allocated to the issued and unissued term loans and the revolving facility. The costs allocated to the issued term loan will be amortized using the effective interest method over the life of the loan. The costs allocated to the unissued term loans have been deferred and will be amortized over the life of the term loans starting at the issuance date. If these loans are not issued, the Company will recognize </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the deferred costs at the point that the Company's rights to borrow on the term loans expires. The costs allocated to the revolving facility will be recognized on a straight-line basis over the term of the Credit Agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The costs allocated to the issued term loan have been presented as a reduction of the term loan in the accompanying unaudited condensed consolidated balance sheet. The costs allocated to the unissued term loans and the revolving facility have been presented in prepaid expenses and other current assets in the accompanying unaudited condensed consolidated balance sheet. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Included in interest expense for the three months ended March 31, 2023 are $17,000 and $37,000, respectively, of amortization of the debt issuance costs and amortization of the debt discounts including accretion of the exit fee on the term loan. Included in interest expense for the three months ended March 31, 2023 are $12,000 and $1,000, respectively, of amortization of the debt issuance costs and amortization of the debt discount on the revolving facility. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company’s term loan, net consists of the following at March 31, 2023:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.842%"><tr><td style="width:1.0%"/><td style="width:85.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.864%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(485)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount, including accretion of exit fee</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(737)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,778 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of March 31, 2023, principal repayments on the term loan are as follows: </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"/><td style="width:86.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.628%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,778 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,333 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total repayments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 35000000 25000000 10000000 5000000 10000000 10000000 10000000 0.001 0.025 0.0735 0.121 P24M P12M 36 24 0.03 0.02 0.01 0.04 10000000 P5D 0.001 0.025 0.0400 0.088 0.005 0.03 0.02 0.01 0.30 10000000 5700000 49000000 60000000 70000000 10000000 0.02 250000 0.001 3.40 P10Y 1800000 17000 37000 12000 1000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company’s term loan, net consists of the following at March 31, 2023:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.842%"><tr><td style="width:1.0%"/><td style="width:85.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.864%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(485)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount, including accretion of exit fee</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(737)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,778 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 10000000 485000 737000 8778000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of March 31, 2023, principal repayments on the term loan are as follows: </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"/><td style="width:86.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.628%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,778 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,333 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total repayments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 0 2778000 3333000 3333000 556000 10000000 INTEREST IN JOINT VENTURE INVESTMENT<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company executed a joint venture agreement with its Chinese supplier (“China JV”) whereby the Company has a 51% interest. The China JV has been consolidated in these condensed consolidated financial statements. The agreement required the Company to make capital contributions into the newly formed entity of approximately $357,000, of which approximately $203,000 and $154,000, respectively, were contributed during the years ended December 31, 2021 and 2020. As of the date of these condensed consolidated financial statements, the joint venture has not commenced principal operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company’s ownership investment in the China JV were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.159%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning interest in China JV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Apyx</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending interest in China JV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 0.51 357000 203000 154000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company’s ownership investment in the China JV were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.159%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning interest in China JV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Apyx</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending interest in China JV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 219000 317000 -51000 -23000 168000 294000 EARNINGS (LOSS) PER SHARE <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings (loss) per share (“basic EPS”) is computed by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period. Diluted earnings (loss) per share (“diluted EPS”) gives effect to all dilutive potential shares outstanding. As the Company is in a net loss position for all periods presented, all potential shares outstanding are anti-dilutive. The following table provides the computation of basic and diluted loss per share.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.159%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to stockholders</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,483)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,945)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding - basic and diluted<br/></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,598 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,429 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive instruments excluded from diluted loss per common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,783 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,796 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> The following table provides the computation of basic and diluted loss per share.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.159%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to stockholders</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,483)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,945)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding - basic and diluted<br/></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,598 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,429 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive instruments excluded from diluted loss per common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,783 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,796 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> -3483000 -3483000 -5945000 -5945000 34598000 34598000 34429000 34429000 -0.10 -0.10 -0.17 -0.17 7783000 6796000 250000 0 STOCK-BASED COMPENSATION <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company's stock option plans, the Board of Directors may grant restricted stock and options to purchase common shares to the Company's employees, officers, directors and consultants. The Company accounts for stock options in accordance with FASB ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with stock-based compensation expense recognized over the vesting period based on the grant date fair value utilizing the Black Scholes model, which includes a number of estimates that affect the grant date fair value and the amount of expense to recognize.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized approximately $1,367,000 in stock-based compensation expense for the three months ended March 31, 2023, as compared with $1,650,000 for the three months ended March 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity is summarized as follows:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,520,444 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,408,865 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146,164)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.08 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,783,145 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allows stock option holders to exercise stock-based awards by surrendering stock-based awards with an intrinsic value equal to the cumulative exercise price of the stock-based awards being exercised, referred to as net settlements. These surrenders are included in stock options exercised in the options rollforward above. For the three months ended March 31, 2022, we received 22,654 options as payment in the exercise of 19,013 options. There were no such exercises for the three months ended March 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common shares required to be issued upon the exercise of stock options would be issued from authorized and unissued shares. The Company calculated the grant date fair value of options granted in 2023 (“2023 Grants”) utilizing a Black Scholes model.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:54.385%"><tr><td style="width:1.0%"/><td style="width:71.211%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.589%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023 Grants</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strike price</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.50</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.8%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company's stock option plans, the Board of Directors may grant restricted stock and options to purchase common shares to the Company's employees, officers, directors and consultants. The Company accounts for stock options in accordance with FASB ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with stock-based compensation expense recognized over the vesting period based on the grant date fair value utilizing the Black Scholes model, which includes a number of estimates that affect the grant date fair value and the amount of expense to recognize.</span> 1367000 1650000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity is summarized as follows:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,520,444 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,408,865 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146,164)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.08 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,783,145 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 6520444 7.12 1408865 2.50 0 0 146164 8.08 7783145 6.27 22654 19013 The Company calculated the grant date fair value of options granted in 2023 (“2023 Grants”) utilizing a Black Scholes model.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:54.385%"><tr><td style="width:1.0%"/><td style="width:71.211%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.589%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023 Grants</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strike price</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.50</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.8%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 2.50 0.036 0 0.858 P6Y INCOME TAXES Income tax (benefit) expense was approximately $(2,267,000) and $70,000 with effective tax rates of 39.1% and (1.2)% for the three months ended March 31, 2023 and 2022, respectively. For the three months ended March 31, 2023, the effective rate differs from the statutory rate primarily due to the reversal of the Company’s liability for uncertain tax positions, including accrued interest and penalties of approximately $2.1 million which were sustained upon the completion in January 2023 of the IRS examination of our 2018 through 2020 income tax returns, partially offset by a valuation allowance on the net operating loss (“NOL”) and net deferred tax assets generated during the period. For the three months ended March 31, 2022, the effective rate differs from the statutory rate primarily due to the full valuation allowance recorded on the NOL generated during the period, combined with interest and penalties on uncertain tax positions. -2267000 70000 0.391 -0.012 2100000 COMMITMENTS AND CONTINGENCIES<div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device industry is characterized by frequent claims and litigation, and the Company may become subject to various claims, lawsuits and proceedings in the ordinary course of our business. Such claims may include claims by current or former employees, distributors and competitors, claims concerning the marketing and promotion of our products and product liability claims.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in a number of legal actions relating to the use of our Helium Plasma technology. The outcomes of these legal actions are not within the Company’s control and may not be known for prolonged periods of time. It believes that such claims are adequately covered by insurance; however, in the case of one of the Company’s carriers, the Company is in a dispute regarding the total level of coverage available. Notwithstanding the foregoing, in the opinion of management, the Company has meritorious defenses, and such claims are not expected, individually or in the aggregate, to result in a material, adverse effect on its financial condition, results of operations and cash flows. However, in the event that damages exceed the aggregate coverage limits of the Company’s policies or if its insurance carriers disclaim coverage, management believes it is possible that costs associated with these claims could have a material adverse impact on the consolidated financial condition, results of operations and cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrues a liability in its consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded, actual results may differ from these estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During December 2021, the Company provided notice of contract termination to an international distributor of the Company. In March 2022, the Company received a letter from the former distributor citing improper contract termination and alleging damages. While the matter is still in the early stages, management has determined that a loss is probable and that a range of estimated losses is approximately $250,000 to $1,000,000. The Company recorded an estimated loss of $250,000 related to the matter during 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed with the U.S. Securities and Exchange Commission on the Company’s Current Report on Form 8-K filed June 7, 2022, on June 6, 2022, a complaint (the “Hattaway Complaint”) was filed in the United States District Court for the Middle District of Florida by plaintiff William E. Hattaway, individually and on behalf of all others similarly situated against the Company, Charles D. Goodwin (“Goodwin”), the Company’s President and Chief Executive Officer and a member of the Company’s Board of Directors, and Tara Semb (“Semb”), the Company’s Chief Financial Officer, Treasurer and Secretary, alleging violations by the Company, Goodwin and Semb of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, primarily related to certain public statements and disclosures concerning the off-label usage of certain of the Company’s Advanced Energy products and the impact such usage would have on the Company’s business, operations and prospects. The Hattaway Complaint seeks an unspecified amount of damages. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the ultimate outcome of this matter cannot be determined with certainty, the Company believes that the allegations stated in the Hattaway Complaint are without merit. The Company, Goodwin and Semb intend to defend themselves vigorously in the suit. In the opinion of management, such claims are adequately covered by insurance, however, in the event that damages exceed the aggregate coverage limits of our policy or if our insurance carriers disclaim coverage, we believe it is possible that costs associated with this claim could have a material adverse impact on our consolidated results of operations, financial position or cash flows. While the matter is still in the early stages, management has determined that a loss is probable and that a range of estimated losses is approximately $475,000 to $2,500,000. The Company recorded an estimated loss of $475,000 related to the matter during 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, the Company was notified of certain procedures alleged to have been performed by the same physician and which are currently the subject of two related products liability cases within the courts. Subsequent to year end, the Company was notified by its insurance carriers that all or most of the ten individual plaintiff’s allegations could be subject to separate </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deductibles notwithstanding the commonality of each underlying occurrence. The Company has determined that a loss is probable and that a range of estimated losses is approximately $1,450,000 to $2,400,000. The Company recorded an estimated loss of $1,450,000 related to the matters during 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 1, 2023, Shiva Stein as plaintiff filed a derivative complaint in the Court of Chancery of the State of Delaware, captioned Stein v. Makrides, et al., C.A. No. 2023-0239-MTZ (the “Stein Suit”) against individual members of the Company’s board of directors and naming the Company as a nominal defendant, primarily concerning the facts at issue in a previously disclosed federal securities class action lawsuit filed in 2019 and settled in 2020, captioned Pritchard v. Apyx Medical Corporation, et al., Case No. 8:19-cv-00919 (M.D. Fla.) (the “Pritchard Case”). The Stein Suit seeks unspecified damages alleged to have resulted from purported breaches of fiduciary duty, unjust enrichment and related claims based on the same set of allegedly misleading statements and material omissions described in the settled Pritchard Case, which concerned the 2018-2019 clinical study conducted by the Company to evaluate the safety and efficacy of its J-Plasma technology for dermal resurfacing. The Company believes that the claims are subject to procedural and substantive defenses, anticipates defense and indemnity coverage to be made available by the relevant insurer, and expects the individual defendants to defend all of the allegations vigorously. The outcome of the action is not within the Company’s control and may not be known for a prolonged period of time. In the opinion of management, neither the alleged claims against the individual defendants nor the defense thereof are expected to result in a material, adverse effect on the Company’s financial condition, results of operations and cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2023, the Company had purchase commitments totaling approximately $4.0 million, substantially all of which is expected to be purchased within the next twelve months.</span></div> 250000 1000000 250000 475000 2500000 475000 2 10 1450000 2400000 1450000 4000000 RELATED PARTY TRANSACTIONS<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several relatives of Nikolay Shilev, Apyx Bulgaria’s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev’s spouse, is an employee of the Company working in the accounting department. Svetoslav Shilev, Mr. Shilev’s son, is a quality manager in the quality assurance department.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The partner in the Company's China JV is also a supplier to the Company. For the three months ended March 31, 2023 and 2022, the Company made purchases from this supplier of approximately $44,000 and $124,000, respectively. At March 31, 2023 and December 31, 2022, respectively, the Company had net payables to and receivables from this supplier approximately $2,000 and $8,000, respectively.</span></div> 44000 124000 2000 8000 GEOGRAPHIC AND SEGMENT INFORMATION <div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, the Company also considers the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to its chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment, accordingly, the Company has not presented a measure of assets by segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's reportable segments are disclosed as principally organized and managed as two operating segments: Advanced Energy and OEM. "Corporate &amp; Other" includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information with respect to reportable segments is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,690 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,452 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,142 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,326)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,136)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,611)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,267)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,267)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,814 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,679 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,493 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,339)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,849)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,871)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International sales represented approximately 26.9% of total revenues for the three months ended March 31, 2023, as compared with approximately 39.6% of total revenues for the three months ended March 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by geographic region, based on the customer's “ship to” location on the invoice, are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.099%"><tr><td style="width:1.0%"/><td style="width:63.100%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.300%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by Domestic and International</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,871 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,548 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,945 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,142 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,493 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 2 2 Summarized financial information with respect to reportable segments is as follows:<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,690 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,452 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,142 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,326)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,136)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,611)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,267)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,267)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,814 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,679 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,493 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,339)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,849)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,871)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 9690000 2452000 0 12142000 -1326000 851000 -5136000 -5611000 0 0 51000 51000 0 0 234000 234000 0 0 -5000 -5000 0 0 -2267000 -2267000 10814000 1679000 0 12493000 -1339000 317000 -4849000 -5871000 0 0 2000 2000 0 0 8000 8000 0 0 -21000 -21000 0 0 70000 70000 0.269 0.396 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by geographic region, based on the customer's “ship to” location on the invoice, are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.099%"><tr><td style="width:1.0%"/><td style="width:63.100%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.300%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by Domestic and International</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,871 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,548 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,945 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,142 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,493 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 8871000 7548000 3271000 4945000 12142000 12493000 EXCEL 61 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( ,EXJU8'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #)>*M6B]NO(.X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>R$Y882;UI:.G#@8K;.QF;+4UBQ-C:R1]^SE9FS*V!]C1TN]/ MGT"-"=+T$9]C'S"2PW0W^K9+TH0U.Q$%"9#,";U.94YTN7GHH]>4G_$(09L/ M?42H.%^!1])6DX8)6(2%R%1CC301-?7Q@K=FP8?/V,XP:P!;]-A1 E$*8&J: M&,YCV\ -,,$(HT_?!;0+<:[^B9T[P"[),;DE-0Q#.=1S+N\@X.UI]S*O6[@N MD>X,YE_)23H'7+/KY-=Z\[C?,E7QJB[X?2'$7CQ(OI*\?I]*M6F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M ,EXJU:J>C\\O 4 *P> 8 >&PO=V]R:W-H965T&UL MM9EK<^(V&(7_BH;.=-J9$".92[(ES! G:9GF0D*V[;;3#\(6X%G;HK()>9@T!OW\VE@-^C+349B(L2)I%L=< MK2]%)%<7#=K877@*YPMM+CB#_I+/Q43HS\NQ@C.G< G"6"1I*!.BQ.RB,:2? M/)<90?[$;Z%8I6^.B4&92OG5G(R"BT;+E$A$PM?&@L//B_!$%!DG*,<_6]-& M\3>-\.WQSOTFAP>8*4^%)Z/?PT O+AIG#1*(&<\B_217OX@M4,?X^3)*\__) M:O-LN]T@?I9J&6_%4((X3#:__'7[(MX(6*="P+8"]D% W0J!NQ6X.>BF9#G6 M%==\T%=R191Y&MS,0?YNI&2ZR00P7N] V4I"L1V!;IDJ.$=5Z?$I2>$M9AK*8^W M3[XFM&53ORN-6[P>-[=ST=?SUW"::@4M[F_;"]HXM.T.IAM^2I?<%Q<-Z&>I M4"^B,?C^.]IM_62C^T9F[V#;!6P;LRXTD)%:_(DEE)I&QYNI55F>RD>JJJ)URWPNH?AC84*96 Z(8%A MP%IYN%/1[2K[':JOR=DK.'L'MDS%80;))X#J>L2]9CQ*K16)RFH"GA6 9VBA MKA,=ZC6Y"2-![K-X*I0-#/=H-2FC9]:Z0X4UT ]/XX>GX?/HX=[&BSK5Y*6M^QI+3)NNUVEU(K+RJNR\M*7G8([S (P#T]V1V06WB./"3V>L4M.Y1V MR.O!8R9VUC'O>W%I!CY&1:!F2*!YM/H*.9:IY1/X, ME]6#%.[HNKUNRTIZC+A$R[Q$\9B3-]$/E];E*],1Q:/-R'Z8]D(OQ,04U: M(7$G3\8Q#*\3+?VO5M!C1"5:9B6*AQS(MT&8S,ED'4]E9.7;GY*L7,>(1*R, M1 P/+;L:(]>O_H(G4LDP\[*/F,$IBS-VMPYHN3[\"MG+AC%>FU[Y,SCH!:2 >,D3>[WBAI7+ M"+BN+FB94';UN!!0CQ@>;E.-=XRDP\JDP_"0LAMFWTSC$,SSQ6ORD&G( MK8F90*W$WRC#;-_#QJV3NYG-DI>!V^Z<]\X8ZSLO-L8R[;"#%H,\&$X5Q+I1 M$HA7\JNP5^.>-2'XUZ/GU.U8&8X1=E@9=MB>K!*+),B7]6XB;J\RW*"ZD1XC M[;AEVG'QD+(+ 3=A:G+Y%_C&19=F]]@UFY0U7>LR"*ZL"UJ&'A>/*,6Z[)9T MNPQ] Y>M<\<>NT<[XS$"CUL&'A>/)Q\9\]JL)L3-JA;7<=G_973>[ >:"2_? M)DV);Q8>-UN#Q=5B*W:8;T ZY>.;?=P[;N;+E$1B!M+6:0\&/+79&MV<:+G, M=Q>G4FL9YX<+P0.AS -P?R:EWIV8/U!L4 _^!5!+ P04 " #)>*M6SZO/ MPID& "3' & 'AL+W=O62A$@NL%FD7N"M[IWOI)BZ--HF[ME/@/OW9:4G:V'%!VA?0 MI!T[_QG;\QL[9T^,?Q=+2B5X+HM*G(^64JY.)Q.1+FE)Q E;T4K]LF"\)%+= M\L>)6'%*LJ9164R0YX63DN35:'K6?'?/IV>LED5>T7L.1%V6A+]\I 5[.A_! MT>L7?^6/2ZF_F$S/5N21SJC\MKKGZF[2]I+E):U$SBK Z>)\= %/+W&H&S06 M?^?T2>Q< ^W*G+'O^N8F.Q]Y6A$M:"IU%T1]K.DE+0K=D]+Q8]OIJ'VF;KA[ M_=K[I\9YYXO985H_H.GK:TW M FDM)"NWC96",J\VG^1Y&XB=!M ?:("V#=!;&^!M ]PXNE'6N'5%))F>F+)C9-:^5-7NEAG$FN?LU5.SF]O+N]NKZ=75\!=36[^W)S=?&@;CY> M?+FXO;P&L\_7UP\S, ;?9E?@]Z,_P!'(*_"P9+4@52;.)E)IT#U-TNWS/FZ> MAP:>]Y7P$X#A,4 >PI;FE^[F5S1MFZ/]YA/E>>L^:MU'37]XR/V:_:3.]GS%K:_8U?OT MDH@E4*,&4GU!?]3YFA3*>>LH;KH*FZYT*EA/88B"X&RRWG7'8N7!!+56>SK] M5J?OU/G 24;5^DY9K<2I7)%2I71>T&-0J;S&%H 4*ON0*J7ZY@@'2>/641C& M-E&$-=V \/HH"U--H M,0K\P"XQ;"6&3HEW($01#+"Y8$IR2E^G@H_BS53P@\CF2&09Y<3OSP6+%8R2R.Y-W'H3.[VY M:#(,6-(B:[0+M?9L$F,SUD&8]!2:1IY=7=*J2YSJ[CE=D3P#]%G5!X**)HJL MF1OI7HJT24X,-2B*^I)M1G@@IM#KZ.6YLNUG];;O= ="Z";A MQ6LMM"(O&M)6ARW42KQ^P6:Q0F$X &K8L0T>@%N:\IHZ\;$S8%;Y)M*B$!GK MT;2*$Q0/R._@!]WT>YU4*\:;O:4J)5@O"QZ2;^(-FFO"PD 8VL6C#H'(C4"+ M^,5>0CP@'9G,P[BGW&8SD&E0!T7DAN(#Y24H&*D&.8A,PL51%/?%F58#2$$[ MVT(W!/?KBD,1-*D&X\"8O#8S93>DM<,?QU('\YV3%IET\WTCNA:C M:$ASAT#D1F"G^7USU61>: @V;2(\H+>C(G)3L=.;LDIRDAZ>%"8 (?:-A66Q M\KV!A(8Z2J*W[.H.*32W;&HZ]@7:C 9J3-0!#;F!MEE>A_196.4%.W-OJ] " M/IS$ S4[ZIB&8F>EC@SF]!59K+P$RR M]/LQ./)./ ^J4H.#-2EJ^@% []CSFC\@EH1KO-=RJ3;F_]'L _! +H2&?\/\ M6@JI+G0.(D*SZ"OAZ;(]\6N,KFA*R[F:H/:#O&V035@:(^\RV3\BZVB*#]"4 ME:6"J!B*112X8H']XR")CF.$WA"4S2!:([/WDS4\V$)DXW3.:;,?H([:V$WM MBRS+=9VAUJ\^,1CG%4C)*E?KV2K39',4(%.IQ0RCH36,.XQC-\9575J7=4&D M&HF,+O(TM]89V"3S&"<(]M%BM0NBP:#NG,RZ$;[)A\VD6[(BHUS\UAP3R!>K M7!/)./2,XT*;610,!K5C-W:S^Y95XX:"K"CTE,XK!48J[)&U;%)#0ZAIA. M8W"';/R6C:PCBB9Z<8A@OVBWF451,E!1X [1V(UH X'MV=" W- X:[?MNVUF MEGWW9.>-D7Y=IQ+28UX)584M5#OO)%+^\LT;L,V-9*OF)=*<2\CI_U!+ P04 " #)>*M6 P;N*+0# #'# & M 'AL+W=O_?BU!$.6 M1'W9+@3TS$HEH@E))>4I$F0]-B;V[=1VM4-N\1UEK(QW*BO,GW;F/QH:E MB0@CH=(2&'YV9$H8TTK \6\I:E1S:L=Z^UG]71X\!+/"DDPY^YM&*AX; P-% M9(TSIC[S_7M2!N1IO9 SF7^C?6'K#PT49E+QI'0&@H2FQ2_^5B:BYF#W7G%P M2@?G7 >W=,@S9Q9D>5@SK' P$GR/A+8&-=W("G@NFG MA]G\83F?(6@M/WVXGTT>H7,W^3!YF,[1\OU\_KA$5PLL2*IBHFB(V37Z WU9 MSM#5FVOT!M$4/<8\DSB-Y,A4P*25S;"<_ZZ8WWEE_H]8W"#7?HL^XK>4F%%H$H5XFOTCJ8X#2EF:,$ES:ONG\E* M*@&U][4MU$*[UZZM%^2MW.*0C U8<9*('3&"WW^S^]:?;8'_3V*--+A5&MPN M]6#"8'E#[ 3!1H$BGJW4.F.PYD*>I4K"^@T)W>$5(VUI*+3[N;;>1G:!ZPU' MYJX>W;%-OS^H;!K0O0JZUPE]G^[@Q7%!B7R+MH+O:+[7Z CX2G)&9$@@I#;B M0MBKT?28PS)*,0X1B*S:W-$(XX4+1'_E M&[-WG&5WX!] 'QMY5L]NI^Y7U/U.Z@5LM$0(8(;=*7R"7&.!=IAE!%W!9A!Q MQK"0:$O@M(AAW[ANHR^F\&M@UHUEV0?XIZP:_'[%[U_&CS,50]G\@!$=0 XM M6ZG]HQJPK>)S 'Z&88-]4+$/+F.'DUDJ*!>:;D[!#XZ8#JF[+!JXPPIW>!DN ME3([G>;A2=(NBP:I;;T:RUQW!>T93*=2JWYPW]@;X8-/E_Q=%JOYRM M=O?AVAKC!>NXE#\GT$Z02P,U:[=,?<6'J]N&IA(QL@9YZ\8'(E'3.&?QI$: -XON9*M6D14* M*" % !% & 'AL+W=O&7Y##OE3G.RY>)$;QA1ZR[-"7@XV2FTO1B,9;UA.Y3G?L@+^67&14P6/ M8CV26\%H4CKEV8@X3C#*:5H,II/RW9.83OA.96G!G@22NSRGXI]KEO']Y0 / MWE\\I^N-TB]&T\F6KMF_;)P%/HSI*DN:LD"DOD&"KR\$5OI@17SN4%K^G M;"^/[I%.9I'8_OWZ-_ M+9.'9)94LAG/_D@3M;D<1 .4L!7=9>J9[W]CAX1*P)AGLOQ%^\HV= !AOH#+_>W# M8HX>OZ+'I]OGJ\4=&* A^CZ_02=?3M$7E!9HL>$[28M$3D8*:'3,47QH^;IJ MF?2T[*)[7JB-1+=%PI*/_B/(HDZ%O*=R3:P![ZDX1RX^0\0AKH%G]N/NQ(+C MUCWKEO'+/IW3C!G+H7(+2C>]NKQ.,<$>=/7K M,;K)RAN[M=4')K]F\JU,,RX5XBLD^]@J=_^H5<\/QBTT@Q$)/3-94),%5K)? M!9<2;05?I7[J#9,H!@Z3B*8X(B]@7)( M)B],E.%G%N\G!?N0=51G'5F'XQDB4A%ORI03]@HRM]63UY1TU.EU# 7=&AJ3 MD1^9AV9<0XZMD$]0+4QJ(:49TCV0QN:J'G<;#SVG1=@U(B0*S(38:63%^:]5 M@(J45;4C6 :+8%)5DU$IG Z$[P11B]1DA2/<@WJD@-B."GN(M%B?H34KF( N MU<@T ;%-]7JMMQE&9MRE(;[?9C98>8'?PTP:9F)E7G %H+QGCAIQ2;<87!QY M;5Z#F>>,G1[@1@RQ57.FW_0RMQ(\1[ #U9W*"S.FVVE_Z >X/:V,9E'85PN- M=F&[>-T5BL&JHF!OH]7;2.@9JK"-U[4A/6B-A&&[AM5HAU$VLG4E:DCL1C-HG'?8#<" MA.T*=%?CH9,EK)JP>3FUUF579(:$!&$;MVL6]JP\I%$B8E>B!_@6UF-NXB)= M11FZOMO>DYK,_''0TXVD41YB5YYW-$25$NERI^@R@U[EJ.#%,(:O(\%+:8)R MJ.:^,8>NP@R]=B&8C$C/IIHT*D3L*M3+#Y^M\_X=XS59M MWM'184K.Q+H\8Y*PR]H5JCJ,J-_6YUA7Y>E-Z_TUOIA5IU%-F.IP[)Z*=5I( ME+$5A'3.0R 3U7E3]:#XMCRR67*E>%[>;AB%V:0-X/\5Y^K]03=0G_I-_P50 M2P,$% @ R7BK5B?]3@&:!0 A"$ !@ !X;"]W;W)K9%,&:092':1NLQT85I553]X$C-$ MF\1L;(;=?U\[9 -Q3 94JU\@)O>>Z]QS_3@.HQTIOM UQ@Q\R]*#^^5J"].J9P/+[^@1Z6#\\?Y@E1/"'IGTG,UC<]KP=BO$+;E'TF MNX^X>B!'X$4DI>4GV%6V1@]$6\I(5CGS'F1)OO]&WZI$'#E ZX2#63F8YSI8 ME8,E.9C#$PYVY6#+#J>>P:D<'-G!.>'@5@YNF?M]LLI,3Q%#XU%!=J 0UAQ- M7)1TE=X\P4DN*FO!"GXWX7YL/+F?3X/Y(I@"?K6X_VTVO5WRQF+)OSX%\^4" MW(=@\O%V_B%8@-D(.HZM7=OE?FB5XM"4.IPFW2[38A6<:K=<%(]$7A/>WVOHWC1%0[ M2L$#2N+^+ <3M$G4/0E>P8JB;;9-$<,QF.)5$B5, 1)V@\Q)WH](S@J2\EO/ M8)8SS',M(0TXXS7M9DV[64+;)Z#O\'.2YP+T":4HCS!XRQG;<_D.(,8['5T! M"[X'IF%"%8&=^&(^O*8;%.&;'I_P*"Y><&_\\T_0-7Y5T;H'^C"W; MAL9H\'),G\Z0@4ZP4!-8@TJKIM*ZD,ISZ-MCND<9=VS#\)L9G[2M+%LBI6WB MNJ:(>6P5M*WZT'07CKC!3K!0DU@#5K=FE97+ZTJ*MU6]J%C2A-@9SW22=!K4R%M0Z8ZXP4Z MP4)-8 U6_9I5OY/5.2%)BDCQY(&B-:@@5:T4!=: MD\ZC\PUX"9UG40A;2;=]SY:2/JG,.M61 LKU#%.""A1F?>C9OBL5O,+.],P3 M%7\X"X :#P/4&=-Z&@!5QP&.[\FYU7H>H!4MU(769/1P) #_XYF FD6KG??A MT&_5O4*E.S(W;:BA=5RJ5=+;9GW+&30 M9X-:$6; M:D4+M**%NM":17 X(("OG!!%3/0&C/4A=:DY"#N M8;>Z?RA(A'%,08$CG+QP8E8%R4KY4LYE7*[P45B@G*E?+;1UMN.Y,DE:E?TY M(0.M(4-=:$V.#NH>=LO[+O$!V^J:S^J6?+;2'>%B"G2B!*%NI":])YD.FP6Z=W*Q UA7Y[ MB^6:T)9'D,*LM1-KVPP=4S8+%&9]RS>A)U=\VPZZL@(9'+V/%O]/X,_+]Z,4 MI'C%O8RK(:^F8O_*?]]@9%.^HGXBC)&LO%QCQ#=@PH#?7Q'"?C3$6^_ZCQ?C M?P%02P,$% @ R7BK5@W]_W?L!P ;#( !@ !X;"]W;W)KI->R E M:[S/Q5?Z^">I+RA4>@G->?D7/%:QDW$/)'LNZ+8N+&NPS8KJ$S_5((X*2!U[ M 5070*\M$-0% KW Z$2!45U@I!GUQ9,/A+AZ1Y%3Q%HS@D%A!J1><2BS,-V M^R$. MUHQN@>S:&!99<5_U#9G(B#5I*M61755UFQ=\AQ-RU9/](B?L@?3FO_P$Q\,_ M;,!]BD4^Q6)/8JVF&1V:9N12G]_(\2>GW(K?6;(K_DIL7(JI$>MAW@_"0&;7 MPS%72U0X&T_;4;&GBK6 A0=@H3.7K]-_94\LAT?!@:!R?$QHD60Y 45-4OVJ MCA.5]'M.4M4WVC+^PL8\],G*M4B.#D0G#@)WC+ZD)73 M0SD[E>G](.\&RIX!77&:$YZ0(B$VD$[5KB G!J2AAM&,F.H4/=6H17%ZH#AU M4ORD.@O),,WXCG*< [H&.Z9Z"O%QL71J=V4Y/6G9U2UO"^F/M4BKVJQ M+[5V0S4F#SJ-ROR.X92H"3')'O JMULZMT;GU@C,(3XP4MP,&DWTB8"O>K79 M-2X,NFW8+2,[G*4O?4.5V51L"*M3W):HT&#W%@8'-@X'NBV.9,?VQ-JM'0W;5J)>_0TT[8N<3@:A MCM06%DSTY2=?=6M#;:P.='N=F]G4^T'0U?3B=0IVI)6P40H/IS-85 M!T>=<7L9OC$V:-AI[5FM5O!7P$)>_8Q7M*]&J58[1]02 M92'Z%L8&-<8&==N^6F<%+I)7 /7J=;RJ15[58E]J[09JW!,ZYYYH0DA:-P\O MUP+IKES?)T^$)1D_T4!>#10RO9&1[F8(#)&>[6]AGU!CGY#;/K5A"L*V(*?8 MNI+J5NK,SW10,S35/8,E2O=9OJK5!MCX+.3V6;?X60U::CA+R4J C/-]N9:: M4&XW\F[!SAPMK@I.PI$.T@PS0+Z%\T*-\T)GMYF.,O& 47)]Q(SA$PO1;M'. M,$V7%4YU*V8),E"^A1%#C1%#;B/VE>R:K*S&+P)R(J==YXR86[@S3HO#,NYP M2XR>O;&O:K5Y-AX,O=*#[=2^22HG6JOGU\\+O/HP9!JL*83Z5HDE:J9[,%_U M:C\CU#BUP+T%%:_7)"D3E#PEY:(_D+:6E'NDBK7U"2&O+BVP[#H92Z"6H+&V M@1_[JE:;9&.I@C-[3BH[*X)9Q:[T4^6!,E4/."D^W@EAVHH4XKLD3U M1^- WU_V5;4VU,97!6Y?M3B%\7>P(O=94:@;7UE8PC)J>P;Q?7V"XS4..(0S M[59=!*8GLH1%EK!@.)WH \_9L#:.HT?ZW+L]#AQ$+?(Y0?A]L,_Y8P-$:!/K#48:<;J&LC>+4T@6E6]/512X@^+ONJ4QM7XV>"<_M&+_MI)Y[2]>I>:K76 M_:<__!99@HQ^SZMW&1P]5;\E[+Y\G8&#H>BC\\.OAE8GK\D4![?<%O(BJ M%Q\:F>H]C,^8R5&$RUGY6DH.WTUDJ[/JU8;JBZ"[\MG]%16";LO##<$I82I M_G]-J7CYHDYP>,%D_C]02P,$% @ R7BK5J%\]/"T$0 +30 !@ !X M;"]W;W)K2_BLH'>\IJ8J62$KR);Y4 MR;)UHFP4JRPG>=C:!W &)'&,&4R &=',K]^ONS$74I3LN)*3?;%)#M#3EZ^O M@%ZN?/@4E\;4ZG/AROAJ;UG7U7='1S%;FD+'0U^9$D_F/A2ZQM>P.(I5,#KG M384[FH['3XX*;RIK8NV+M!D< M%+:4__7GI(>OV3!-&Z;,M[R(N7RK:_WZ9? K%6@UJ-$'%I5W@SE;DE%NZH"G M%OOJUV_.;BYOU/L+=?WAW?;Q\_]/+HQJD:<%1ELB\$3+3>\@;Z8,$KW0X5,>3D9J.I\L?WT'L? M%KJTOVN"PDB=^S)Z9W,MR"AS=1U,-&4M/_BYNK"E+C.KG;K!CP8PK*/ZG[-9 MK . ]+^[-"0,G.QF@)SKNUCIS+S:J^A=X=;LO?[G/R9/QB\>$.^D$^_D(>I? M;\9O(*/.JO5G=65RFT$=YSY4/HB>]O_YCV?3Z?C%N2\J7:[YV^3%2*6?:=_V M;[9.O[#6HRVLTT'5)A3Q0*UT5+;,TAM,CB]J\OS9=*0:P K+ED8YO8ID(/K, MIJ$O;PU^UL$PT251@;6J %JV L_FL\D:\GZLG=L,RVIU.IF M'[.T<&7KI=*JTI'#%Z*G0B2ZA=[*A:J,KYPA14R>OHC*@;,(@8)O%DO(7'I: M!VZKX/,FJ^.(M.*:G/:29-\;9YM"73L="ZT^]F]O-R!"A$^&-,A:]@X?HOI@ MRN86W !U3T]>D'))B9F/A:EMAK@<%B:LTU[>^<-C>7 WE#OWUTIO0@F!0>VN <_017)5W)S2V@K=-G, M$36:8 )X.P,T=:CI30Q3!T2Q1!D00KAG?N:-W&;13. MF@AWCD!+ M_<(X%\PC MYT^1F9R#W5GQT?2/5P9TF@@F(:'339DMU2S V=+K"=$,4>W(-*6M+4,?.Y<6 M:\6@$@F"KFR[$ERL(&-KBK@0 Y)88(*39 MF 7#7V!: G")9V!D,W:46*3)&@OG9]A&.+04(R4/PL<"G$#%I5_%#?JFJ)Q? M&T,+8*5R@<#!A"1,@SWY0<%F)3(6/427-C6P2TEC!/@7$-XN2HLLH4&[].7C@-P1V%+W*QG1-7I4"X14=CZRNQ-XDSL5 M +%]O(:, ]P/T1Z0P&KQ$HE/*#@=HS\ *9V7? (\G?Y,:,DH5Y'_0\KWI;IB M]4U.&/Y3$?7GPYM#=>&]9(&WH5E 'Z@A+14Q&PG\XNU92LL'JO*1$T>7\=]* M%+O1U6>U,%&CX:5PPAKZ!*'<4)UH2T$!5!R!.E*H M*(@""3'/.=]$4.%T1QH< &G_FT%U0,[DT,629%Q^[@#]9I#I*PDX+W8:BFX% MIWJWBKBWXD+?@^O*FDQTG$E4W^5?O7X!V,ID'$LY_+;O8B]K M,V3A-,COUK!22K4B9-G_V%4G%U_V(($K07# ML9DA7.C2^";EL9H S/[.$:/SS($C/NA_2'AJWWFD]@/QYE2CE0;VYK38S A- M>,%^'X\10,L#R+O@LK35TW3RGS+_%VU.&ERV&HR="KNYRRF0\E//_CU?\%4[1$AGV17^] MHJ]TJ1?2%=^D6 MVJ6=-!B6:V>*9VM7%HJ_&F!>N-6_YV?INJYVYFN(LLU#5O MJ).CJMWZ/-6C;>._9O9*#;204\"P.?6Q_"G-D:EP[EX9^Y'Q$JVP5*]5,!47 MV*38HJTAS[MY(9I00HPM:1I&D[&%Y_& A\1!)BN;/]%IA&6YJN'PFLD/X;7[ M%1"YFV H:DRX.]7S.CE:GC09S6[!R,,9=M)=,O$9S?$< QU M6)U:Z*4."WG@K(S];,($M TC"OTVR7NN?]#J!XF:[63F4%WCIT;+!("64O:P M(;&7K-V/\<\R'A>0_F[@U[D.>51O//[KYK [EYS[G"O8C7;W[.:\ZY<_?YQL(^!>;^SR9>\/M MB@8-M+G5KB$[(2=RBUES;M2<'TOQO,@-TJV,H BO%))EH,;!<;% C00:H^3 MF@:BB'XP-5BAT9)O9O4@A ^&_W?6G M,K*U-/FA#30C#,P@K:!.I9TD>-?BLZLI.L2V&OD3]/'KTI0[3&D^VXB5;4Z% MS@J@Q^?<9VZ K,57' )LMY[:23:55'3&0NV9H]F[0VO#)/Y\3$E,_$-F&ZDE MNO!;.N"AT%FZ]89/(+QX9,_]R0&5=9;GW#,):6TT%2';<-=-'K8,GZQ]?UQ- MU+Y@0QFR[$^_P,Z([%,.&1@)AQLI,? !%,RZ*S9\K?>;S=#UE<[_)ZFCK4[D M#& E?0"_E=.IYR'^%\;^="Q(I:?O:MW=8QQ4C^V!(XC,T#>/G[9&D-TS.NNYJ#JFGSXI#U 8D;YO.C1='QXW/U,0T@2<%BU MQ UVZF4P" 9R"T'8DC*QO43PAW@ZWSPT" MP%^:[W4JITD&PI@A5[JG"* <$JF>Z]JT;ZT)#M4E&8UB,Q\*^3X+);*]_)NF MJ:BB!-5;#:[1]]'I*\F$]S6B+K)VX+S9]YC.PGZ@)S/:G_ 3^\)TNLL7YM;Q MX4I<&C?G\51W&--)D!HM.3R2*JW7N6RA,W2*!%([;]=R2A=\--94M /H&&\< MT.YZ>9J(L#\0_SE]/OMXI6CHR._F7EP(G@SI>;;?W9!%10^T1EU +F5&2VIS M&C79.8WB@T.3SG!U0O)(W8C0/!I2_VJHH<27#N!JGVBTMU*VT-]5[#PTOK+Y MN:[413+QY2_J8R"GVBC M8^(R6QH)>>-^S[ZE=?0.7^8;JP:$N2ZRLA+@"OD]Y!+@[Q5Z4SP1Q7+XZ+VI MOTB4_*J7=<@W@BB=57/ 01T9@DR)Z,X@A7B2V/=S*Q,R:MD7)MY71QAG%Y:* M/2U]:4S3%2X Y7Y#?Q4@#D_'2 #L"3E'4X8[ITBZ9=6][4YNN."(S2?S?/!0 MU71^&K-@NQ.J+U*!%I"%?T)/I9Y\Q="YDY4;<;[)A0X^@TR1QG847@FS[169 M:)P<(E F,3.=?=I)C&8/9%>ZWK.&3;/V+MGF_:Z[Y^8/QZ#K!DMUNBYT0T7> M[KC3K;LG\OSRW^HL0\J(*07_;Y>6FY!VJ6Z&_YJ*; M\P'9E#'$QIC\7C<3:-W#MUIJ$)1Y%Y>9'XD51VWGG+IC_$S&@.E:U_@SOH%M&G+9TOWE:#U1^/#:9>C6$T@F\H3"9[P;RJA.EQMO^U\6-^]T8YCV U?4 =_ M=UJ-MN0>%I)<;01#=X*VJGZ$E96VG"LYF%9U9[%>R!W7!]M*-TH)]IA&FE'N M$O;=P^:-(,8C*@646 W?_4N7%FC(B4JVX4-O#@BT+R-IZ9*B8VD"=>6-V&4P MD*&ZZDX]F#<9WX+(C=-;UY+PW)1+UB!1:B\>#TO6JTWJVM'5_G4BF\N5J-TB M#D]0M&P@'#ZVY6/@(N/+-2VFG_<^S:<$0GR7^?G24G^[:X8"\>2_OG" (F=_ M/?,T[ROO7!EK5[6G=G)>).<--"#$_Z+J>^7E[MB4:0+30X1V$CX9#C/'XZBV MZY;K7#.:NL"DFM+XW]D:G46V%=VJW'V,TP_R^J[I+QK=??/0-_?<7:2>12[\ MY/]&62Z/^3)=F@CQ,9,.@2.[1*#DFXZN9G>3?3)#?TPQ/)A@N!3PK!E?.8#; M$Z#3F=,0!3,6)YU_/"3[KOO^1X,_X4"J7O ?JE" !L/RUQS=K]W?PIS)GX#T MR^4/:5#2+"SLY\P<6\>'3T_W5) _3I$OM:_X#T)FOJY]P1_)X4R@!7@^]TA, MZ0N]H/L+H=?_!U!+ P04 " #)>*M6$3JJ;XH$ #X"0 & 'AL+W=O M4O[]/;:7;4X"3KK[DMCKF6=FGGFQ3[?&?G<5LZ>? MM=+N+*N\;]Z-1JZHN!9N:!K6.%D;6PN/K=V,7&-9E%&I5J-\/#X:U4+J;'8: MOUW;V:EIO9*:KRVYMJZ%?3AG9;9GV21[_' C-Y4/'T:STT9L>,G^KKFVV(UZ ME%+6K)TTFBROS[+YY-WY09"/ K]+WKJ=-85(5L9\#YO+\BP;!X=8<>$#@L#? M/2]8J0 $-WYTF%EO,BCNKA_1/\38$(51+O[2-LF^/>D#DE9>HM3"3T_N[E87%S=TGRQ^'9W=7MY]9&N M;[Y=8;VX^(J#Y>G(PTJ0'14=XGE"S)]!G-)7HWWEZ$*77/Y3?P3O>A?S1Q?/ M\Q6ZD+V2BF/^=L M]OK5Y&A\\D)@!WU@!R^A_Z=<_C]$NM3TN=6,U$R.!N0KI@]2"S E%#W)\[G! M'[UY_>HXS\O/E7:\63.]/IH,=RY<:&6HQ M.KP+8I/\9&&YE)Z^&.?8T9M;T\B"IOG1WI!NX72;X(N8>1?CD'4CI T85)N2 M%6$ 8N4\K7L[ FC>Q:(IV'J,0#+0M:B=WH$!-H5JRQ /RJ9,-9;$+!UDK_@&&S\N2X"#O)R:XR0D,V+"W_:"6JBF V M"7A#K8-!TIB.\'\++O<5)F1PAG\VF(P<()SK8O25\!A 2@',8:Z%)@ADL+!* M)H?-1LLX3\V:A,),!Q<F?NDE!1BI:+X^J);WL63_D+BQWEXX-\CRYZ(C#!<89P*EE4X6YA"Y,I [U0&87 M/CXCN:[OD4#CL@;/B/*&&V-C#RT,"EF':@A-A3*6KD!D#V#K7ZG-\]0>":/C MMG,HE-2C;0+=GP42:!^HF],IDZ M]!&*.F1<&_22",F% ZA-_PMZB 1U31& MQ:\9T%BCL89?H16[="'2'4+0#Z&Y@+83'%4BRJ$6^TJ'S4KC<"_7< MVM"#SB@9*"YW^AQQ>DY5 ,021E#K+5ID^-34'NW*UU =#]\>9F33.R-MO&GBW;XR'B^%N*SP-&,;!'"^ M-L8_;H*!_K$W^QM02P,$% @ R7BK5G,A3=), P ^P8 !@ !X;"]W M;W)K;93^;BI$"S]K(C%3 MK15I> U2L.5 M!(WE/#B+I^>9N^\O?.:X,7MK<)$LE?KN-C?%/!@Z02@PMXZ!T6N-%RB$(R(9 M/[:<0>_2 ??7._9K'SO%LF0&+Y3XP@M;S8-) 66K!7V3FW>X#:>D>/+E3#^ M"9ON;IH$D+?&JGH+)@4UE]V;_=SF80\P&3X!2+: Q.ON''F5E\RRQ4RK#6AW MF]C0QB$DPR0]P)?VT:6>+WTJ.KE& M:95^@$MN@M*KMV!#+>!,A"#8DO0XG%JCKFCT M>)&.FKZB^[I_VWUTC>8T9;AX ":$RGVH5O6>'HA?MB7AJ20*,A]7JC7H.[R MMJ&@"JYI=&R]TZDFA_LYS!6-)N-X*6LNA:4B3QLN5U-X>2/)1(RDVAP!U75> M^<*^Q!SK)67:;>[8I@_3P'/(PG0R\>_3\2E\H221,-@E*0G3-*8G%=N_.C_=XO?4$L#!!0 ( ,EXJU93?%<[&@< &00 9 >&PO=V]R M:W-H965TJI'Y)().]VSEW$G&^4_F$R(2Q[ M*?+27/0R:ZO/@X%),E%PTU>5*+&S4KK@%J]Z/3"5%CQU0D4^B,-P,BBX+'N7 MYVYMKB_/56US68JY9J8N"JZW5R)7FXM>U&L7'N4ZL[0PN#RO^%HLA/U6S37> M!CLMJ2Q$::0JF1:KB]XL^GPUHO/NP'B%Y)#(16)) M \>?9W$M\IP4P8T_&YV]G4D2[#ZWVN]<[(AER8VX5OD_96JSB]Y)CZ5BQ>O< M/JK-[Z*)9TSZ$I4;]YMM_-D1#B>UL:IHA.%!(4O_E[\T.'0$3L(/!.)&('9^ M>T/.RQMN^>6Y5ANFZ32TT8,+U4G#.5D2*0NKL2LA9R]GB\7MTX+]?OMPP^Z^ M/K+%[.&6S?ZX8?/'K_/;QZ=_N9?;?WR[GW^Y_>/I?&!AE$0'26/@RAN(/S P M9%]4:3/#;LM4I(?R SB[\SAN/;Z*?ZKP"]=]-HP"%H?Q\"?ZACL$AD[?\ -] M/IN*)^*B MAX(Q0C^+WN5OOT23\.PG?H]V?H]^IOVO8.XO-<".[DMF,U4;(&B.&7A*LAU1 M[$8DHE@*[58>".1/[+=?3N(H/L-3%$S"D%W5,D]EN78!BL]4_MJ=Z8G[^8(=PTY&4_?SI"S/6;7+ MIVJ73WM+H^!T/&$1;)R.H=V8SVA,25W4.;7__,+1 M,!B>3(_9T3@(1]$Q:U/WE0U9,DHVF5 LX\DIFP3Q>(2X2Z1R[;LASL#1-7 Q M;#P*V3B"VR.G+T]L_<4 M!1,K'+',JA9%EDNH3V5CRV8"K15HP6,_BA)58I<<52NW3:3Q$J 6O,2P<'%F MW+"E$-#_4N5*4^*HBH0,FWDBP9I4VC%[<[MMMU&=':,660S]OWO;): +B,]MM_O4< /U^_JT*UH MX+*"3KC,.&1Q!^"*)S*7G:"Y9>,H&K-O>0$P0/^CXFEP" 11G?* @7T4AV"K M.L^WJ!R3:+GTP)&MMV&Q(TQ+]SGP+/*MQZ[UOT%_%SEY#PI;'96F:D(4GZ;! M9!P&81CV77(GB=*I2UR'%:G45#JZZ100F2VNT1HJF;#A) S8JWD3' Z<0T8I MPU.!L#'Y!=4)\/$FNAD#MI? F;I4(:@JWWCA3[@A5#J87U5N'PQ3("BA%IBN M"WM!VN'&*&I13H_K J_5M100.DX+E69=\AHU#2DJ;GS6^2>X#39I^; #M'W! M\B44\B5U#41_.%4^Y( @,VW6O9.N>J2X@&XER=J76 M%MJ"8!/L2934[^_+%)]M6H*AW3QS8^2@8-S*89UU746>(_=,30IA8Y/))#OP MR;L!4EU3(?"HK:BNIWWVA!=OVIW..&%(O1^5#/<()!?6OML; M?"OW0?"RK*$-H]RU:X#2AO]I$IT&8WP[M.UF);6QSDQ+8]=/[U\K;.KE?]$. MF&-Q]"M#"T$.NK%#PV/KU4 'ZFU%A-M,JWJ=O5';9X]=IZA<;,M&4FOG,>X\ M/["JD>M(<57GZ6'S]HB(IG@]?%T,/)$T721Z7=.@AK]V!^)*('=+#U#%MTWM M>Y]Q(7OCM@/#V\!*E[.N28D"9TCH"ES1IX#+N/?RDR/Z1!GK^*VHPHW'6RUS MN>9^>FA!"".5&GCV12;+)*^I7 ($[T<4CR/0."C6 %QS&EZ-G$A=)T#W=!@W#0SX MVVTE^N_=&0:=FQ\FYMK=;ZF$Z]+Z2^!N=7>%GOF;X_ZXOW^CLZ[)]5RL(!KV MI^,>T_Y.ZU^LJMP]"IT'0 ^RNE;/M"!G;_6+C\/U!+ P04 M" #)>*M6BCPZ$%P# "5!P &0 'AL+W=O9YYQC,>#P]*?S,%HH7G4D@S"@IK][=A:+("2V9NU!XE MK6R5+IFEH=Z%9J^1Y1Y4BC")HFY8,BZ#\=#/+?5XJ"HKN,2E!E.5)=,O4Q3J M, KBX#2QXKO"NHEP/-RS':[1/NZ7FD9APY+S$J7A2H+&[2B8Q+?3MK/W!K]R M/)BS?W"1;)3ZY@:+?!1$3A *S*QC8/1YPAD*X8A(QE]'SJ!QZ8#G_R?VGWWL M%,N&&9PI\1O/;3$*^@'DN&65L"MU^(3'>#J.+U/"^#<<:MMV+X"L,E:51S I M*+FLO^SYN ]G@'[T!B Y A*ONW;D5=XQR\9#K0Z@G36QN1\?JD>3."Y=4M96 MTRHGG!U/9K/5X_P.YK\OY_?K^1HF]W?P]>'3? 6SQ]5J?O\ GQ>3Z>+SXF$Q M7P]#2SX=,LR._-.:/WF#/X4O2MK"P%SFF'^/#TEK(S@Y"9XF5PF_,'T#:=R" M)$K2*WQILP&IYTO?X%NR%[81:(#)'"99IBLF#/PQV1BKJ63^O!1RS=B^S.B. MT:W9LPQ' 9T3@_H)@_&'=W$W^GA%;[O1V[[&_C\D["K_9?7_S6F]C9@#/E/O M,,>]5;9 326M-4H+@K,-%]QR6LT4G7%C":"V0%:P58*:!9>[6_B!2YI2E2$* M\R-0]K/"I_\.,RPWQ.@&)X=[]J()"^^AW^[3N]--F[6-DI73TNE%\.%=/XF3 MC\U:ILJ2&]=H#/0&$:%[KYQ:Y55FX<"T9M(+3KM]2 ?QOTQ.0;U )A@O@4M3 M$29#ZA/.@/M"BUN]09O>_:1SSK!%+X )V.)QRP3N:*A1,.M%DG>Y^^?N#9(V M#*(8UH72]B>+NO26KGB_LXM;42>%/CV_*$X-=Z,LM7'_6]"]B=H9T/I6*7L: M. ?-33S^&U!+ P04 " #)>*M6,QA_SJT0 4,@ &0 'AL+W=O>_L!@ 0IIS*U5YCX;?;BOS MS:Z4O9GEA:Z-DSIO6Q<5T M,GE]L9:Z/'G_EG_[V;Q_6S6NT*7ZV0C;K-?2/']01;5]=W)Y$G_XHI%041 AN_!9HGZ4C:V/T:Z&558?F_8NO73F].1-985ZW#9G"P MUJ7_*Y^"'CH;;B<'-DS#ABGS[0]B+C]*)]^_-=56&%H-:O2!1>7=8$Z79)2O MSN"IQC[W_O[+P\?/C^+NSU\>'GYZ^-OCVPL'JO3L(@L4/G@*TP,49N*GJG0K M*Q[*7.7]_1?@)K$TC2Q]F!XE^),T8S&['(GI9#H[0F^61)PQO=D!>A_5W(F/ MVF9%91NCQ/_G2 &K#(;=?+^CW^X?#UY M6-U_-(N)42]]6ZEN6S4*53 M1N5"EZX24MSCLW8C\55EC='N6<@R%W_&?EGBR]W2*(4X=>*,:/SQ#[?3Z>2- MW],^Y)\OWYR/Q-SOE^NJ7/9./9-6S"L#I2ESSFONZNIQCUNB?'GSQHKMJBJ*YU?5M@3KMIE;G6N2D>@N/;>5 0-$^2>=W\M:?&I* MIOKY'^+1(-IX+<"H=#OKP$*9:5ETED%%:U%4LA2D9YVI2)MX*Q2BP5A12P,5 MX1>CH,J%J=;" =0$OO#?,P0P(]1&%<]1=_[0J+&Q>"1A=_0I:E-M=*ZL #+C M6-'41/1T=@V8* I"O(7,= %SC416 46M(TFK!=@M-?98LB8TE>2PWB[I@5&; MJMC0IDCI>U@Y3!U'!R:GB4GB;5T;;;$4S\\T&1Y^IQTI&V%:(@W1D]/+2;OG M3-,Z.J,B?7=6=0B3,%C(*]U*F_P .2_48:'[XGE1=$ELRB54L)1.88F&>]1@ M&6[=0"6MK%V^X92_PMB"H\J[.IU$:46HWQJ2N!*U,AFT"B]DE:E"+_6\4$A@ M&9&V8#%3>B/YMY*"=*/(LY^1C4C;NN3(Y?4FA\0*.<6M?,CLF.Z 09'MH P< MWT4*!HI;[""+_C>K@38?MY78(E(6#>(2_Z4$T:<9T ?A8BU3L-)GZZRR*#;$ MUU9AB"^'(H,=RGLJ&5_3:M;3D'@>)W;<9%LU12[F4-Y&ZH+5.%=NJU0I_MJ4 M2LPF@2DZXR-TO9XKDQ)2BO"^2QTC*LN. J^8P%=5NT#7GW8U@EEM'9$@V&4' MX.3<.R2Y3Y:QRE8 >2%SKX?6"O!0V^H'6F]J#@G&W(K@B/@OE]9K2&8KK3;> M]E!E5#5<2:^;-<6$*AN(+,U2D5D>L*&#?W,E#<4$)0V H\3_Q )/&' ,Q0?E M(K@5%0KP!/)W=@2*H?Q7 "I_57Z!^/KW3U]$73163,:7/^Q$#>@B"L'D='R- M9[SL9CR[_D%DLLB:0KI 6LQ>3T0N^30HX^QR"F+$&^H+<<,190 M0I:D',,!ND_5FQU%NG729\ A!-MA5A/T1 51)"("(*;53^)L]OH\(%C4'!:2 M/T'SL->>1A(B=7F_*PJ<0*T$9ZHA[L!X!1\D!_9ZP1;$@FE@=0JLIJRESI/, M(V(ZA^O* &H4/L.HUI=U38ZC!'(!="&-)H%(>*;-@#82D N?*<./V.=1PE!. M[SGL(%I1+""7@'U='H#ENQ32Q?-HUQ 256SGC#7(2TX S"*K72R40G#7C;&- M;'W!LW, +=;1%C8UV'%.Q3I-%,RJ=PV$(3]L7S]CCO%[?P"%G82E1S9%:& M"TJZDJI2>*-FU1&-JR2+JUP;%R&-,7_TT7C?23M!?JY(1')+Q6BT8;A%4:@7 MZI#R1>, [O^*NE&+A9>XA=4UW+[*(;\=)@ %$FI;*HR\E6@[)8I" 80YJQ:R ML2JEL*B1%7*T>B)D4*@6J 9"+<1F0LMDR8^ZL9CJ%HN-&\IS2'+<;90D+170 M@O833X6..2MX.A4E?"A1(I,C^!4'AZT*G;,YYK+@JL5/)?80>RR^I!KM4ZS1 M.NG2QRXS.?* Q0(;Y7\3;#1F9J#6@X5UL0L!F M)OG93@VQ4W5&5VA5 ?N 7 PDE'*CR83_3XF2#%6&@4J"\'TU[@6<06[0QO-( M^,[EA81[9=_FU5,L;;G IIUS5:J%9@9\+S3F3@U0KI &65AN35G<'1IL#BC+ M;E%C(4\3=&-I:.38.G5=:,_+ ;\>3%ZNRV_'M<%'VV'>@?;!FL$U-TP3G4FT#YDM4K*%6ZYDWH,J> MUMO6EP$*8(W6"[IL2!TUTC0Y>]C55O=# 6/W4E4OB^O=DY-MM&T!)*>Z J'2 M$!+/%4)"I=)E+ZYZ1LC50AG#!- REA[RH27?LH4?; !#T.^U3ATI_KU$/\QX ME]Q_GO)WG('3]P%(B3U+Q]RS26*VCXT[6 CVNYWKL6@"%BYZ[C+D:3R8"=$# MKGV/NY+>-7?X[%N6H]][^:X\Y/41)G.-*L%0SD[-Y@#I/=<^Q"OO96ZE+[%6 M>KDBL&!XB"MV Z=CW= (?:+Q3X-P#L57"SI@A)V)'&RWTWJIO;IC'^SC1%]K M5,;D1FY+458IY0:R0R;\'HJ<+4SUI!&"-*$[O1[=^'38P0)X(*#:'WW\O-^Y M<'LQLXZX*XFZ>('#3M+YOF*N5[4MTH@4SN58,CL&IP6!OZ')*0&RA_'>S";( MTH;;GH(8C\)\#FG5NPA:PHK;.>3RDNU,(U_X-4VC8"FNP19"$YXAZ#TS&P4F MG1V>>B4[^'L7JO_D H?!]&P0*+^D<1]]R2*I;B&7?O0E60R+J+4=@7EVYVP[ MJ=94:0^.:"HZ!*USKN8H!Y* MPE)O2#%F$%Z D6?BHC)Y ')_#JBBVF((]1H,I]' T<940?54!A>TNG!V)Y10,V"DH5&$B_)L0>-'M$60D(D,OG>?*9$&[,S0\/WPM=> M9%Q\O\LWDINOAQ*:@#W4,MRI*"[$4.@8*+9X/A]Y%5+>?*4($ )%JM:O_M0. MFT]?M[F,M')ZTWXG,/=PYV>/]!R?KH\7,%U%<4_2 9Q.ONTF43R#N59^ D(? M2.D;6>P6!O@HNX76T/41]R]4;GP/=-/\2_!N!D?SOJ 1><20T'?W3#.-T(5\[TQ* [3]^[,W)/@1B@>TX; MK@DHJE5>H@P9).Q1_;?+E+L\?UX2D<=4^5J+4Q"@K-X<35C)$* 9#_HNL'AY#<*R3I& M)1@@Q*$;[(#HO$@O&,\\5LR?=S>%ZT@"\.=A-Z.;-]M@0\EU?#O/Z+4W""J@ M6T%_!U(Y[*8VY%1#/'KM1S[X!B]7J&M@V-UQ29=TJYFV 3]KT;@W5^C*.1\)8%(K0[F6A>E(FT]8/>;R.#+W:$1LG(@(?"Y>"WI,&F'SI MJI0"?Q0VQK#-M,F:-:DAX\08(Z*MH+D2YS*-AAA<-+/R]A3&]7>KL8XWJB>* M@,.^Z&?9G5Z:STR-]O2'_0D&#U2R<"W0X;3?N,WUHC$9!S9)9I &O&^FLG(G M[NL*?/+=8J\61C&S7'+LTZ463VVC"%%?9S[DV.WJ!H^X&CA/];-MP+$*]45B M^2"YA8KWH8<&YR1G1[Z.='3_$%HR;7>&-_]%UI)P9.='H$/#T.&R^K.U"4_^ MZ5'9'AK/[4X AZ-K&'?:1L,VWC"2^6CXNL'QNQ!I2-=Y2V(;>:)I#;2RHO[: M7XA/KWW[9%]+.334*WFX MZ*DRI7*:RJ#I[,9OI#_RDS]?\6XXGT?S\A1PY-M,*D^HY_!C7(;S]EZ;L/P5 M%Y.U]D'[W=<)PQ'$;X6E,+JGUPV& HB[&2*>YLTO!$K)58!OH=BCF#Z_SL" MVY\F7(YOA]Z$P9^UOW3D0BD6,);5D,JB)!=J$FTK?Q%EXV%;Y3-KWR8AD'V" MC%'=?P'HT/CB<15)'Z+:OA$0)PFH-(S3_R*LMB]>;0U?E!&]HX3*6A M*!>P>VP-'MDA!)KWITJ4X[>2*4(;0M,G?9(7*L\.N>JJII3VJKR.#G\1>&-93!4>'OJ+W M#,/(/FF,CSV:$;_76PY>(Z8Q]9YE!@'@Q63:NUG\MYWJ<' ,2J#+],H 7:Z" M&T\B-&=AJ.8G*[^+.)\C+.OV59)X=,I>;@43Q1=2%%]E]]MH=N+3RQL_XZ2Y MP8P_]T<#(P8S'T:]QGT(]\+KGL-K(^+;[HTH7YUW5K;W\CLN_SM+/6VEOOS_ M$/K8N+B3P'O3#Y9[Q,5%>*\S%::+"GZ\#7#5%_!'7NRE^E4W(YN;FX/C'C: M?J_[JLJ.4[ QZ;U#5H?=$YT%/N6W;2^G;_Q;>9TOUV+*'.#C:S$;S68S^G@3 M/CZF6RIQ??U://*[(1UFDOJ&7@B_Z+RIOU9FR?\>@:I?Z,N_M)]^3?_DX II9TG2I4 MLG8QOKD]\AHA?7%7S>__SRKEJS1]72J(,I05XOJC0 M7X4O=$#ZAR#O_P]02P,$% @ R7BK5FFCP"_) P 7 @ !D !X;"]W M;W)K&ULG5;;3N-($/V5DH<=@83B6\(UB00,H\U( M, @8]F&U#QV[$O=B=WNZVYC\_5:UG0 CB';WQ>E+U:E3EZ[*N-7FT1:(#IZK M4ME)4#A7GX2AS0JLA!WH&A7=++2IA*.M68:V-BARKU2581)%!V$EI JF8W]V M8Z9CW;A2*KPQ8)NJ$F9UCJ5N)T$S)7.M'WLSR21 Q(2PQGQ'C M9;JT_@MM)YL>!I UUNFJ5R8&E53=KWCNX_!*X2CZ0"'I%1+/NS/D67X13DS' M1K=@6)K0>.%=]=I$3BI.RITS="M)STUGU_>7MY=W]S"[AF_?:0"!SJ]H-PX=66+Y,.M1SSO4Y /4%*ZT+_T [UJKC!@:7=+-$F;*H4'KX,^SN76&2N6O]YSN M,(?O8_+S.;&UR' 2T/NP:)XPF'[^%!]$IUL8#S>,A]O0_W>BMJ*^S_G?F**0 M42[BXWUP!<*%KFJA5H#/F#4."> M[WME+S!'5$!YMKJ4N6!>4C$*6:73G%H+';VY7Y"VRJ0HP3HZ8,:V W[QP.#/ M1AH2?LW':7J5CX0K:NE(W5>7G#?<>BQSU%Y<85NN@'LIZ1.8="O0"Q!U;?2S MI":#=+V3C@[WHRC:YZNVD%GQJT 2I2P 0N6P$X^&G31%H4;?YV-+&R@XD\3%]T_@0KFF4EMI2?;HN]F)>(A?(6;UZAMU1O >[ M2;K'MK?@Q0='C'H\A/>:1_BJXU=HEGZN60IHHUS7_#>GF]%YUDV,%_%N[I+S MY)J%$A>D&@T.1P&8;I9U&Z=K/S_FVM$T\LN"QC\:%J#[A=9NO6$#FS\4TW\ M4$L#!!0 ( ,EXJU:RW8^;K0, $T( 9 >&PO=V]R:W-H965TS=SEV.@;3YT^D'8 M"]9$EGR2'))_WY5L*&D)G7[!>ME]]ME'TBZ3O=)/)D>T\%((::9!;FTY#D.3 MYE@PTU4E2MK9*ETP2U.]"TVID67>J1!A'$578<&X#&83O[;4LXFJK. 2EQI, M511,ORY0J/TTZ 6'A17?Y=8MA+-)R7:X1OM;N=0T"X\H&2]0&JXD:-Q.@WEO MO.@[>V_P.\>].1F#RV2CU).;?,FF0>0(H<#4.@1&GV>\12$<$-'XT6 &QY#. M\71\0/_9YTZY;)C!6R4>>6;S:3 *(,,MJX1=J?UG;/(9.+Q4">-_85_;)E$ M:66L*AIG8E!P67_92Z/#BX<8@][SJ09WG'+)M-M-J#=M:$Y@8^5>]- MY+ATA[*VFG8Y^=G9_7SU\.7AES6TOGY?K]NPO%_!^O-\=3\)+<$[HS!MH!8U M5/P.5 +?E+2Y@7N98?;6/R1:1V[Q@=LBO@CXC>DN)+T.Q%&<7,!+CKDF'B]Y M+U>F)9<[ TO4L,Z91OACOC%6T]7X\UR^-5S_/)Q[+F-3LA2G ;T'@_H9@]G' M#[VKZ.8"V?Z1;/\2^O\[F(M0YXF^BP\+9G@*>!"K)90Q;2A),^,U:WW\,(KC MZ&;C[>Z7:S_OW;2!&TA54586,]B\0L:?>4888',$206&2]I&4!HKXQ'VZI3+<5R+'W>'6C&G#'8HD)IUZ^4(4' 0H*9WT,&AZJ@P[1*C^'A( "S5O--53,D;:FXI4^Y$AEJ S]!*^GT M1TG;C0:=Z_Z@#7WS%\+]T)&!AVAJ,$ MKCK#ZRMX9%HSAQ0/(G"7L!??P+GJ$9Z4>%)VYQN9>VZ5M'6U/ZX>>^6\;A%_ MF]>-ELKJCI( @5MRC;K#00"Z;E[UQ*K2-XR-LM1^_#"G?H_:&=#^5M$-;28N MP/$?Q.PO4$L#!!0 ( ,EXJU9U;J!C704 &T, 9 >&PO=V]R:W-H M965TQ)W*: MATX?('(E8@P2# !:5GY]=\$C4NJX:5]$7/OM[K<'H-.M-O;"]G6)!>VLM*%>#. PG@US(HG=^ZM=NS?FI MKIR2!=X:L%6>"[-;H-+;LU[4:Q<^R$WF>&%P?EJ*#2[1?2QO#B4NZ#WOZ&C3]CQDNT MLOX7MO79T; '266=SAMALB"71?T5CPT/>P*S\#L"<2,0>[MK1=[*2^'$^:G1 M6S!\FM!XX%WUTF2<+#@H2V=H5Y*<.U_>W5S\?K28+Z\NX>+FW>W5^^7\[NW- M^].!(W0^,T@:I$6-%'\':0CO=.$R"U=%BNFA_("LZDR+6],6\;. [X3IPS * M( [CX3-XP\[5H<<;?L_53!@\6E (4[@5.\HL!W-C1+%!/_YSOK+.4)K\]93S M-?;H:6PNG6-;B@3/>E0;%LT#]LY?O8@FXBV/UL@9(ON0==^O(IE2ALX$\LM# IZ#5<2D/%I8VEC-S!AJAT5*A$ MHDPZK-)5ZHBM:!6I:!UY8D(7?-:DH$J1:X5T_@J7'.%@,:F&/?K3R297L[^,CCY'X2/2FD%]H7S\T%#\0 M1[+80(E&ZA1J:9+AO9K%5#B$M9 &'H2J$"HGE?S",CX 2I YRR33BJC+=8J* MS,EDDI%_B:I26A505/F*%%*<6!TU,*8Y$P[$>DTL/J.-R>5=D3.-'J'QAL+4 M.73(^9Z?HBR-?O0:U0Y>1L%P,@W",&3R_Y4O#AGK=IE!)-]\2T%N*4 -@3QL M.T( PGH(RI^T#@:IFHQ#K^I'8>)^$]PFS?TM(=T.I&TNJMHESB5%-Y@]AO<= MKVU2??*]GX]1A.DJ(V?0))*\*:D4$&XJ9RE-4XX?\7^)"7J(U@:8!.,X#$:C M$;R$:3^*X5>."P%&P2B%5R]F<12?=-\+SF?%)E#LR/DU M2I9_'8TF0309O8%9/YQ]:\@AH3 -IK-A$(W&9,6D'T\/:\I[?]@3*/^H:_CB M[3S>#[#84J.PL-H1E<8P^X8U/W'$AT\4E"'4/.C&3YI,Q,^54&US2*J\4H)O M\6\)IECP@:=T(VMLCZ/1>>4OP/J/L)>M/92(1ELJRKM M,K@+?8?,6VQ#NV$H72@.; 6(%95^'ZY_-">IF'WC0'(U!9I/QJ,.F(PNF]NK M4=F1031$OP1A-&P/>W?(_BW_%)K<(BWMR-KH'$3E,MW4&65O532;M;+#-I,(E7 28/I,_]HKS4U3 M2$25S_'77#!Q>.(GOLJL7XE.WNPU6?%4B^W#GA!U#2/OV_Q[Z:OS@[3W1VNF MTK!!P_[D)ZK8$OUEF%);28E;V$E47^NWVW_0G-J*6\]LW)_M23HT.;PF!W8H MC'T#DZ=>%(.])V".9N,?NMP?J8'7K\%NM7M+S^LGY-?C]4.<0K^A&@2%:Q(- M^]-Q#TS]N*TG3I?^0;G2CIZG?IC1_P$T?(#VUUJ[=L(*NG\8YW\#4$L#!!0 M ( ,EXJU: )2H>L@, &4( 9 >&PO=V]R:W-H965TG29;8!I(TQ3(L;9!T:X%A'\X291UZNE-Y MI\C^]^.=9#<;8K<%]L6^%_(A'Y)':MH9^F(K1 >K6FD[BRKGFK,XMGF%M;!C MTZ#FF])0+1QO:1G;AE 40:E6<98DQW$MI([FTW!V1_.I:9V2&N\(;%O7@M:7 MJ$PWB])H>?D@ M\*?$SCY9@V>R,.:+W]P4LRCQ#J'"W'D$P7^/>(5*>2!VX^N &6U->L6GZPWZ MN\"=N2R$Q2NC/LG"5;/H-(("2]$J=V^Z7W'@\\;CY4;9\ M=+SN91)"WUIEZ M4&8/:JG[?[$:XO!$X339H9 -"EGPNS<4O'PKG)A/R71 7IK1_")0#=KLG-0^ M*0^.^%:RGIO?O+_Z<'L-'R\^7S],8\>(_CS.!^W+7CO;H3V!6Z-=9>%:%UC\ M6S]F3[;N9!MW+K.]@+>"QC!)1Y EV60/WF1+;Q+P)KOHZ=S4"!_%"MY*FRMC M6T+XZV)A'7%!_/T(W7(^N BQ+#.\GX!&K6# E3'X9IZ^"]$$ZS@Y? 7<)M&S(!!G"1]81RG/S^RM3-T*O7[\XS=*3X41CZ&[OQF] M=]8^M@.% MF_L'SKK@UB&"&!^;EE@D/?7A->VR\O*)=WI3+X2N)4^D$>2D4.R8*4O+(V*Q M!@&/0K4]&%^93G 88/!'LPP/#(ZP9\_/S<*!CUZ6G+__\'M8I>=]?7E1;I]( MQ(2\56'9@H4EUZK/4,&)(8_B<1E2FN+[A;'I'=G_5Q-EJ]2SE ES0][RP)T) M[G-^Y).U".D+3VI72>A==35^KK_$3UI_C;0, \ZRJ5:[?@IL3["R%9<7? 4A>@.]+8]QFXPUL MORSF_P!02P,$% @ R7BK5LZQA-*-# <2, !D !X;"]W;W)K&ULY5IK;QLW%OTKA%L4"2#+DFPW;P..G31IUXD1NUM@ M%_N!FJ$D-IRA0G(D:W_]GGM)SHQLV=LT6&"Q^R&MY\'+^SSW7(Y>KJW[[!=* M!7%3F=J_VEN$L'Q^<."+A:JD']JEJO%D9ETE R[=_, OG9(E+ZK,P60T^O&@ MDKK>.WG)]R[=R4O;!*-K=>F$;ZI*NLUK9>SZU=YX+]_XI.>+0#<.3EXNY5Q= MJ?#K\M+AZJ"54NI*U5[;6C@U>[5W.G[^^HC>YQ?^JM7:]_X69,G4VL]T\;Y\ MM3)#_T M%CP=W;-@DA9,6.^X$6MY+H,\>>GL6CAZ&]+H#S:55T,Y75-0KH+#4XUUX>3L MX\7%^^N+-Q^NK\3IAW-Q]O'#]?L//[WYO*E+56ZO/X!JK7Z3K-_KR8,"+Z0;BL/Q0$Q&D\,'Y!VV]AZRO,/[ M[+55I0.R*G@AZU*<05U=SU5=:.7%N?:%L;YQ2OS]=.J#0]+\8Y<7XB9'NS>A M0GKNE[)0K_90*5ZYE=H[^>&[\8^C%P^8<-2:($W_10<\E%]#U M0HE*E;J0!GF_TH42NBZ1HFXCM!?%0I*[E-/_5*68;L3,J2\-'"T*(W45W6U: M<0.^#I")D"QEO4%6;\14%;92@(CI[RA;$:Q82:=MXY.0@3!R[1N=HK=TME!0 MJ9Y[Z,+2K,,EX$44MG$>US.!/\2T\;#;^Z&X:HI%5HFVU'5AFE+E6U"\:)PC MO:T3A'K*"54MC=THA?U+#8/UM G611V@\%(%3=>#+*2P=:%<#;U8)\#=9T5I MEI6N+'LTZ88;95-T)M$%/"6G&N[:))E#]G_VE29[5]:LX&H8+D7=5%,H"HE& MS1$@R:#G@9M&\LYP):G2="YYIXQN*G%II*^D"*I8U-;8^2;N! "G4'AZ&PNQ M;%NP1(W4-@"NPB*Y/BGWPW=/)^,G+]@+P0'1R"SR-+T^5>)S;=99L-1;% M!ZN1-K:,FP'SA^(]O6JT6D&#L) !*=&%C?:6);)+!F4HTBOE8L[I&L4KX?P7 M8F'76.T&.3$*F4RO5;+IKL+2.:THCN&VK^%B1'[9! 67SB4E68QML %>,=C* MD%C6!=U,R)741DX-;/E@ WG)!S@B+X/Y:FYQU>IGE[I.25')&B((I+8U64BD M+#R%7..:0/=!>Z2L)!??]A"Y6]TL44>JI%U*O=)E(PT\!M^G7>5\3O8$-: , M 5BAFT5ST?&PE3007L(F.$_-9E24T)'J;X8R VK">,2YU+&FHP".(WB#DRE7 MJ$RD7X@9. R^=VMT. "Y<9A+F4%TST4I\+>5K%SKM&5#OZ^,"ZMT0SG9.:, ME6WSHHTQA9.=U4H=]/S>)9\.E !+Z[U&,*.2A?54K=Y;V _OVGM10.'J2,Q,^@LHEB_H&M_8!0A:%:Z"^[ &)CH&[9SND9U"Q,5)M M1FMRM:\7BG("O=&3.V()XRV2I4NN/A3SE/*]Q759V8;07]94]6",WM9X82.4 M1XW3[BCS&,'VH6H?DJVRVZB5GE60 O&DH-%VM"(G\=7IRH$@O$L&U&$ M.7"3Q8LN%AG(E:Z ATE0RJU6B$-G>-(X+DJ%'6OF:^AD#OI$S@)- MX&Q=XUZ\0]REZ^"W$(2] L8)',66D^TM88[2U&]A9$RGK'QF"7W!A>:NBT)W M5+&[M2/G 8_5G%Y-R#<4ORVT48DW\#X( WQC3 N7TB%G$,PY1:X'6M0?2A5W M8/ $5G6I>JM ^5F;5]LIIV*)+;'DAF]CO^\GQZ/!:#0BGWX_IK_HWS;JY)"3 MTV\G\:R3P*0DYE3/S#)&G3S/_9\T ]"E81;^"N);')=IB86\ZNK7-YQ32ZS M!=A<6R/P' > (FN;^:+OO-@J_;\3B,3N84QGY%:%4AA/R>.@R6C49M.KU]PK MQ*_#*[!1!?V0*RK"^9N;9!G/*9Y'7[N;79TEEOI)+:WC7D)CJGBZ_PLJWF"C MGQLPG2>#E,IXSC=^S#EPB[:0ARQAYT*:&>,-19@@'!4"$#*Q,'1H."1R#M$^]+TW$&<8 M4PPI.Q0_65NN8,&G!ODP'DWWCVF)4TU=DJY+AUIRVFSZ $K L(HELT4 MK*[/4DA2V0[L=X8N.YOM@X"#EC=>QM+,LNX)R&FY(HJ(*JR5FV^VYS):D&@; M$^TH=-W1O'O*- ^>@]O,#=(](TZ$T+ME)[Q2G^E=T=3T)MHS)76+26W#.#4) MS7C ,YD_Q0$N&JM]1EET^#2']3H%8U+R3MAL][WM,8S1D5(G6<+Q:/%@AQ$T MB9!XJ!-GEZV.L2/'J%G7''H>;]CSE5>&5%CIN7414-..=!; ;?N!$>HK1\?! MG='Q&^83GN]I'MFD:<1R._HCT\A:9=]_U1"BTUG)'QY!2*,MPKASVACT>"04 MT?$ PVT-(/^MS.7HR7'+7":#XS_!7+*$_POF,SI,M;^>J%1I52>Z?C-I%?342#! MV-JV 6BQN7=.1I-,WT0Z 0Q\XC?UZ2@2:FW(E<"5!TPC--A]:!"#2-%Q<7Q* MK020U:,J':EIVT ?,V-A3K>..;U:HNT'0F6RBS*&%;IS< 1,KVB,(8LI^R7U M(NJ?9L-#6!'=5ZCM_/[/%MAX<-0;#B:#HS]18IV,G47F_]>J[&,>-=/'C8&X M6N@5F%]0U Y]CQE'SBT10($I'ET-6;A__GNU?7/]M:U2(JZ_0 M@ML1(7/N7C%$%GSO:=TTT^ RT^!XI".KG/+MF18=Y=26QF>3R(&D_M[QQEL4 M<":9O5&J^$;%8\V=,]E,P;5T0-*15_10A#2>?^6/#MWP,QF-G\5#5Q5">V\R MZOOV$I+HHTA)_CU=;F[$1?IZ6MDSZY PZUE@VI")=3AUA M3/P0,$-$@=A(KK(AGMC4OS<(MJHQV"VJ/!3E^LU?5"2Y.-%C1GXX+4UOI $B M@5$7=0^*TTZ\)]2:V \Z'\*".BJ2Y[(TUU^&Q6IJIH; M9::I\9RN A_N/E=D\Q%$F,WXPO-CG$W[(-@K\;88?8^WI?,_3.%W0ZHT[%']CU/N)3MB&7^ M'/,UWUIVV?X-'PDN&_0<@IK^E_#3D'K18=N,MK\[E00(<5W16\?\8P^F6W6(OXAH[[:_)SF-/Z/H7H\_1H$WYH@SV,4,2T?#)\=[PL4? M>,2+8)?\HXJI#<%6_.<""*8&PO=V]R:W-H965T/109LGFQ,Y>"ZDLN,H=ZZ\C6.;YE2@[>J2%.]LM2G0 ML6AVL2T-81:<"ADGO=ZGN$"AHLDHZ!9F,M*5DT+1PH"MB@+-<492'\91/SHI MEF*7.Z^()Z,2=[0B]WNY,"S%+4HF"E)6: 6&MN-HVK^=#;U],/@NZ&#/UN S MV6C]Y(6OV3CJ>4(D*74> ?FWISE)Z8&8QH\&,VI#>L?S]0G]YY [Y[)!2W,M M_Q"9R\?13009;;&2;JD/OU"3ST>/EVIIPQ<.M>V C=/*.ETTSLR@$*K^XW-3 MAS.'F]XK#DGCD 3>=:# \@X=3D9&'\!X:T;SBY!J\&9R0OE#63G#NX+]W&1Y M_^MT?7\'B^ER_2>LE]/'U72^_OK;XVH4.\;W5G':8,UJK.05K $\:.5R"_+;GD1&Z6O GX@*8+@WX'DEXR> -OT"8["'B#UY(EB8XR6*!Q1U@; M5!;#Y;#PUW1CG6'I[VMYU[##Z["^;VYMB2F-(VX,2V9/T>3#N_ZGWI*!;V%1_&D)1YAE0M)^PY,R^,SS"JY0R/P MP[N;I/_YBX4'5+@3:@=WPG"S:=,!- 0IUU5D9+C@IBE\R8479+NP)IUI@PTP M=N"!3[H66EA;ZLI2!X0%5$!%*?61R--R.<%<%R6J8VAZ'UNHH,8TU95R7I.1 M#\<#Q#'TGIRV$O=M*M<":E5'@Q\52L%7I/"9D3F!G]1H;<67)Z6+&&NV\))Z M<6A(_F1AG@N%\.U[P)=6-P$A83WPV&GU^L% MP/?]) @=/C9;4AB;DFE-W;7P=Y12L6',1IMJ-Y<(7JMY^*S"5F0V85WP$*X*_6P;+7M4S.M)^R+>?U. M<0WXLEN0M&777O?SQPA,/?MKP>DRS-N-=CR]PS+GYY*,-^#]K=;N)/@ [0,\ M^0=02P,$% @ R7BK5F/'(Y;X!0 LPX !D !X;"]W;W)K&ULK5?;;N,V$/T5PKO=QH!@6_(E=FZ <]G=/.2")&T?BC[0 MTM@B5B*U)!7'_?H>4K)B;YQDT19(3$F<.9PYG5*F5H>M\+6^L.=6*36?>B>'!5\0?=D?RMN-=ZZ#4HBXW9:I9TBIO/:_3/WG?X,N.&SE3VATAL>MP:MUA"R&OE3S<.&PKCWBD)4*T3>[FHA;^4YM_SD M2*LETTX::.[!N^JU89R0+BCW5F-60,^>?+FX^7(WO?UZ><:FU^?L_N++U<7U M [N\_GQS=S5]N+RY/NI:K..DNW&->5IA1J]@]MF5DC8U[$(FE&SK=V%?8V2T M-O(T>A/PBNL.ZX\OQ&X*TMSS92H&#>.:&%\L-"VXI80):15JU='*9QD]RRF9K9B8,YO2BM%3 M*F;",B-RD7'-*%92Y2)F<6* M\&KD"AB *"VW&YK,+"57&7B$1&DT(!/ X5J6LH.&. #%Q*FC.5,-L0K'P M'2_GWTC#8+TQR64"/IRI+EM=/]LR@#]RT#,3F; K9V4B3*SA')L+R64L> 9W MJT;N.Z),MMY]+D@71MCFG#E57"<.Z-P[X.BJ=![)N+<.FQJ#C6,31!@FE06' MCVB@@)JM/-0[;D*JIKI:H0*I_0%9S_.!)U$G ,E6V_%.>:7V[ =G.7%3QXP[ M6\T&5(<]/&O_:G;F+??A,W&FC,,S !=@LN 9PHF]D$OQMYN T57HO9!=J@U? MGY-HFCPB#I"YD*07*Z]VM'$#124KK!*[?Q&Z?F>ZJ<*K1*4 TLTK).(8I9A MO*=E0YB#7T M>H0*_AJIFMT78GM1?]"N?RL/G"D!D^@0+V2';?]?&VWY$YN1I+G8(1H%T6B_ MW8SO,1[]7XR'O6 <#MQ#,-J?_$CY8-+_"#[M= ]WONSZ\MO2-@Q)>?JX;GQEJ@GI_0!BRA#42C MSN075Z?6$XC>3[(DXSA8QV%$E0%3L:,0JU*L/M%?J3SNB_K!!U M<-CS.J[_+T@M-"_0&X&T@(^!/]ECJY/59N7/W:2Q)SA:HMZA246!M?U;>,A\ M!W8=HU; CJA$3$%U''J[/?R0G;Y'^+2M\@[FG6-M=YSQ?7,[$LW41S9VF81Q M/Q@.QC^(]8,(K"G\MF2D+LOUCBELE:2> ^;E2 M=OWB%FCNJ2?_ %!+ P04 " #)>*M6M@<=B$@& !A#@ &0 'AL+W=O M M$('=A]4^.#,G&:L>>VI[0M-?O]^Q)T/:A;0OB;]"OHN_P92X]75C]M\I#<=XYZ8B<%K+6X=8^O*/& MGR/&RZSV\5<\-'L''9'5/MBR$88%I3+I7WYKXO [ J-&8!3M3HJBE6]ED.,S M9Q^$X]U XT%T-4K#.&4X*;/@L*H@%\;3R>QZ)CY?B9O;R]GEI[O)W?7G3^+5 MC=4J4^3WSOH!6GAO/VL0IPEQ] SB@?AH32B\N#0YY3_*]V%=:^)H8^)TM!/P MHW3[XF#8%:/!Z& 'WD'K\D'$.W@&[[-;2J.^2ZZ*KKBPQL/97*8B,;FX<>3) MA#1A%^)*&6DR);6889)0D<&+?R9S'QQJZM^G(I0,.'S: .ZS-[Z2&9UW*M;E M5M09OWPQ/!Z<[G#OL'7OOGB9#0:G%Y-9M,X')[N">5]3?G3 M8O<5LD"MW&1VWXJQZM[PH+NE^=H@ 75TB;<-1Z<7CG(5Q ?K/7GQZLY6*A,' MH^.]?7$'H^L$GQ72++'.?JBRDLHQABAM3EJ Y3#R02Q:/1)H2#A71D8N@.>$ MA:P3ZM& +CXR7>?L#ZHBI[@];7/(AUK)N29LR] :7#4-:E<4I/->L#WP2^U4 M6(-1YD%XRO@+#1B!M)4&>WGHZ&NM4#0":M.&8$7MH5 84"#L?T L>QHTR,;0 MMPKT1PSA?>-C*&0 RV@-, _R@NTQ&"2=5LE@NS1J4_Y2@[@1"XK!T3&X'%#E MFXC","^L4TN$3.MUD^*N>, T+184>3<*2V-JCBC\4":04Z6H\&N1^SE!W+#) MX?R1V(.92@UFNTR/X.4CYJ M2?GH%Q2Z C*:A)[DW]\6%M)1LC07Z&(.![H3 46I9,Q;EF,;T,-2XX@#Z8B5 MU#7M(P>>(XN""]PSAF)")0+@> $G81KAXL;7'(4>1XLHW"QRL;3Z,T4B&1CXL"NG'^>A=!5J03G&7 M@WDRV>1THVD-?%,O(%]SV\"6PC+_\=4L!R/!J1P$B70G[5AU.U-XW*;P>&<6 M9@5;E]1D*&A<3.,5X:E\[D:ZQ\7(;3?&'QXYM=D7L6$U'?F>=Z2C%-E]&YVR MZ.=2KL722<-9!G.I6/5)/H8Z8L1SH:H=3CL$!_:6P/7L@O^I*Z&S"Y$HL;7 MPY-N1-H$$P0\BQ@_3#;<']%[_\] ['T#-YN3ZSNE@HM>@JP3Q<2#ILF?32=> MBF*\%2QP#TBM(FHPJ/J^89NIEC!GEA46!W@Z03?&UL?53;;AHQ$/V5T3:J$FF5O7(M((5<6J0FC2!- M'JH^F-V!M;)K4]M \O<=>V%+)<*+[1G/.3YC>V:PE>I5%X@&WJI2Z*%7&+/J M!X'."JR8OI0K%+2SD*IBADRU#/1*(I&W=TSYLC#6$8P&*[;$&9J?JT=%5M"PY+Q"H;D4H' Q M]*ZB_CBU\2[@F>-6'ZS!9C*7\M4:DWSHA580EI@9R\!HVN UEJ4E(AE_=IQ> MR_*%YZ88>ET/Q!MM9&5CLP*:BXJ&?VMKN' T W_ 0[P"QTUT?Y%3>,,-& R6WH&PTL=F% M2]6A21P7]E%F1M$N)YP931Z>;Q^>?DPGMS,X?V+S$O7%(##$;/>#;,-+/DI3 M;% 8J=[AANNLE'JM$'Y=S;51]"]^'\NX)DR/$]I:Z>L5RW#H43%H5!OT1I\_ M1>WPRPFY:2,W/<4^FE'MY>L202Z [Z4?$WF2YKC(_55PU)!)JBYM,+<'F0)A M(4LJ4RZ6?3B?"'+)M68BUQ= +Y(5[DEN,,-JCLH94[:E[VA0<59J.(/43[I= M-_G?YK"4,M<$:+=:T/*CJ 5?E:1@ M?B TBORDDT(4^W$KA>_$U;>D&^Z: _4FD',MZ?-F*#*$\S3N7M#8ZES 0;X^ M"&IS9Q"%?B]MVT7D=WH=./9BP4%-5:B6KG/8&UL+4Y=7XVV:TU5=D__"Z\Y& M5[?D0D.)"X*&EYV6!ZKN%K5AY,I5Z%P:JG>W+*C!HK(!M+^0TNP->T#3LD=_ M 5!+ P04 " #)>*M69]3/Q%$# #T!@ &0 'AL+W=O3C:2?5#5Y0:>*ZYT&.O,J:Y"@)= M5+0F^D(V5.#*1JJ:&!RJ;: ;14GIG&H>Q&&8!S5APIN,W-Q<34:R-9P).E>@ MV[HFZN6:Y%WF%BP;67L1# 9-61+E]1\;^8*1T&/4K*:"LVD $4W8V\: M75VGUMX9_,GH3K_I@\UD+>4/.[@OQUYH"5%."V,1"/Z>Z WEW (AC9][3*\/ M:1W?]@_H=RYWS&5--+V1_"]6FFKL#3THZ8:TW"SD[@O=YY-9O$)R[5K8=;;9 MP(.BU4;6>V=D4#/1_+U=]N M,/OC^_W\)W(B7P*(6I-,Q$2'ZA?QRTI,E$UM'C]6-DD_4$M00Y9#Z:9PC:E$A&?7B;&A?^MA/!S&V M>93 7:L$,ZVBSF;#GFU?0XQ+<13!C:R;UB"35V]KI^7&[ @Z17ZE+W?2E?HV4^I=9#A'&N,P07>LK%)VB MK5M.#"U1*[">!2.=&J$GJ:4R[%9'Z;1.1QV];<83(#=$E;8 M7++\$G(_SE+,6^#I;#NE0QLDNL6Z:,C2$+)P\ Z<#P)U_R/6-@HO\9_[@SR" MJ=84"U%1+ W*/FC"*2ZF+M[KSAX[NL$;):JIVCJ]U5#(5IA.E/K97M*GG9*] MFG?O 9ZQ+1,:.-V@:W@QR#Q0G<9V R,;IVMK:5 E7;?"9XDJ:X#K&RG-86 # M] _=Y#]02P,$% @ R7BK5M40QT=P P =0< !D !X;"]W;W)K&UL?55MC]HX$/XKH[2J6HENWGC= A*PG,IINT7 WIUT MN@\F&8A5)^9L9]G]]S=V0J ]=C_DQ?8\SSPS'H^'1ZE^Z S1P',N"CWR,F,. MM[ZODPQSIF_D 0M:V4F5,T-#M??U02%+'2@7?A0$73]GO/#&0S>W5..A+(W@ M!2X5Z#+/F7J9HI#'D1=ZIXD5WV?&3OCCX8'M<8WF\;!4-/(;EI3G6&@N"U"X M&WF3\';:MO;.X ^.1WWQ#S:2K90_[&"1CKS "D*!B;$,C#Y/.$,A+!')^+?F M]!J7%GCY?V+_S<5.L6R9QID4?_+49".O[T&*.U8*LY+'KUC'T[%\B13:O>%8 MV7:Z'B2E-C*OP:0@YT7U9<]U'BX _> 50%0#(J>[J0Y,X7MA-61M%JYQP9CR9S5:/\SN8_[6I/0]^04H>L51#-]D83(-\R+%]&>\ M3Z(;Y=%)^31ZD_ ;4S<0ARV(@BA^@R]N,A$[OO@5OB5[<;$!*U*8)(DJF=#P M]V2KC:+:^>=:R!5C^SJC/4^W^L 2''ET8#2J)_3&']Z%W>#+&WK;C=[V6^SC M-9W/M!0(<;;G@AJ.^%L.;7J['<&+&9^H-NDZ9-!DJ M*EFEL# @SDXAD72&M2$ 224KV$E!S8 7^UOXR N:DJ4F"OT):%.3S.WJ'2:8 M;XG1#DX.#^Q%$1;>0[_=IW>G&S=K6UF45DNG%\"'=_THC+XT:XG,A/\S.07U HE@/ =>Z)(P"5(?L ;WR4G#NM XQ,JE M4P:C5M ;P)K9P)Q%76!1&$)$^.]NU]FU@KA6"KV()!+A1AJ2=17V>AV]AUZK M&W7M[K<&41^N'2+_HA7FJ/:NX=L2I.-1=<5FMKE3)E4K/9M7%Q+5XIYVF'9I M1]#@IM?Q0%5-OAH8>7"-=2L-M6GWF]&]B,H:T/I.2G,:6 ?-33O^#U!+ P04 M " #)>*M6E/+01PL# B!P &0 'AL+W=OAF:2B/+?% IPCB*!F')N RF8__M5D_'JK:"2[S58.JR9/KE H5: M38)NL/EPQY>%=1_"Z;AB2[Q'^U#=:K+"%B7C)4K#E02-^228=<\N^L[?.WSG MN#);:W"5+)1Z=,9U-@DB1P@%IM8A,/I[PDL4P@$1C=]KS*!-Z0*WUQOT+[YV MJF7!#%XJ\8-GMI@$HP RS%DM[)U:?<5U/9Y@JH3QO[!J?'N4,:V-5>4ZF.R2 MR^:?/:_/82M@%'T0$*\#8L^[2>197C'+IF.M5J"=-Z&YA2_51Q,Y+ITH]U;3 M+J=L8:RFN_!K5[$- M5F\WENN/,U.Q%"I@+I? +)!,:='J= ;'UY*<5&V8S,S)/]LPWR##(72C3A1% M\"!9J;3E?S"C)J(:N3$UDRE27I?TN#?JG[SWRDA)54O; 2Y346>>3IIJ]"U. M3/&96\@1X7B8#$]>,S,[,6T+P3RTMT"/X>Q.?. M[&T;?8C]F=%R $DG21*W'*Z7=)'H+<@I&?3[ Y@K^Y9,*_BN(P^WYE:)>NFG MLP&O<#/"VJ_M S!KYMZK>_-ZT,DLN30@,*?0Z'1(9ZR;B=P85E5^"BZ4I9GJ MEP4]8JB= ^WG2MF-X1*TS^+T+U!+ P04 " #)>*M63&298+P" #7!0 M&0 'AL+W=OA]C*LNAXSF'@P7?)<8>N.$@9SM3@HR+^LO>]N]P!.BU/P'X>X!?Z:X#52J_ M, M%U,Z6-/Y(UG06K%-BOIJX!H*:8%NM*^2U$:O M?] []L\2/C)U#8'W%?RV'YSA"YK\@XHO^(1O+D5$"I5,Z68',V%0H3;P>[31 M1M$_\^=4TC5GYS2G[:.^SEF$0X<:1:-Z12>\O/"Z[?LSBCN-XLXY]G!)?1D7 M*8+Y;PM-Q)PL0.-7 !)D&8R"QGXOWRHN=[M_<: M9"E0Z83GY/!*[T5M:AK?6M0:2GI*8!JV]+BRU'U8)0KQPQ\!5,\HJ0K:FEFX M+#03L;ZJZFL7'\:XXT+8ZO!#=2A2$^4+^-X=K8%W"W.:8JG4&I@QBF\*8_]; M,!)&^?L;M&Z\*VCYP96-?8;/Z_8LZUT'3I7+/6JV#-6N&BD:(ED(4_==<]I, MK5'=K/_=ZY%'R5-J&E+<$K1]?7OC@*K'2&T8F5>MNY&&!D&U36CRHK(.=+^5 MTAP,&Z"9Y>$_4$L#!!0 ( ,EXJU:2L9A '0, )X& 9 >&PO=V]R M:W-H965T47)>HC1< M2="XF02SWFB>.GMO\"_'G7DQ!Z=DK=2#6WS-)T'D"*' S#H$1L,C?D(A'!#1 M^+''#(XAG>/+^0']+Z^=M*R9P4]*W//<%I-@&$".&U8+NU2[+[C7TW=XF1+& M?V'7V*9I %EMK"KWSL2@Y+(9V=,^#R\(?:\FT">Y6=FV72LU0ZT MLR8T-_%2O3>1X])=RLIJ.N7D9Z?7L^7MU]N_5]#Z]GVU:L/B>@FK+[/E-;3N MV%J@:8]#2W&<=9CM,><-9OP&9@(W2MK"P+7,,7_M'Q*_(\GX0'(>GP6\8;H+ M2:\#<10G9_"2H^C$XR5OB69:@Y].F>&9\!D#CD7M<4<\$"_)90Q M;:A(A7$J3E$_"WZ:^EV!L%&"ZI6B@'7/ "JM'GF.!BP=9JJL:LM\6:F-JXK? M&#I>S[2Z<%=HQ%>O EI<$I:J#?F9#N!3AI5]]H&<7G/;7[C[Q'!;EZB957H$ MM]2K? 1FK>;KNF%H%5"U9 ^%$CEJ ^^AE7328=)VLW[G*NVWX3-*1474P-S[ MBB4J[)&0M]@$-D"MRUABY<1?G!"7I)W^U= -:7P%WUY)'<&?UT7AHVXO:N\G M@S;,I.47_I@Z$G!)+X_426M<&D3MTK/1JOPSG93XDG*^#_6]:.X>VR^LZ;G M/)LWG9O*"VAG0^48I>UBX M ,=?TO074$L#!!0 ( ,EXJU:H+O])@P, )\' 9 >&PO=V]R:W-H M965TL>%%[[>&+O@CX<%6^,"S=_%7-',;U!2GF&NN>=P?^X;C7)V.PGBREW-K)UW3D!980"DR,16#TV^$,A;! 1.-[ MC>DU5UK#T_$1_7?G._FR9!IG4GSCJ=F,O($'*:Y8*&38>*KD'94\3 MFATX5YTUD>.Y%65A%.URLC/CQ>OS[*^;Z63Q< ^SY\?YP]-B\OKU^0FN7ME2 MH+X>^H:NL8?]I(:<5I#1!Y =>)2YV6AXR%-,?[7WB5[#,3IRG$87 1^9:D,G M;$$41)T+>)W&YX[#ZWSD\X8IO)F2EBG,V8%2S,!$*9:OT8W_G2RU490O_YUS MOL*.SV/;&KK5!4MPY%&1:%0[],9?/H6]X.X"\[AA'E]"'R^JT@&Y LJ,9 NR ML+FM@>5IO<+V3*7Z'/&+T.>)+TXNJ0J(FP-P7=*JASP#57"-4*A>(+P7!IMB#W/U\ ,W&."#J*6.X)>JQL% MK3B.X3/TVV$$?Y!0%C!LQ<&@->AU(6IW WBH<5/X\FD0A=%=\Y^Q/*$ND+H@ M41M;(;?V5V'<:X6]^!H&[6#P?R*4<\FF23KHM_J#3BN,N\2BUX[Z<$',;B-F M][*8U"N![N&#%N((=$R526"G&51#/B7D9^G6#,)-9P?(#)$PDI6#694/+ M:QL^2&E^>MN)8NLZOCRO7+^R<8R".S=QP==N);R[AM)PP7^XD,%4,,H547W4T8.NNW!B:5!E<$5.7! IO0U],ZIY9\TS0S5VCT-&A)9YJ;J MG\UJ\_I,JJ;[?KQZNBA9UIQ")W!%ID&[3^JHZCFH)D86K@4OI:&&[H8;>D%1 MV0.TOY+2'"?V@N9-'O\$4$L#!!0 ( ,EXJU96'&*![0, ,$) 9 M>&PO=V]R:W-H965TFG; -N2+/+A0XJ4--I) M]4,GB :>\DSH<2,QICAKMW648,[UJ2Q0T,Q:JIP;&JI-6Q<*>>R4\JS-.IU> M.^>I:$Q&[M^]FHSDUF2IP'L%>IOG7#U?8"9WXX;?V/]8I)O$V!_MR:C@&URB M^;6X5S1JURAQFJ/0J12@<#UN3/VSBZZ5=P*_I;C3+_I@/5E)^<,.YO&XT;&$ M,,/(6 1.S2->8I99(*+Q5X79J$U:Q9?]/?HWYSOYLN(:+V7V>QJ;9-P8-"#& M-=]F9B%WW['RQQ&,9*;=%W:E;-AM0+351N:5,C'(4U&V_*F*PPN%0><=!58I M,,>[-.187G'#)R,E=Z"L-*'9CG/5:1.Y5-A%61I%LRGIFT5+&?7-[/;!YC??KM;W$P?YG>WT'S@JPQU:]0V9-"JM:,*_*($9^^ !W C MA4DTS$2,\6O]-A&MV;(]VPMV%/"&JU,(? ]8AP5'\(+:^\#A!>_@+7%#"69@ M@854)A4;^&.ZTD91KOQYR-T2+3R,9NOG3!<\PG&#"D2C>L3&Y.2+W^N<'^$: MUES#8^B3)=5CO,T0Y)JJ8<\W%65AV@Q?/8,N'3K$_2CZ8>Y+5ZGIWQC#.A5< M1"G/7EG89[F8W<"D5&>(&X83GQ3G::A MZ7L!Z[5@T/6AV?7\@/K4]GR_19H&R6M#L7 0>^A]2RKTU%+X1%NH_EFLR8*P M57U+#RP5#P3MQ3_)=EONK4@;_@0K%+A.#X@RC_7ZK;K]*.+L_XJXW_$&?F@[ M7J\_?!OR.Z,.Q6 M&5OO 75F'EJ_]HMCE?S?N,N#ADANA2E/V/IO?3^9EL?RO^+EY88*;I-2BF>X M)M7.:9^63)47AG)@9.$.Z94T%&S73>B.A*M65CY&UBT) B;P &0 'AL+W=OD/ \QL4FN7D7Z7\EB\7K?,UMN"QV@VS_(%[>'5,ISQ)Y[]L7Q( MU;/V1IE$"Y[(2"0DY=/KUHUY&=C=/*!8X]\1?Y5;CTF^*R,AON=/V.2Z9>1; MQ&,^SG(B5+]>^!V/XUQ2V_%GB;8V;>:!VX_?=%KLO-J942CYG8C_$TVR^75K MT"(3/@U7[E"Q@6,1R^(G>2W7-5IDO)*96)3!:@L64;+^'?XH_Q%; M 6;G0(!5!EC'!MAE@'UL0*<,Z.P&= \$=,N [K$!O3*@=^PF]N7O,@7)\S"X54J7DF:KZ^\_$&1=$6\2I,H MR>OC*4O57R,5EPUO;Y[8$_E&R<.C^^1^?;YY9M^^DE\=GH51+'\C7\@?3P[Y M]9??R"\D2LCS7*QDF$SD53M3K>=&>URVY*Y;L@ZT9))[D61S2=QDPB<-\50? M;[\7[[_3OJ4!VNK?MOG?66__NUM+*]Z'Z3DQ.V?$,BR[88/N].%!F)P3X^)@ MN*,/_RI>SHEE%>%6T\MQ1.NV>;!U>L2^:\*]X\.;-M[7ASM\K UG1X>;@X;P M0!].^4B][OVF?:_ED;VI0;OP[ ,>2\9BP)DT^'N5NN?6B5(S$%B+A*C2,Q#8CX28VNL M5V#Y)Y27X47?,(RK]LMV^H.:K*5_=Y/^76WZ_RYDF?IB[DYK()OW^WGNL:9@7UDX*(YL,0%@MA0>;%!Y\+(7) M:/VALRF5M>2IJ8S$'"3F(C&*Q#PDYB,QAL2"04,M;O>;:QE_L+* FSQA.)MUKOU'1?8Q=;^V24C, M1V(,B04@K);MIE&=T3?T9S96Z7@>2D["6FYW^J9. M?;.&:BY4HU#-@VH^5&-0+4!I]63?&KXRMGCO/PA\DY6.N.C.CF#=VQ_70 MJ>_J4,V!:FZIU4X;['XFHXTK]7+/S6FJ=8\.4V1F@/57*A&H9H'U7RHQJ!:@-+J-5(- M?9J?;.S3A Y^0C4'JKE0C4(U#ZKY4(U!M0"EU>NO&@4U]<.@Y3%J&HZC.,I^ M-E8$=* 3JCE0S85J%*IY4,V':@RJ!:6V?1+8[AX\"V16(YZF?LCSW>Z86O#$ MQ^K8,B$.'S7WSJ#CH5#-@6HN5*-0S8-J/E1C4"U :?62J<9CS=XGZYU!AWNA MF@/57*A&H9H'U7RHQJ!:@-+J]5<--YOZ\>9[D6:S<,9)+,+DC"S3*!E'2U51 MX4*L#IS7A0X[0S4'JKE0C4(U#ZKY4(U!M<#<'[*W-+VU:IC:?&><^L3>FGI: M_&*)S-+5^F!U)UYX$N:/GE-UU)IS\BUI'-_6;\O)10,=X89J+E2C4,V#:CY4 M8U M0&GUVJH&Q,V+3]:M@XZX0S4'JKE0C4(U#ZKY4(U!M0"EU;\V5HW06_H1 M^@]TZ_3BJ14"U1RHYD(U"M4\J.9#-0;5@E*KS<0\/!7+JL;K+?UX_=_3K7M^ M%8U% QWRAVH.5'.A&H5J'E3SH1J#:@%*J]=6-=_ LCY7M\Z"SF6 :@Y45/.A&H-J 4JKUU\UE\'2CM5^J%L'G6T U1RHYD(U"M4\J.9#-0;5@E+; M[M8=/EEG5;,(K*-F$:![=7/%-58-=$8"5'.@F@O5*%3SH)H/U1A4"U!:O;JJ MB0M6]Y/UZZ"S(*": ]5R84!G9X U5RH1J&:!]5\J,:@6H#2ZO53S6*P!I^LZP:=Z0#5'*CF0C4* MU3RHYD,U!M4"E%:OOVJF@Z7_[O\17V_0"R=7!'3N 51SH1J%:AY4\Z$:@VI! MJ1UYD0N[FE1@ZR<5W&1?GN?\RWV8?N?Z/I@>.C7CH9H#U5RH1J&:!]5\J,:@ M6H#2ZH5133FPS<_5![.ATQ*@F@/57*A&H9H'U7RHQJ!:@-+J]5=-2[#UET$H M!GY4=:EZ2ODLDAE7G;(SDO!7$DFY:KY:A]X\N4:@4P=*;?L(WC'V+N_J0ANE M4,V#:CY48U M0&GUY-^ZM+M^3H ZQ,13\ECD_?KXT)CMV"NN8R^YCKWF.O:B MZ]BKKF,ONXZ][CKVPNM_QT4'[&JZ@-WY9#TRZ(0"J.9 -1>J4:CF034?JC&H M%J"T>OU5$PIL_940/M8C@P[Z0S7'WK]0>G%.9:]+!AW.AVH>5/.A&H-J 4I; M9W][Z^97"Y[.BINM23+.A^;7]^#9+-W&ULK99;;]HP&(;_BI554RNU#3D#@T@M MM!O2UE70P\6T"Q,^P*ICI[8A[;^?G=",@HMVL1L2)]_[^GD='^B57#S))8!" M+SEELN\LE2JZKBNS)>18GO,"F'XSYR+'2C?%PI6% #RK1#EU_58K=G-,F)/V MJF>W(NWQE:*$P:U N5EW_&P5>P 34?7$K=,MM M7&8D!R8)9TC O.]<>-U!V]17!0\$2KEUCTR2*>=/IC&:]9V6 0(*F3(.6%_6 M, !*C9'&>-YX.DV71KA]_^9^76776:98PH#31S)3R[[3=M ,YGA%U9B7WV"3 M)S)^&:>R^D5E71LF#LI64O%\(]8$.6'U%;]LQF%+X(4?"/R-P/]70; 1!%70 MFJR*-<0*ISW!2R1,M78S-]785&J=AC#S%2=*Z+=$ZU0ZNGFXNKG[.1Y=3=#Q M$!0F5)Z@,W0_&:+CHQ-TA A#=TN^DIC-9,]5ND^C=+.-_V7M[W_@_P.++Z35R_\@L^BLO6P!07KVA(9$:Y7 E ORZF M4@D]H7[;\M6&H=W0++*N+' &?4>O(@EB#4[Z^9,7M[[8TOXGLW?9@R9[<,@] M'>-2SQP%@F!J_9*U/*[D9O6OTS!HMWON>CN!I:B3=)JB=V1A0Q8>)'O4*]W, MLT+P#*25K3:(MKKU@\#;8;,4Z;&SLT4-6W20[9HPHI?7#"TXMR^ :*_7,(ZB M';3]HLCS(CM:W*#%!]&^"BZE'K=Z2A.PTL5['7M>D(0[>)8JWX]".U_2\"4' M^;[K;]DU'W5-JDU?GSF(3R6G(#-@&=APDSV0L]#?G8.VHBBQP[8;V/9!V-'? M83Q%#)0-KKTW][U6)XQWZ"Q57M+9Q7.W]FQS7NJ-IC&X0IT._GG*NWACD9FC\"Z1]02P,$% @ R7BK M5L/%DJ;S! A1L !D !X;"]W;W)K&ULM5E= M;^(X%/TK5G:TFI':)G8^@"X@M92JE=H9MK2[6JWVP04#T20Q8SNEG5^_=D@3 M0HP[H/ "2;CWY-SK$_O@=%>4?><+0@1XC:.$]ZR%$,MSV^:3!8DQ/Z-+DLA? M9I3%6,A3-K?YDA$\S9+BR$:.$]@Q#A.KW\VNC5B_2U,1A0D9,<#3.,;L[9)$ M=-6SH/5^X2&<+X2Z8/>[2SPG8R*>EB,FS^P"91K&).$A30 CLYYU <\'J*,2 MLHB_0K+B&\= E?),Z7=U,2<#&OT=3L6B9[4M,"4SG$;B@:YN2%Z0K_ F-.+9)UCEL8X% M)BD7-,Z3)8,X3-;?^#5OQ$8"]'8DH#P!_6J"FR>X6:%K9EE95UC@?I?1%6 J M6J*I@ZPW6;:L)DS4,(X%D[^&,D_T+\;CX>,8W SOKL#UMPLS/@ MPA. '.1JT@?F]"LR*=)1-=V6#2NZAHJNH0S/W8$W8O(Y8N+M!(PBG @@BP+# M'VFXE (7X-\[&0YN!8GY?[I2U]B>'EL]M^=\B2>D9\D'DQ/V0JS^[[_!P/E# M5WA#8)4VN$4;7!-Z_Y$*'(%ET8QET0SRW@Q=_6O0( -5T\Q+W^OX0==^V:RK M'@0AZOA%5(6P5Q#VC(3O".?G#VG2.8XIDR$/[,+ M.O+K&_@;O$Y=M]W:8J^)\AT/ZMG[!7O?R/Y===4.JR=+#6PX(3J^?HT)](/. M%MUZ4(!\3\\V*-@&1K8#FG#!TO5L+3E*F;2//?)I=R&D6R&D6<#G-Z@BV M:_?VZF-=#W+T[#H%NX[YH9+=T[$Q9NT[S34$5BD0.N4BZ1QQOL_!&^I$4VC5 M5FSX!7B,.3]'U(EGO$"A?2 MZ-K<%%JU\G)UANXQ56M<^_=N14-HU5:4ZSXT+_R'JK:^CL-MHZ*)\3P4[)!M MN=9#\V)_CR<+>8F]_0)+(]+>(]406K7NTC7 X)BB-7J2O5O1$%JU%:4[@69[ M"1D-R*&JS5&K[MK=$JTV:(>Y1J6E069+,Z#Q M,A6$;?RG4G0YG8D59EJG;4;<^S]\0VC5^C:OE4-76MU1@J[TM6G-0E7%I;9#9VMQ+N>HE:LS;>UP:0JM6 M69HAU#ZF1!LU2$VA55M1&B1DWB0Z5**=VC9PV]O>;/T@:,W8WGA'HEY0W6,V M#Q,.(C*36 MO/7_!U!+ P04 " #)>*M6P9Q?[8$# !@#@ &0 'AL+W=O2J M4W4O%C. %=OK[*ZA?/N;73L.7,U&KB@OP+O>^3._V:>9T9;Q)[$&D.1[FF1B M;*VES"]M6T1K2*GHL!PR?+-D/*42FWQEBYP#76BC-+&[CN/9*8TSRQ_IOH#[ M(U;(),X@X$04:4KY[AH2MAU;KO72,8M7:ZDZ;'^4TQ6$(!_S@&/+KE46<0J9 MB%E&."S'UI5[>>/VE($>\7<,6['W3!3*G+$GU;A=C"U'>00)1%))4/S9P TD MB5)"/YXK4:O^3V6X__RB_E'#(\R<"KAAR==X(==C:VB1!2QID<@9VWZ""FB@ M]"*6"/U-MM58QR)1(21+*V/T((VS\I=^KP*Q9X"@S0;=RJ#[?X/^$8->9: C M9Y>>::P)E=0?<;8E7(U&-?6@8Z.MD2;.U#2&DN/;&.VD?Q6&TX>0?)K>3KP-/D_O'\@?Y)YR3E7LR?L)2!HGX@/V M/H83\O[W#R-;HE-*VHXJ!ZY+![I''/A,=\09GI&NT^TU6-^\9160BK^;2(M MM?O-VFI#7HJ<1C"V<,<)X!NP_'>_N9[S9Q/XB<0.PM"KP] SJ?M!P:,U;@Y" M5QQ L3?A&C7:XI9BGA939\_&/_<&#GY&]J:!I%^3](TD(4V )( LUV3GK:9OGRS.(GYL ML1I5VZ*58A=[:$['Z3>##6NP82NPE&:8'.C#= E ="I@GCVC?EO$81-BKQGQ MHD:\,",6<7WI"5^(DB<2JUPU#LI4[N M:>^6-_2:[X,*U6CZLZBO:9%K3#=^0,VPP(BH6).3S=:5Y<%AZSL&= M7L']BES'?4UV7'.V$T)4\%CN,/W/F8@EP>VL[DZV?PXW IIU73V=C;-YHM2I M!+;WTG]5>V%2O(HS@?.U1'FG5_G]02P,$% @ R7BK5HO71PK7 P I P !D !X;"]W M;W)K&ULK9=MC^(V$,>_BI6>JCNIMWDB#VPA$@M4 M1W6WAWAH*U5]88(!ZYR8V@[L?ONSG6R Q'!4ZAN(DYGQ[S^Q9YS>D;)O?(>0 M "\9R7G?V@FQ?[1MGNY0!OD#W:-K00!.=HR@ OL@RRUR=$Z+%ON=;;C1G>[H2Z82>]/=RB.1++_93) MD5U'6>,,Y1S3'#"TZ5L#]W'H=I2#MO@#HR,_NP9*RHK2;VHP6?)6#=Z^# M7SGX6FA)IF6-H(!)C]$C8,I:1E,7.C?:6ZK!N7J-<\'D4RS]1#(8#F?+\0B, M_YJ.G^?C.1@\C\#7Q:?Q# R7L]GX>0$^3P9/D\^3Q40^?3]" F+"/X"/8#D? M@??O/H!W .=@L:,%A_F:]VPAL51P.ZT0GDH$[PK"%\@>@._^ CS'\PWNP]ON M(Y36[MZENRV346?$JS/BZ7C^E7A3^ I7!'$@U8!!FK("$@[^'JRX8'+1_6,2 M6$;LF".JG?C(]S!%?4MN-8[8 5G)SS^YH?.K2>[_%.Q"O%^+]V]%3[1>M 9[ M^,HH(2:M98!0!U!%XI#$G;AG'\XEM&V"T*]M+L@Z-5GG+K(5S0N.C,NL#!"< MSQHY#;*VC6/F"FJNX"ZNE&89YJJZ&=F"UKQ1M\G6MHD[D9DNK.G"^]XGH^LB M%> (&8.YP.8$ABT /VR^6H--US5#1C5D])\@"88K3+!X!2F!.)/EA1>2.D6R M/BL#K+:GB3]JL;E1M],08#"*O<"L(*X5Q/>J=)U6D;$C.>UEW D:P#\P MNB0^:[CN3>*E7,A,-M$<"/@"]I1C<:UH5)',U:IB;)MX3M2] GGJ@>[-+I/, MH>J &K!LAT8\KSVWZS8!#497DWAJ4^[M/O55[!"39\!RVZ$7>:KEU6Y+"\;N MV%S5!!<5V6LN68-1?#6YIT[FWFYE"RKD.C7"4ZWK7@F=5IN-0B]L:FA;Q5TO M;HBPSXZ0ZOPN#V5;67=E[=I(-^&ULQ5Q;;^.X&?TKA+LH9H TMN[)- F0 M6,DVP&8F2#*[#T4?&)F.U='%2\FY%/WQ)67%-"WZLYGYA,[#1)+%\U%'O)Q# M4CQY*?F/:L9835[SK*A.![.ZGG\9#JMDQG):'99S5HA?IB7/:2U.^=.PFG-& M)TVB/!NZHU$XS&E:#,Y.FFNW_.RD7-196K!;3JI%GE/^=L&R\N5TX S>+]RE M3[-:7AB>GR_*'/+F>G Y&,D_ M:AY>/,PCK=BXS/Y()_7L=' T(!,VI8NLOBM?_L':!VHRF)19U?Q/7MI[1P.2 M+*JZS-O$(@=Y6BS_TM>6B+4$0; E@=LF<#<2>-Z6!%Z;P-M(X&Z+X+<)_(:9 MY:,T/,2TIF8U33-JL_D%S(DU8QR5I&T(-^+M*X.Q$5Q_# K M%Q4M)M7)L!;YD:C#I(T]7L9VM\3VR$U9U+.*7!83-M'3#\5SK![&?7^8"Q<$ MO&*/A\2)#H@[&\D/B.1MQ M%+ !,8818Y:L$-VM2!HIWNH->PVTMQ7ZL2;7157S1?/\__Q-W$"N:Y97_S)D M]&*)YIO19#/TI9K3A)T.1#M3,?[,!F=__8L3COYNXA$3+$8"TUCT5RSZ$/K9 MPPO+1(UHRA(I1'O,V3,K%HS4E#^Q^H"\,<#^7*3/-!.-6B7Z M_HP6B9&CJ%/[' -'8&!;CI# -(Z.5AP=@1S](;MO2=]T5[[I+>UYGI'3=:*]B<$#8*^-)6C$RYVGR MX4=NPQVMY=,[]#>>&,Z3;8'!0M,97%/&SGX5J68\-U("IW=&3>-M%L9@4FNB MD-!THEQ%E L^:*,PTZI:R!:8)&55FTN0VVV(CSI-#AS+FADD-)T9);T=4).> M-5*[G)(Q9Y.T%G6L/3A_$OVY5.-&GE 5."I:C(6F\ZE$N..C>AD'4U./4=%B M+#2=2J71'5BDMR5Q2I,T2^LW(WM!I\)Z05E#C3M*CCNP'H^70T8' MA,[G69K0QXR1M! ] *N$-J>U46&VF,=Z'^YN\H0JP['0=)Z4$'=@);ZS91.7 M[EFR$%>)K+5&VC U]Q@5+<9"T^E5&MXYPFWH,)7Z&!4MQD+3J53*WX&E_TW) MZR?ZQ$A6TN) BN B2>:&CXPL#5-2&CZR*GR"R[L%Z[7 M&SDRS MN+ ]N'RMVQFT><.>D2P8PG$ALE"U/Q::3I;2_BX\ O]UD3\R+@M8.Z%#YLL9 M'3G2I<_Q&'GT.T->7KA9(5$%/A::SI<2^"XL\+?S)8>$W@O>7M1UQ^3=S9$? M.#/6U/5A EQE ES8!%R^2F=D'G%WC5J_0P>JUL="T^E06M^%M?YY+B14^A_: M3-2+\C39;[P'1K75I*YA&#_:&$K%BJCSI$2["X^\&WF:I%4B=::9(E39[G9' M];T.17V(<5>)<1<6X[:V49QN6*$#G##7C* M#7BPAN^GGC]LFP:'Y\92Y\6!S\X%Z?C[Y]Z*J MQ?D#X_GJQV_/C!=R-3:Y2@OA(-/BB=S)<=5/]]^N[CX;Z4:U2:AH,1::_EJ4 MH?*.<:L]JB="18NQT/0%OLH3^? ,R.^4I\U\[[9I7M\\]]'IW^$XUBMY^[ W MOK(W/FQO,/KW1G#4ADXKC5+?5@A7UDA']T*[5/QMPUNPKFQ M+J^H[@<+37\3ROWXN.['1W4_J&@Q%IK^R9YR/P'L?CY0]5O$8(5#1 M8BPTG4IE>0+8\NRQVC_8S^+ @:QIZ+.8&&G MS*#Z!RPTG1+E'P+8/]PQN=6,[/D>2RY2RZ.$BH#;VAR#>8BZ30ZJ>P7T\& UA1UOP'9_'(; M*Z"^<812["&LV']*BIH\J9RF2XLEX_#*.CAGME2CHL58:/I;408A=%!%:XBJ M_U'18BPTG4JE_T-X$9G% '2+M-G;'D7'VK_-?5%0)3X6FLZ6DO@A+/$O5CVN MW ?M0&X6EN:+'-H9)=Q/\L.!K6GJ0_*'2O*'L.3_K4Q^/):OA"9-3W) IHMB M4I&Z)(]L^=$OFS1G[W0:^YH=00(RH6_&3W+@A-9<]F$10F41PAT;/:UU&$(& MFYDR&H/-Q:]P(&M:>MG1:6U+)]@8?*0FFKXJZ9"$NX]3'U8A5%8A_/D/R']6 MO6R92X-S9MWEHKH3+#3]K2AW$N)^=QZBVA)4M!@+3:=2&9@0-C![-8['^ZPC MA -9T]*':XF4:XG^_ZYEZU0:G#?;XHJ*%F.AZ>]%^98(U[=$J+X%%2W&0M.I M5+XE@GW+/C6_A=CQI0 VH^6C+B>%\6A==5'>$A::_ M(^6.(A^W%<"T,V-4M!@+3:=2F:,(-D<[EQ.WZ7&ULM55M M;]HP$/XK5E9-K=0V$%X"'41J@6U([58!W3Y,^V"2"UAU;&8[P*;]^)T=&E$U M15VU\8'X[+OG>[U$L"0;<:%[GM+8U87OJ_C)614G\L5"%Q)IF[M544_FAC,!MXKH/,NH^GD%7&[Z7MU[ MF)BPQ=+8"3_JK>@"IF#N5K<*+;]$25@&0C,IB(*T[UW6+ZZZUM\Y?&&PT7MC M8C.92WEOC7'2]VI6$'"(C46@^%G# #BW0"CCQP[3*REMX/[X ?V]RQUSF5,- M \F_LL0L^U['(PFD-.=F(CW#7D 0/!,0[ ("I[L@RA3HW"589R) M!I/1<#PCEQ\FH]'-Z-.,G)$I'GR2)L!BHC0Y@;3;-3J0L8%,?Z]26: UJ]%L1USH%8VA[V') M:U!K\**W;^KMVKL#6ANEUL8A],CM*Y=45 DK0MLNU';6.JK7\-?SUQ6,S9*Q M>9#Q3M!,*L-^08*EBSO%M,ZIB('$4IO*8RP 6WLZSIJ=5K6,5BFC]7X&R[Q MW01E'7 ]E=(\&/8N+U_BZ ]02P,$% @ R7BK5G%WY0B& @ O@8 !D M !X;"]W;W)K&ULE951;YLP%(7_BL6JJ97:0DB MI"-(;9-ME9:I2M+M8=J# Y=@U=B9;9+NW\\V%&4+330>@@T^YSLWX$N\X^)9 M%@ *O924R;%3*+6Y<5V9%E!B>^U1)#&O%"4,'@6255EB\?L.*-^-G9[S>F%.UH4R%]PDWN U+$ ];1Z% MGKFM2T9*8))PA@3D8^>V=W,W,NOM@F\$=G)OC$PE*\Z?S>0A&SN>"0044F4< ML#YMX1XH-48ZQJ_&TVF11K@_?G7_:&O7M:RPA'M.OY-,%6-GZ* ,>[ MS]#4$QB_E%-I?]&N6>LY**VDXF4CU@E*PNHS?FG^ASV![[\A\!N!;W/7()MR M@A5.8L%W2)C5VLT,;*E6K<,19A[*0@E]EVB=2N[GT\G#$MU^FD^GL^G7);I" M"_W@LXH"XCGZPMGZ:@FB1!-8*33#JA)$$9#H? (*$RHOT!DB#"T+7DG,,AF[ M2LWX?/2TFZ/SLXF\;5U?5EN:WI?G6M_^& MKTT\(3*E7%8"T(_;E51"OP8_NS+67H-N+[,U;N0&IS!V]+LO06S!2=Z_ZX7> MAR-)^VW2_C'WQ!3>E:E6A59E=MRY^GC'ZR[UXY,9]<;?$V8 M1!1RK?.N(YU:U-VRGBB^L1UJQ97N=W98Z \,"+- W\\Y5Z\3T_3:3U;R!U!+ M P04 " #)>*M61_79V!@# "@"P &0 'AL+W=O['W=_S.4&6\8?1 @@T5,<43$T0BF3"],4?@@Q M%FRNF:,"37<06:[X>Z I3(B%&XX$FD< M8_Y[!!';#@W;>#;,R3J4VF"Z@P2O80'R+KGA:F66E(#$0 5A%'%8#8U+^\+K M:__,X9[ 5NS<(UW)DK$'O9@&0\/2"4$$OM0$K"X;&$,4:9!*X[%@&N4C=>#N M_3/]2U:[JF6)!8Q9](,$,AP:?0,%L,)I).=L^Q6*>CJ:Y[-(9+]H6_A:!O)3 M(5E2YKY-02/?#/4,O^A!S+ ML2L2&K\]W*H(]]X<;I_75-,J7U(KX[4.\&:,^DH?SB*ULT93*H&#D.CG=^6( MIA)B\:M*]9S:KJ;JAG(A$NS#T% =0P#?@.%^_&!WK<]5BC4)\QJ"[:G9+M5L MU]'=.3RFA$. ?)P0B2.4:4N6J6Y$53+6XMXK8Y,P+X=U,YAN\!NWU>D-S$V% M.IU2G4ZM.N,=,01:<18CRNCI[ODCQ?FKTJKS*B/':I49Y1*\]K$[[7T?KS;) M?SP@W5*";KT$H3((0(LT22("O*K.6L)[ST23,*\AV)YRO5*YWG]I5+TFU6P2 MYC4$VU.S7ZK9KSV'UUL*7(0DJ?WB:AGOU:Y)F)?#SG>^<^NL8[]H3^;.[!(# M7V68>9E-5R_L(_MBG$^+?S'Y['J%^9JH9A;!2B&MLYYJ M+CR?!_.%9$DV(2V95/-6=ANJ$1JX=E#[*\;D\T(_H!S*W3]02P,$% @ MR7BK5A, Q)M5 P Q L !D !X;"]W;W)K&UL MQ59=;^(X%/TK5]G1[HPT;;Z 0AX_3L%!%J!4.S]LB#(",!>2I66R M8I 26CS1:UF(@P2%TYS@E0E>/:'S3H)?)OA&:,',R+I%$@5#SG; =;1"TP-3 M&Y.MU!"J/^-"IO/IX@GN9G#_EYK!IY/U<)2K3^H&5S MG"7ZS.P0CX"MX9X1*F&)J]HAR6O<<'+>X>7#P^,REC E$8X.LZWE<9*J+<7.O9: 1\0OP3?_0R> MX_D-?"8_GNZUT/&KNOL&SW\';R%9^!*S),)<_ '3;SF1;W C)2>K7*)5@D$R MF#$:JBIP57Q"-W!')>982/A'?P[X4GR/?YN*6VS>:=Y+J);0//=8?V]E!1ZYZ_J*A;*>JV*IJIWIPP(0#5OO9-]O;:)*B ZQX(NN@, M:H*Z)Z(O]"G?-O#L53Q[K3S5Q?N9LO=.6+H]K\:R=<-?+/M5)>>J5ZQ_N@;5PS]E!2K3>40OIUYF> M!GF#3HVI?>"'4LPWQB8*"%E.9>$8JM7*BMX8 U9;'VN+:GS6=YC"WRH_H,Z, M@ 2O%:1S>:5JQPO+6$PDRXSK6C&I/)P9QLIF8ZX#U/LU8W(_T1M4QCWX#U!+ M P04 " #)>*M6=3W2V!<$ !$0 &0 'AL+W=OHM8+(?61JGMO6W+ M8$,B+._XEL1P9\5%A!4,Q=J66T%P:)PB9GN.T[$C3&-K-#!S,S$:\$0Q&I.9 M0#*)(BS^G1#&]T/+M0X3<[K>*#UACP9;O"8+HIZW,P$C.T<):41B27F,!%D- MK;%[_^!VM8.Q^).2O2Q<(RUER?FK'GP*AY:C&1%& J4A,/SMR -A3",!CW\R M4"M_IG8L7A_0?S?B02"6IKO( S:7[1 M/K-U+!0D4O$HOIC@:X_?UTL;M#L<8X6 M'\?S1W0])0I3)F_0+7I>3-'UU0VZ0C:2&RR(1#1&SS%5\D-AXMN&)Q+'(4Q> ME<8#6P%7_40[R'A-4E[>&5X^^L)CM9'H,0Y)6/:W06,NU#L(G7BU@%^PN$.^ M^P%YCN=7\'FXW-VKH>/G*61.R(-?KU%[?C_%8EO2&P4B!:>2!: M=>BC)]BJ&)<28:4$728*+QE!BB,H_>!UPUE(!-03+%4:5 4B1>\8=+UG[4:W M?JL'&=X5%598M?NM=FY5HM[.J;>;H!Y2EJC3&D[)MR\B7V%UGGPG)]^I+< I MB3GL)UAQ<5]%K=-D@34$5A+:S85V:[/T8G9R$B*\(P+>3(?]"MYI4L'F!*L0 M=CA37^@:-JWT]DU53-('M0N)\%OM?N\D7556+:]?G:Y>KJ+7@(JLU'ZDHW>1 MCBJKLSKZN8Y^;=E]UNME"WN>H5=9>?TF*Z\AL))6USF^7)W:K$WRJ@HY8U@4 MI%Z<^>>).:,5;+=^O M6_VBK&XN:CU_MHB:0BOK/+8*;GVO,(X5O35+&SI>Z*N@+4B@DU82D;> )= ? MH97@4;[ZV6&-!3R*>%RSU-Q&VXBFT,IA.C82;GTG<3Y,/]@.,]SB3M?MOGL+ M5UAUNOW.F2(^]A!N?1/Q@H7 0+*26*WK3Z>G(;2RT&._X=8W'/]C%3?:JS2% M5@[3L5MQZ]N5_U[%[_L.K^V<%O%[(^>D@NW"83(B8FW.V!*RD,0J/6[EL_DY M?FQ.KR?S$WV^-X?4(TSZ<0 .4VM0AAA9 :1SUP4^(CUOIP/%M^;(NN0*#L#F M'@7Y _M5C]!U02P,$% @ R7BK5HLG/47+ @ >@< M !D !X;"]W;W)K&ULK55=3]LP%/TK5H8FD ;Y M:L/&TDC]8!J:@(K ]C#MP4UNFX@D#K;3P+_?M9-FI0L=F_;2VLX]YYYS;5_[ M->/W(@&0Y#'/"C$R$BG+,],440(Y%2>LA *_+!G/J<0I7YFBY$!C#.0:)*2):W8%20IT7S3Q_;.FP!D* '@M@!7&VV4:5LS*FG@WU],OQ M9!R>S\CT^G)^?A6.;R^NK\@QN:*<4U5D2.R22U;(1)#S(H;X.=Y$$YT39^-DXNPEO*3\ MA+CV.^)8CMNC9_IZN+-'CML5UM5\[DN%32B'XPF>L)C,Z1,>?$G&6-!B!7K\ M?;P0DN,I_M%7NX9[T,^M;O:9*&D$(P.OK@"^!B-X^\;VK(]]QO\3V;,R#+HR M#/:Q!Z%DT;V^:#&)6([-1U!U?_M,-TR>9E+=9QW8KG?JF^MM,SU!WM#J@IZ) M''8BAZ\0*6I:"@(/52J?\'#C[E1JIP0VJPCP&L3D$(^\4/LJCOKT-TF&6](< MQQL.=@SLE?*/N^%U1KU7&_V#&>\W,_8'RW9WS.Q-][=FS*TVE@-?Z>XN\-A4 MA6SZ0+?:/2!CW3=WUB?XL#3OP"^:YE7"6[["K249+)'2.CE%@[SI],U$LE(W MRP63V'KU,,''$;@*P.]+QN1FHA)TSVWP$U!+ P04 " #)>*M6"^[WIT8# M #M"@ &0 'AL+W=O$Y,/UEQD5&E)Z*N2US 20I MA++4=ATGL#-"F17UB[4'$?7Y4J64P8- ,;A;7<&2/CRI3S)S.Y M30:68X@@A5@9%42_5C""-#6:-,>/2JE5VS2"N^.-]@^%\]J9*9$PXNEWFJC% MP HME,",+%/UR->?H'*H:_3%/)7%$ZW+O<&%A>*E5#RKA#5!1EGY)L]5('8$ M//> @%L)N 5W::B@O":*1'W!UTB8W5J;&12N%M(:CC)S*A,E]%>JY50T^3(> M?3X?7DUNKM%H?/=P%.(S-%$\?D+CW 12HK?7H A-Y;N^ MK32"463'E;EA:X!?2<, M@VXS1E!C!*T8-\\@8BI/ GV0)QFA%Z-T&M%&!$6ZWJ4('U:2%?4&=!3 M/; MXSG'?H"# ^<3UE3A\?\/:++3_YQPCZS7"SWL'SBRBYKLHC7UOAB@E/4R*D62I#:F*[K5R-1;4T&^X&N(/= MYNCBG=J/C\[,EU!55PO>P7([!\XVSBXNTE@%M+>%OJ[A'* M(Q"]_="%'2<\@+F]"O )=\%^+K\DF/[>KQ=TW-Y?H/9.!Y*!F!=]ED0Q7S)5 M-B/U:MW+794=S'9[V0CJ&UWGC40IS+2HT^GIZ.BN%" M]Z,@S ;]?<:YVDR,@;K#C7X#4$L#!!0 ( ,EXJU:KJRO%P0( -@& 9 M >&PO=V]R:W-H965T,U9(4=>IE1YY?LRR3 GLLU++/27%1$ M%EX4,/4ER1+5-/?'^+ MQWQZ!B_A3-HG[)UO/_ @V4K%\V.P5I#3PKW)Z[$.9P%A[XV \!@06MV.R*J\ M)HK$D>![$,9;HQG#IFJCM3A:F*8LE-!?J8Y3\>+Y[QP=HP0VA EX(VR*,I6Y::(:%:%,?HY\I048&#\YDDT<6?@&61?N M>:$R";,BQ?3_>%\+K]2')_63L!'PGH@V=#M?( S"+GP$'V1&!,H&Z&Y5F*Z% M[KY5& /4FNB&IS G!WT.%8R%(,4:K?UKO)1*Z$/UNZX.#ONR'MMQ6&[%_F[&B6]2DFO4*+*T3X("^GO/7<$44958L)Y\6)$/WT>N4.2V]P?4G:_M=S-2WT76'4?_;-KD*-9VIDI(^+90;O!4 MN]78'KMI]<_=S7Q]?]=4SQ2&*QT:M ?Z/ @W1]U"\=+.KB57>A):,]._'A3& M07]?<:Y."T-0_*M6>$0ZT;<" T!P &0 'AL M+W=O$G\<<^YY]S$U\.MD#]4!J#) MKLBY&CF9UNLKUU5Q!@55/;$&CCNID 75.)4K5ZTET,2"BMSU/2]T"\JX$PWM MVJV,AJ+4.>-P*XDJBX+*7Q/(Q7;D])W#PAU;9=HLN-%P35>P /VPOI4X&"&7\W',Z=4H#/!X?V-];[^AE215,1?Z%)3H;.6\T'V/NY M,'RQR)5]DFT5.\#@N%1:%'LP*B@8K]YTMZ_#$0!YF@'^'N"? @;/ ((](+!& M*V76UHQJ&@VEV!)IHI'-#&QM+!K=,&Z^XD)+W&6(T]'UQ^FGFSFY'W^=+TAG M!IJR7'7).7E8S$CGK$O."./D/A.EHCQ10U=C4@-UXWV"297 ?R9!0&X$UYDB MF1_4Y@=M[ ?S&LW##AN+ M)9 H>4Z6Z3\8HMM&RFOVRB<]\/ M+X?NYMC1TZA+KPYYI/.BUGG1JG.>IF#[!?[,M6))-32)K*CZWE%^KQ>\[9^H M;,_8Z?=\[V6WI<9AK3UL91K'L2PA0>4:\ MJ@N>08*UIKADT'LCP2?W\ON>= MR&]-^J^_C7O4@ J0*]N7%8E%R75ULNO5NO6/;<<[69_@E5!U\#\TU7V"YW;% MN"(YI$CI]2ZQ_K+JT=5$B[5M*M6(&^"/"T% "G)P &0 'AL+W=OOM2R/9NH?2L2YU;\7ACN??Q)I2B5[2)!,C9RWE MYL9U1;2F:2@N^(9FZILES]-0JMU\Y8I-3L.X#$H3%WO>I9N&+'/&P_*SQWP\ MY%N9L(P^YDALTS3,_[ZC"=^-'-_9?_"%K=:R^, =#S?ABLZI_+IYS-6>VU!B MEM),,)ZAG"Y'SJU_0X(RH#SB-T9WXF ;%9>RX/Q;L?,0CQRO.".:T$@6B%#] M>:83FB0%29W'7S74:<8L @^W]_3WY<6KBUF$@DYX\CN+Y7KD#!P4TV6X3>07 MOOM(ZPOJ%[R()Z+\%^VJ8_M]!T5;(7E:!ZLS2%E6_0U?:A$' 7AP)@#7 ?@X M )\)".J X+4!O3J@5YJI+J7T0$(9CH\^E[GZ MEJDX.9Y\GDX?GJ;WLZWJ8?;B?31[NY^@MH3)DB7B'WB"6H:R;5 ]UE,8Q/@JI-NSASOS_P.6XF$ M1A0,+]K 6#'G].?GM&.-:@^97 M"DIN<(;[B0N!)LH?RU8TBQ@5Z(]/ZACT(&DJ_FS[.2I@KQU8S"8W8A-&=.2H MZ4+0_)DZXY]_\B^]7]OD0<(($,P0V6M$]FST\80+*=1D$^7;XYNPTF8-[ZJM M@EV6L&("?A[COC=TGP]M UHV.@W-OI6&X_;/%JK?$%\D;!56$S$;4ZLD*Y. M*EC_P$G/\XZE (UH2+ELI%Q:I2!@!@AD:KQJ-5]!3UA6D2$@8 8(9(@>-R,'W35F#DUFF=]4W$VIB':*K M#2"88>.ZL7']G]DIT'N6T+BH2(IG?YL3*Z3KK00)(T P0Y[OZ6K/@\[*F@CD M$I1&H&BFS8/:V?^^U+3'=W;GGSP[_=Y)00$UIND$:R?8ZF2F6KTH"5DJT++, MTG_.UN1W->KP@O#1Q&4?K?/] D0SW>@JWK?6MN/9-EW0'/$EVBA#*@F72V'U M$YS^X-ZQ(-#:'(IF"M+5N6\OSZH1M/@'I9&:=J[]-/7HLMZW M%KO[%%735N=&R4[N+ NTPH>BF59UC>\/P%,8LJ:?@-((%,VTJ7L$W]XD=$OA MZU?T3_8!.^OY$4T UDT MI;%1RG\BF[*SNMZJX'2"!3-=*E; .Q#)RX&;0I M:02*9MK4S0.V-P^=$M?.ZNSQM!=I::Z@QC3]Z 8"VQN(:?ARKCZV1W:V =I5 M0-%,:[JKP#WP' 7M-D!I!(IFVM3=!K:_-.B6HZ!]!BB-U+3#![]_^"K"]*/[ M!VSO'^H<_3\%LIW:!W\NH>:LS*CWNPLBFE^:I<(290 MQ+>9K!8Y-9\VJ]!NR[57KCZ\6L(V#?.5>A*CA"Y5J'=QI1[_>;4JK-J1?%.N MDUIP*7E:;JYI&-.\.$!]O^1<[G>* 9JU>>-_ 5!+ P04 " #)>*M6.A$S M'=$" #\" &0 'AL+W=OZM*'OF$8! +VE">-^(A,BZILF#"%+,+V@&1'Z94Y9B(;ML8?*, M 0XU*$U,J]5RS13'Q/!Z>FS,O![-11(3&#/$\S3%['4("5WUC;:Q'IC$BTBH M =/K97@!4Q"/V9C)GEFQA'$*A,>4( ;SOC%H=WU7Q>N ;S&L^$8;*25/E#ZK MSFW8-UIJ09! (!0#EJ\EC"!)%)%C]$58BI:LJF&-E.CI?R8 MJ&V?"B:_QA(GO,GUW6!V[:/Q8#+[@6:3P<-T,)K=?GV8HE,?!(X3?H;.T8B> M+X&(G &3O<>ICTY/SM )B@F:133GF(2\9PJY($5K!N7DPV)RZ\#D-KJG1$0< M79,0PFV\*854:JRUFJ'52'B/V06RVY^0U;+LFO6,W@ZW:N!^,]R'X!!\2XU= M[8VM^>Q#>P,)%A"B,6;B%=5F:3+,QQ MWY"I@@-;@N%]_-!V6Y_K/#LFF7\DLBT_G MU,Z>$FM':^-,[_T/CD2V98I;F>+^TY2]/^" +8U,[SU)QR3SW;T-.[^J=JSP MQ=RH"RFPA:ZO' 4T)Z)(JM5H5<('NG+MC _;W5%1B?_2%/<"F3(7,>$H@;FD M;%U&PO=V]R:W-H965TS,=J#[ M]CL[(:-5FE757L"^W/WO?I?XW#L(^:!V )H\IHRKOK/3.KMT717O(*6J)3+@ M^&0C9$HU;N7659D$NK9!*7-]SPO=E";!$PJ;O#-J7H]#X6X=O M"1S4R9H8DI40#V8S6?<=SQ0$#&)M%"C^[6$$C!DA+.-7J>E4*4W@Z?JH?FW9 MD65%%8P$^YZL]:[O?';(&C8T9WHA#K=0\G2-7BR8LK_D4/B&YPZ)3V?7=8CJXG]S- MR"P)>*<"[S2I1[,\78$D8H/GVZ#3%8/C9Z+JR NYKI4S\V8?8?_WISB-"=^( MTZUPNJ_$P:%I#@"^R2::[C]I&O.]D2:L:,)&F@G7(#DUPY,RHB@#=4:0*S:? M*C)JH=$N80\\ASJ\0K[MG?!Y+3^\>,98ZQ9&ULM9IO;Z)*%,:_RH2[ MV;3)MC(#HG;5Q#K=KLFU;6KWWAQO[!69$?9C\Q3PK5:FLG \XH<.]4% E@-M!&^P840)<<1? M#MF%>Y]!9.65TI_1QF0QT/2H(N*2.8LD;/[OC8R)ZT9*O(Y?J:B6'3-*W/_\ MH?XM-L_-O-HA&5/W;V?!U@.MJX$%6=I;ESW3W7>2&FI'>G/JAO%?L$MC=0W, MMR&C7IK,*_ -V$O@.O($E":@']W>/]\^CI^V0,1@\8 MS.[NIW3IZF3P^@"OP3#8T8/:K2\",K/BH,W"!";,=-[SD7_^8 M87#QZ1)\ HX/7M9T&]K^(NRW&*\O.DIKGM9RF]2"#M1B@"GUV3H$=_Z"+"3Y M6)T/D4*@Q1N3=0=]=.<6*16G=G -#/@%(!T9DH+&QZD*3#^/;?A]D46;/*$9A90DU#;8S@VVEP8D_IQX!%RX-^<6^#*@'^$TGB,\9 MJ?%$KKUGZ:IM05@R+HOJ=DI1N"VTYPH9EJYG805+5F;)JK#$"&\4X]-5Y$UF MPA+*:Y<=B"&EP<7**FH.6R?SV#G.(WGGB!!*37;$,4"&6;(I">J6?"HKJ>FS MF_GL*GT^LC4)TH%,3](OP"=,YK=*;B4AJ'Q2*@NJ:;>7V>T=PT+P'Q@M MWFQ_3A;\;D^"U6\I;RAE3[UI-:J&FU(KMG2/^^ 982 5;ZJQ3:KAIM2*C45Y M8U$](DCS]B^SGM4K76AC2134N[ T+6-U$75-YB0)E5!U.A6D>H69"!K(*KN7 MAAF]LOMS(!_,F0^JH>\(@$@5]HT((UT9@M5UU/69HQ^L8K]JB( BR0E&*T.P MNI"Z1G,@A&HB/(4BH A^@N'*$*PNJ*[AG YA%1Z>QA%0Q$#!=&4(5A=5UW2. MBK""%644\7@WE1INB/+2WC2IAIM2*[8Q1U#8.R64 MB]24>Y A1X-#2@:C2L#L'JHNJ:SM$0J=%P M3 -^F[,9 9]M;_,5Q*,N==L0T:6-:5(--Z56[&%.FZAS1F) #5%CVM@FU7!3 M:L7&YD2+U$1[F!C$!YG"I5<9@M5'K^LN!TUTU,/.$UA!\KBS#8WR0P99F-DU M!5(Z!PT:.0T::AH\@A<,D?@$-)+$E-]3J NI:S1'0J,*":N!P1 !3_*N0A95 M?EFA+J:NV9P"#34%G@(-ALAZP@L+68SPQD)=4UW/>Z^=CWI8>#0WI'+%UW[B M6PM)F/#:0EW9J^LL/!*LXO4J(9C3K<^21079WFQ-S"A>"5+:?PMOQLG* MEEPF66@SM8.5XX? )4LNJ5]W^,@&R=J59(/13;R:XY4R1KWXXYK8"Q)$ ?S[ M):7L8R,Z0+:":/@_4$L#!!0 ( ,EXJU:AKPZ*_0( ,0* 9 >&PO M=V]R:W-H965T'43B58HT M*()V^S#M@QLN)&IB9[:![M_/=D(*-$5K1;\DMG//R3DWU_%M;BA[Y"& 0$]) M3'C+"(5(KTR3!R$DF%_2%(A\LJ LP4).V=+D*0,\UZ D-AW+JIH)CHCA-_7: MA/E-NA)Q1&#"$%\E"69_.Q#33W"-%J&0BV8?C/%2YB!N$\G3,[,@F4> M)4!X1 EBL&@9;?NJ:UL*H"-^1+#A.V.DK#Q0^J@FPWG+L)0BB"$0B@++VQJZ M$,>*2>KXDY,:Q3L5<'>\9;_6YJ69!\RA2^.?T5R$+:-NH#DL\"H64[JY@=Q0 M1?$%-.;ZBC9YK&6@8,4%37*P5)!$)+OCISP1.P#)4PYP ;@YP-5& M,V7:5@\+[#<9W2"FHB6;&NC<:+1T$Q'U&6>"R:>1Q E_T+\=3-N3FV$7M<<] M-.L/1OWQ'1J.KV^GH_;=\':,OJ(!T"7#:1@%Z+P' D.C^[0&.;?:Y5<\Q0&T#+F-.; U&/[G3W;5^E9F_$1D>VGP MBC1XQ]C]&8ZAM#HR6%7#U&]G[=N.[EET5Y#;>(VM-4*315CFKJT02X MB((R64>1;TW\B5W\9K+)36?5ZS3XH MOY=!M8I7+Z^^>J&H?E31D A@1'\&')VEP;:>CUOK?468XW;_;Z[SH@I+HKR&5SDH0W.G'TB +76;Q%% 5T1DIVBQ M6K1B;=V '*QW5(NF^XQGFJR_DV?D,B(X,EK5,V4305'<=#U3( M'D8/0]EF E,!\OF"4K&=J!<4C:O_#U!+ P04 " #)>*M6\!&XM2X# #N M$@ #0 'AL+W-T>6QECNJ7KPY;.(;5TC\ZY1])U+3*LS5JPVP5C M)EJ50M8CLC"F^A#']6S!2EI?J(I)BQ1*E]38KI['=:49S6L@E2+N=3II7%(N MR7@HE^5U:>IHII;2C$B_#47^]CD?D6[ZGD1>;J)R-B+W9V]_+)6Y>A/Y^\F[ MDY/._?G58?S, >G@P@!BXNGSQ)_2QJ0O]Z7=\%,KY(FG&&T0 MH-DL6R9T'#EN-F4\+)3<[DU"?,"JTY)%#U2,R(0*/M4<6 4MN5C[< \",R64 MCHPM"INN"Y'ZEX>[O@?UTNB47"KMGVP)[F:33)7.F6[3=,DF-!X*5H =S><+ MN!M5Q0 :HTK;R#F=*TF=APVC:5C9&1/B%AZF[\6>]JK8V;<.[)ILF]90T_0R MO@/ZNVI>>U>V]R+=J.(/RGQ:VNE(UX<"93>:%7SE^JNB-8"I=W%U6E5B_5'P MN2R9G_RS$XZ'=,.+%DKS7S8;E,K,!I@FT0/3AL]V(S\UK>[8RFS*:57@GGNO MT//?7>7_\JR^Z]R:#CHL7E#'KO)_FLPF;X&DZ^B M)@?';S+)CM)CW+R_=PX)>T>$-AK!46Q$OL'!3FR31M,E%X;+IK?@><[DHY." ME3=T:@_S>_IV?,X*NA3FK@5'9-O^RG*^++-VU TL1#-JV_X"T^NF[3G0YN(R M9RN63YJNGD]=,[(-F[6Y@'"(7+LKC& <*B=A,\;4&)+QNP,BR\&YC>8"![0)6.Y _ MG =J*LQ)$MA5S!OV!.-(EF$(U&*X1M,469T4/N']P9Z2),FR, )8V$&28 @\ MC3B".0 /&)(D[CUX\#Z*-^^I>/L+U_@W4$L#!!0 ( ,EXJU:7BKL

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 63 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 64 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 112 256 1 false 44 0 false 7 false false R1.htm 0000001 - Document - Cover Sheet http://apyxmedical.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY Sheet http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY Statements 5 false false R6.htm 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 0000007 - Disclosure - BASIS OF PRESENTATION Sheet http://apyxmedical.com/role/BASISOFPRESENTATION BASIS OF PRESENTATION Notes 7 false false R8.htm 0000008 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS Sheet http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS RECENT ACCOUNTING PRONOUNCEMENTS Notes 8 false false R9.htm 0000009 - Disclosure - INVENTORIES Sheet http://apyxmedical.com/role/INVENTORIES INVENTORIES Notes 9 false false R10.htm 0000010 - Disclosure - ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT Sheet http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENT ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT Notes 10 false false R11.htm 0000011 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Sheet http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Notes 11 false false R12.htm 0000012 - Disclosure - CREDIT AGREEMENT Sheet http://apyxmedical.com/role/CREDITAGREEMENT CREDIT AGREEMENT Notes 12 false false R13.htm 0000013 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT Sheet http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENT INTEREST IN JOINT VENTURE INVESTMENT Notes 13 false false R14.htm 0000014 - Disclosure - EARNINGS (LOSS) PER SHARE Sheet http://apyxmedical.com/role/EARNINGSLOSSPERSHARE EARNINGS (LOSS) PER SHARE Notes 14 false false R15.htm 0000015 - Disclosure - STOCK-BASED COMPENSATION Sheet http://apyxmedical.com/role/STOCKBASEDCOMPENSATION STOCK-BASED COMPENSATION Notes 15 false false R16.htm 0000016 - Disclosure - INCOME TAXES Sheet http://apyxmedical.com/role/INCOMETAXES INCOME TAXES Notes 16 false false R17.htm 0000017 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 17 false false R18.htm 0000018 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS RELATED PARTY TRANSACTIONS Notes 18 false false R19.htm 0000019 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION Sheet http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION GEOGRAPHIC AND SEGMENT INFORMATION Notes 19 false false R20.htm 0000020 - Disclosure - BASIS OF PRESENTATION (Policies) Sheet http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies BASIS OF PRESENTATION (Policies) Policies 20 false false R21.htm 0000021 - Disclosure - INVENTORIES (Tables) Sheet http://apyxmedical.com/role/INVENTORIESTables INVENTORIES (Tables) Tables http://apyxmedical.com/role/INVENTORIES 21 false false R22.htm 0000022 - Disclosure - ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT (Tables) Sheet http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTTables ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT (Tables) Tables http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENT 22 false false R23.htm 0000023 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables) Sheet http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables) Tables http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES 23 false false R24.htm 0000024 - Disclosure - Debt (Tables) Sheet http://apyxmedical.com/role/DebtTables Debt (Tables) Tables 24 false false R25.htm 0000025 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT (Tables) Sheet http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTTables INTEREST IN JOINT VENTURE INVESTMENT (Tables) Tables http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENT 25 false false R26.htm 0000026 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables) Sheet http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables EARNINGS (LOSS) PER SHARE (Tables) Tables http://apyxmedical.com/role/EARNINGSLOSSPERSHARE 26 false false R27.htm 0000027 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables STOCK-BASED COMPENSATION (Tables) Tables http://apyxmedical.com/role/STOCKBASEDCOMPENSATION 27 false false R28.htm 0000028 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION (Tables) Sheet http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables GEOGRAPHIC AND SEGMENT INFORMATION (Tables) Tables http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION 28 false false R29.htm 0000029 - Disclosure - BASIS OF PRESENTATION (Details) Sheet http://apyxmedical.com/role/BASISOFPRESENTATIONDetails BASIS OF PRESENTATION (Details) Details http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies 29 false false R30.htm 0000030 - Disclosure - INVENTORIES (Details) Sheet http://apyxmedical.com/role/INVENTORIESDetails INVENTORIES (Details) Details http://apyxmedical.com/role/INVENTORIESTables 30 false false R31.htm 0000031 - Disclosure - ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT - Schedule of Assets Held-for-Sale (Details) Sheet http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT - Schedule of Assets Held-for-Sale (Details) Details 31 false false R32.htm 0000032 - Disclosure - ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT - Narrative (Details) Sheet http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT - Narrative (Details) Details 32 false false R33.htm 0000033 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) Sheet http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) Details http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables 33 false false R34.htm 0000034 - Disclosure - CREDIT AGREEMENT - Narrative (Details) Sheet http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails CREDIT AGREEMENT - Narrative (Details) Details 34 false false R35.htm 0000035 - Disclosure - CREDIT AGREEMENT - Schedule Of Long-Term Debt (Details) Sheet http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails CREDIT AGREEMENT - Schedule Of Long-Term Debt (Details) Details 35 false false R36.htm 0000036 - Disclosure - CREDIT AGREEMENT - Schedule of Long-Term Debt Maturities (Details) Sheet http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails CREDIT AGREEMENT - Schedule of Long-Term Debt Maturities (Details) Details 36 false false R37.htm 0000037 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT - Narrative (Details) Sheet http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails INTEREST IN JOINT VENTURE INVESTMENT - Narrative (Details) Details 37 false false R38.htm 0000038 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT - Rollforward of Joint Venture (Details) Sheet http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTRollforwardofJointVentureDetails INTEREST IN JOINT VENTURE INVESTMENT - Rollforward of Joint Venture (Details) Details 38 false false R39.htm 0000039 - Disclosure - EARNINGS (LOSS) PER SHARE (Details) Sheet http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails EARNINGS (LOSS) PER SHARE (Details) Details http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables 39 false false R40.htm 0000040 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) Sheet http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails STOCK-BASED COMPENSATION - Narrative (Details) Details 40 false false R41.htm 0000041 - Disclosure - STOCK-BASED COMPENSATION - Summary of Stock Options (Details) Sheet http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails STOCK-BASED COMPENSATION - Summary of Stock Options (Details) Details 41 false false R42.htm 0000042 - Disclosure - STOCK-BASED COMPENSATION - Fair Value Assumptions (Details) Sheet http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails STOCK-BASED COMPENSATION - Fair Value Assumptions (Details) Details 42 false false R43.htm 0000043 - Disclosure - INCOME TAXES (Details) Sheet http://apyxmedical.com/role/INCOMETAXESDetails INCOME TAXES (Details) Details http://apyxmedical.com/role/INCOMETAXES 43 false false R44.htm 0000044 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES 44 false false R45.htm 0000045 - Disclosure - RELATED PARTY TRANSACTIONS (Details) Sheet http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails RELATED PARTY TRANSACTIONS (Details) Details http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS 45 false false R46.htm 0000046 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details) Sheet http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details) Details 46 false false R47.htm 0000047 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details) Sheet http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details) Details 47 false false R48.htm 0000048 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details) Sheet http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details) Details 48 false false All Reports Book All Reports [dq-0542-Deprecated-Concept] Concept DueToRelatedPartiesCurrentAndNoncurrent in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. apyx-20230331.htm 4 [dq-0542-Deprecated-Concept] Concept DueFromRelatedParties in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. apyx-20230331.htm 4 apyx-20230331.htm a2023q110-kexhibit311.htm a2023q110-kexhibit312.htm a2023q110-kexhibit322.htm a2023q110-qexhibit321.htm apyx-20230331.xsd apyx-20230331_cal.xml apyx-20230331_def.xml apyx-20230331_lab.xml apyx-20230331_pre.xml apyx-20230331_g1.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 67 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "apyx-20230331.htm": { "axisCustom": 3, "axisStandard": 17, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 449, "http://xbrl.sec.gov/dei/2022": 29 }, "contextCount": 112, "dts": { "calculationLink": { "local": [ "apyx-20230331_cal.xml" ] }, "definitionLink": { "local": [ "apyx-20230331_def.xml" ] }, "inline": { "local": [ "apyx-20230331.htm" ] }, "labelLink": { "local": [ "apyx-20230331_lab.xml" ] }, "presentationLink": { "local": [ "apyx-20230331_pre.xml" ] }, "schema": { "local": [ "apyx-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 395, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 5, "total": 5 }, "keyCustom": 43, "keyStandard": 213, "memberCustom": 20, "memberStandard": 23, "nsprefix": "apyx", "nsuri": "http://apyxmedical.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://apyxmedical.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT", "menuCat": "Notes", "order": "10", "role": "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENT", "shortName": "ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES", "menuCat": "Notes", "order": "11", "role": "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - CREDIT AGREEMENT", "menuCat": "Notes", "order": "12", "role": "http://apyxmedical.com/role/CREDITAGREEMENT", "shortName": "CREDIT AGREEMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT", "menuCat": "Notes", "order": "13", "role": "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENT", "shortName": "INTEREST IN JOINT VENTURE INVESTMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - EARNINGS (LOSS) PER SHARE", "menuCat": "Notes", "order": "14", "role": "http://apyxmedical.com/role/EARNINGSLOSSPERSHARE", "shortName": "EARNINGS (LOSS) PER SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - STOCK-BASED COMPENSATION", "menuCat": "Notes", "order": "15", "role": "http://apyxmedical.com/role/STOCKBASEDCOMPENSATION", "shortName": "STOCK-BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - INCOME TAXES", "menuCat": "Notes", "order": "16", "role": "http://apyxmedical.com/role/INCOMETAXES", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - COMMITMENTS AND CONTINGENCIES", "menuCat": "Notes", "order": "17", "role": "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - RELATED PARTY TRANSACTIONS", "menuCat": "Notes", "order": "18", "role": "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION", "menuCat": "Notes", "order": "19", "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION", "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "icea0a6dbf6c34a688351e2f5840efa13_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "icea0a6dbf6c34a688351e2f5840efa13_I20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - BASIS OF PRESENTATION (Policies)", "menuCat": "Policies", "order": "20", "role": "http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies", "shortName": "BASIS OF PRESENTATION (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - INVENTORIES (Tables)", "menuCat": "Tables", "order": "21", "role": "http://apyxmedical.com/role/INVENTORIESTables", "shortName": "INVENTORIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT (Tables)", "menuCat": "Tables", "order": "22", "role": "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTTables", "shortName": "ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)", "menuCat": "Tables", "order": "23", "role": "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Debt (Tables)", "menuCat": "Tables", "order": "24", "role": "http://apyxmedical.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "apyx:NoncontrollingInterestTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT (Tables)", "menuCat": "Tables", "order": "25", "role": "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTTables", "shortName": "INTEREST IN JOINT VENTURE INVESTMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "apyx:NoncontrollingInterestTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)", "menuCat": "Tables", "order": "26", "role": "http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables", "shortName": "EARNINGS (LOSS) PER SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "menuCat": "Tables", "order": "27", "role": "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables", "shortName": "STOCK-BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION (Tables)", "menuCat": "Tables", "order": "28", "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables", "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "i4329db9485b349278676f47f9db880a6_D20180101-20181231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromDivestitureOfBusinesses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - BASIS OF PRESENTATION (Details)", "menuCat": "Details", "order": "29", "role": "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "shortName": "BASIS OF PRESENTATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "i4329db9485b349278676f47f9db880a6_D20180101-20181231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromDivestitureOfBusinesses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "icea0a6dbf6c34a688351e2f5840efa13_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "icea0a6dbf6c34a688351e2f5840efa13_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "icea0a6dbf6c34a688351e2f5840efa13_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - INVENTORIES (Details)", "menuCat": "Details", "order": "30", "role": "http://apyxmedical.com/role/INVENTORIESDetails", "shortName": "INVENTORIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "icea0a6dbf6c34a688351e2f5840efa13_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "icea0a6dbf6c34a688351e2f5840efa13_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT - Schedule of Assets Held-for-Sale (Details)", "menuCat": "Details", "order": "31", "role": "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails", "shortName": "ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT - Schedule of Assets Held-for-Sale (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "icea0a6dbf6c34a688351e2f5840efa13_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "i77f3598d2ffd4b38a71027240261f43c_D20230314-20230314", "decimals": "-4", "first": true, "lang": "en-US", "name": "apyx:SaleLeasebackPurchaseAgreement", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT - Narrative (Details)", "menuCat": "Details", "order": "32", "role": "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails", "shortName": "ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "i77f3598d2ffd4b38a71027240261f43c_D20230314-20230314", "decimals": null, "lang": "en-US", "name": "apyx:SaleLeasebackTermOfLease", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "icea0a6dbf6c34a688351e2f5840efa13_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccruedSalariesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)", "menuCat": "Details", "order": "33", "role": "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "icea0a6dbf6c34a688351e2f5840efa13_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccruedSalariesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "i4757b1c61bb84e9cb5d8c7ecbde121b9_D20230217-20230217", "decimals": "-6", "first": true, "lang": "en-US", "name": "apyx:DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - CREDIT AGREEMENT - Narrative (Details)", "menuCat": "Details", "order": "34", "role": "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails", "shortName": "CREDIT AGREEMENT - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "i4757b1c61bb84e9cb5d8c7ecbde121b9_D20230217-20230217", "decimals": "-6", "first": true, "lang": "en-US", "name": "apyx:DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "icea0a6dbf6c34a688351e2f5840efa13_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - CREDIT AGREEMENT - Schedule Of Long-Term Debt (Details)", "menuCat": "Details", "order": "35", "role": "http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails", "shortName": "CREDIT AGREEMENT - Schedule Of Long-Term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "icea0a6dbf6c34a688351e2f5840efa13_I20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:UnamortizedDebtIssuanceExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "icea0a6dbf6c34a688351e2f5840efa13_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - CREDIT AGREEMENT - Schedule of Long-Term Debt Maturities (Details)", "menuCat": "Details", "order": "36", "role": "http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails", "shortName": "CREDIT AGREEMENT - Schedule of Long-Term Debt Maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "icea0a6dbf6c34a688351e2f5840efa13_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "if3f9fa1ecfdb48119493afdf30b2022a_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "apyx:NoncontrollingInterestRequiredCapitalContribution", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT - Narrative (Details)", "menuCat": "Details", "order": "37", "role": "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails", "shortName": "INTEREST IN JOINT VENTURE INVESTMENT - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "if3f9fa1ecfdb48119493afdf30b2022a_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "apyx:NoncontrollingInterestRequiredCapitalContribution", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT - Rollforward of Joint Venture (Details)", "menuCat": "Details", "order": "38", "role": "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTRollforwardofJointVentureDetails", "shortName": "INTEREST IN JOINT VENTURE INVESTMENT - Rollforward of Joint Venture (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "apyx:NoncontrollingInterestTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "i8b4980f0f2ab4be298429e6c68c4337c_I20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:MinorityInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)", "menuCat": "Details", "order": "39", "role": "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails", "shortName": "EARNINGS (LOSS) PER SHARE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "menuCat": "Statements", "order": "4", "role": "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)", "menuCat": "Details", "order": "40", "role": "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - STOCK-BASED COMPENSATION - Summary of Stock Options (Details)", "menuCat": "Details", "order": "41", "role": "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails", "shortName": "STOCK-BASED COMPENSATION - Summary of Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "i0923d48d68ca48ff8f5bd3c8e49e430f_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - STOCK-BASED COMPENSATION - Fair Value Assumptions (Details)", "menuCat": "Details", "order": "42", "role": "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails", "shortName": "STOCK-BASED COMPENSATION - Fair Value Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": "3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - INCOME TAXES (Details)", "menuCat": "Details", "order": "43", "role": "http://apyxmedical.com/role/INCOMETAXESDetails", "shortName": "INCOME TAXES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": "3", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "icea0a6dbf6c34a688351e2f5840efa13_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "menuCat": "Details", "order": "44", "role": "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "icea0a6dbf6c34a688351e2f5840efa13_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ia7e994b58a5f469cb23af8692f7bf53f_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - RELATED PARTY TRANSACTIONS (Details)", "menuCat": "Details", "order": "45", "role": "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails", "shortName": "RELATED PARTY TRANSACTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ia7e994b58a5f469cb23af8692f7bf53f_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details)", "menuCat": "Details", "order": "46", "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails", "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details)", "menuCat": "Details", "order": "47", "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails", "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ifbcaac0596f94746b5646bea0416c4da_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details)", "menuCat": "Details", "order": "48", "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails", "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "ix:continuation", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "i8ef61e5dd37545a3ad7e31b677f88c1d_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "i72aa6d6b09e54d8d88d99ce693a6fac4_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY", "menuCat": "Statements", "order": "5", "role": "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "i72aa6d6b09e54d8d88d99ce693a6fac4_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "6", "role": "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000007 - Disclosure - BASIS OF PRESENTATION", "menuCat": "Notes", "order": "7", "role": "http://apyxmedical.com/role/BASISOFPRESENTATION", "shortName": "BASIS OF PRESENTATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000008 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS", "menuCat": "Notes", "order": "8", "role": "http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS", "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - INVENTORIES", "menuCat": "Notes", "order": "9", "role": "http://apyxmedical.com/role/INVENTORIES", "shortName": "INVENTORIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "apyx-20230331.htm", "contextRef": "ic1859d1f280245f78801a6687dc86e14_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 44, "tag": { "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Liabilities and Other Liabilities, Current", "label": "Accrued Liabilities and Other Liabilities, Current", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Total accrued expenses and other current liabilities" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilitiesCurrent", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails", "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Adjusted Term Secured Overnight Financing Rate (SOFR)", "label": "Adjusted Term Secured Overnight Financing Rate (SOFR) [Member]", "terseLabel": "Adjusted Term Secured Overnight Financing Rate (SOFR)" } } }, "localname": "AdjustedTermSecuredOvernightFinancingRateSOFRMember", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "domainItemType" }, "apyx_AdvancedEnergyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Advanced Energy [Member]", "label": "Advanced Energy [Member]", "terseLabel": "Advanced Energy" } } }, "localname": "AdvancedEnergyMember", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "apyx_AtTheMarketFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "At-The-Market Facility", "label": "At-The-Market Facility [Member]", "terseLabel": "At-The-Market Facility" } } }, "localname": "AtTheMarketFacilityMember", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails" ], "xbrltype": "domainItemType" }, "apyx_ChineseSupplierMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Chinese Supplier", "label": "Chinese Supplier [Member]", "terseLabel": "Chinese Supplier" } } }, "localname": "ChineseSupplierMember", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails" ], "xbrltype": "domainItemType" }, "apyx_ComputerEquipmentAndSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Computer Equipment And Software", "label": "Computer Equipment And Software [Member]", "terseLabel": "Computer equipment and software" } } }, "localname": "ComputerEquipmentAndSoftwareMember", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails" ], "xbrltype": "domainItemType" }, "apyx_CreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Credit Agreement", "label": "Credit Agreement [Member]", "terseLabel": "Credit Agreement" } } }, "localname": "CreditAgreementMember", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "domainItemType" }, "apyx_DebtInstrumentAnnualFeePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Annual Fee, Percent", "label": "Debt Instrument, Annual Fee, Percent", "terseLabel": "Annual fee" } } }, "localname": "DebtInstrumentAnnualFeePercent", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "percentItemType" }, "apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Amount", "label": "Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Amount", "terseLabel": "Borrowing base, minimum balance" } } }, "localname": "DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Percent", "label": "Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Percent", "terseLabel": "Borrowing base, minimum balance" } } }, "localname": "DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "percentItemType" }, "apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Cash And Cash Equivalents Balance", "label": "Debt Instrument, Covenant, Cash And Cash Equivalents Balance", "terseLabel": "Cash and cash equivalents balance" } } }, "localname": "DebtInstrumentCovenantCashAndCashEquivalentsBalance", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "apyx_DebtInstrumentCovenantTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Tranche One", "label": "Debt Instrument, Covenant, Tranche One [Member]", "terseLabel": "Debt Instrument, Covenant, Tranche One" } } }, "localname": "DebtInstrumentCovenantTrancheOneMember", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "domainItemType" }, "apyx_DebtInstrumentCovenantTrancheThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Tranche Three", "label": "Debt Instrument, Covenant, Tranche Three [Member]", "terseLabel": "Debt Instrument, Covenant, Tranche Three" } } }, "localname": "DebtInstrumentCovenantTrancheThreeMember", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "domainItemType" }, "apyx_DebtInstrumentCovenantTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Tranche Two", "label": "Debt Instrument, Covenant, Tranche Two [Member]", "terseLabel": "Debt Instrument, Covenant, Tranche Two" } } }, "localname": "DebtInstrumentCovenantTrancheTwoMember", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "domainItemType" }, "apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year One", "label": "Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year One", "terseLabel": "Twelve month net revenue target, year one" } } }, "localname": "DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Three", "label": "Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Three", "terseLabel": "Twelve month net revenue target, year three" } } }, "localname": "DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Two", "label": "Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Two", "terseLabel": "Twelve month net revenue target, year two" } } }, "localname": "DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "apyx_DebtInstrumentCovenantsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenants", "label": "Debt Instrument, Covenants [Axis]", "terseLabel": "Debt Instrument, Covenants [Axis]" } } }, "localname": "DebtInstrumentCovenantsAxis", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "stringItemType" }, "apyx_DebtInstrumentCovenantsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenants [Domain]", "label": "Debt Instrument, Covenants [Domain]", "terseLabel": "Debt Instrument, Covenants [Domain]" } } }, "localname": "DebtInstrumentCovenantsDomain", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "domainItemType" }, "apyx_DebtInstrumentDefaultApplicableInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Default, Applicable Interest Rate", "label": "Debt Instrument, Default, Applicable Interest Rate", "terseLabel": "Default, applicable interest rate" } } }, "localname": "DebtInstrumentDefaultApplicableInterestRate", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "percentItemType" }, "apyx_DebtInstrumentExitFee": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Exit Fee", "label": "Debt Instrument, Exit Fee", "terseLabel": "Exit fee" } } }, "localname": "DebtInstrumentExitFee", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "percentItemType" }, "apyx_DebtInstrumentExtensionPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Extension Period", "label": "Debt Instrument, Extension Period", "terseLabel": "Extension period" } } }, "localname": "DebtInstrumentExtensionPeriod", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "durationItemType" }, "apyx_DebtInstrumentInterestRateFloorPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Interest Rate Floor, Percent", "label": "Debt Instrument, Interest Rate Floor, Percent", "terseLabel": "Interest rate floor" } } }, "localname": "DebtInstrumentInterestRateFloorPercent", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "percentItemType" }, "apyx_DebtInstrumentInterestRateFloorSpreadAdjustmentPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Interest Rate Floor Spread Adjustment, Percent", "label": "Debt Instrument, Interest Rate Floor Spread Adjustment, Percent", "terseLabel": "Interest rate floor spread" } } }, "localname": "DebtInstrumentInterestRateFloorSpreadAdjustmentPercent", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "percentItemType" }, "apyx_DebtInstrumentLockboxAccountFundsToBeAppliedToBorrowings": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Lockbox Account, Funds To Be Applied To Borrowings", "label": "Debt Instrument, Lockbox Account, Funds To Be Applied To Borrowings", "terseLabel": "Lockbox account, funds to be applied to borrowings" } } }, "localname": "DebtInstrumentLockboxAccountFundsToBeAppliedToBorrowings", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "durationItemType" }, "apyx_DebtInstrumentNumberOfMonthlyPayments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Number Of Monthly Payments", "label": "Debt Instrument, Number Of Monthly Payments", "terseLabel": "Number of monthly payments" } } }, "localname": "DebtInstrumentNumberOfMonthlyPayments", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "integerItemType" }, "apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Number Of Monthly Payments, Extension", "label": "Debt Instrument, Number Of Monthly Payments, Extension", "terseLabel": "Number of monthly payments, extension" } } }, "localname": "DebtInstrumentNumberOfMonthlyPaymentsExtension", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "integerItemType" }, "apyx_DebtInstrumentPeriodOfInterestOnly": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Period Of Interest Only", "label": "Debt Instrument, Period Of Interest Only", "terseLabel": "Period of interest only" } } }, "localname": "DebtInstrumentPeriodOfInterestOnly", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "durationItemType" }, "apyx_DebtInstrumentPrepaymentFeePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Prepayment Fee, Percent", "label": "Debt Instrument, Prepayment Fee, Percent", "terseLabel": "Prepayment fee" } } }, "localname": "DebtInstrumentPrepaymentFeePercent", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "percentItemType" }, "apyx_DebtInstrumentPrepaymentPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Prepayment Period", "label": "Debt Instrument, Prepayment Period [Axis]", "terseLabel": "Debt Instrument, Prepayment Period [Axis]" } } }, "localname": "DebtInstrumentPrepaymentPeriodAxis", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "stringItemType" }, "apyx_DebtInstrumentPrepaymentPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Prepayment Period [Domain]", "label": "Debt Instrument, Prepayment Period [Domain]", "terseLabel": "Debt Instrument, Prepayment Period [Domain]" } } }, "localname": "DebtInstrumentPrepaymentPeriodDomain", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "domainItemType" }, "apyx_DebtInstrumentPrepaymentPeriodOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Prepayment Period One", "label": "Debt Instrument, Prepayment Period One [Member]", "terseLabel": "Debt Instrument, Prepayment Period One" } } }, "localname": "DebtInstrumentPrepaymentPeriodOneMember", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "domainItemType" }, "apyx_DebtInstrumentPrepaymentPeriodThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Prepayment Period Three", "label": "Debt Instrument, Prepayment Period Three [Member]", "terseLabel": "Debt Instrument, Prepayment Period Three" } } }, "localname": "DebtInstrumentPrepaymentPeriodThreeMember", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "domainItemType" }, "apyx_DebtInstrumentPrepaymentPeriodTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Prepayment Period Two", "label": "Debt Instrument, Prepayment Period Two [Member]", "terseLabel": "Debt Instrument, Prepayment Period Two" } } }, "localname": "DebtInstrumentPrepaymentPeriodTwoMember", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "domainItemType" }, "apyx_DebtInstrumentTerminationFees": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Termination Fees", "label": "Debt Instrument, Termination Fees", "terseLabel": "Termination fees" } } }, "localname": "DebtInstrumentTerminationFees", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "percentItemType" }, "apyx_DebtInstrumentTerminationPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Termination Period", "label": "Debt Instrument, Termination Period [Axis]", "terseLabel": "Debt Instrument, Termination Period [Axis]" } } }, "localname": "DebtInstrumentTerminationPeriodAxis", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "stringItemType" }, "apyx_DebtInstrumentTerminationPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Termination Period [Domain]", "label": "Debt Instrument, Termination Period [Domain]", "terseLabel": "Debt Instrument, Termination Period [Domain]" } } }, "localname": "DebtInstrumentTerminationPeriodDomain", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "domainItemType" }, "apyx_DebtInstrumentTerminationPeriodOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Termination Period One", "label": "Debt Instrument, Termination Period One [Member]", "terseLabel": "Debt Instrument, Termination Period One" } } }, "localname": "DebtInstrumentTerminationPeriodOneMember", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "domainItemType" }, "apyx_DebtInstrumentTerminationPeriodThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Termination Period Three", "label": "Debt Instrument, Termination Period Three [Member]", "terseLabel": "Debt Instrument, Termination Period Three" } } }, "localname": "DebtInstrumentTerminationPeriodThreeMember", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "domainItemType" }, "apyx_DebtInstrumentTerminationPeriodTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Termination Period Two", "label": "Debt Instrument, Termination Period Two [Member]", "terseLabel": "Debt Instrument, Termination Period Two" } } }, "localname": "DebtInstrumentTerminationPeriodTwoMember", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "domainItemType" }, "apyx_JointAndSeveralPayrollLiability": { "auth_ref": [], "calculation": { "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": 10.0, "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Joint And Several Payroll Liability", "label": "Joint And Several Payroll Liability", "terseLabel": "Joint and several payroll liability" } } }, "localname": "JointAndSeveralPayrollLiability", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "apyx_LongTermDebtMaturityAfterYearFour": { "auth_ref": [], "calculation": { "http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long-Term Debt, Maturity, After Year Four", "label": "Long-Term Debt, Maturity, After Year Four", "terseLabel": "Thereafter" } } }, "localname": "LongTermDebtMaturityAfterYearFour", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "apyx_MoldsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Molds", "label": "Molds [Member]", "terseLabel": "Molds" } } }, "localname": "MoldsMember", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails" ], "xbrltype": "domainItemType" }, "apyx_NoncontrollingInterestRequiredCapitalContribution": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncontrolling Interest, Required Capital Contribution", "label": "Noncontrolling Interest, Required Capital Contribution", "terseLabel": "Required capital contribution" } } }, "localname": "NoncontrollingInterestRequiredCapitalContribution", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "apyx_NoncontrollingInterestTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Noncontrolling Interest", "label": "Noncontrolling Interest [Table Text Block]", "terseLabel": "Schedule of China Joint Venture" } } }, "localname": "NoncontrollingInterestTableTextBlock", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTTables" ], "xbrltype": "textBlockItemType" }, "apyx_OEMMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OEM [Member]", "terseLabel": "OEM" } } }, "localname": "OEMMember", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "apyx_OtherAccruedExpensesAndLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": 7.0, "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Accrued Expenses And Liabilities, Current", "label": "Other Accrued Expenses And Liabilities, Current", "terseLabel": "Other accrued expenses and current liabilities" } } }, "localname": "OtherAccruedExpensesAndLiabilitiesCurrent", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised": { "auth_ref": [], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Stock Options Exercised And Warrants Exercised", "label": "Proceeds From Stock Options Exercised And Warrants Exercised", "terseLabel": "Proceeds from stock option exercises" } } }, "localname": "ProceedsFromStockOptionsExercisedAndWarrantsExercised", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "apyx_PropertyPlantAndEquipmentInService": { "auth_ref": [], "calculation": { "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Property, Plant And Equipment, In Service", "label": "Property, Plant And Equipment, In Service", "totalLabel": "Property and equipment in service" } } }, "localname": "PropertyPlantAndEquipmentInService", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "apyx_ProvisionForInventoryObsolescence": { "auth_ref": [], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Provision For Inventory Obsolescence", "label": "Provision For Inventory Obsolescence", "terseLabel": "Provision for inventory obsolescence" } } }, "localname": "ProvisionForInventoryObsolescence", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "apyx_ProvisionForObsolescenceInventory": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Provision For Obsolescence, Inventory", "label": "Provision For Obsolescence, Inventory", "terseLabel": "Inventories, provision for obsolescence" } } }, "localname": "ProvisionForObsolescenceInventory", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "monetaryItemType" }, "apyx_RepaymentofFinanceLeaseLiabilities": { "auth_ref": [], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repayment of Finance Lease Liabilities", "label": "Repayment of Finance Lease Liabilities", "negatedTerseLabel": "Repayment of finance lease liabilities" } } }, "localname": "RepaymentofFinanceLeaseLiabilities", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "apyx_SaleLeasebackAnnualRentIncrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale Leaseback, Annual Rent Increase", "label": "Sale Leaseback, Annual Rent Increase", "terseLabel": "Sale leaseback, annual rent increase" } } }, "localname": "SaleLeasebackAnnualRentIncrease", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails" ], "xbrltype": "percentItemType" }, "apyx_SaleLeasebackAnnualRentPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sale Leaseback. Annual Rent Payment", "label": "Sale Leaseback. Annual Rent Payment", "terseLabel": "Sale leaseback. annual rent payment" } } }, "localname": "SaleLeasebackAnnualRentPayment", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "apyx_SaleLeasebackManagementFeeOnRentPayment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale Leaseback, Management Fee On Rent Payment", "label": "Sale Leaseback, Management Fee On Rent Payment", "terseLabel": "Sale leaseback, management fee on rent payment" } } }, "localname": "SaleLeasebackManagementFeeOnRentPayment", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails" ], "xbrltype": "percentItemType" }, "apyx_SaleLeasebackNetCashProceeds": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sale Leaseback, Net Cash Proceeds", "label": "Sale Leaseback, Net Cash Proceeds", "terseLabel": "Sale leaseback, net cash proceeds" } } }, "localname": "SaleLeasebackNetCashProceeds", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "apyx_SaleLeasebackPurchaseAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sale Leaseback, Purchase Agreement", "label": "Sale Leaseback, Purchase Agreement", "terseLabel": "Purchase agreement" } } }, "localname": "SaleLeasebackPurchaseAgreement", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails", "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails" ], "xbrltype": "monetaryItemType" }, "apyx_SaleLeasebackRenewalTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale Leaseback, Renewal Term", "label": "Sale Leaseback, Renewal Term", "terseLabel": "Sale leaseback, renewal term" } } }, "localname": "SaleLeasebackRenewalTerm", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails" ], "xbrltype": "durationItemType" }, "apyx_SaleLeasebackSecurityDepositEqualToAnnualRent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale Leaseback, Security Deposit Equal To Annual Rent", "label": "Sale Leaseback, Security Deposit Equal To Annual Rent", "terseLabel": "Security deposit equal to annual rent" } } }, "localname": "SaleLeasebackSecurityDepositEqualToAnnualRent", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails" ], "xbrltype": "durationItemType" }, "apyx_SaleLeasebackTermOfLease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale Leaseback, Term Of Lease", "label": "Sale Leaseback, Term Of Lease", "terseLabel": "Sale leaseback, term of lease" } } }, "localname": "SaleLeasebackTermOfLease", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails" ], "xbrltype": "durationItemType" }, "apyx_SecuritiesRegisteredNewIssues": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Securities Registered, New Issues", "label": "Securities Registered, New Issues", "terseLabel": "Securities registered, new issues" } } }, "localname": "SecuritiesRegisteredNewIssues", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails" ], "xbrltype": "monetaryItemType" }, "apyx_ShelfRegistrationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shelf Registration", "label": "Shelf Registration [Member]", "terseLabel": "Shelf Registration" } } }, "localname": "ShelfRegistrationMember", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails" ], "xbrltype": "domainItemType" }, "apyx_StockIssuedDuringPeriodSharesStockSwaps": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Shares, Stock Swaps", "label": "Stock Issued During Period, Shares, Stock Swaps", "terseLabel": "Stock swaps (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockSwaps", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "sharesItemType" }, "apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received", "label": "Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received", "terseLabel": "Stock swaps equity instruments received (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "sharesItemType" }, "apyx_StockSwapToAcquireOptionsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock swap to acquire options shares.", "label": "Stock swap to acquire options, Shares", "terseLabel": "Shares issued on net settlement of stock options (in shares)" } } }, "localname": "StockSwapToAcquireOptionsShares", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "sharesItemType" }, "apyx_SuitAgainstGoodwinAndSimbMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Suit Against Goodwin And Simb", "label": "Suit Against Goodwin And Simb [Member]", "terseLabel": "Suit Against Goodwin And Simb" } } }, "localname": "SuitAgainstGoodwinAndSimbMember", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "apyx_SuitsFiledIn2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Suits Filed in 2022", "label": "Suits Filed in 2022 [Member]", "terseLabel": "Suits Filed in 2022" } } }, "localname": "SuitsFiledIn2022Member", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "apyx_TotalRevenuePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total Revenue, Percent", "label": "Total Revenue, Percent", "terseLabel": "International sales, percent of total revenue" } } }, "localname": "TotalRevenuePercent", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails" ], "xbrltype": "percentItemType" }, "apyx_UncertainTaxPositionsLiability": { "auth_ref": [], "calculation": { "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": 5.0, "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Uncertain Tax Positions Liability", "label": "Uncertain Tax Positions Liability", "terseLabel": "Uncertain tax positions" } } }, "localname": "UncertainTaxPositionsLiability", "nsuri": "http://apyxmedical.com/20230331", "presentation": [ "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "Domestic" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://apyxmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://apyxmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://apyxmedical.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://apyxmedical.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://apyxmedical.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://apyxmedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r504" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://apyxmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://apyxmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://apyxmedical.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://apyxmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://apyxmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://apyxmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://apyxmedical.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://apyxmedical.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://apyxmedical.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://apyxmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://apyxmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://apyxmedical.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://apyxmedical.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://apyxmedical.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r506" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://apyxmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://apyxmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://apyxmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://apyxmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://apyxmedical.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://apyxmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r501" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://apyxmedical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r503" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://apyxmedical.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://apyxmedical.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r181", "r226", "r238", "r239", "r240", "r241", "r242", "r244", "r248", "r292", "r293", "r294", "r295", "r297", "r298", "r300", "r302", "r303", "r532", "r533" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r181", "r226", "r238", "r239", "r240", "r241", "r242", "r244", "r248", "r292", "r293", "r294", "r295", "r297", "r298", "r300", "r302", "r303", "r532", "r533" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r287", "r288", "r289", "r290", "r345", "r431", "r454", "r477", "r478", "r492", "r494", "r500", "r534", "r545", "r546", "r547", "r548", "r549", "r550" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r287", "r288", "r289", "r290", "r345", "r431", "r454", "r477", "r478", "r492", "r494", "r500", "r534", "r545", "r546", "r547", "r548", "r549", "r550" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r287", "r288", "r289", "r290", "r343", "r345", "r356", "r357", "r358", "r430", "r431", "r454", "r477", "r478", "r492", "r494", "r500", "r528", "r534", "r546", "r547", "r548", "r549", "r550" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r287", "r288", "r289", "r290", "r343", "r345", "r356", "r357", "r358", "r430", "r431", "r454", "r477", "r478", "r492", "r494", "r500", "r528", "r534", "r546", "r547", "r548", "r549", "r550" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r251", "r252", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r493", "r499", "r536" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r251", "r252", "r463", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r493", "r499", "r536" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r26", "r498" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r256", "r257" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Trade accounts receivable, net of allowance of $359 and $668" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrent": { "auth_ref": [ "r31" ], "calculation": { "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": 2.0, "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Bonuses, Current", "terseLabel": "Accrued bonuses" } } }, "localname": "AccruedBonusesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedInsuranceCurrent": { "auth_ref": [ "r31" ], "calculation": { "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": 8.0, "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Insurance, Current", "terseLabel": "Accrued product liability claim insurance deductibles" } } }, "localname": "AccruedInsuranceCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r31" ], "calculation": { "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": 11.0, "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional fees and legal related contingent liabilities" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalariesCurrent": { "auth_ref": [ "r31", "r481" ], "calculation": { "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": 1.0, "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Salaries, Current", "verboseLabel": "Accrued payroll" } } }, "localname": "AccruedSalariesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalesCommissionCurrent": { "auth_ref": [ "r31", "r481" ], "calculation": { "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": 9.0, "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Sales Commission, Current", "terseLabel": "Accrued commissions" } } }, "localname": "AccruedSalesCommissionCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r73", "r156" ], "calculation": { "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails": { "order": 1.0, "parentTag": "apyx_PropertyPlantAndEquipmentInService", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less: accumulated depreciation and amortization", "terseLabel": "Accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails", "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r18", "r498" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r364", "r365", "r366", "r521", "r522", "r523", "r539" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r98", "r99", "r346" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "verboseLabel": "Stock based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r85", "r87", "r92" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Proceeds received from issuance of warrants" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r360" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Stock based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r160", "r258", "r265", "r266", "r268" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "terseLabel": "Allowance for doubtful accounts receivable" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r40", "r327", "r414", "r516" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r327", "r414", "r490", "r491", "r516" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of debt discounts" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive instruments (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r118", "r131", "r158", "r178", "r234", "r240", "r246", "r261", "r292", "r293", "r295", "r296", "r297", "r299", "r301", "r303", "r304", "r388", "r392", "r401", "r498", "r532", "r533", "r543" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r151", "r163", "r178", "r261", "r292", "r293", "r295", "r296", "r297", "r299", "r301", "r303", "r304", "r388", "r392", "r401", "r498", "r532", "r533", "r543" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent": { "auth_ref": [ "r71", "r498" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 7.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.", "label": "Assets Held-for-sale, Not Part of Disposal Group, Current", "terseLabel": "Assets held for sale" } } }, "localname": "AssetsHeldForSaleNotPartOfDisposalGroupCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails", "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]", "terseLabel": "Building and improvements" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r59", "r154", "r479" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r53", "r59", "r61" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r53", "r110" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrants, exercise price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Warrants" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CoVenturerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other venturer from the perspective of the entity in the corporate joint venture.", "label": "Co-venturer [Member]", "terseLabel": "Co-venturer" } } }, "localname": "CoVenturerMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r78", "r284", "r285", "r464", "r531" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r521", "r522", "r539" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r17", "r87" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r17", "r498" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value; 75,000,000 shares authorized; 34,597,822 issued and outstanding as of March\u00a031, 2023 and December\u00a031, 2022" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConstructionInProgressGross": { "auth_ref": [ "r72" ], "calculation": { "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress, Gross", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r338", "r339", "r342" ], "calculation": { "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": 4.0, "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Short-term contract liabilities" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r338", "r339", "r342" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Long-term contract liabilities" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateJointVentureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Corporation owned and operated by a small group of ventures to accomplish a mutually beneficial venture or project.", "label": "Corporate Joint Venture [Member]", "terseLabel": "Corporate Joint Venture" } } }, "localname": "CorporateJointVentureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTRollforwardofJointVentureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r66", "r239", "r240", "r241", "r242", "r248", "r526" ], "lang": { "en-us": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Corporate & Other" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r45", "r433" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Other costs and expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r86", "r177", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r321", "r328", "r329", "r331" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "CREDIT AGREEMENT" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENT" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r13", "r14", "r15", "r119", "r120", "r130", "r181", "r305", "r306", "r307", "r308", "r309", "r311", "r317", "r318", "r319", "r320", "r322", "r323", "r324", "r325", "r326", "r327", "r415", "r487", "r488", "r489", "r490", "r491", "r517" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails", "http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r15", "r120", "r130", "r332" ], "calculation": { "http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 }, "http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-Term Debt, Gross", "terseLabel": "Term loan", "totalLabel": "Term loan, net" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails", "http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r112", "r114", "r305", "r415", "r488", "r489" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Mortgage loan, principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r33", "r112", "r334", "r415" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails", "http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r34", "r181", "r305", "r306", "r307", "r308", "r309", "r311", "r317", "r318", "r319", "r320", "r322", "r323", "r324", "r325", "r326", "r327", "r415", "r487", "r488", "r489", "r490", "r491", "r517" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails", "http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r34", "r88", "r89", "r90", "r91", "r111", "r112", "r114", "r129", "r181", "r305", "r306", "r307", "r308", "r309", "r311", "r317", "r318", "r319", "r320", "r322", "r323", "r324", "r325", "r326", "r327", "r330", "r415", "r487", "r488", "r489", "r490", "r491", "r517" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails", "http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r111", "r114", "r535" ], "calculation": { "http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedTerseLabel": "Unamortized debt discount, including accretion of exit fee" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r113" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "terseLabel": "Debt issuance costs" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r57", "r229" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DilutiveSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "DilutiveSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r347", "r361", "r362", "r363", "r368", "r495" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "STOCK-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DueFromRelatedParties": { "auth_ref": [ "r123", "r138", "r159", "r294", "r295", "r296", "r302", "r303", "r304", "r426", "r519" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.", "label": "Due from Related Parties", "negatedTerseLabel": "Due from related parties" } } }, "localname": "DueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r125", "r137", "r294", "r295", "r296", "r302", "r303", "r304", "r426", "r519" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.", "label": "Due to Related Parties", "terseLabel": "Due to related parties" } } }, "localname": "DueToRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Loss per share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r170", "r191", "r192", "r193", "r194", "r195", "r202", "r205", "r212", "r213", "r214", "r218", "r396", "r397", "r449", "r452", "r483" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Loss per share:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r170", "r191", "r192", "r193", "r194", "r195", "r205", "r212", "r213", "r214", "r218", "r396", "r397", "r449", "r452", "r483" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Anti-dilutive instruments excluded from diluted loss per common share:" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share Reconciliation [Abstract]", "terseLabel": "Earnings Per Share Reconciliation [Abstract]" } } }, "localname": "EarningsPerShareReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r215", "r216", "r217", "r219" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "EARNINGS (LOSS) PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/EARNINGSLOSSPERSHARE" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r405" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of exchange rates on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/INCOMETAXESDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r87", "r146", "r166", "r167", "r168", "r182", "r183", "r184", "r188", "r196", "r198", "r221", "r262", "r337", "r364", "r365", "r366", "r375", "r376", "r395", "r406", "r407", "r408", "r409", "r410", "r411", "r421", "r455", "r456", "r457" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r419" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Current portion of finance lease liabilities" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r419" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Long-term finance lease liabilities" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r418" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "terseLabel": "Finance lease right-of-use assets" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r57" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "Loss on disposal of property and equipment" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r43", "r178", "r234", "r239", "r245", "r248", "r261", "r292", "r293", "r295", "r296", "r297", "r299", "r301", "r303", "r304", "r401", "r485", "r532" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r38", "r117", "r126", "r141", "r234", "r239", "r245", "r248", "r450", "r485" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r5", "r6", "r7", "r8", "r9", "r10", "r75", "r76" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r179", "r371", "r373", "r374", "r380", "r382", "r384", "r385", "r386" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/INCOMETAXES" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r180", "r197", "r198", "r232", "r369", "r381", "r383", "r453" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "netLabel": "Income tax (benefit) expense", "terseLabel": "Income tax (benefit) expense", "verboseLabel": "Income tax expense (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails", "http://apyxmedical.com/role/INCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r54", "r60" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesReceivable": { "auth_ref": [ "r124", "r139", "r508" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.", "label": "Income Taxes Receivable, Current", "terseLabel": "Income tax receivables" } } }, "localname": "IncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r56" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r56" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Trade receivables" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r56" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": { "auth_ref": [ "r56" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.", "label": "Increase (Decrease) in Income Taxes Receivable", "negatedLabel": "Income tax receivables", "terseLabel": "Income tax receivables" } } }, "localname": "IncreaseDecreaseInIncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "auth_ref": [ "r56" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.", "label": "Increase (Decrease) in Interest Payable, Net", "terseLabel": "Non-cash interest expense" } } }, "localname": "IncreaseDecreaseInInterestPayableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r56" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r56" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r113", "r128", "r169", "r228", "r413" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOperating": { "auth_ref": [ "r41" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.", "label": "Interest Income, Operating", "terseLabel": "Interest income", "verboseLabel": "Interest income" } } }, "localname": "InterestIncomeOperating", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r172", "r175", "r176" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "INVENTORIES" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/INVENTORIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r509" ], "calculation": { "http://apyxmedical.com/role/INVENTORIESDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/INVENTORIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryGross": { "auth_ref": [ "r512" ], "calculation": { "http://apyxmedical.com/role/INVENTORIESDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Inventory, Gross", "totalLabel": "Gross inventories" } } }, "localname": "InventoryGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/INVENTORIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r162", "r480", "r498" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://apyxmedical.com/role/INVENTORIESDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Inventories, net", "verboseLabel": "Inventories, net of provision for obsolescence of $428 and $457" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://apyxmedical.com/role/INVENTORIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r153", "r161", "r220", "r269", "r270", "r271", "r432", "r482" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r511" ], "calculation": { "http://apyxmedical.com/role/INVENTORIESDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/INVENTORIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r69", "r512" ], "calculation": { "http://apyxmedical.com/role/INVENTORIESDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "negatedLabel": "Less: provision for obsolescence" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/INVENTORIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r510" ], "calculation": { "http://apyxmedical.com/role/INVENTORIESDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/INVENTORIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r537" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r30", "r178", "r261", "r292", "r293", "r295", "r296", "r297", "r299", "r301", "r303", "r304", "r389", "r392", "r393", "r401", "r484", "r532", "r543", "r544" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r22", "r122", "r135", "r498", "r518", "r527", "r541" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r32", "r152", "r178", "r261", "r292", "r293", "r295", "r296", "r297", "r299", "r301", "r303", "r304", "r389", "r392", "r393", "r401", "r498", "r532", "r543", "r544" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r28" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Credit facility" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r28" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Remaining borrowing capacity" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails", "http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r15", "r120", "r132", "r318", "r333", "r488", "r489" ], "calculation": { "http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "totalLabel": "Term loan, net" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r29" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-Term Debt, Current Maturities", "terseLabel": "Term loan, net" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r83", "r181", "r323" ], "calculation": { "http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r83", "r181", "r323" ], "calculation": { "http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2027" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r83", "r181", "r323" ], "calculation": { "http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails": { "order": 6.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r83", "r181", "r323" ], "calculation": { "http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r520" ], "calculation": { "http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTScheduleofLongTermDebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails", "http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r34", "r84" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails", "http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r80", "r81", "r286", "r287", "r288", "r529", "r530" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r286", "r507" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "terseLabel": "Costs accrued" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyEstimateOfPossibleLoss": { "auth_ref": [ "r287", "r288", "r291" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.", "label": "Loss Contingency, Estimate of Possible Loss", "terseLabel": "Estimate of possible loss" } } }, "localname": "LossContingencyEstimateOfPossibleLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyNewClaimsFiledNumber": { "auth_ref": [ "r529", "r530" ], "lang": { "en-us": { "role": { "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.", "label": "Loss Contingency, New Claims Filed, Number", "terseLabel": "New claims filed" } } }, "localname": "LossContingencyNewClaimsFiledNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyNumberOfPlaintiffs": { "auth_ref": [ "r529", "r530" ], "lang": { "en-us": { "role": { "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.", "label": "Loss Contingency, Number of Plaintiffs", "terseLabel": "Number of plaintiffs" } } }, "localname": "LossContingencyNumberOfPlaintiffs", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "integerItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]", "terseLabel": "Machinery and equipment" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r37", "r121", "r134", "r178", "r261", "r292", "r295", "r296", "r297", "r303", "r304", "r401" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "periodEndLabel": "Ending interest in China JV", "periodStartLabel": "Beginning interest in China JV", "terseLabel": "Non-controlling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTRollforwardofJointVentureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDisclosureTextBlock": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.", "label": "Noncontrolling Interest Disclosure [Text Block]", "terseLabel": "INTEREST IN JOINT VENTURE INVESTMENT" } } }, "localname": "MinorityInterestDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENT" ], "xbrltype": "textBlockItemType" }, "us-gaap_MinorityInterestLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Noncontrolling Interest [Line Items]", "terseLabel": "Noncontrolling Interest [Line Items]" } } }, "localname": "MinorityInterestLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails", "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTRollforwardofJointVentureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners", "terseLabel": "Ownership interest" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MinorityInterestTable": { "auth_ref": [ "r37", "r44", "r102", "r106" ], "lang": { "en-us": { "role": { "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.", "label": "Noncontrolling Interest [Table]", "terseLabel": "Noncontrolling Interest [Table]" } } }, "localname": "MinorityInterestTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails", "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTRollforwardofJointVentureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MovementInMinorityInterestRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]", "terseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]" } } }, "localname": "MovementInMinorityInterestRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTRollforwardofJointVentureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r174" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r174" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r53", "r55", "r58" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "negatedLabel": "Net cash used in cash operations", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r39", "r58", "r127", "r140", "r150", "r164", "r165", "r168", "r178", "r187", "r191", "r192", "r193", "r194", "r197", "r198", "r210", "r234", "r239", "r245", "r248", "r261", "r292", "r293", "r295", "r296", "r297", "r299", "r301", "r303", "r304", "r397", "r401", "r485", "r532" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net loss attributable to stockholders" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r104", "r108", "r164", "r165", "r197", "r198", "r514" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Net loss attributable to non-controlling interest", "verboseLabel": "Net loss attributable to Apyx" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTRollforwardofJointVentureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r191", "r192", "r193", "r194", "r202", "r203", "r211", "r214", "r234", "r239", "r245", "r248", "r485" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net loss attributable to stockholders, basic" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r204", "r206", "r207", "r208", "r209", "r211", "r214" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "terseLabel": "Net loss attributable to stockholders, diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]", "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Abstract]" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r148", "r185", "r186", "r189", "r190", "r199", "r200", "r201", "r259", "r260", "r263", "r264", "r377", "r378", "r379", "r394", "r398", "r399", "r400", "r402", "r403", "r404", "r416", "r417", "r420", "r422", "r434", "r435", "r436", "r458", "r459", "r460", "r461", "r462" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "terseLabel": "RECENT ACCOUNTING PRONOUNCEMENTS" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "International" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Abstract]" } } }, "localname": "NoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": { "auth_ref": [ "r93", "r103", "r105" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.", "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance", "terseLabel": "Contributions from non-controlling interest" } } }, "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r101", "r337", "r521", "r522", "r523" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Non-controlling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total other costs and expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r234", "r239", "r245", "r248", "r485" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "negatedTerseLabel": "Loss from operations", "terseLabel": "Loss from operations", "verboseLabel": "Income (loss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r419" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r419" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long-term operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r418" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r238", "r239", "r240", "r241", "r242", "r248" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r11", "r109" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "BASIS OF PRESENTATION" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r157" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r35" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r47" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "totalLabel": "Total other loss, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingIncomeExpenseNet": { "auth_ref": [], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 3.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.", "label": "Other Operating Income (Expense), Net", "terseLabel": "Other loss, net", "verboseLabel": "Other income (loss), net" } } }, "localname": "OtherOperatingIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherReceivablesNetCurrent": { "auth_ref": [], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.", "label": "Other Receivables, Net, Current", "terseLabel": "Other receivables" } } }, "localname": "OtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]", "terseLabel": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r52" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedTerseLabel": "Payment of debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r49" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r16", "r335" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r16", "r335" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r16", "r498" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred Stock, $0.001 par value; 10,000,000 shares authorized; 0 issued and outstanding as of March 31, 2023 and December 31, 2022" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r513" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "auth_ref": [ "r48" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.", "label": "Proceeds from Divestiture of Businesses", "terseLabel": "Proceeds from the disposition of Core business" } } }, "localname": "ProceedsFromDivestitureOfBusinesses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r51" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-Term Debt", "terseLabel": "Proceeds from term loan" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r50" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Proceeds from Issuance of Warrants", "terseLabel": "Proceeds from issuance of warrants" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualClassifiedCurrent": { "auth_ref": [ "r31", "r79", "r82" ], "calculation": { "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": 6.0, "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Product Warranty Accrual, Current", "terseLabel": "Accrued product warranties" } } }, "localname": "ProductWarrantyAccrualClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r142", "r143" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional Fees", "terseLabel": "Professional services" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r150", "r164", "r165", "r173", "r178", "r187", "r197", "r198", "r234", "r239", "r245", "r248", "r261", "r292", "r293", "r295", "r296", "r297", "r299", "r301", "r303", "r304", "r387", "r390", "r391", "r397", "r401", "r450", "r485", "r496", "r497", "r514", "r532" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r77", "r465", "r466", "r467" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "ASSETS HELD FOR SALE AND PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENT" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r72", "r155" ], "calculation": { "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails": { "order": 2.0, "parentTag": "apyx_PropertyPlantAndEquipmentInService", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Total property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails", "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r74", "r136", "r451", "r498" ], "calculation": { "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails", "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r171", "r267" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Provision for allowance for doubtful accounts" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.", "label": "Purchase Obligation", "terseLabel": "Purchase obligation" } } }, "localname": "PurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r344", "r425", "r426" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTRollforwardofJointVentureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r145", "r425", "r426", "r542" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r145" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Purchases from Related Party", "terseLabel": "Purchases from related party" } } }, "localname": "RelatedPartyTransactionPurchasesFromRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r344", "r425", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r542" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTRollforwardofJointVentureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r423", "r424", "r426", "r427", "r428" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r100", "r144", "r551" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).", "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent", "terseLabel": "Number of positions eliminated" } } }, "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails" ], "xbrltype": "percentItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r19", "r92", "r133", "r458", "r462", "r498" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r146", "r182", "r183", "r184", "r188", "r196", "r198", "r262", "r364", "r365", "r366", "r375", "r376", "r395", "r455", "r457" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r225", "r226", "r238", "r243", "r244", "r250", "r251", "r254", "r340", "r341", "r433" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails", "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalariesAndWages": { "auth_ref": [ "r515" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold", "terseLabel": "Salaries and related costs" } } }, "localname": "SalariesAndWages", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesAndExciseTaxPayableCurrent": { "auth_ref": [ "r26" ], "calculation": { "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": 3.0, "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Sales and Excise Tax Payable, Current", "terseLabel": "Sales tax payable" } } }, "localname": "SalesAndExciseTaxPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accounts Payable and Accrued Liabilities" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r34", "r88", "r89", "r90", "r91", "r111", "r112", "r114", "r129", "r488", "r490", "r520" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-Term Debt Instruments" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r524" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Basic and diluted earnings (loss) per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r12", "r23", "r24", "r25" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/INVENTORIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r83" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Schedule of Maturities of Long-Term Debt" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails", "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTScheduleofAssetsHeldforSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r115", "r116" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": { "auth_ref": [ "r42", "r67" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]", "terseLabel": "Schedule of revenue by geographic area" } } }, "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r63", "r64", "r65", "r70" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails", "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r63", "r64", "r65", "r70" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of reporting information by segment" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r94", "r95", "r96" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of stock options and stock awards" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r97" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of option fair value assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Secured Debt" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r222", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r248", "r254", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r282", "r283", "r486", "r552" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r222", "r223", "r224", "r234", "r237", "r242", "r246", "r247", "r248", "r249", "r250", "r253", "r254", "r255" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "GEOGRAPHIC AND SEGMENT INFORMATION" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails", "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r46" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r56" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r538" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "negatedTerseLabel": "Canceled and forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r538" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Canceled and forfeited (in dollars per shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r349", "r350" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding, end of period (in shares)", "periodStartLabel": "Outstanding, beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r349", "r350" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding, end of period (in dollars per share)", "periodStartLabel": "Outstanding, beginning of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)", "verboseLabel": "Strike price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails", "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r348", "r353", "r354", "r355", "r356", "r359", "r367", "r368" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Share based compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r87" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r149", "r222", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r248", "r254", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r486", "r552" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r36", "r87", "r146", "r166", "r167", "r168", "r182", "r183", "r184", "r188", "r196", "r198", "r221", "r262", "r337", "r364", "r365", "r366", "r375", "r376", "r395", "r406", "r407", "r408", "r409", "r410", "r411", "r421", "r455", "r456", "r457" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r182", "r183", "r184", "r221", "r433" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r16", "r17", "r87", "r92" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Shares issued on stock options exercises for cash (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r16", "r17", "r87", "r92", "r352" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r36", "r87", "r92" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Shares issued on stock options exercises for cash" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r17", "r20", "r21", "r68", "r498", "r518", "r527", "r541" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "EQUITY" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r101", "r102", "r107", "r146", "r147", "r167", "r182", "r183", "r184", "r188", "r196", "r262", "r337", "r364", "r365", "r366", "r375", "r376", "r395", "r406", "r407", "r411", "r421", "r456", "r457", "r518", "r527", "r541" ], "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r412", "r429" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r412", "r429" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r412", "r429" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/ASSETSHELDFORSALEANDPROPERTYANDEQUIPMENTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Cash paid for:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_UnamortizedDebtIssuanceExpense": { "auth_ref": [], "calculation": { "http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.", "label": "Unamortized Debt Issuance Expense", "negatedTerseLabel": "Unamortized debt issuance costs" } } }, "localname": "UnamortizedDebtIssuanceExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTScheduleOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r372" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Accrued interest and penalties" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/INCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r540" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Warrants term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/CREDITAGREEMENTNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r204", "r214" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average shares outstanding - diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r202", "r214" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average shares outstanding - basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10(3))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3),(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.3)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.5(c))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "https://asc.fasb.org/topic&trid=2122394", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.19)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r501": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r502": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r503": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r504": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r505": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r506": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r531": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126982154&loc=d3e400-110220", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907644&loc=d3e11281-110244", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12524-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 68 0000719135-23-000027-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000719135-23-000027-xbrl.zip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

  •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

    "R;5G?A2CSQX(= MOHSWZW.?._6ET]]&],N&W(OR@30W*"6T$5'K]>\[\;V?=@K\[&4;[UB'?_%J M+;P_M!Y>H\C_]Z^_'"!Q_YC6KPW^^I\.]YP]DW:M39F\>(E>SL:B=V".4BE> M02=)22O=FZ$5CF'XBUAOR]UO@/Y-11]#9__EY"6[+'8:DX+U/-/FBE]8KBR^ MARUX]GBUA>P$FFWNY/VL'Z 2^4]>7J@KU0[@C/HG:^RFR&6V_9B7Y2J201J' M H$D2!F /&"*X$(&?(I\S (F(LA6VSV#]RZTP]!6!-;R)7*YD)0YY:V57'9T M= 25"& :$$A!&C(*((YC@&2B=CXXHCQ,?"ABJP_"0*AFX/K14(6,IYC''&#* M$@"#( 88!1#$A!(_I7&24+I2NU::3PO6\10+ALOL&S8,@HD_3UIW15[YO?I M:=%^OM _KA^U \*[R0N]1_8NM]LBHX];0M?"V^;>)\6M^6:KY%OKRSYLU$LM MRJV[#]8I5(Z^14<#S_J9.57HY1?DS!7#/@ZW8EWMBM16_NFN()N2,/T0RTM: M;@OU]U68LI3Z& 'D0P)@$@N 112 4(A0K6^:IIC8\&#?A$MCQT9>KQ+8.Y;8 M^V,GLZ71VXNY&4.X1')BWA@'HC4AF"+CB"9ZIYN5/$R5?TDIQO<-MD*_9=IO MK8S:M_DCW-F6ZY(@BB-$ %!;6P%%" >2B!]$ODX$0&%TM+8:IUL M:02SE]63>>&1]3K_KMW/U4^\D=TCC?#61D<[YL9FB!,D)R:8G4C>K6 B^Z9- MCPM]Z,&SK:>_DMZ['P]BH_?5MT*?GY#UST[MCUZ,W%DD[5/-;:/T*GW&:NF_ M9QB]O!5T^V&CF*HZ[[HB1?&DC,W+>SWV*DH%"<(P4J022 !3% .:^CY@48P9 M2U/B"VQ#+UV3+8U>[D1QK_8K9&-''9UXIH)"%H04A"E'RB9,," RAFIO'"1" M[0%3/X V;@1G>,[@6-CC>>%M1/LFQAY4,SYV!=7$?/PQWWP!%51:X OOUZ)K MQVS-N"8H.&+IC!]3[;Z&W*1WU^<:M#AJ[E[Z6X+$NQ71$_98A1#"B',8 4 MA@!%# *IK ,8:[=Z9&5O=%4L%<@D>U0]$RVNY@^M"V&F1/4J62\\(M7S\]1VX?'^L?8FJ<]8L&A#-EQ6G84RB* $"(@B@ MI R0U$] 3"E2>X[$ARBV.V5JF6EY1TX[0;VLDM0VQ.(\GHPRCL(H!2A!'$ ! M T"XVB/[@3+3 AFJ?X5V$2^CT9PGLF4"+,VHV %"$]/P'IQ:Q MO+Z3+\)). M%)R%D9R?9>9PD4Y53\-"NB\?['A7(VV?;M23WEYNN XO>="[0 M[V15NPLMK4 "N$#%OM)G$940&IT_&0S MZ=*^BUIL[R"W6CE[R;U:=$_);O:YM *_FWVF@G1B C)#T_NC%MPP?L *5MZD M_E2[H]GA?3;[:\,\GN6'P%03O;Y3LW?D1W6FSW^W&FL6$A^BW8['!]T[U) 1 M4A2%X%6P[.>O1+U)UX];G:VEX\]6&%-(60@!Y3JX-1$2D)BJ70UC2/@$$Q91 MNR""SOF61N![<;U2RWOAY0=9O9^RC5=6&K2?>P\"W=1V= ;EY);C#L7/-8JU ML-Z1M"Z-1B-8G)F,W;/-;# :J7YJ+IK=-HQA]*FE/K34?/8;V3X6V383Y>V. MSLIK>5-D&Y8]D/6'S7\*4MQ]SU"*QB# /(;$* M%!\BQ-*X2+U[L1W/#(+>C'RF!G1B1GIYE-ZHH/:V6E9/">N.D,9 Y8BE!HDP M*W6- >DEGXT:RT6DU.6/K%P12A(<$P&DK\PGF$ ?8$PDP").U \IJ]*"AL9' MZ2F61E O-@[>'UI(RS#N,T":$=(X>.;=N?8A,S)TYUCY20)VJ@E>,4SG6,'N MX)QG5SIV]5;A5ZLXQA0%+ 0IY0) B!- 4L0!)R&.(QPQP1/+*.N.Z9:VY*O$ M=.]A[QE^V'N&Q4YNZ^CJ+K1'>M6M,7Q-E[KS #\S6*;VI=>3+<.1_DQQ8R_Z M\[M&N]"O\F]BHZ;0^2'LJSAX&P-&"/<% 9$(,8 !C0'"D *&,>9QE#+(PH$> M]+8YE\8O)[[(G> 77B/Z* =Z*_36_G,7@,[M/C^+Y7CW>2NH@[WG+L!]+>>Y MW0L[QGG>AY*%[[QUJ-=RG??IUN$Y[[UUH%LKVXAK66=#O23G+MRJID]_;">SOI';JT M!F#FRI5E,_6\+JP!H)RXKH:,,30D5 =$W9$?;[.2K?/RL1#[X*4D# .$! 55 M71N(: +49I8#B6",(J*X#%KQ5<=<2Z.GIA*'DM4["#NX*D$7R&;TY BZB=EH M,&I#"FGUX>&N:%;K3',7R.I3^4PQK-Y;!FQNIF/-MW6UU.[9WM7VWF&VWR57]J5ZK\CZAF3\PT:9E-F6K%=8 MQYYYED;5!S&]!R4G4&S-:DGMK+TV M6,TL/0=@3G*SMNQX4'-EV;;/,:M?UJ/K2INN[?&AX5EE> MY1N=$R,V[.G3H_:-7]C+:!F+U@6SHJW()W=0.*ETAZDC8"^^ XTT_C@/" MK RQ<193U3??S %4ANJ?1DN9WN@B-.H-*;/R\T,A"+_>_)44F:XJ=DNV(EC! M@$H)$06I8A0 14 !CA,?$ I12&$4I]3*Z60Z\=+H9B><5RCIQD1/=6!M1C=3 M(#CW(6+[>4;;X_N;1>Z(R.P^J&:)"ZK8]I7C-;J!Z,[ALO@?CMF*HOM MZE:]-+MS:<(33"+)0 @#!B#%%%"HB"?D*8XEDB*-N GQO!AW:;SR6?L2RFW& ME/G^FR#:)U@'([[-[Q77&WJV7X+7S20C()GV_YYF*'0[_JX?JB*Y[[[(0J6E8*O*.,2!A$#/*4(0":@ MVIH@!H(DI!0CQ ,_79VT5NK][ME+8O1BFW64G.KTX3KMVTE_2 -H." 1BP&,-#&39P0$' <^'X,(>?F91@,)UVA#:4U)[UQOO MMBH9,!FJ-@=T[M&=ZX#.#/YG)UVS\_G+.\=Z#/;1VU< MRV/SHFDG<967V[+ZKNBNM[R9\]#JA"0(,U_H>"T9 JAWM8A%$' 9)XBD,H"Q MG2=ME#B+^QI4-AE];I,=F6U#8[U&/C1#E]QLCV)&"WK@4[!WTCD!SY7K;IPP M\SKTG !WXN9S,^H X_GZW6^-^TK1.,(I%0!'+ "0QLI0II #$D)&?11%8614 M6?WYL$NC/"68A?UU0,? ;AVD\\30Y7SV?5G$CXS&XY M_=?1>8L?U8Z6YC^:7C/O'S>\O,O?B,N'AW6F6U;O ];+%>=AR")"@&X]I0P2 MF*KO+Z(@Y@GWL?0C)(T,DE%2+&U1-I+OVE!=>%(+KYL[4N&16O[JI[T&@U/R M+!Z5P9*?XP',?4RX>QB7NX=1*>+=Y=X;X36Z5#_-^C &9TQ.\U!>*X?2X<,9 MDV!I#ZI%RJ7%X*^5A&FO?T=:YH#!1N8YB5+'S:V2@,0R#0D@(J$ ADD,$*$$ MQ$2B +,PB6 \*+>I'G]I7YDF,V>KY1N8N]0 9[9!'0''Q)Q_R%$2916_.D%2 MTG.E727#9LS7X23;WVJK=W$H<\]J'.1DPB'96. ,6< M@23R11Q'ZO]I8-,9[]GH5NMUAE9XNT[H'GG1\;LJ0/HU7RL4+1?RQ"?-TD\ZH]^0PHDCO!,)1RO[^=BSKNNS:KUJ[=C%8D@#1GGP!<( \A#"K#:%@(*N52&$^40F:<,]DZWM*_TW5=1B*H9 MD\6VHA]4@\V<4Z@F7OSM53LKB>O:G5IFIR!:;,*<@CG3;FL\J'9[*F.,.C=/ M_:/,MTLRUNC9=LC\K@%\>U/D3 A>OE>2G@T]N=SPOQ%]W+(]"MR*"0IH$B4@ MBC$!,*&A+E,3 *%L+BZX^D[WLR2O-GWYAQ(PW,+=]L,YZM'[?9-_%9L*;Z]KL?;/VHOB%: M$GW6^UB_P=?R'2DVVLMW(XKJK/=CMA$?MN*^7/DH1A0R]0VBA*H= >+J:T0I M"!#&(8HP9+%1Y*)KP9;VC3K6RSLHYNTTJ[]=1[KI#,R==CK@N(Y2]O[0&GJ5 MBI:1+\X>N9EOXC4>Y,3?OUF?H7U.OF/ 727QNQ)KWJQ_QV">E EP/?ZK? 8N M[_6QT"IA* E90 !GB0!0( %(E& @0Y9&A%(>)U;]=)U(M<0/ -BS1[8_8AM0 M=\KMTYN%SNV?R3\'EU]XM6:+H?'G0"^#PQN9_ID(_#F,CMG[Q> #$S'95\$? MU^):'KKG7,MC?]6=/FRY$S^V;Q0P?U\)')'$%R%(0Y0 B/4!72I3 /W CQ"# M?B2M>F#8"K T0M[)KQ?V00/]TW-GJV4FINUC,:/?*<&>F&E- MI81#XW@H?J[R*VVGGS>[%0VU+MOZH\[-4K5BDH0 M/V4^# )1* =Y S@-,4@X(B&-!#JUW9$=WZ>Q?'97DRODM/3@@YJ[]4&K"%5 MC8=K:D8:@I0]Y73CX(I96F:9ET"Z53WAB9[+A]&![ORS?=*&5[Y1H]850E9^ M% BU%Y6 I;$/((H0(&$: !$'$#$_@9'9:5GG+$NC@EI(;R^E9?68;D3-6& T M3A-S@#U$U@30"8&CY7]^CED7?Z>:+Y=^]\7.[(#F5>5I&E ,)1 1XFKQ$PZ0 M0"%0+P<+*8Q]$EHYIEIG6AH!M'SA!K% .[R#[8'%L<% O%S8!)/00OL\KVT7 M=--#_PT#;8,7'IA;H37(UEGEH=EG=U/D4QR&*:"^(@THD ]H&" (Q^&$8H" M$E@=9II-NS3R.'-B]5SPP^&L/(ZG@'6OV5$P3+Q6C1&PJDU[5ML1U6F?CS=;?=JS:AQ7J#U_@9-N&>_* M;79/MN):WJA_R.BZ3K$+4A[B "8@#7D$(((8X##EP&>08EW,7B1X1,>,\[,N M;=GNI*SZ9C1R5IF-HUIGM"!N]CUVCN/$Z_ZTA<8QJ#NAO8]=H([MH]$-TC2] M-%KF?,U^&MTP]/34Z+EY&!4U5;)N2+%]:KQF-!$A#P4&82A2 &64 !0)'Q 9 M2B$ICJ/8JE//Z11+(YE&0J\2<: 7\@R09G0R#IZ)N<,2&6N::%?>$2>P<6AI00&E' @X0!R"$#A$,$8NK+D(L 1\C*M&B? M:FE+_:W8Y/?91K^6?[$MS-D*I]E"=P/2Q O^[6G(J;(7I!1LJRM6BN'0B^^W5SB$K6IF60FP 97 MMQL,W&L5L-L+/$E=NK-P6)2>>W[_:U67.ZM%1P&Y\]%A7=:?)^HJ4 M7]^O\^\?-C(O[I\?'S*)X@"&"4BA(DX8:I\KBC% (0\0\X,P95;6E^&\2V-4 M+6K5*=F3UL:8*=2&)RSN 9SZW.5(8J\"4LOL'0D]B45F"92S8!&S66<.';&" MXC20Q.[V@17PFC:LUP^B(-J/]%E\J7+Z5H+A4$H:@(A HLRXE /*@A@@SD,2 M\RCQ4ZO(L]:9EL8ZA_;!^4Y4KVQDM2R(UPJN&>LX@6QBGCF@M9?2^]R'EGUQ MO#XD7!7*:YUGWJ)Y?>J>%-#KO6$@/2AY\\U6R:XN^O)AH]:?*+>6'\_N09;T M+C\3U-M).LF'T@P45Z]U]V3SOMM&BI^\X&9W#>T(2K;5E_9:[KZT!]>=(#1" M) E +'VF#UDIP&GH Y1$@4PAA%&(K&SQCLF6]BG.PKA(EN]VVQU347.U0M4 M5G-<%S=%_BU3BJP08;ZN, 4B/U%F=!I#@(1/0<#4KI[H;KWP&7/TXMO-&BY1FY@QA@-F3!BF:)PABU*P/W_)O_VBAJAY M0OWE0 ^] \]"#:;J[6C!^'IG!R3[9A.Z']UOV2:[?[Q_0]1KP/:%B$0X$]W:#MPKNO958_54*//B7H M?RJ#CUR<8OU:QS$7AX8W^GA7/8%&$Z]1I;>$D+LG,?HLQ^D3>>USGO%/QL5Y MD#&D \Z*^L=^[7,D8^T-SIC,QQK<[T0;OM4'C@O^YNGW4O /F[W7Z))MLV]5 MD, J(3%.8(H 8T$"8!(0@!/!0 0%2R7VD1])RV8HAE-;?7YFZI3"] [N4=#Z21R+,..SJ'YH'DB^F>XQ&'HZ)WG)I_9Z*DPK#\5.;(\^>3_]7@/\\Y%; M_[+_;1_2]<82,7N'M956&<"VM.SXR0\41!_5,-BOO MF"G^DFL,[QJ?>7)7D$VIS:U\T^1.2,J%U$5Q" TQ@!AC0'3#YU3$6(@H"!BV MZJ_9.=O2V.5YUL61N YR4TZA-B,49P!.S"DM[3<-HY+C!B5OLV^BW&;;QT)/9;819:E,_%C ",8D +K;IR*4@ *, M*05)BAF&$LG$MR(4@SF71BO/VU!MOPJ/9^5#7F8[$^8J+X1'&_GM*,;D$9@1 MC6-@)Z:;YY@>R:OQ/$CLCG,LX''$/"8SSLH_%A"\9"&;6\>6/1]9A+TJ1;R" M7$()::QH"W( DS $)!8(1%R21*2$,]^NOHY3\9;&<,>EO)TUPZDTM0V%&=SC+L(W*5E]OR&(MEJGF96 ^I1]226] MUP^L&G5P**\PAB(D. 5!Z$L (T4&B.!068DT]D5$@C"-;,YOC\9>V@'MG9YC MN#?]S53X0BXD7]D<# .RK-)VJZJH6T]'(\U9<.E7II*[2F4OLZRCNPXU_ M%?F7@CQ\S1A95QGI$$4I@B$&./!] .-( (2#!,00A2B.6<*P44Y!YRQ+^T(? MRV==8K$=R^XEZPRAB1>O#3A6U1=[E1]1B;%][-FJ,O:J=URAL?]BIV%5'S:5 M^^CXQ'UO3L(8I@E+$H!#GBH&(#X@)(( Q9C),$&8([OL6FL1ED8/50B*K))D MJ@UZMA/==915UV,Q^_Y/"_;$3-,3[K-7XBC<9YH$R,$@3AL!U"7 $B*!# R MC @R&6E ZL-GLA95. E[.^Z;=ZUK'Y<"<8YIPB"F*880"G4EB2(,$@E%ARF M?N0G1F4C.V=9&JUI.>MX'RWHA;?5S2)S6?_*(F"^%=5NRG*&U=0.7 W3QP-, M54_-:UG_R@5,%HD#+N":*3-@&&QV0?]]<'1&];?>/%_8?I_\S^+R>R\>FAYZ ME=_?YYO/VYS]O7("E]>/VW)+-ESQ[RJ($R8X#@$1B@]A0D)E"$8)"'$B4@%] M)%.CT .SZ99&D4WF8RVR5\E\49_!E-Z1V+8)HYV(=[.F>QPGIL^Q$ Y((35! M9D0B:>?P,Z>3FJAZFE1J=-?0R,AO^?J;&N>J$#S;OB>L"KMLFL;XH93(EPAP M&D.]MR0 8U^"0"J8TRCU8S,V,9IM:62R%]:KI?5VXMH&1'8A;+9-=(;;Q.31 M"MD$_7J,,'$6$-DUU\P!D09JGP9$FMPT."#R013;IQOU)FSU2=0_'K,';;#N M6YNO9,2DB!$!24H9@)1A@"B70(2I3X,T#$.[(I3]4RZ-2W827WB5S/6AZ4YJ MZ^C'/KS-2,4MBA,S2R> 38"-IP7W*LD=\HPY3.YB(/LFG#L$TA" ,Q&0IG<. M=9=_OV1,IS,K;E.S;=1?6>67UV?B5U_5&R3*#YOC:[(-RQ[61X[:$ L<"LP M#L*JJR !%&(($)9^C""%0C [__EHF9;&7@=9=2V9#2<%+[W?'[@N*Z,78JV4 M3J(]NG*OUN :7RZ>KJD;?M9G-C%73O^X!KCHG0'LS&<_7J*9G?C.(#SUZKL; M>J@1*:0HE'%ZM,G]4):/@J\"+FG*?5TT@DD 64P XLP'H8Q9%$F?$[,(A_ZI MED:[>TF]LG;#9)68WD]JY9:5W#_;FHZM*)N:C"ZPF]Q4W,'VW'M5"^K2,.P# MPYE!V#K1S(9@G\*G!F#O'?9>\+?-@!269ZU>HJ4ERG(HA-63<-* IM%>@YWCP=+KDA3_I7E]^5 MS7G]4!72.?)5_TUD7[YN!;_\)@KR1;S[(0J6E4)9$TS#LPO J-:0I1O]J3=)4$-[\"\R;*O=H#.DFF>SU)7N>#^CXOI*A2R9O$GZPI M6?=AKB$<$"X$ ID17^DL#0&*. 4<\"5F0P#!FNTI_=_-]1GL%-V+3 MYU4"[V:))U9+8JT_GINJ?YA68LPV?/H78)[/I9OG^<_W=3S2>Y?]N--<.U5K MW9?S+31^3 OY]/7+^T_UI3.&W_6'S7SBD;UN=O5,=IVBJF2J@$6"Q92 @-#* M;1L!*M1N+HB1B ,?L9A8':MUSK:T[=9.-JOD-#-<#:G=%5I3T[(A4,,[V70! MX+J5S=FY7J>739?:K( M", P20#G$91Q+''$K"(+6^99&C%Y 6>O&MUFZG*S>23K]T*H MG0*K2K!'2>(3#G5>DR%UXCK#KG!;9O&(/A:W9ELD!S3?ZD-&XLV2R=# MO%8WI39=.IHFM=XR;,_S8<,*G>GY5M3_K2+GBD?!C^M#B51@CF$$1"!B %D0 M T0H4CC3)$[\)(*)$:':3+HX9JTEW%?8J[RI>55^;W -+B/PS39,KB&=F(=W MXGH_[03^N8GQK4">I*B7#42.-E9&4\ZZR[(!X>66R^K>T6;=32$>:D=Q[0&^ M4\]$-)F(G".*@A0!739,V76^KRP\' -**5&D1%-!C1RV=M,NC9)./L$'V9N# M':^2?K!!T_4(K*U"1\#.;2"V8-J?)#KJ_1YJ.#H"^;5L2-L7>(P=:0"5A4G9 M-=IK69<&&G88FB9W#R#YR^W=5_$;*?XN7J:7\U#MVB,_!I%,U+8=IVK;3K@R M-06+XXARGTOS0DFMTRR-Q"^W0$D*:E$MT_9[ #6@:"SZZ[-7@&3WV7SVP?G6^^:)K+FGZ_8ULF[KZ MMSOV+:]ED\)&UA\V_RE(43'Q*D2Q;H4K0<)UJV+*0T!]B #'#"'B"Q3XD:MYCT*J)/"W^-&LZ\1?I5ORGR=\>KS]V$K[LNFYZ* 5$8!BP$70MF MJ?H;3A)?;>P9]&.$*>%&I-8UR=(HZYF<7B6H93_+3DB[B"-[Y,)::GY;1/B7\.9/=:=P+/U%YV6V0& MY;/A) [8[4K&N[KW<+ MFF:?[_$(3>VJ;:#927CA-3*Z^WYW8^#H ]XRR:Q?\&Y%7W[">ZX>7"Z5/[+M MWXC.X]H^57.0]=6:E&4F,\%W;R\608JPP("QE("JFSR.D@ P$H[XFA%M_[7LMO'19D"KL9:4P YL0LTDCL[43V&IDG8!-+<-Q5336: M=>[2J390G*F?:G7[@*/CUA*M'S:?1?$M8V(5HT!@',4 85V-!PL):.!#("*$ MTUCM,@1B)OT_#>>S8J 9>H+N)*Y[ >]+#NOD_UI@B\-2 [2["6@"#*% MFR^/"S=?>!\VWNI\X3:8)CYCJK-=7IV9FUQ MV\#=85F*;;DB2*:I5-L_'_H4P#3U%0,3!OR AA3&D D:V_1=KH==&KW6+9=) M)9OEMJ^&R7";9ZW\U-NZ;HWM]W#/%'2U9ZL'G7>/]DR1DSW9\W\='1']5DCR MN-Y>/CRL,Z:;"'S8J&V-*+>WVBN(0@ZAY$P7@Y< ZA:#E",?^!SR@$4L3=#0 MF.C.B9>V"VN$O?#(7EQE -7R>H6Q^]4:?P-C:")4IW;6OHS2W2-\$-W;R>[= M3H?PX*AH9TB_5EST<,3'1$@;P681(]T]WFM%21MIV1$G;7:_BXHD^T81$1%! M&,@4,*0+29.( L7^ 4AA[*,XQBPT*R3=/JX>1@'O2+')-E_*&U%4%=0.)!"'*(WB%/B" MI R)@$- P2X9)%,?,'\P*HJ4=M$2Z.!CWE9>FI36]>S_(O=VF]%TVSUN\!H MXO6_$U$?K=<5(B>A@#XD')% ZS2STD"?LB^)H/?Z@2%T9-V41]25?N_(CQOR MI V.W7E0+(0?2*'L !Q2 ,,P $3J"%H>8TJ"4/+(+IBN>[ZE$4,EKK'!3N\>'/3-[M_GT:+KRQ4\HZ;P._NDA/SDUF&%*Y\59FERC* J1 M+P4%C/@)@%'$ (W3"$@F,66^#X,T<%2799FY7 85+>Q2N\RQMSY_&(_HW ]T M\7*YZTQ=[G;/U:;:II2=^T=GZ*R8Z8%,[:(SFF[CM6A+R/H8Q]$?JKLXCCE@ 1A#%)?D#!!(4\A6SU4 MM/]Y2XJM(9\.[&G]+'W" M]NBOUQ#=I 6Z@Z;GYTK*[$Y0?"2T7R &DB<$0,93@&@<*Y0X"HA$"8O"H16K M%GHF555.6N=D<^%MA&6AAW,0FJW7DF*2@US4G3N1E> MK114SXE2UZ43]8QK_[?K6[AO]=?6U7'Y?EZ38JCT!K7G6+=O@H6ELLB'_ 5NLS]I2=Y!G.U6#6K?#+ZC8[R8.Q;CT[C13#OI>?Q/:*E%]O MBOQ;Q@5_\_2[DNG#YGVV49LZM;V[9-OL6]WW(\$ID20) 6*^!!#%!*BE+@#E M ?(98A!SHU1F^ZFMOE,SI-TIR3VF1->%%2K9-6_)G=P>V0MN]\&R>!9F'YMI M$)[X0Z'!U5)[-T?@_J0E5V3_L[<7WKOLA]F:VNT1Q0RVBYOS\%T'![/PJ6J7?WSQ"9H(!CN_:N=O2G$\R[H6]5\&0_WW[E MZ B?J_R;4)2QO5-V%/LJCKO3A 2*B$D)0A(ERC(A$< BUOTU([7*612CP+Q1 MA^FL2UOY)_$3.]$OO$;XDN( C*X>7"CS_Q>Z.2Y.H1TL\TVC\H>O'Y0 MF]QJ'_Q&R+P0]75WY(>..=T61,VA3,?BJ:H$_DF!H>[492_5K;M$YU6:,D8P M)("G2-9MT@D. ^"K'6R:D#"(1&"S59U0UJ7M;:ML1EIIH_9;6AV=P32@D>AD M#]?,)EW((YOX$U5+[_VD]?S9TRS@'53U#KKNGFAS?:7NA?=&_$P;ULFG''@:N,W9W[_F:W5'J2N-;9\.V>H(XB"&%% 9 M"+5G\-7?1(A %/DB96' H@A:G=RU3K6TC<*[__/[A[O_M#Q+:P?2\-S+"3Q3 MGU$="?DO7BVF=[G=%AE]W%;1F=OS](+DZ!&J?:-X#FUZ%3PY7 M^N\86EI:/)",OZN[J5]N^+5NI5Y73-L%NW 4L9@G$O!((@ )B@ F- !!1 7U M)>4P,,HFLIAS:>31B'RNZSQKPF:&E",T0=^,:!QC.C'C[.!LQ*W0K 3V:HDG MJ3!M#)"SZM+],\Y<6=H8@M.JTN:W#K19Q)>JBE>=]Q6$:2!I*($(, ?*9&%J M)QM!(%..4L3"4&*C(HIG1U\:N33"V7:;.X^7^>>9676UTE0Q?>JC(\5C3VN?0I M!X*J#09,)08T203 0MD,:0(#$5N=0II.O+3E?2RW/I'CVNG+=]):EI(P!=^, M!J: =&*&>(EF[4(OR\=MR*#)1@GY15L M[W=3MN^0FLEP DE =" 7CP!41@5 (0R4G2$Y3A,9P=2J64[K3$OCHW>7MY\^ M?/KUL_?3Q^O/GW_V;M[=>I__U^7MNW$E_&R37IW@-3'9G"OB-TFF:B\8$]7Q M>Z4B@;>GB=$P)]$ONPY@B(H$YVB 1(!/9Q M&/D8IU8N4X,YET89'S[=O;M]]_G.^_#)^]_7ZB?OK^\^W?U^^T[]XJ_J][^I MG^S8PP1X,QYQ#.?$C-)R]O2L4O D#&,!DR.N,9EQ5M:Q@. E_]C<.K9"R/D@ M^F7WWM>_>U%X(H$(13*, (J@!!"C*C,;@Y D,B4(,9+: M.5"DX4]41EP_ >1T2)\*]4F42E\"VURIQ.LNPKT*]+Q8?A9)B M5R'E2=L0S>&0)&H3BY $(M017RBD@&K"%W&81+&R4@FT.IKKF6]IO%VEL&]U M"GN=AB2\M9;<6P\M]M2'MQD%.T1Q8DYM)/4J42_VA9F>ZB IUV=PAK@XHKJ^ MV6;E+D/57Y*1Z6UC6\J+\BJ_O\_*4C'8[N Y4GO;A/($0"(3[;_W >$1 RE" M6.<4Q1!:E;'OG&UIS+(K5<;V@MIZZCNQ-73/NT)L:I_\H=V\*+V#I).VG>^ MQ'GW^7-SO5(3^@ZUVWO1=]TT($.ISG2Z_%*(*K&[2=D(4I]S&8; %[JL4*#^ M0 Q+$"9AB'S$,:%&?K+V*99&$DUNW5Y*BT28\Q!VTX(;8";F@I>8#,D2.@^. M14K0:)!FRO\Q?H'L\GPZU>],ZCE_YWP9/)V2/TO7Z;YR *D=2K3?BB]9J?U\ M_)/X7E5A*Q6Y\40@/P"1KP\!:!KIUO8QX$$H8!@RSHE1S;3^J99&-%(J] MM+J,VG(R3T$WVWJZA')BKAV)HO46U!0:1[O0WNEFW8B:*O]R+VI\WS"JN5J3LKR6 M?R.ZW-CVNKC5E<,^/6J;\%H>..Z*K->Z%D]S7=E?'16-?2AF3#4CU%-OG;4F^G2SD5&M *\2 M4MD\E3[5R>?!**I5TG7"=DKM[W 8]>H(7T=L.%::69M6)Y_Y@8L63.$G36 !*2: ,NB0 6$0I2&3""94D#+@PWB5W MS[4TBMQ+6W>^WQV)^KA_-$=;!;[8W?PS;1! M'@ZCW0;9#)C.'7+/$/-MD;9'-KQE3#V@JCK$K6 B^Z;#1U8<$DB9#(': M!5-=8-T'B"42R#!FL9^*-!1&1-HYR](H],.^[HY7[(4<5('G)9QFEN1HD"9F MS>,J-MY!P@E.63N1<%IZYN4VBX>NOB_J>>6%T_OLTU6?A7\ MUSSGY0IAR.,H24$40T4!84H!XC !+)4\D>K?$F:Y^L]-L[3EOQ/.^Z*ELUWV M9X$T7?=CX9E\X3<"7GA[D"H9+[Q?B[QTN-GKAL+9RC\[R;6S M(J]O\J+(OV>;+SKJ]#"O78C6 M7'^#PK06@PVS32O+XJ;(9:;6$TQE+!,"B!^D:D^:ZDKC* 4B"9F D1_R!-H4 MECT:V^I3,D,AV$HTW>%$VO81. ;,S/ <",/$'%\C<-.-@+5E>4971^;D\:VF6GY:V3OK1XO[9(Y7 7E61[Z$6V2;4JAMG QO/ M'7H3K_(*N(\'X&I9/2WL+J/2'7 V06K. )PK2FT$D)9Q:D;0= >J=0\Q8Z2: MD2[/0]7,;K&C5RZRU;O--ML^U?%O^J3TDWK:*TQU_B1.00 I!C *8D B(8 ? MQ S%$J$T,,I^:IM@:41:R^@=A/2TE&84T IB-V&Z@&9BEK1$Q7@]]ZE^QC0J M!?OSE_S;+^K6VBI2?SD80ZT#SK*D^]39K>/>ZX;81CH?^_-W\G"77[)_/&:% M:)*SZR[J*\H#&F$. 4)"&4<^UKL8$0/F)X@'/I>), HR-9EL:8NZEJJ.T^=> MOM'-S[U2;+?K.C,&0TH M,VV>6U"&]TS4@[ZM_^][DA6ZDH8XJJ*A*TVSK>!O,]T^<\-OR5:L%%EC/P@# M$#%=B%Y& <"8<1"G@D5!2,,$QD[;SH^5>&G?@YV,'F^$])XRL>:.&\R/?LYF MWK-%/;VI/SH&;>1[NLAKK:MJ2.*X$M*%MW\G=JI[6O<9V\:[>DQS=8H?+>^R MFL.[@M^Z'[RSB0=L&NKV!75]A*:I@:XZ_/%0-VA7J0-)SF.$U9=&)A+ $,< ML9" A(D@D=1/>$",MP_&TR[MPU$WYR!-G8]G75!V_4^L:RY9/@B#3<0D\$[, M[$W;DP;9G=2>$ML[DKL_QF\,M!9;C$D@GFFSX0IJNVV'-6*=&Q#ST>;;BEAK M^&Q38G_WV .T3V)[1SG *QV5M>C1?E#6=L/08[)+SM7+4%ZI MOUX7=_GWS8IR%'$I(V4<1R& 4>P#Y,,4Q"**41)('8]@=U)V,L?2B+,Y%FKD M5!:#_BDO/"VK[9'9*:"FIV:C8)KGX,P.H0''9ZT8C#A!.QUSYD.T5J5.S]': M+W75.OC#AJT?>;;Y?MZ38+O5AO11QND?V1GS)-ILZT\ BM\#Q%4H"0-"6J>VSNUE5KT4]L)..6WB+_V S,\T9C]$TB5GRI;C8Y">K#WY(*%>N97Y&"#[VYZ/&MW.)"J+ M[:I)K&@JT&*,%./8-;W$32# M,610R% QEZ(R"2#%$I"$)B ,91I+K@\TJ;W)/P;,US#>=V"JOWA77[,-\?[W M7T<"JW:T$0U\98G[<=4F4N?("0H2B5@J Q^EJ;5-/A[6V:SK"1 U,YK'8/0* MYN_\MFX;0!.U>7S=GHYMEF3K=4/=9&1;!;'L6U>3]:XTU"75@>U,[=+#6"8X M@L"/:LYEUK/E>ZGVM,N^/G>"698Z- M'H#IKMLMK).3RFA$!VR7S2%RMADVF'+FK:XY"*<;68M[AQ[-O;L7A3)POOQ: MY-^W7W74'=D\K<(DCG&LN <%4FU:H12 I%$$XI1#S!*8L,0H:+IGGJ413W, MM9/5JX7U&FEM#^G.0VMZ4#<:L'D.ZVRQ&G!^77@/9-?I6:>_<66(DZ+TU/ZI3D RS(2S>01F MAHEC8"4.:/*-]F)5OGY6,ACC9,"2(XY2"-E)4"(1: M0I^".-3M&62 !;-J6F\U^Q(YJA&^BK-_)KYWD'_P%LKNV9A3UB2(ST!>KL > M1&+6H#FD,_.Y9R*+GO)6/.A32GT2*?/BOHJK??/4 M_&/5)W[%*(X0B3' E& A9\ 1"$"?D"(%"*2,K J]3M AJ41WTZ%NMM)):>W MU\([4N.BRGALKOBCTL76BS3@B1DZE:9]#E/[F"9Y!/9NI^$@NO)"#9!@7J?4 M<(A.?%0CAK)W6=T51)\;?7ZZI_EZA4)* C]F@!+N QB'&-!(*E84H62$IDF* MC5)P3D9>&KDUPGFU=.9NJ.=P]3N>!H,P,;,8ZF_E6CJKZR!GTO.19G,?G57@ MV&%T_H*A?N+WV5K4[:)6 J:!GT8$D) 1 )G><<5^")"D-)8!3:2D=L[AP^!+ M6WJ-EU,+V/13L_4"'P%GZOH=!L<\_EX3) ;X>$]5'N'8/1IL9F_NJ1JG+MPS MUPSUDVRJ'X\U"MB7'["%WM0!XAS0R5T?#8+?,WWF MT\A\<6@B=N$=Y';I]+ "RIF[PVS6F1T=5E"/N+H#-V,<9;!-SSC/$CB3=%>5PV:S; !%GG;J[YIJY3;>!VJ<]NDUN M&D8?[Z04;)M]$_LV:KJ$4^V/?51;F^L'450.AG(5^S@.?1R!B$92V3B!#P@7 M$! $0R8Q@]PN;,Y\ZJ41RUYR+SMJC=A5G6TL]F8T,PVB4V]Z]F >^BA6I>YT M*T6UJM3GLG%I.NN%,QPO1XQD,?&L]&0/R$NN&C#",.)J*A-]V)2/A4X?W=7, MDFE,D(\92#B" "9A JA$@?:AD$"F4"!H9?&TS+,T2MI5SWHH*J!KYE2&D+\CL6[BV(6[&30YPG)B(=A#N19R@@6L/"H[HI6V66;FD1]67 MQ-%W^>A>CG>BN,\V%??<5"DXES^R=$=2>[78WA]:<,,37&/@NUEC"C@GIH]70W)P4\71B+Y6 M_\139"?IC]B)CT4KQ//CO%;7PTZM.AH<=M\WLL_V+?G^F[(3BXRL%2?'E(LT M9B 4OC+?<[X08VV7Z&HIE9-AJ; MB5GUJ,6V1F@OXG0=ML\!X;K!]K,Y7J>_]CDU6]MKG[UXZ))GA:Z!^%;4__VP M499?_KC9EC?DJ0KD4EP:^#Z4 !&1 JBV; "'$0<802BH3^,HQ';+OV?&I5'! M3CS=*%'+9\L&?0";,H-#V"9GB5I&[Z>=M#_K?/<]D#<]0 Y@"T-PG#%'WWPS MLXBA^J>,8GKC8':IO4Z'(.([\6/[1@G_]U6( Q(02 '1YV PT'L]+C!0;Y>0 M$*9!1*QB>KLF6QJG?/AT=?W;.^_N\C_>?;;FDW9(C:G$"5#3L\C._WR<6:!% M]2I9'8;0FD#BCCO:IYJ;-GJ5/L,8_?<,(XNWC^(NOQ5KG5QU0XJCDO:7&WX4 M81)%D,J $! &2/N(: (P0$(6.)'+$Z5A6+4A8_ [_R6%2F/H=Z#DA_S4-#9"S\Q&,1FLDQ;(V4G3>X"X5.]^_9 M&^?S]W;)_.42)D '^IL!A&G@.C. MSX%D"!,>\R"TRQ\_,\G2:*V6T=L)Z?U1BVF;"WX.3C/C:"Q($[.<-3[VDR[\1W3YR>UW<9E^^;M_]$ 7+2G%3 M9$SL_[%L_K4,5I1(%B=A"&21L%I"M&&R3#O)0W!J833APUV% G=5WK](9D_)/8KA(I8Q9P!@*21+J\3@HP M9P(0XC,J8!2'D57(XHOQET9TO95TC4 S]3P/AF)R9W-3EUF+IIEFUWOCBCQD M6[+._JL*1:PONO":N%GU[YP<\Z8P=*EYDJW0 M>?' Q(2R%-OR?XDU?Y\7NN7GIWRK'])96(K<2W#7RSA-Z./ MZ4"=VI=>/;ZNA);VAV"GB5!E.D/ S"SE4FA-WD\R9(# +F M)&]BV"AC>[5_%NQ1]VUX*QYTN?1W_W@DZ[O\&J?MY/5X+;!N+*K6VS;W2"6SU[G>QCX'@_.P MR="=F-Q>-BS? ]W([E7">W>Y5XOOW4X)]-#&\"X!?Z5.\>. ']$]WA0[\W;R MO2.^4G]Y4TW;&\X;CS"X4I+.%&'ZS?NPN2GR+[K_=16DKVS I""!-<1@BA@)H61VI;:ZED?^QJ#HD^:$1UKH64BNXADYZ-Y!-[8I_ M@=9.3N?9'@9PN*MLU#K3W-6,^E0^4\&H]Y:QAN2->G>^JK]?JK&K3CPK!$E M&(X!C["R'%-* 8DE FIK'&)"61 G1OD?!G,MC2UV GID)^%0<^445EM#]PNW>,VU*X;A=\K&7(6.(ZPVEJ1,3?33H=X);NL59=V0ZS]EJ&65_&0 MZ^I#G_)-4P1Z%TLJ$Q'0) !,EY*%#/F "EV:,O8%P@A1CJPRZ5IG6AJ/[@7U M_F]R__#_>-?;KZ959?M1-36X'& UN;G5R%B5D@3[>O'.PBB-P7!F;+7-,[.I MU:/NJ:'5=\/H\B=7^3>Q(9OMW7>Q_B9^RS?;KY_$]E:HWSZ*.U)\$=O_%*2X MWH@5$ISR0 1 8E\HV@AC@$F8 ![ZF/H!]GUDU)EPE!1+HY1:8N]>B^QMQ-8K M:J&];27UA?%QQ;@G9&#+S8'[Q/1T4O=CI\6%USR-2A%/:>(UJGAW MS=/0VGC7\SR-P058IGDJKU65Q>73&5.VQ1Y5BUHN%H._5H$7>_T[JKX,&&QD M*9B;?)VQIT.*,0I#DB0)!5$2J:]1$L2 6[?SQFVZ=5C(4?^SI,5NCR#4CH"C$0 4I"*3 EE"=DMVARW *(8E]""'R)*( I1@#QD !=;R&6G&.6&H7%G1E[:1_ZO7B6.8+G M8.M>UB/!F'@]6^!@O&P[-.Y:K^JVH[6J?CJLTW,CSK) .U39K:0NTGNN' M6>6_99N\V TNRNW';",^;,5]N1(2QA++!*0)0@"2D (\WU51ZGV^=9..?4G+JIGC M2G">,BDQ2!%G /I2[7FX%" .J.^KI^(3FHZK3MTV]=+(ZNJK^DF4.DXWWV>G MDSKA3*^QH\ZO?QE;PKKU<9B>:4P!\N2G'&>+6A\J 32B>W_LA'=;G]82L'Z:I7UL+IE:PH]U9?"W0F8LLVY5?A9-,QMY M/$83?QAV GK[8CGN ]6[07#6C_SL)#,W(N]2]+0#>>?5 [V#=:#[K7C("VT$ M?]C(O+BOOE\'E[[^@!42N?((F4\[K#[0 X<07:'/OT%2Z M>[75JP*;=BET 8W"1'(0C<_\ ME+N I5LUPSLI117N>"/4*['9DB]BE:(T3 ,4J$]\F@*(N \0Y!#$D81(1H($ MU,J/:#7[TI;[7D0OVX7;Z9(#E@TVLD Y@ MS4P.-W!-O.:?([43S+(T9&O&:&&++F.'S.)JQP6AT M)B:"6KY];XY) GX[,7#:C>/E'*_0=*-%S?.]-=HN'K;>]S&_53W0CTV,_-.A MH_PJ"3 />(B C @#,! AP'Z:@C1":O5C% C?RFG1.^/2>.!COOD"U$3W1WD% MZRH2_BBEP(X=^E$W8PJG6$[,&H=$@4K8"V\O;E7ND[EN]&.,C2,VZ9]O5F8Q M5O\ERYC?:%]6Y5:GZ%S^R,H556P2I5RQ2B@A@#S0P94H G[H)RB(L62),"VH MLA]U:VDM$C.. ]A]YIT \S$"_0E)OV; M>E-P+-)21H,T4\Z)\0MDES_2J7YG5 TCMMWS-=ZXV M%BG!L8\!9M@'$%)=)UQR@""-4!*%E/A&L9$O!UX:@56B62S,8XP,N&J@YA,S M5"75$%HZUMZ"C :B,!,%=;\"=KQS1M-.MCF^?CZ..2/E,V8Y]^]#<\"JE"?= MM/3IKB";DE0-IRKS.XFC%,(TT3V1"8!1R &EL:\V,2R$$OE!$%B%7W?,M336 M:42M&O4^>4?"6NUF3$ VT9F3A"+")R>* U;&8$QRP&L#AB"NZ9IJ5*PQ4 M?LD5)K>X23,_RK1N$JU7$,M0;5I2 *4,=8_:$-"0"T!9JBR0,) Q-2IH:S[E MTICC./VD_G4GD_WFZ'/5V=";*5S\SX:OFKK<# MT)?'WG'GP&@.QO)'Q5JW@HGLFXYW_R2VNZK.?A(3R'U='COHH$.3R"3$7$+F M QJ02*UY2 &F @)&4\E)$J>(6?I!C.=>&BG??NK7=S>7OWG][=[>6G MSY=7=Q^N/WUVG-VYB6."OWGZO13\J#S^I>?KS'/3GVLEM6 M^;)_+&;FR[1@3TPQNK)YA?5.?(\^>3]I#;QL\_-1>XZ#%I,D[ T'T54Y,7L! MYBTS-AB@D_)CPT<:Z<[]N*_#2V@2B"B6(.5(MTA+=(LT&8.4A&G*?$8HLJI; M>#K%T@CMJ"+7Q\$ECD^!M/35#H)G8@JR1&:X>_9$>=<^V8^O5(:X5<%6[^OI ME<.6]M](H39*V_)RPV^S+U^WY?7CMMR2#5<\*^Y6(8(R#F(& !2F ,/0! M3E,)U+(7)(X(%M0H09>:VMBK9C7:&;;TMGH&9FQDW/D)S=6I@?=OB.T#8BNND,; MS3EOIV@;&$ZZ1EO=/(S<_DJ*3+\CNO1B&B^0 )RD#F(0P"3FB,;(R7,RF71H%-%)?>%]JN2M[GSR3W+;WDQ'ZALX2 MYYA.;9/LX/SU",[G0GN-U"X;0-F@Y*P%E-&D,S>!L@'BM V4U=U#3Z2^-]&Z M:JJ;(M^HO[(Z(4G-V'0^_[ YOB;;L.QA+1@OHH12!0!@N ,I$ P80 M@J7/9!#YAN?3+H5:&K'=OKMZ]^G.N[RZNO[]T]V'3[]Z-[?7G]3?K][]IO[! M,M+&R6,S/<.:]V%,S(@'.;W/VC>A3/?2^_V!:[M*DV.MD.X_?W3E7J6)@G9< M8NSLT,N!2#,?@[D#\?1@S.'8 ]/ \[*\RJO!A1I:#5QW\HDQ0RE/ ^3$$"& ME $9Q@%((4LA]6$LB979>'Z:I;&IEM)[)N:PUCXMH)HQXWBH)N:Z 2C99WQW M@N JV?O\)//F>7I+BW7VUBY*ZE8_]6OY>BJI\[RI@/$EAG.@B^Q! +'76 M9^3'FD!KUTC":;6F$BK)=5G,8P82@&'*<80!I!0"%. .)Q0!$.PI18U9)Y.<'2*&,G7V7V%TW( M/LM+6Z8X =+0ES0"GJF]1EJTIPH7+5I51?M:RHR)XL)[]X.M'_61KK(LRBJA M_=<\Y]7%GT7Q35WD?<[7W*$[J04H5XZCE\//ZR)J4>[$&=1VW? L@RJ/(=-I M#$W[J(1(3"2BP&+L_6:@68W^RKXXUI*+N>ZU('8E-6^=!5%-'U0Y5=V(3;/U6^@X/?/B:)8"%)]">ZJK$4 HS" M (11*L(0"#7FJ;(E+'2GZ1=3=A&M%+G9Y1$^-D]*;Y*C%';2N M]A_C!9IWQ^(,P),]CKN11_I7/VQ8?B^T#W>% A02JM@UHHP#*'$$J(082)\B MGX:8(KMXXC-S+(T]JV.#X]1*A?= Y^D1D(GPDU0D/L#85P:H4'\00BF(91@Q MCBA$,5]MQ!?MAKF;'D]:#LQ:-N^GM9+N9_>H6OKWAR$UFU=_!Y86T&%]U@[U7?OO MCV9X':_]J8JMOOHSEP[['*F!"NWW?ROJ_W[8?-A\4Q93KAV!*QZ'!#%, *-0 M )@FB=K+JT^4+Q *F8PB&)(!?-HYZ4*9]4A"NZ7?C; 9"8P';!XZV,GI_;23 M]&<=Y62"G34S&&'BB".ZYYJ5+8S4?LD;9CZK_/&Q/94QC1$0$ M2*P#"4*6 !0$(8A1+ (>*I)Q%LEY5H"EF<*Z@JW>KAZ' AXKX2QJ\_SC,&.@ M*4&>F)24Z.W@7GBUX-X?S7_GCKWL1&_Z.,OSTR\EIK(3'(OXR>YQ!G3N>ROH M]L.FW!;UF8HH[K--M2^X$466\^N-:#J\Q&IKGPJBV"U"%$ :4( )D8#X$,8B MB:%O=B1B->O2&$[+[1T$KQ/I&]&]6G9/"6_1%\\8_VYVFPS5J<]+S0 =TG'0 M&%F+=H13(#Q3K\*QKZY=-T-;H#I;'1H/-E\?1%O]GC5)M+[9U8[XIA /)--- M3411"-XD15UN^/7VJRBJ.#FU5>:$(J@;D"#, !21LFHE3( OHR3" I-04"=; M91-I%KJ';D3W1"US?526:[$'A<\.?%)#M]S.@'_5O?CN&33B5X^@4J".P9UT M@VZ#X&0[=R,A7GE+;P-4_U[?:K31QO!5_DUL2!UHQ+Z*N^_YKH^D1(D0:M^? M8I'HV%^IJU+-\^W3KLWMY;AUF] M5_G]?1/]4 5&'-=56Y$T"2,2^<"/$PQ@* A (D3JQY!%PF]$DIMM :?%C_#SG2O.A21R?>@ MC6 77B6:R\WE.96=;1J?#3[S9O"<8J>;O+-7#5NO-X4.:]H^W:AGMU7;0EU6 M\D';&F^>=->LJBEC$,=IB#$'F.EVNR1* 6(R KK5;L2PB'EB53'=8,ZE60(? M\\T7\#'[)KAWIWZ?Z?#A:O,\J >F">AFJ]\QE/]_=^_>'#>.Y8G^OY^"$7=B M;U6$,)<@ 3ZF(S9"EN4:[;HL7TO5M1WU1P:>,J?3F=IDRF7UI[\ '_E.)@"" M%.M.3[MMB23.^8'X\>#@/ :F!&<4K2G" A=/O&$RXJAD8@'!(:%GP@JQ>ZTJW=V7YHOLPSZ#,(10X Q+J1+.00+4A21@0 M"8QPAK!,4KL0$F=1ID92NAY(50RX2D6I8E87RP78K0=<-.I9QI6XSY89C8TS M!P.SVYG2RU?!QAM?3@!U%I/1_8F]W M?)U0>"]_58)\G;\VR5'E+($XP1D, 8I"!!!D F19F *A%2KF MXI-8;W,\'I?6'1U#(01C.0AYG&D#&0-%[C&0<1I"$B-$&+-5:MEL%";4YT#IG^J_\YTP\*7ND?AR MB860Q7H6,Y1+'E,0QMK'F[$,Y*G:'$2I))3C$$IB%*M^89RI\7[# VOR(_B) MUB+^W(8H6@1&*OWE@*4)"E0A@T#)$O5^YOF>1SS'$F.9^JS/3RPFX#:]5_^ MC34]=^S]%@Y^ %DAI43,-HX/5O!X_QPC=2OVO9JP?L+'GUK^UR M[W[V*(O=2+UVJ9M=["VLO&S>3Y9C'N(\ W&:.B+< $8?X>#E*9*UB@(O MQZ120BM6L.:#3LULMU(W4: /Y-5\%U+7 5^\^5\3E9E M\"Q6=1"XY:;6<"[,MF/^$1Z8DK?@-J'A2F;U*@>UU$$EMDZRKD/&?4:&V0#E M+3C,:-"1X\-L@#@.$;.ZNX^SLGJNIL+M"5Y0T< M/V=5/>WX.7^Y8V'SDS5[=PH]OWO=7M*S8CKC6=G M8-+;+8.^J]]N+71]L'VR7+K6LBV47NJ$G6I35[1E;KRG\ PX%;[*I@\@X;AU MU(>#^*BP^H!#N096\:K/#9E_)@6_6]R0YV)-YDWV?IRQD&:*\46$)ZNL48.S#%0^SC"QN0F]QYV'XI2=^>I>.F#^EDY0RG* M\\\ A2&$*1I2D,N$IYD1F[&0VW9+4H%D]EZ[U2 MYDK!-LX1C!.U'PPE2'$6ZEBC$"A+(0;JM6!9$L*09%99T)VC38T JMXB&T>W M98QS-ZYFEH(WM ;F@%;.K>OZ*JAD'<0'982*)U.A>ZQ1304CM0]-!;.;_)7 M^U/,OXLJ7>236'\1ZJ.O)3M MLT#6I92?R>/?.L+#!@.3DG\VCW,M UBN[^4ORR777> ?Q.I[P43YL)SS&'FMJG2$M:M7DE<]MR7AUXFMF\ M?E :^)/1 E2)6564;@4-M*0^J_M=0L-;;;^S XU^2PL=U_2[>X48-OXOB MZ>M:\.OO8D6>1)L,_;Z8OZB?'E>P%,J #2F4BBJ$SB;+,""48( P(RR+PPA+ M8<,7EN-/C41:\0-2RW^JE"@(>*V-^\FJ[2R9L=" V ],31O8&]&#;=6/6NS= M,J170:.1/\9R1,X3C=F./BJW.4)S2'BNCW$\5&3*P'^9ZRBW]^)Y)5A1F?KJ M[W-1'7@N^/6WY6I=_*MN37*NBMHLBB6$1.B(DS0$B&,*LB141)G@4 H:LAQ* MJ_-'3X)-C3=W] KXCF*5F4%V-+(\N?0UCTCD>01S#K(8);J.$@$Y)!$0$4UH M&C(NDM2A[\NHT_D&?:I%6?Y'0"8^MX8'V&^P\H8^Z]Z9F%V=KH*-5M4<[>IU M%;2:J;_-*U^$OF2CGL?#<<^ ^SI']R76N$?NGL$\.IWW_7S'R%'V5?"7N;B7 MF]+)-R^KE?K;(Z%SL6V'2DA,I5 ?8D&I[G6044 I1H!)GL@P0U$$C;*(;0>> MVG>WE5M;RFTU\U?+*$]3S,UX=@@D!^;171!W:J$W8@=_5((/TW+6%BU?(9.F MPXX;!VD)QE%PH^W]#D>(C[HY0>/4_2Q6NB?T+$_S5'?+!DFFR8C%.: 1Y #' M)).Q)H<<1T"EN# M\[R>B U,+I5T[?'.5= (V!,5BQ.UGNB,=%1FB9+=T5<'!)UG6J?N&^^PJD/J MO5.HKNMZY._0RT'B]#!(_ ,I5E56X759OGRK(\9U21E6[U>_P1G.8PRC2-?8 MTD6-<]U@)@U#($.$$8_C$.=6Z0VTSIZS? :=%I_)/L,(.G[.SZ" GTS]&7;$ MWB%Y1^W"MWT\HPPA;4@#0BD%2!()2!QCD.*<0BHPRR/7 +SSHT[M(V#2Y[Y/ M:]H._ T,\2%0'9BI#0'MWY^V UGG\#@_"+]5,)SEJ]LGVNTR4!:Q;1T/>ZM( MMLOZ=<2M&=SLMHW0F0BZT5&AOB\+5HCR8[$0=VOQK9Q1C!.!, 0)CG(==<( M19$ $8L8$QBE*+;*T#@_U-08O$K/V!,U^$,+&U326E8'Z4#8S!KW@]O '.T* MF;41?!D-3T9LQT"C&J&7%3XT(@WN<".+=R_%7 =^7"]X^]>[;\^KY??*-"V; M3V5&$!$DX2!/HQ@@&.> ( 8!UZD9L80\2JRJ@!B-.C4*:26M#FZ+'7'MR,,, M<3,>\8[CP)2R!^'F'[LB#Y M;@62)Z8Q&W-4TK&"X9!_[&YVHZ+W3;VT#\HJ M4AKI4-VR[9%-J)0ZIQ1R9;:D60IR H7Z0XB-%WO M J;EM".;\YB:$8P7I$;92[8@52)ZK\9S$0=/O'%^G%&YXJ*ZA_QP^0;7C)MO MWY:+JH)BY0J;Y2E*(($09"2&.L^& "HH!XD07'?;%E%H%1AZ.,#4&*"6KRVO M^F_AOX7F515+&(CJ]7 M'][=H'I2ZI/C7]7$?/WO_Q=,PK_%\"K06_'JRO>"5>TN\Y:$KGM+*:-& M_X\.IE.K2MLS[\B\ZLV,692F,I<@#"-E?22$ II'#*2,8!R*)$N8D>'A*L#D MV$CW@-/$4#7Y$UMY UH+W#NQN7L^K)WAWE$>VR^^35VNL%1N\^%C^1Q(R =LL:[G_O6Z>)&6AODB9L]QW4+N]<15[U<3WJ@J7TPCALUJXLM.XI-K-GAAEY+]NM[/%6]L+U;M1PO_XJ5INNI74!\*;M MVR>QGF&$2(:2&$":Z%CF/ $Y(8HETI3B/&%ARJP2*[J'FQI-5-)67:2O=#4C M.UZX@"P7$ UHQLAHLG7KXPV*CL;*;X(4<; MWN7(U.USF[Y][9$IS)N-8G\F81S"&%,A8(H DA8"DL0 Q$3!.LB3+F=5VKGNXJ3'"4=>W[9&#>VF> M"XB;L84_' ;DVYG:VP0_5S.P?*('W1QK"P0!RF0.TCB)$8X%%Y#, MGJM@THX-SBJN BJ=BH4RAXI+X1 M60)HJK\RT.= M2\RM7@1_MUR\E*)LZDS,DEAB%K(<)#)/ $+*%L_5K &>$T;34.2"<C M3,T.;X0,:"VE=1FP$SB:L5QO= 9FKQ:81L!-21FO1;;.(^"O8M:),<8N?W5> MS1.UK#HN=EOMG\2Z]N[I!(CKM6(4^K*NBLHL/RD5EHNU4F=>^0#5BE.4,Z,4 MQ9"$%, X%0 E.DP8*RN+X1!#PJ,4\LB&":PEF!I+Z"KWVNX6CQ?PZN#W#>5R&XN[08K#\9SO!Y^IS8 MCS_JI\89GL//D/N#W$/4BW7E>M9A1;M)>N^+DJE%_;+:J>:'&844IFK'GZD_ M4)QP0!."E:6:1BB#7$!LEO?XZ^VGQX?@^M/[X.;^T^/= MIU]N/]WP&\%K_;H^WF\6]F#/P:IK^B&F\?8=HO! M1X]\MP?F5%R\PU-<.T7_UTM9#_:X/--.]G>BZ]FLZR2(F3X:8PDF(!0B!$AM MS$$.J0!9 M-0V7XR#ZW*#%A+,#6:^[Q:,B%X&:P$$\5WM375;\8VLV\I@S]K M^6UW\=9S8[C#'Q+QH7?_6]DK WJ_,W6P[4Q]%30J>$_><8;/6]-JV_%';F3M M",]Q9JE(U_8].DE8=IQ&"* (_R%* \U &<" %&9,JB,,NX MM(H..C_4U,BMK=<\WTILV?ZV U8SNO(#UL"\M"/D3I'K 7K>7D;#5SV5\P.- M6T_EHL)']50NW^'#8?F=%/-ZZ[F3R?AU.5?/*ZONNC-)J8)5&4@12QE $G.0 M18FRG$*(PP0RD0NC\GJ.XT^-2\ZZP(/XPRZ/_H;>,&-HNGUAYH]Q#9JL=SD?E#IM/8Y[ M^7&Y>-*U[G1>S2R'/(YX(@$G0EE)4DB0AQ("3$,>A9QC'EL5DKH\Y-08;K,5 MK': 55'I^9)8]G R0-J,O_SB-S!E[4-WM[-YU@(#+7&@1?89.FD*C[?PR8L# MCAQ":0K <1BE\9V]2\/409J-@R-B(:4$89!!J"PJ$:4@"_,0Q)&,11(AQNR< M3V?&F1JO[!>*:6K!-$5?G(.RSV%L[CSOB=P(7O)M)9=:R$%+N9S"P7]%E[U1 MWJJPRRE5.^J[G+SP4]:$T-F<9ZC;LH9 _E1W-:6H+L42'=!WZ+XR\"S,%+Q%[]+P*[J M2P\$.ZN^N#QWO*HO/;3>J_K2YSFNENBB0@RA/4\12C*/4TBR]/.C4OBL/7Y>K-:CVO*P1?_?4P-8V M-4#=U%#UB^7@5FN#W9]*WJ 5^"K8B#Q P+,-1-X,6H,A1[9NS4$X-G4M[NU= MWO#S2CS7K83JWA+7/XIRE@BI:Z&D #%"=#-V"2@.(Q!F,H8R9!)BHR0)P_&F MQCY'U96V0K>-4/[0WX0_/NK?]A?[8;Y(^YMXEL"Q,OK./>BNS[Y)N M':;?Q5OM*)N+8G:MGLOULS_,R=,LB1')=0\!FC.A,UWUH32* $IA F,1)3A# M)L1\].2IT>]&N$!+9T83QW!U\VLO$(8^Q3'3WW@-G]7UA+E5"O;O3\OO_X^Z MI[:TU%^V!M;QDT99J&<5:)?C^0N<(W!UQ9'/J^7W@@O^[O6W4O"[Q=WBNUK@ MNH496Q??JXW%#,N(H) C@#A7:S&#".ZS6$I 3$;6V3W .II6B+*M\ MI@]"+1+"$>0IB4$" MV5+0$89F1-,'F8'I9 \4+9O76->36ON+;-U__-AQK">5.Q&U>OHZ'_U@/J@Y MO?ZV?-&[W5@02,(82,Y"@&0J09YB 1B27) TC*!= >%S TUM4?^Z7*V?R).H M8MZO@N=5L6#%LWJ7225NGX8P.^B:+7,?F(WMD]%2!M?=6/5L!W,,Q"#M8':& M><-V,,?*=K>#.7&]8R;Q7D/WUT_BSYLY*;Z5'XJYX)]>JJ [M2N)*<,Y2%BL M]B@T)""3* $TSD,A<8BI72DS@S&GQA=*QH!50@922VF95VP LAE7>(9N8-K0 MTNY4?'G5S4K^#&J)@TID]9-*:(])Q^8(^M]BZB#J?(91C'BE$HQA*@B$.0ASD"C*]:^>K.G56O_K5=\6<>.LKB[E:H M7<<7KG*S$1[85\%?YN)>-KU-OH@J7D*7KI/+U;=JK'>OS2^WI+*, =JYT5% MSF$:Q=+T8+9KH*F182WKI@S1=C76XIH?W':B>_D+138!/U=@^%C:[OT8SWNBS%NM0U@9OHT)!F1-!4@A0CI -R$<@C'@.9 MDDM*A(>P1B&8V36]H!E[O-2JU@%?!5D3/'5_/ M(>"ST>O1&./W=SVGYLFVKFWY1JTBWGWG6]L3U@C\LY?I/LA)- M9G-&J-H@B1Q0(G-E .0"$ $C(!,)XTBJOX=&!H#A>%-;_JW$59>M2N2J7'39 M"&T1YVF =34+1>?U1OSE92B MJA&U>\U,YHCD,,8@SY41AN(D CEGNE]B*!FC.221U&Q+@@4F\$2NHY IVA+\*#F#?N]*?)>B*G2U' M5W .34OGY[@&_CRO!"NJ+Z7Z^USHORA:O?ZF=['_JC_=$+$X3?(0(,$)0"23 M@,@T!GF&829R)"5/[8* +@\Z-6;;E;FR/,F.L+;A0 :8F]&9;R0'IK!=<:^" MC< 5GM#J$#)D#Y"U\R&#(D4.)S$$X#BNRN-=AY_NES65?RE,YJ3KJ'O($ M)IFRJF@"%?WD6/U-4MV*FN(3ULCD:?$@K MH"VVT#\5W70"#+;#GO VN,TQN$/7.WVG'LGU]ELH@[3Z NA>-4]"#_SN=7O)YUJ6 M:[4CY_?/^L+R_F5=KM4'OE@\-9&,!))4)+1J.8,!BF($LHB&($\4O\"H6"WV\IQ9=+8-[#67_$\UE M+KG(.,"8YP"%.B18Q QP+$(9BRB+<=A,].V"_V6FN95UI$D6RCB>Y/2:;5'> M=,(&-B0JP4$E>;"K7;"C7A4IM'-=HV)0Z7@5-%JJO^S.N>^@Y\$FP5> D7?Y MQ@T]&@K>HZ"DP09R#5?2;5M6S\M5)8B.>1 W.NMD]7JSY&*&4$Y$G$4@9@3K M)O;FM.HB<;9D_FJ"L41"N:@D3S0HML&,G7C MWDW- Z Y,-'Z -(AQ,D(GAZ13MW/'SG@R4C9X[@GL]O<]AZW4@JVOI>W/]A7 MS7"Z[,V]CEK_JO^KCP&_D[FBN/*+*->K@JT5+ZI?7"_X_@]VKIQA1*.8"PPB M01. 9**,4BFYFAXL\HQJH]0JHW4 &2='8Y6*V@@5C9)5T;(R4):.+L9A9X@. M,:EFIN@;3]70'+F9I5:_NEI7G3GS]:HN[[$C^U6P5:NY1#OB#WZX?T>=^_6B MMYSW:D=2+7J/N?T#SI G2W4("4>U50>$^-!:'7(HYV(EZJU=OWY6*T='CVPB M23Z)]2R-DI"*# )!>0H03"D@>1B".$]CG$".I5EW'9/!ID;QK:P5 VQ"[*Z" MA;!,,>I$6.9(,H0RP+3[#V40*H11KOX6II*$F234JHZ5-X1'J%PU#L)F'T)? MN W\16O%O HJ02OD;K?(?>I SJ6JS$5(_%68.3_4V-5F+BI]HO+,Y7O\5PY^ M>%X)PNN>.?J"MAPK(X@C+$) XB@#*)($T#15],VC5")EV4ML5&VJAPQ3X_(3 ME86#LA+=7S7<<]-A<%0\/,B#1[%BQA?@+-/4>-SCYY,D>,+NML4/;[T*(>O3U4G49=3^[!/_[?G^?)5B*K5YNC6TLE^%D=#5[D/=$:,OMA$ M56R/PMO8BLO9C?9NZDOH^'(VGQUG7)?Q)76/'+\7;Q@Y%O$#*59_)_,7<5V6 M+]_J!77[XUEH#_/?EW/U&-W_2!N8,RRB3"0\ 4RD B!967P)!VE*HC!5?TVA M5;>S$62>&F.U4@;?-V*.%*MF,<]F/#BQV1N141WCV;3>0:5XL*/Y5;!Y)[;* M5SOS"<2XV4_56T>]64C\UXB#LY\";Y%Q#D,[?KSTQ_!.#2+X^Y=5L7BJNW=6 M8^]\*-7@8L4*)>4LR7&.>$0 2Y2ABXA.N:12 "QB2!*<$T2M6K%;2S"U#TLU M@V505"KHP(922QTL:[$#T-IZ_'%9UQ6>(PYU?I!K;?G%TZ-8?=/NWAG$ M+$ER2H'@C (4409(SE,09NH_"6(\SR*;V(#=AT\M%D#+U726L#[^WP/-C']< MH1B86K18H()""^:SPONQNMY*N>\\>N2:[<=*'1=G/W%-C\*#GY:+91WDIXN> MLN4WH0VC12EF1&0YC[$ -,-YY:O'")95 MZ;WYLBP=5O$%?,W6M3_4!E[I=97"74F#6M3@IT;8\\EL;@4++Z+BLW+A^<'& M+V%X4?&3M0POW^5&(VHO]DUG!2C;H;;=KU_67Y>KXE_*=E;[%TP%3D"7;A;<8IGE < MF% : !]J )MMX592?V1B (O>;W0I M_AF,9$I#HKA$62( A' MN=IA=8JF^)_+8K'^NUBL7W8+2\6Q-;2XOB UNBZJ/*Q MT77YEMYY&+<_BO4'(6:42HEE#@$+&0.(*9+(.$]!EN*,((($@N;1KR>'F!HW M:+$"*6Q"6D]#U\T!?@ 9>.D?!==7X'SP (YSJH(#2&^5B7 1K#XY!@^58; @>0="0"'5SJZM%L'5^/:*F>0[,,1INRX9LMR7=;)J(VTEA[L(S@-G=9]0!K:3[UQ3]]>PL3>+7U. M;U^>Z*/GC^M\/J?>D;_Y[(7V_8)_)3^*;R_?-A'B64(A$4!$NBT64W_D:1P" M)BC/HCQ$,#-*!3UZ\M1,DT8X\[; ^SAUK]->V@^\/ANY/&XYSFK;HP/P_O-& M:_Y[4HW=OK^G+^B]1= GSL6B,JKJ>)'WRV^D6,RRF.:400[2+%'+D289(*DD M(.1IAF/"0X*-SG?,AYS:.CVR!'?D;H*H@C]JT6U:+YG!;[WM\ #JV-N0,?%T MWJEXP/6M=BXN^/;9S%R RF)S<^Y);[79N:!9Q^;GTIW]S]6^B\6+T'UE;G\H M5ER0^_U%+)]6Y/EKP:Y7 M@FR[A5,J612F""B"K\[<0D H4L2?29(3BM,(&G4J'$'6J7TQ]EN_5\KJ4Z"G MC?0!4>*[G\3YGFK[\[HWG,!13_7JN:O:<;6:!AM5@ZVNP7H9--H&&W7UG&\5 M#K3&(W69'VR"!C@L]"WIFQTI#@1YU\'C4$,Z'D_65?\.:OU=KV_(:O5:+)ZJ M"/19GJ<,,8) A',(D/H39!G%(*99EG(H9)Y"JX-*DU&G]H6H2G)JKYU.;ZGJ MR#5R6QY:&B%N>'SI&\>A#S);"(_+FY)UT$I=9[=X/-2T0=-K M<'3D:76S&Q=M*EG\OES]\V[Q>;5DHBQG-,QI+&@(0A3I@I5Q#/*89(!C'B8A M3###B0WYG!YF:FRCA0N*A:[XH\6SXY@S2)J12G]\!F:1C8!708M2(^15\,MJ MV0&6-75T8^&)*\X,,BHY="MZR 87KG9;_M=E*=;ESUK$^\\>=>V>5.MPR9Z^J/<1Q.=5VP7O@Q!M%4R2,+59R&+ MH5JV2.!0K=TH!B)/>)PR&*?8R UE.-[4/MU;&7M%,9V$UOILH2]@8Q\L[("G M!.Y?NO4DBLXG"GW1?*OC!%M4^QPE=&%D<8YP\C%O=8C0I5/'"4+G;:Y]OQZ^ MD?G\W4M9++1-G\8*0XXX2"+=Z9%F*PFU(]X#(PA=I!XM"+ZZ3B/7IO[3]OY%Y;)Y4Y[JUU^C)7OP9; MZ<[ [T7]OW>+.M'WD?P0Y1?!1/&]2L$B#+*0R!#P.*'*;$(9H E'@'$*(60H M3E+<=ELW=748C6ST,N\W7!]XF34=R ']TS5D@8_M3+_K+U3#;25 MW,%6<)]N*BNDO/FMS$8=V9%E!<6Q9\ON]C?O[/YE.9]_6*[T+V=QAL,DTU^, M!$. QYH+LTH\NUG:&!& M':C/=_"'5C=H]/49SS'HA+QU]=-N(?\:!4^-@!ZP^_>IT3RW5'Q?E&R^+%]6 M8ALO)B"/4H@XR"A55JZ E!$. BC1) HQH1@[J7%XHG!I\;XUP\/MX\/P7_> M?GP??+C_$CQQZAF>*>U3/:](# M6(2IHB\*0LB9#GI. 4U""I(LRCC)&(UC/\UCMV-.C="J>IX?B^_*^'E4/R]T MN&IUX&>9E&$#>T_J<@-S8,;J@:,_>CI&9FA6VAEQ&F1T#($Q!YVXU9?7]IHQ M'8Z[Z\@*TP2G/--6E4P XHD$&6021OX7F(!G,5GACRC?V$YT&X["3LN-?^F/=!L)=5L7Z% M$7TLUNK-CV&6)8I10!8Q A"-$*"00B#2E J&<0RED85SZN%3,V4JH;0S#D8_ MT9^#5ESS(]XC]"Z?[_;!9&!^L(7#ZGCWG-Y.9[M'#QOM8/><&KNGNF>O<:QH MLWHBB^)?E1?H9KDHE_."URZA!?^LYK\-\;F7'XH%6;""S!_43RI747G*$4#B M&)((IH#%2"WQ."6 Q"P"%,N0S,#Y2UG9F"RVE7M*MA3KG+^[*JG.6VC8+#5<'B_T% 3 MX*N:D&_QQBU&-!"X1[6,AAK'[7OP:[%8ZL]+VS#]_L^%(L&OQ7,3]$>>Q+O7 M3PK"Y6*MX%1/>JHOF8DT"9,48\"B$ &D3V_S*%8;2D)0*%"DXU%LB-]9DJDQ M_$9PM1^J5;&C=_/Q48 >F+#WQ0M:5:Z"+?A;;?0QZ\$-]67^J+DWIIXX MV%V.48T4>:N=].J%S,MK6JY7A*UG6 K&&(T!PG&F M_D 4T"A3YC%F:99F),,1LG+OGQ]K:A38BEH93ZVPP1^MN+9._0Z0#9WY?J ; M^MC1%35[%_YE/'RY[CM&&M=E?UGE(U>]P2T^2^%]$**Q6#I/"U!-O &DW1_@%:F"*Z"RW]L$G:#YJ MU]F"-X6:=9T@>BI4MXN+6X&ZZ@D3*$RWJXE90;J].]R,KOUG?RP6XD[MC\M9 MF"4DDE3'4X0Y0"+A@,@<@1!G$N.49+E=5Y(SXTR--P]>Y^ /+6E0B6II:)T# MULS(\@#7N.QIAI2U<74!!T^&U;E11C6J+JAZ:%!=NMPQ)^%T"^JZJ]SI^-<9 MYB1)92P!Q#0%*!$9R#B)0")$C&1&($FL]F8.,DR-1IJ.B$7=MKUM-=FF%@2B M:>!=!G*YJBN).;><=)DQ,PX:>!X&YJ=F"FKYVQZ55Z=3!+81W%H%T3D! M4A2=S:CLLP+<\?05\N\@P;CQ_.X0'07K]WB4L_^J.EBXEQ4WJZ&)4OI&]_F8 MA8@ADJ(04(()0!G!@(14 "[U_V$1TIRU(6*/5FZLB"K3:[&I!N^D$S<65=0D.?ZZLLR.- M[RCA"/ *2Z(ZZ20*U)UR *.:, M)S21/+%+[[P\YM2LJU]N[W_Y?E_."O,Z.'?][N[CW>/=[<.F;,+C/^P8PAAT,](8 LJ!>61'Y$V= MA/7K(%%+MNAX(A?C84?E&ULP#BG(^OZ!"H:5%PK0_**N7)=W32.[WT7Q]'4M M^/5WL2)/XK8YE/J\*IB8<10E)$P)H!#E .41!WDD(Y D%$<"Q4QF=H=ZX\D^ M-6ZL)%=;%7W$QY6)0%9E\"Q6]7&?[6G?F*] E(:0DA3@..$ 93@"N;H:@:J;387!5="B$#0P!"T.007$B%7K_,_>6*7L/$H^ 4_*H%-B7?1N !'> MII[J-N9#6W&W/YZ+5?4$,X:$J0PIS3(0T0SI[H@49#F,U#\Q0KE 41:/6G:U MES93,Z%N] GK7'&@WA7)6K-S%I5U -6;OC:>/JQ3>1DF\*DU_=+N8%)OMK>H M3//S.\8<3Z2V;#]=IO6)'F/:?%>J]2.4H^]UN7C2.0XZN.97LM8%6PI==?UY M$W:C1EFPXIG,OPA=XDT]6B?XEXS,_R'(:I9Q244>)H"&NE6H@"'(PD2"-&*9 M3!F5J5VKT+X"3>UCJE-C+#VS?:?$T&,[(M!#>W)U#4FM2Q6P=Q4TZKQ>!1O) MZ]HG6O9 "^_1M>L)1E\NW[[BC.L*]@3>D8O8UW-[=E7^)-8SP9B,J(P!12@# M*.0AR',*%542'/(\S).(V#GV=A\_/<];*UVA$P 6H@H^?EXMOQ=EE1Z[5$N1 MEDJHWWM(>UH]^FX[3 M.TJ=[3.]>XUC=^FF0F=3C:#ME(Q%2I6%&(&0$@E0 A.0I4(M4P89T@=:3,M>TZ>A-%NZ_0$:>!%OL&DD'*(/=2<&OAI2GQYDW,[4 MG8H>M:CNOMI'EOMO:N9U /6_!-<1U'JX6B\@A0>OBP$;O_/AI6CN2UGE:O)'W*E!6ZORE:I]$&%N)MHRC^%%8=+HV MGQ@S0O&#\QO5'=D%NY5WJ!3Z#F@&2:8_-=X;IM5WJ-^=8-]UX^!^KKN%W@)^ M4&_@3!*1\H1SP+#D=4FC+)?*7@D9$325L?K=0,ZMK113LV34.VBY2W,#W[L; MRPW2-_-=:6$#+>V;.*N.P1K?0[4CPU3=4L1QE(HS".4@+##%D=EN\]?6KLU AGF=R^#Y@9\SC# M,#"C-'(%?]22>0QC/JFQ)UK8?_:HR_VD6H?+^/1%]IU&;JM>]Q^*N5C=J/W% MTW+U.A,29QCF'(@X$@!11@ 54CN+\RA2TYU'F7&SD1//G]H2K44,*AF#5DCS M;B.G$.Q>L1YP&7C-VD%BU7&D0W&GIB.GGC=:WY$.979;CW1=YOA%W3^"KQM8 MW\NZP,U.J]EWI"S8+"%YPK(L!4CJKN BCT >)1F(0X8XQHG(L56%>:O1I[;< M-S$]I(GIJ0/'@N5.;VB@T[<+YEZ8RVY^##_P0Z$^M %P&$2U;;?>U.G:$?XJ MJ,3W:"2XH.;+B+ :>UPCPP66(R/$Z2%VC%=Y6]0G];>'68JP1 )3$.64 H29 M #1*H-I'Q$1FG,84,1,:VSYR:MST?JE^M^YX_<]!T\T@;@H/3 N_?;I[O'T? M/#Q>/]X^]%_OQSIVF!/-Q?4:;OZQ7;X[CQIE31Z+WBZT$[]Q;F6J7JU-_YMW M9*Z#JA^^"J%;IUYS7FA7/IEOB\J4[U[5/YZ7)9G_LEJ^/)=WK>N_1QF(8BE]BJ$_-(G16EC?5HY_$@KTV#46NUS=DM7I5/_P[F;^(&8PDY2+%(*)2 MV8H\Y"#+DQAD<1;R#+&$"V%W5&8PZM0^(U59RNJD7LV"[1F9"L1O\ M#*PL@QV!VQ9"/@^^+!#Q=M!E,N;(!UL6,!P?9-G#HL[;'..VY]5D"'XZL?'VA_ZKF"6"0BH%!9)%'""1W N(H?-SN;OMHB0?!JFBXVQ_LJWX=/JFW:"93F.!,E\!F.01(0@IR MEB5 1DF"C]L%_XN_':T&([T;8L'_ MHF^%F3T]P7D>T2#O6_EI[U7YR]1WLIRSB51R,I7Z+U6SR7(J?%=GLAW>L9VA M>H'$:B7J>M;U84^2Q3$5(@6,Y1*@3'VX"(DDH"*$$G$ND] J^^S$&%/;ZFQ$ M#"H9KX)_"_\]#&'P3%;!=RWPWP(87H5A]=\VD)2\K+\N5SI9\&]!V+:!U?5$ M=B-,2=70[UL"JFO_UI9-D6\<3$F7U6>D['P)^ HYFH M!+QJ6KQZ[()X'@5?W0]/C#!NU\/S*AYU.^RXU#D0;244M:G7O/K?NT7K*6YR M_G4)F#"7,M3EB1+=ZQ!1E(*<00(DY1C2$+,HPY919!<'G1KU?%HN0-4<>G.T M)BYX'=WQ-B,(WR@.S!BMN,%/K< _Z]*>F].@37$/SX5ZS$'R%PIU>ZRYZ6.Z@$MPPY-0#? MU%[Q">G@YDMO-!U,&5. O%DV%P<#8[C&^TXV"OHCO8O$B/BB9=0R3 M[@_T>['^>O-2KI??Q.KV1Q-&>5V60OT_?R0_E%441W$H&4ATT4:4I!G(!=5_ MI)*P.&4B,SIGZB'#U$CJ@*A$H+?Q15@\(/7&8BP2CDEH/B Y9KL^C[,_.;Y;?Q6K3QH]%,A9( MY""&+ &(D AD7"1 45LL0YJE(39R)AT]>6H450EGTL7O F"7#\B=81B868P1 ML#H3/ZFMTV'X_I-&.P4_J<#N\??I"WS40*R3LN*()"@F$L2I/J.F" ,:YA! MQ"&)!)240AM[XL084UN,#^RKX"_SJLQS5>EJW5:ZVHD=='0$[BA M#]\.,7MTPJQGZ<(A,XHSQB(.$98H^8$1 EN,$9$G"*:2"\L2JJ$A/>29'-8_W M-_\+O+M^N'T?W-S_^OGVT\/UX]W])TM2Z3E)A@0T'O0C1@J<"-U5+*6$#BJI M?5*5'_Q\T5I/:<:E0#_0'=&EI\=.M=K"UEE*4A1CPAB0F(0 85VV.D\30$64 MQ^K=D#FSJJ8XHNQ3H^Q:]6"CNZY%5&D?5.I73MLM ,$. CKXR"67W]F+/N8; M9GPZ.,7W9OA#Q@F^,A.L 3'4F<.8DO__K!;$Q5.0MQ#!/47P3RW'@+(, 4PSHOZ3,RBMBD*8#3NU MS]Q&ZJK[%6_DUF4BZJXGJXWD]DF#!I-@]CGQ#^W 7X)-TYBM=%?!/M0W*Z&6 M3* +%_A-'30'RF/JH,&@HZ<.F@-Q*G70XF['["/QI(GTBWC6W2063QOG/B0L MR:,T!)#&1)^&"$"$$(!2!O,,AR%-K +>S@TT-2IJY PV@EH?E%R$UHQN? V MM&O#!2O[1(4+0/C*+#@WS+BI !>4/8K=OW2]&RU\4M+J\]?E7%WTU(:[-<7_ MD91QG,<<) (F *6"@SP5!(2, '$$U5T#C4J79@H?4@91O>,G,O\@12K*I;_NBQ? MOM5I15^*\I\?5D*T$GY1F[X9B2%E-*6*>R+%/2B) (T$ C#FJ?IK9-+C>7]:Z25VL+O+:'4>F"'&HK_HSM7P M^DOXL2"TF!?KUQD.$<(TTS'-E.L"BDC7SN$@C1(JDEC$W,PC9S+8U#X.E;C5 M"4%9"ZQ[,6N)@WDKLD4-P$M(=Y.];_P&YND:.B5JT,@:-,(&'P> SJ)VHD<( M1RJ1 IJDRYS&) &%2.Q4DXWE.0\33V7JY)G,S<_[2@%:$NQEV MN%?]48^Q(=="I^JKUUY4LEI6Q[X$M9EI[1/ @1GWXP%JM]VHV5?$-H3"5S'L M2\.-6P?;4/FC$MBF]SE8;@_J :5N68FIU625GU0N0Z@=R\)D<7C@;F6']TAMXM'P-SV=5H MC)"%U=4?J9&,+9M7R=T-G'@!A@XBOR MHVNH<>,]#)0^BO(PN<B0E6\+B;=D?..!1\[!MP7D./7>^@FNW=(63SK)57]_'M4CJI40 M)ED*$2<@DKJ^FI01R)*8 <%)&B$6R@0BN^9HQX-,C6KVTWVO BVG$^.<1-30 MW],3IZ%]/'O9O680.;0^.X^!MTYG)X88N;'9>26/^YAU7.NXZ,F"-[MHM7<1 M)$XE$#HI# FF#]CR"$0))TF:HXP*J_2P[:,GM\"59)8K>0N3X?IU4G[H5:O= ML?XCO(YU];4ZMP\>=TT>*72T$H^O<%M_MV2E>Q.4G\6J.GI_7\Q?=)WF-B:9 M1P1#7=H4ZH1Y%&<29"C6=0:QVAB$B,695:NJ"^--;:5>+]8%X%K&XKL(BITB M$J(J.:0,V:H*%:_5".:Z'Z>NW<^6W[ZI[7159_D_[-;ZI2DQ(P"/0 _,"JVD MN@]>':YT%332#A(W;HB,)PZY--JHQ&*H^B';F-[F'%/^6]E\W#"G#/,( BK5 M'R@6F:*;*%1_B%SF,0Y#9A7&N?/LJ5%+%;>T('5>HG68^ 8Q,S9PQ&'@E:^# MYG][&";F^U!=?R'>FR>/'=%]J-*) .ZC2]R6Y/WJB2P:Y^.-VNLOYP6O8_46 M_+-Z ]KCIXUCDLPWN;?EMG">$$*F' %,B 0HS 6@L3(E9)Q+ A%C++5*%?,B MU=1H8%>IJV!/K2IZ85P.3UU@39TU^7H'V M1)M^9!J5<+W">$C5?A_N4.'T9;52C_I0E(S,_R'(ZG;!W^M$BSA,2(8SI#9X M"=/IO0SD"9- 9B1'(2$B#XTXNVN0J5%P(V=0"QIH28-;W=_&.!&F$])N>O0% MU,!LYX217974"R"X%4P]]]#Q:J=>4&NOC.JE:]VLN=\6*\&63PO=Y^F1_'@G M%D(6Z[*NF:)^\%FH'4@3F==F4UPSMGH1?,9(SF44"QU.$@-$10PH3J&RX3C. M\IC"A%EUTNHAR]1HHQ%KV_5&?_6?6_GM#+$^4V1F?HT$_, TM*N%KN<>M'I4 M!:ET?2O]PXTNU91LDM@:=?Q96AXP]61?]9%D5*O* V2'MI2/1SI&XS555YIV M/[K25/W/@37G]X']X__>?LEN/GMRY?;3X_!Q[OK=W8@(&)=5,3JE&A+@?8?.%V,RJV:@Q4H;8GEKZ"!QVE&#>N ML!]41R&'/1_GZ/X7ZYJJ=;&QZ^^DF.O!'YME4.[(?M4> M4EJ>-5A/C^&)Q)"@#WUN(=:MN?F3%O_G8*. 1KU6(7C8 __]!?#MSSA< ?1U M$F(]_KCG):[P')VJ.#_(:T3&#&8ASB,J $EU3VL9$I"QA +"$:,TSA,AK$*Q MSXPS-6YK(P%^*A8!7\[G9%4'6%21%3][B:SH%U$Q(5[JB*08/'QBG+")281+ M6(9)].0#W3CP7E8\\TG-_;W<"<)^O_Q&BL4,)4D4)4B"C(:*&BB+0!:A!$ 2 MQ,&1X\I%D(XHCG M (4P5$8'#4$JL)"QI"',X&PAGG0RB!G!F ULM$KR>I7L#C_<8M$R!\JTYVTW M!+5PGAO9-Q4Z*MGMJ,=P(LSHQR.XXU"0%KC=2"EPZ[+\11LWT8K?M*.^O8BP M-479 >:)I@P''96J[( XI"O+N]THZV;Y=_60EY58-?&/E(0XS9$ 499E ,4Y M H1%',092Z,$*G;B5JVF#P>8FJ5SLP3?&P'M..8(.3,VZ8/'P+RQ \4 ,:3G M%/>T_H\>/^I*/Z?YWC@1G_KY=R73AI]KP M9&Y"TS?T$=[GNYNKT_5^MQ56JSB)E5"_KON\+'5QWZU.'H_Q1@+>UWG?T.*. M>S X$OA')XACC6OW^2E7Z]E>E&W5R*O*AI4[C MG#$4.]:0;8:P6MJC58UE3:CV3O58YY*Q+99FQE8_A 9>V3O"706->(,4A3U0 MW7\9V': MRK\>J!@1ZG7PRL=BKN>[DKS6)W!;Z+T8"R2G%"UP*-0?;N3. (9 MQ13(-$YADB0,$:/2(<8C3NVC_L"^"OY2G^3[=XL2IT9X=]/! M("@.S YG^U%5$@AF;;U_$1^4M#L%X!39SV":KBRXP@)$VK^YP=96J?@EK0 MH!'QJOU+H(4-[A<6)7[. ]M-^M[@&IC;G9&R*O1S$0FG2C_GGSI:J9^+BNW6 M^KE\L(<2L D%P#E"0&$(JK^ MR),D2F4DHLA\5]X]V-1HH$ITF;?R7@6DDCBHCDJ+1F:;[>4%J$TVY_X ''IS MKK'[N,6N%C;0TF[BR3QB9[,U]X?A6%OS/EA:[M#-P.G>H5]XQH@[=#-M]G?H MAO>X!ITLQ+V\4090GH-A)AK,LPD"%+68=E;I M(91F9J<+,N/0\ :-VPMH6)N,9W3V9!,>/GU4H^^,:H=6W;G+^KH U5Y7_$GF MFC!F,(-,2)*!''.=*$\1R"F&(!$T00E-H8[.<_+][8PR-9/LT.FWJD4-=!=+ M5X?5+JBV7CY'J$9V[S525A]^'RBY^O,"?0,/?<[=[\1BZ[ M$_*?]]6=NMBQ8LC>7KGN:H_3))>Z2II(=+TT4A4TPH!""5.9(AY+JRYSQT-, MC05]%1(Y'F#<4B)G%3PJ)G+^2M?= MBJ[_LER]ZN3P)HV\%*OOHIQ%4&U8,,0@32*U<9$H!7E,))'TJYF MV?G!'+8O R_WCZ(L_T-7)OM>E'K7KDL]+&FI!"B94+-JNY,Y"[/IIJ87=&/M M;QHA@XV402NFS[W.)2B\;7O.#C3R#NB2PL>;H8MW]*2+4XT>&(4"23"JM%1UV!3LP[N/OW]]M/C_1?KKAJ=B%IRP[3[8VS9 M8? &&":(^":)-V]E8:+T6:+PWY2BS:>^E_NNUW+[>A.:BBB"!, 8QP!E2!D7 M:Q;BO#Y3D/$29JWU,UB(8D AG,$A#S)**Q M3'!H1R?GAYH:E522!JNMJ';,T8&I&6OX06I@QJA!VI'R*E!R#E" [S(:GJBB M8Z!1:>*RPH<487"'-\?J-56[(,+6,XES2@C.0 )C"%":0)"CC $6XS15E,'" M*.OI5VW'FAI!G/89MM):GKYV8>SL:75![DT MJFS@8SVZQ35#_9'\N./JZ84L6'7.\^FEVG;+)$Z31(9 1%CH3I.5/;38S;1QU!G,-W92#]//?EE M52R>ZO29JB-)6?WRX4_R7&IW[/IUYQRGWC,)/DLC1B57W(.%Q&HS@T- XB0' ME*N]#(V3)*46]3-Z2C,UZZ7N&U5JF:O#&/5=+G8.+U>-V%4G[ZI[=VG8OMO/ MW'7SU^@S,O2)TB"JOFI:_E4I!K=/>:7.KU9B39),I,.)D MC951,,*D628@> *Y.U&A[R C)C1XPF,_\<'70UT^B5_%7'X13X7>T^NWNSGZ MC@B)2!:%(*,9T2G](&845= TRN0^8%C/8E=.&^LX :?+9 MZ0_/T%^3(V2<*C*?@,K13-[K0HNE[PZESD1-,KGJ>AB+'.'&$0()CE@- 4 0;#-.$1)ADWJI9I M/?+4B+&1O2.3F!2#S]M04 _\S6M?^ATA*XCK$VVK;G)]>NY]DYT>X)BX3^(,?[M_1%!7; M=*;_J07BYZI=?8U%T((1:#2"&@Z/>?IO,HV^:@",*_RX]07>9&*.:A>\C12N MH34W:M@5F=\MN/CQO\3K+".2P#R%:BLK.$#Z,TZF<#7ZIF\F+^LB^_B0:AM?65>?U*S^WZI:_[.(D*3%#,!>)1*@%*1 M@RS1Y7=93"(N,$HR;!-=>VG J2WS77F#KT94^4/+1#C^^QMAAM=CDG9)#=++F913&DD60:R M,(H!(B($.<]3(+&Z+R,T1]"H$,KA@Z=&'3=5JR,E7*"E,[<+]L"Z; ZX0C#T MYLU,>ZMO_RE5G3[Y>P\:[4M_2OS=#_S)WSM^UVLOVN?54HI25^@B\P]BZ_ 5 M$(8H(A)D#$. 0DA!GDL!DE37UH^)S%-A]57O'&YJ"[-U C_OB!M(T;B"Y^*I MZMI4-P_7/?74#LKIL,-P,@R_]MX@'NE88U?20(LZ0$Z>&2B^OO+=@XW[C3=2 M_.@+;W:7(^64I5B7FY0Q@O*$I3@'.4:Z$YQ ((=) E@JXC!*<)P@:D4Q>X^? M'*4\/-P^6M8V.P#,D :<81AZV5>"#9)(=UIG7ZMZ_^'CKN*3BAVMVM-7.784 M6RZ>=&UR'?C^J![1[#@AP6J"=:"Y^OH#A$-=L%CM^K.,P(RQ.*?$JLC/Z6&F MMFJK2ECKMA+65: E==S3G\'5;%'W1VO@Q;U?,LP4*/O67ITX^&KA=7J0<5MU M=2IZU)*K^VK'(C[JW?A*2G%/Y\53$_B141+%) 24Z(*#F*CU'_,("$PDXF$, M*;2J6GX\Q-0(H)4P6&Y$M*S.IG>,! MQBVOS?6)JAB$*8)PA(3$. M:(@ (9*#4,*8"1[)%%I5S# :=6I+?R.T+BZU*_;_W6:]N!;2,)L$,YKP#NW MS.$%5?O2HC8H^:HN:C3FN 5&;6 XJC%J=;,C/;W0LN %6;WJ5BS-0%6?#RP4 M^?!3!2?OVLNXAPP=^]_E8* M?K?X4"S(@A6+IVNV+K[7(<#M5Y.S!(4)AH!QS "*100H2AG(HU1B*1#BC-GP MA+T(4R.0*MA1SI=_-C4S92MZ0#:RVQ&*P[28,N,*Z%3^@K\%/ M6H.@6/P<;)0(MEH,8NNX@^B)Q1P$&)7>W $ZY+T>3W)WSCXVCIY?R;J)P/@B MGLEKE8]]+S^O"C7TLX[_^B1^K!__%//OXM?E8OVUG&4X23%E*4ACJ6RH$%.@ M8[= @B/*0LY#G%J%:O629FHTJ5YC9._1=9\,<\?O*!"/[!]N='F]"OXAR"JX M7W@L=N0%,X^^9'=91GZ_T,=-Y.Z>L4[HBCY9OE-9ZC6[E>:1IAF M- 69K!J*$PQH*D*0<(@%C6&$N%6;K=/#3(W>ZHT1U6(&;$=.RZWD:4@-]Y&] M@1IZ$ZD%!)6$P>?Z!0VN=?7RI\KO<15\4BNI2AWR79^M&QI?N\O3@XR[M>Q4 M]&A?V7VU&RW\G:P*77Q:Y[I47A#"4JJP"@&&N:X/'2IJ2&4$\ES +$Y(RK/$ MAA .!Y@:%;3RU5EL+AZE(PC-"* /, ,O?2M,K)?W.<4]+>RCQX^ZI,\I=[B8 MSU[7HR'$3L:WYN8F7A)!Q#",.! B$P"AD( LY S )(4T(3#GB7U#B)-#36UI MUU4*G.-0.S U6^%^D!IXK9\HY;"5TW,[B$XL?+:#.#W0^.T@.A4^V0ZB^PZ' M"DO[+?#J@M#WLMI2S%\;NZZ\_;%6]H0V7G.NRRZD A!$U'Z H@1DL4Q!C$D* MXQS"E!@%M3B,/37ZJ.75YRC?:HF#=I]V%8A6:(L:,Y8ST 2IH#KC4 M.0H4H31"QE^&B\--[6.P$3B0RU50;)KB+'=DMN"GRW ;T+]7$ =F_"U^2MA@ MVU3H?BC\+"C=*XXCL7@O/.TXVQB>3IJ^_)3QF-E8HSTR-K_+,<2\X?/'Y37[ M/R_%2J@!G\5J_?I9S?QZMRWM+!5)%*84 :D;QR(22Y##. $X(T)F29I(FK<] M5\QV]>:#&RV&_=8K0W-S$Q=<:EO]N9&[3P]JBYDP\P1X1GK<&S%RLGJ3&( M??RA9W"Q<'\>/N&MO)UG-.EP;IZ[HS=[?EZU\77UDQ__7#9];B0F L6Z@06# MB38X!MV-GNI>U#T1=ALB#K\\]Z*]J^J%T'@5^^U\V=4%7Q M?F'KJA-?5=6[*C5WLRPW!V*?EV6AW[CR=EY\*Q;ZU[4,ZD^FO7109)K:AV ;[?#<2AZ(C>AVG@4?4V;F91AY M(@;^?.QIT[1IJ.LJ:H4V)_5JCC9*!5NM-GT;&L7\^1X\HNS)#^%#HE%]$AXA M//1/^'ST.8K>?9<^JK_]C__6_D3]H?,H_L=_^_\ 4$L#!!0 ( ,EXJU91 MG)GO"FL F1! 5 87!Y>"TR,#(S,#,S,5]P&ULY+U9=]LYDB?Z M/I\B;]W7&UW8ES[=,T>6Y2S-."VWI.SJOB\\6 (VIRC20U).NS_]!*A]-46" M^L-5I[)L69:)0,0/@8A +/_R/[Z=37[YBO/%>#;]US_Q?V)_^@6G:9;'TT__ M^J??3]^!^]/_^.__[;_]R_\#\!]OCM__\G:6SL]PNOQE?XYAB?F7/\;+S[_\ M->/B;[^4^>SLE[_.YG\;?PT _WWUC_9G7[[/QY\^+W\13,C[?SO_9^%*9I9S ML"8Q4,E[\%XY\"+[XKD(V;K_[],_)ZVDU=& P*A!H46(PGD(/O."H5CA\NI# M)^/IW_ZY_A+# G^AS4T7JS_^ZY\^+Y=?_OG/?_[CCS_^Z5N<3_YI-O_T9\&8 M_//53__I\L>_/?CY/^3JI[GW_L^KO[W^T<7XL1^DC^5__H_?WI^DSW@68#Q= M+,,TU046XW]>K+[Y?I;"8QRE,_BG-SOY<__[/^S-" U&Z^I?+ M[U_P7_^T&)]]F>#5]S[/L?SKG^J_A2I2)B_6^W\O_N&?;Y;],L<%(66US??T MC[NEI@,DMW?FA2>3J[_I>3$'&R^NXHXWBT^M2]N%C. M0UJ.O#2,B9A IQ)!,1<@2*<@*VMXD$9B%G=W7"E>$,DK$2PP_=.GV=<_TP>3 M*(2H7U1VB!4K'BQWP9;-Z+XZ<:?TLR.I% QZ7I2.,C,&?U)Q%SX M5F3?7NTNU;?%N3=/O\SF&>>D,JZ6"_-T1[0/X7KY$W_^$N;T09 ^CR?YZE]7 MW=%"5LM9 \Y=B(7(_=,OM.N"\SGF]Q=2>7)SJYTM29'BZB=;2/S?SL.?C63Z8YK=T^8X*IL0P,T >,EV>QD%T@O83DM RY625:0*(.\NN!0?9/QPV MYV4G8#B=A^EB7!E_">C@D&ED GS& ,I; 9$[!(S(> @V\93;W [W5EX+$JI_ M2&S%T8%1<3!=CI??WXTG^.'\+.)\5)@QJ?@ V7L#*C!/-K-F4+*S-F&T+&VG M'>ZON!8*=+\HV(J#74C_&#^-*Q.FRP_AC&P>S62)18.-Q ,5=21&: _9:B&B MS"T1. \ \L?Q:4'&]0Z4%;[L R5[. M)(+%Y6_OQU/D(R&YDSQH,%$J4(X9"#I'<+*0GB2MF7P+8^.1I=<"A^\='-OR MM"=@[-.71_/3V1_3D2;OR3ARK'EF!93R @*&BFUN.,84G?;M8'&S\'JA*_:3 MH&)#AO:$B=75>#3_.)]]'4\3CEBQ.G!=(&DDTUI&NAEE]H JJAQS('\[M0/& MO=770T?'DRT2 M5WHK.-Q>;3T =!SBW)AU XN\OHI./GZ>3:\B,)E9C(SPF930H')R-43/0'.> MK4]%^K2=WW%_Q?5$WW$HZ\]"%.L]W2K!;;=*^W]%=<3?\AYIV9,8J, M%R3<C]'D_6CNK$,;N=E.X]]9;CW!=QRVW)QYG1SZ@V_I0V..'#<26#1HB S*"1L$:5^?/7U(-)] M(+(!:[N 2'W&G>^')7Z:S;^/BG9.62' )N9!24L(-]: \%G(("0RY1H@X\ZB MZZ5-=1^#W)R17>#@Y"Q,)F_.%^,I+DC3:8M%ZP0VD))3055KN B(.@3.+!,A MM'@1O[/H>CCH/MJX.2.[P,'!&/"=6,A0E(WK/M(TM7C-OK[D>&CJ..6[)QBY 0(2?U32.6?K;R6?BV^+H M?%EK-ZIG/;*Z9.:# 1Z\(I6'"GQ"LHBRPV@D*TZT2)IYCH;U0-)Q=+(QF_L M#7%N'B:'TXS?_A=^'V55F/;90LF9>&.+!*=9 9X5$R7'8F4+&^/>LNM!H^/( MY?;,'!@->V.F-M5KJ[4+7=Y9; M3_H=AR\W9][0KY07#O*[\2*%R7]BF%\5%!@=M68*P=?'%R4=@@MT^1GO-$_* M66>V2WUY:N7UL-!Q&+,)2SNIT;C8Q$6IR3OZWF+DE4U)NPC(+7'%TR:B50:8 M]])9;K@JV[UK/+GT>L#H.(C9AJE=(:/"^V(+06N)NC@@@@WI/)8A,'*@)%US MW@N"OFU3W7=OX?50T7'-^(?%;UGB?+^!3"%]& MJW2XBH>C\FX\#=,T)E4QNZCJNL::8U)D%QQ$@XZP)LFLS$H",X7^X]IP\UQV M60F+N +"Y:(7)PXGR\75=VZ.WDOHVE2O7*VQMUC@\!*Z2_VEL76]B:Q\=CDK MLK45;2(:!4$(4L69.>.R3J23=X*9>X0,"YUM)/LH2+9AV, MHC+!<7(0;4!R+ER1$&42Y"428ZP3*H7G&N=L J!'"1FF><;ND+,]MSN S-'R M,\YOR%_< C\WP0LG#$A?-"@1R5"L72"*\C&F7%"DYZ(UF^#F:6J&:;.Q._ T MXGL'"#J#DAF<4ZKF'PLUTSS^0E9:A]FRX]A3C[IV_'BRVP1)K_. M9^=?KG"ODV>:T];0>P25T4,(NH!,7&>;A$']7.+SYN[7NA0.T]YCAZ;/[N33 M@5[Z.,)]#CSRVIW5F]HBIW9G#2R EM79)"5M7',7 M[<6 :?ZXM6O%M EW-X?&;!DFC?3.[ O.E]\_3@*Q8YIKF.)+#<76.QPECR4& M"ZJ@))@KA, YW>;6YB!\(=>A-5*>HZ<'9[Y)I+$9TSO0+4>TDU!+5-YC6.!Q M[2!]5'XGQ5G9-7+,S1*V7/$=2#5]\$0NW8 MW@&&+AY]\-&M(!/,&TR@F:7CP+.#H(P%6UB2Q8:G#LF^"G%K-R#4][PL?1% MC.S VGT_#G$\&2_'N""S:Y77_GDV(:8OJ@FV_'[-FI4*E+01G4PUY;T%[Z2% M&!"Y\USPTMKR79>V8:W@G:=J[$1$'6B>6_NZ[WQZ$62,G Z1)T[1\2&7$;VB MG1@1D'N/NG6.T]/4#/L$OQOI/PVQ;431 :BNGH,_AN_U7>8J!A$*EBR2 LY] MN1C"XTR68$J4W%C2TKYUH/!Q2KH!TU9R?N(-?@NF#PB=F@%:MS _IR7OG+:5 M@?>09R-CF,O..V"LQL961XV7 JY$VJJ0.NE[B68/,UE?O.JPMUQCY.R6YQWH MH;O1B*O]7'4Q&0FK@HYT($@YU_DM@JQ$U!PL"R@9:7#E6JFE MAD+H %*W Q0/]J(SEF"4 =J4K\?#0:TY!1/IZM?"96Y;AQ6?HV?8J-".X-1, M !V Z?UL^ND4YV=O,5XGKK@47$AH(,@C32! - ZL/@(&<.& MAW8$G6W9W0-B'KF3HV4Z&P2RY\CEL))#T$)"9IIE9I,VS3,^-K2+=A9 VA5> MMF-V!X&E)^[>6X'2HHH6-W>^ M?EO!=*"8'KV6;VV'U*DW+$B@?5DZATR XS9#D5IPEZ1F2KZ&:?1"E+V&L;T[ ME+442@<8VY]-5SSYZWCY>?]\L9R=W3BI=XZ.DQZCU716JDOAC !?'PH5QBRM ML/45L3'6UB2M&XM\=YC;A9 ZP-[]B,CMG:"6R=77Z,SJF!UM(/*D@$7&'#/: M^O9AA">IZ<9PW^'=V484'8#JUB9&*@FE8@H0?:Z694Q GHF 0B>#*2.$4ZV5 MUJWEN['?7^5YY47,[L",?X8C-NOB=3&0(R?_)A=%#DG(8 J+@JCUQ3[7)6BS M1@1;O0'O+.?Z55#42!0=*)^/5^NNMG11\BL%W;JY,D?YD=$*"B@Y\INO: M210JMHXE/$+&T%T?VDCX8?[^5NSN #&WVBY>TH])6AX-<%6?@P2+0!Y%#>!+ M7G1T!GEI;FC?I6'HM).=8&4K1G< E+V<5YDW8?(QC//A=#]\&=-=.'(J,::# M!\82(W\S2P@H$)*W-CNGHVB>=OT$*<,Z_SN"30NV=X">8UR&\13S09A/Q]-/ MB[V4SL_.)V&)^2V6<1K3#Z:R&K6JL=#:A M3_QTO6LC<_96LYJP7@=C:$7:5)!SFNA+'W+2SXZI:J.+-J%\6.?_U?37SH7: M@<[[421EI(IC4LH,VG+R1U@.="I% M391V^#<*YU-Z0?T31L^?9K1S"W%TLS MF+UVQ]J/*X%\QF7]AW=WTZI][=TE7J>7[3/;>LW&MI+X.)9,P+=!"1 MOBH%34G(I,WM3>%7:&P[F4D,'27>$GAWP MN0,_XDZ$A8@@=E5.T=<37+%LFO?.JNWY7ZOO/]FT8^2R8,%9#Y@<.=JJ9+(W M4ZB.MB)V*AV*;:W,&M$^='AVU^IN"!%W .V[;V!D\1S-5[S.JU>.CSA?3?,: M99O09Q,@(RN@;) 04K1@E(X\>TUZOW4JQ'J4#1WAW3$L=R">[D!W,2]N[WSY M>38?_Q?FD31.6UTT%%-=\USKCQS3=(XD2PQ95LT34Y^G:.@X\*N";"MQ= JN MV\,(G?">_/U2Z8]D>]"!\2%YL%GX4,<4HGD-=+UT!.0.8\<#P&M3@72*K\/% MXIQ.2C;):D_&+$HA20W7,:G9*,@BAR@P1Z9;^ZI/4S-T\'< 5&T@A@X =2NU MY,D+GEEC4E$!A#/D,%E6>R23ZU10T/WNLH^F]0O7&F0-&^#=.<1:"Z8OK#VX MYR.=&Q>] A.EIGM>.=J*2X0,;@H7Q6G?NI/1,^2LA:WF(^R&P-96@N@14Y=J M. 7NC=8)L#;75L)I\%Y;2*YV!A2L.-6Z==H3I*P7JF5_/V#:0 (] NFVE:BC MC='(5 <&UY$UFD'4@@$7B45E33&Q=>NKK<>V\Y\W_-],%C_3&,Z34_KUMX,/ MIR='[XX^'ASOG1[2WS9[T'SBXW?VF+G.=AH]9%[,#+I&Y34$&:D@940")]AJ M8&L!9Z0!CS8K9G4P.YK1]("4[5-@O^+T'-_147RLGO+@VV4.2FUW2?_ET_!M M)+G0!I$.1JIAN9 D1!G^ M7V>SO$H\P?G7<<+%R6R21TH;JR+I9($B@-(UFU.8!-QYC$I:JYIG0SY-S;#O MG+L 5R/.=X"A7^>SQ>+C?%;&RY&2P8ML!= YB'2E6^)(8 K0"B&=]$Z&UE'1 M6\L/^[BX"Y1LRML.4@TKP"NT+^?:W'2!+IG@5(Y)%$1 '6;[EJ[AR6SU+'ZYJY&S 7V1!20Z MNF4SS\2A(B":3%>L9L(TCV,^2]"PMD\;F3\P?EH)H ,T50U*)MJJ@NX=XF)D M;$$G8H(8E0*Z4SUXF3B8Y+GG49:8VT\VNTO#L";-3C"S%9L[@,E)F(3Y10[V M7\,GHE\RZYS/ ;R+Q P7&<3B!%AALS..:,)]LZ M<+T>9<-:/;N!5'N1= "TZUZ"5[P:91NUKO.1D]> MF=9APT?(&!8MNW"QMN5U!XKEJGSQ8@?7&QI9@CW!V]6DJ02*>P<^)@?:8'(^ MBE1TZ_S<)T@9-IEM%[!IP?,NYI9?;>3J4HUT@\: !8J3J>89Y.H&1K \9)%5 MRDRTMG/ND3!LCMHNP;()CU\.$G\!DBE^JIE)IVU;:]Y3EY<[JH-GN4VY!"X@ MQ/JPG+V&P+6'(&K9=,IH5>M,H>:4 M)#.:[+YB P)!:8)G-\>+G3L,W7!Q\(R:2Y,;3,/]^2)Q=/-$8@@>=R:74(!5G M=*TK1EP.M>E[\.A<]L&W#AWM<#L#I[[MYHKM0_C=G /:XN4Y?H-3K"^.3-E$ M9$<0&&@;9'N0-VWKDW0A\-%AEVPW:3/TRLG.!LK M#$\:C(ZAHA[!E>* C-/HE&?1Z=:]^VY67P\A/U6*R(:L[4"AD&UYHU[7ZJ,D MDJ^3G35X)NI8;VO!)4<;U"9+&9T4HG5WDA<3N1[$?JK\DMT*J@/U=&>#(ZL" MCX*\'*Y"!F61[-.2,QC& HLLJ=0\I^T. >LAZ*=*.-FIU=U6#>= MY73T1M7&NL9+4#X+B%S6;@Q:.R%TQM3ZG>4I6M;#S$\506_"]@Z4R_U]O F+ M<1I9HW@0@I,!9Q2H6C(:L&A@R9?(R &PLG5^VZ.$#)N4U$;&/P#.RQG>(6K> MCB?G2\PCG33G10I@=5:EDF3]$_T2B@T.69#.AM:7TQ.D#)N:]"K(V83I/VL- MTOY?]C[\>G!R^.'@WWX_//W/N]MI5(AT?XU7J49Z=F/M>RL^T_PS9U5JDT]@ M6A,T);EF(3@&.K@H$2QM(^BG0;,WV#C!T;P]O M9V=A/!UE*9Q+#('7ABS*JP)!J)IT;H53F3'EFMO4CQ'2"6:V%_1]\VAKKG< MG5O%YK_A6<3YJ%C%T)L"V=09\%[56'I6D)&'E(+AS+8>2_2 B('=L.T%^W1) M_P9<[@ F3PQ3NMP,&FT8!@XQ6U+$.A)KC# @,SIEI?9:@@7VQYO!I MQ_T.H'1_AM+E+F21.@N/9/+91!8@U]51C< %FNB+M%FV;C+R."7#%H^T!T\# M?G> FL=?5B[W8E7,VOL".C%>,_TD>.%K+%W1WSCA"FN=3?D M=X"C:W/P/9V)53K*R$F"O'$U3U30#A0Y%'40*3">6$(;@XFMZQH?4M%)4_J& MCM5F#.X (H?3-,>PP+=X\?OA]&'@XIC.PKO9_(\PSZ.B@B8EZ@$%K^.SB65! MFPR2L1"4(.'S]@4 +R*Q$P]L0T0\S ':F7@Z0-^=+G(N1E+.AD% _.Z>8CTQ-+K8FL]EB M%DEA(N\A00 B]D-C#&I7$VE_8!QU<;N+?+5+;7P^KK2[HOE%\1MSM7YQNEB)?R0#:BZ*!>W0T7&.$7S1'!QWKM!._[L! MF8/W87I=_.Y0ACUO5W1U]6V?('WW">QK39$?-6I!P$8.WDH+2@ M#=I0'\"8]MD:77CKJ.N+B1R\\]/0$&TDOPX NI?_]_EB68WRQ>GLB?#BZBC& M^T?Q&(G3B_$2+]OO77#F&-/LTW3U*2LFC02YD,[SVL!&U.%TQ/C(I('$2R%; M2CH7VH>$=[NGP:OR7PW^7:%CT/KMU5"]BU;,?X0OQ(Q$^YOCY?&_N+)&+"2K M0O9@G:9@N MKWK',QEBSA%,4O51FFX5\C\U)*,3V3G)2];:%G@QD8.W#^A*&6XNOPX >JMD MRLND)8\27"0+6T66P 5R#*T6OBB-++/6Z;0OK$;;92>!5X/4AASO "MWXF1D MV2;NI 1?NVP0"Y!L7K)^97&DD&U2L31_.'EI='*7G0*&B4Z^A.M;QFT.IKFG MV&0HFO;-+4C'2:\R2WI5,G*Y(L^"7"Q5!A6X]3-7T]R)JN5(^'"AR@+T.T00"F,$*P.H'46R# K\JU;Y\"\F,I.'J*W1= C];R[ M%%<'=M\MB]4B*W0/!$C(ZF2SG$DU1!"1G8QT49, EY,0*GY0F]DC> M.D=T%_L8]JGZE4$\.! ZT)YOD59.XY6(Z>L)KF0]S7MGU23^KXLGSABTS=I9 M4+ZP:G5+"%EKB#H9ZT4VK'GCJ'7H&E;C#H^>V8Y%.2 \5]'V%>/J^ GR_@ZG M7XG3L_GWH[B@)18)IPE'P@EM:A!3(O%,>?K*,_+%:LTF<]59O%^G^\3SQ@^7 M&E8Q=H.U'%-DA\6W[_. D7Q7FK83DCKAT&K20( MRPOMBGZ)3#K(*%TP02K6O-W0>I0-FZ#3#3AW*,YMFS"WBW _3$#21.JJYT46 MB?0ZJ392Z2$#$R5:)ES0IG4^PQ9Y8CM+PND.A@W$U8%NO*WLW\[.X[*<3_92 MFIT3GT?.QX3GY@E):!-=9ETN>BB!TT:?XA7<,FQW0' MR^:B[!*>U]R[S,.XB>::4&<;*> J$>L4&2#T>:Q&SI(067NI6S]-KT_=L+DS M/P%4FXBU2\!>W0S$=QQ_715;.BRUYR>'P',=Y)<".,,T2.GI:.K:O+CU!(9U MZ.JM]JL-)GX(O2T%U(4+\W!7'^?X)8SSVTN*+KNG[TWS:C;%WF*!9*PD=(EQ MFT"45/,J0P!?.Y0P4R)=$V1)^]:MR#>CM+=2KU>"9G,A]C/TZ#%KY7J"Q*VC MR#G2?YZ<.8>RUJQ)NF8,AZR#,L(K&5QK+WQ-TGHKWWHE3&XOIDXUYE7(=5P3 MSHU#)P)"J04^RL1JW)#!S J6P)@A]K5NI/8L0;W58;T:UC832<]J[LK8&0A\Y0I29NCWT!I92%&@2"+EIG)Q,G">!U8/D-E)\W"7BF-MI6X M.M"/9$M<%1)>5+;>>34G5_[FX1PM2E9X!LVU)O85,C>$3\ DRY%+G02V;OVT M/G5=IN$VP\G]%[[="*T+QW=]5HZ**PE7KGSM#*AB(!:2T0O>^VSHT'/3?%+P M^M1UF5*[*T#N2&C]7MCOQM,P38\SDMF03) 63-2%W++(ZNMZI#^:&%7P+,57 M@N4S5 YK3[[VA=U*7!VDQB;$O)IU_&C7']+]EY7_MSH!U2E(.B8Z8VAJZE%P M])4,((*(S&H;"K]7I?ITNNS+E^_R9FX&B-FK2J<'@_'6)FO]-[$1C\K[V?33 M*<[/WF)]F>+Y:+.:>?D^&L(.9/E4C.'8F(2A,Q%,I93;AZB?H:<+B,U M.P-:(['T\R+R^-&Y4MNC5!*ST2J(1=66\K4G;XD*O/.!3%L=$%L;=\]3-.S3 M6Q=Z;2/A#&W*'>.7B[,S*Q?(U2.@>*<@U>%@2U*"DN[ M2VF]+FX_7FO8%[77--(:\[T?Q;4^$T?),>]$[0JJ-/E5'C4X]!+(+;0PT^'VYU5C'6*VY<(L9=&J.=?ODQ6K R3*U8>3LML?G8AS"NF:BUL)/\# M1%%U6J,,Y'UH#FB*+3%K[E1K?*Y)VK!-FG>&Q%T(I@,3^:;F=YQKP:^TQ@O' M"D1C:NI!91&SG,X-2FGH!"7;OBSV#@D#=X#K\7Q8Q_3HI?Q#\EKU+3X:/XI3"_;PNW/IHO9 M9)S#9(/[H,CX_#Y/J.NW6SK0;R\@0YE^I3&@G.!@]TJ97LN#:"M4Y* M;D+XMKIH*R+>CA=I,ENBMG0*=$O'FN>=K.=1,-U_OGSHU)N#EIG@R7U5AY M##Z!TJX0US('R;TBWTPKWSQSJ 7=0Z=4OBYF'[Z9OK+D.]6QAQ_^G?32T?'A MP48*]?8_;Z$]GR2GD:J\;CE[U"YDDWA)IF9L5#A%A.CJ&"+M#6;-2O+M M^R$\2<[V#N^#C[X!;LFLN#K[/3K-:K8!!\]HO][$D&1)BERQW6^U$U74"A,/ MW=]&$NA4=>R=G!RE_TI<'__;[X<=J M]&RB5];^[!9*9[.---)(3U;=76.0UL D5\UFZF0T\BO 2?JE1 M7-G=R*E7G;:_?_S[P=N#__A81X*=T.D_.OW+P?'^[\?'I #>'^Z].7Q_>+JA ML;3^AS?1:IMMI95:NV@O4XWI5?^/,+FQV[GE!!"Z15GMI:D$,_46M&1 .RV&Z<2R1BCDQH"27(/G10%R[;200VG_JS&:D#*[A&2'HPP><5Y-:IEML_/GA[>+KWZ_'!P:8&VOV/:#*)\3FR M&NFE6F'TB)W/G2RY6(14:]@4=R34HCTDG;V1R(QO7FWX."7;SV2*C][-B*5D MJ^I YA!!N1 @%I$A9N<# 5DEV=J&>H*48;5) _D_G)VT/=4F&"V ^ M>U#9)W!*:Y V,EF*$=FVGO/\/$7;ZIK?QM/9?#4*^>)S'SL$PL42=:BU)J[F M#Y!WX((@-\1A,71=%BU;.Z]KD#5P[+L=3N[KHM8BZ50O'>P=?SC\\.O)^Z.3 MDX\'QR=_V3L^V$07/?HY+?3/CPELI',.PGQ*(*H9_:N90=^*06 M>F0=(EMY1M=7Q5&Y/73L&">UQGC5CF&%@EC'DEWU;+C!F>3<*H* ,J*V=/4% M/-)7W!(@+,^%7.;6#L96%&_M::V[^IO;J]\<(2Y"**%8$%AC%RIE<%H$,.BU M9*8DW3QM8$N2!_;<7@^?#SR\5Q1UI]KR\ ,IH(/3O?_8-$_@YI^W\>^>(*=9 MGL!EZO)C;\+&>5MJ>V#,6)L>:7 9+02F59$U6SKLH)G]4^0T2XQ_-(3!7?:1 M' 1N))V?-C?\!7MN8]K$H5>E]Q&JH8NE+/Q\CKS;+;*-L-INO/\< TT2RZZ M95*!EBZ!LCY"C"H#W2[.LZB%5JT]GA<1N'4![#J+W1P/:XV(F=/-JB.=NV0S M1!G)NU&:1Y.]8;:UU?DR"H=56;O#UH.:U]W)K5.U=GSP?N_TX.W'O>/3_SP] MWB/7;+_Z9AOFI3_Q66TRTM M1&_HY"]'%VEH\)!FX+3:V5F _HFE;G?74YS\&_"R-BM(A:![WW\R^$^&3$G![]6>^;P MP[NCX]\V#G/]Z"-;Z*H7D=U(99W@IWIO'>.7V7S59_X*;DGXR"0/(&I1EV*6 MX":BA>P,#SG17S=W])ZB9>L.#?<^]S'4TTX5:A^JEU'?G:P SQV'A#Z@$ 9U M$3O>;G3<34)-U$_SWWWJQIJJ;FR MAAO(*$L=T$8X7+7A-B9&@\%XV]JG.@ZL0P97D&EG*= M:5<,1*L2^3HF&J5K@D_[P6POH_'OH0;Z)7A\04W>]C+MH@?)94'0_7THYWC2 M(9(W7*.'.AL(6I#WG8LM/!>Z3MJ/*'^3^>*O;0D24S1B] ZN71=VH9^JFR#E0>Z9Q>2Z53AK%L5O+DV>N$*KUGJO$,] M]N."59&3EUX'$%)DNJT8@L\Y@)$*GF]%G7DH'JV&+(N#&OTA MX])&T#HR9IE(,;;V4'],5>_%S2_!RMK%S9O)I%<]MFX=\!:*[(5+O&IY\RY5 MV3.EJ4P7YT6NF"R,D%-S=CSC(!T+202A]2X&7>^JR/GFXE^G;/:>,1 8.HXB M0/#,@')TG"+F52P[1<&B$;$U*[:AM]]RYY=@ZFG3;<<2[%0-UBK-S37+)(9,:+*LYW]);PBZ9"3I+R[U4)C1OFO-CJKHL?7X)*IY6*DT$T4/< M]'I'OX7E^7RE#.\.O;VG&K$D2]ZNAA 268@B\3J*OKX+(VEJRZ/3S8.F+Z1Q MV)C^3F&W R%U>G_]J*)]FZ#H6I_\&F7Y.[P3?U!T3=K(N&@+&*B7 MPB2WG$..@2YYPCMX@98N>>=C,3JQL#O/_T6D=EJ]_Q(,/6TE[4YHG>JKQ\OF M-]=8SW[>[NK\=QDBV*Z:.B9'WIM#P&0EJ#J>+'A1ZA47O$E>J]SZK6+8:O^; MP_1X_L7)DH[.11+&XG+>]O=[YXIQEDO( ;*-M=L.F1I.&C(Z#&-.&"%M:7T? M;$_U3UWS_Q*4/JT]7T7@784^'O0RV/LCS//M'?][F)Q?H&"Q.#^[^-Z]W?-$ M9G,1$J2IK=-S%."2U,!%DL[SX!)O/92O[0X&#IOT!?U7 D*G]L0/RI(V-RS6 M^^!7J*S:H:GQ9 T-]U:F'#5@[22E7!V?HJ,$%G))4A7,OG7Q]L[JJVZ.S+T5 M;@U5?//]\B]O9; G0U!0!:0,=$64.E%=VP@H3?1D^.=B=O=,\2)2.ZW#>@F& MGM%S.Q-:5_?Z,7[%Z3F^(_8>T-F>3\-D_WRQG)W16GO+Y7P<5^[@[-ULCN-/ MT_WZ3#P?X^+-]U]Q]FD>OGPFMW&.X5:9FG,V9T/^::K#JC%I"*J0-(+-*3O! M4;7N:;K#[0P\DG6W&!]6^)U>[(\4_;W%91A/6I4H7GW:CBH4'R6VJP)%SJ10 M.3&0*050M=V'(Y812.IXMIRY-[RQANBB0/&BJ]/UY[X)$UH)3SXCUE3#O9S' ME80PN;'SZ:31'[[,%F'RZWQV_F5!'S$YSY<%PJN.*N>8C[[@/-R8V2/G,2L7 MB*&*-(1B(M$A9+&6=C"O4PC:M![<^$I;^WLHAWP)^A_O"]87@GHP9\[C8IS' M8?[])*QLM^J-[GT;+T:V<,DMXY"LL70?\5I0)2T899/($9ETK8.23Q(S=/U' MA]"Y;YDTD6,/@+PA_T,XHR]OM9=Y.SL+X^E(L%*,5Q:X%L0G;334+)?:[BK9 M8)CBKG5VP8^I&MBC:R/^^Z!J*XL!T;7*+]A;GG[&W\+\;[A\%U+-S?W^&YY% MG(]*,-QK14P28C7O""'RD(%GP9*-I7@F?F2N/K_$P/!H+,A9B/H6!<"QE/+#"PD[Q#7+3@ M: ?WT=U4W)5*U4HK7Z($S>JT68VU0,K5.@(N?4!7>&C=Q_[GV:X^IL7EW&7!B5"B/)&@-**0]>.0EH2DG1B5#N#RE_XB)[ M].-[0L&F8ILUY6$'ZJ.F\"^O4OCIWZR.!T](UZU"L(G3H4C&@S,R ?KD6*'] MM<\U>HR.8?O._ S7U];2ZQ"!E\)-M66GY^0S9$-Z7)(*=EE(*++0 M(4+#T+5^V'](15]@V42V]^&R':,[@,H%[5=AA]7YR4$5CBZ X/7\,*8@VCJC M2$@?,]W2.K8NRWU(Q5I04?_(M]N6DNL.>Y?'T3'F-!,>3"R!#$Y!>\B2 5-* M.,.IC= P\)V-+V3X+E0T8W0%83C#1,5]J6B^0N^(C8 VIDSQ(T; 2R.7K:,7_H -#=<,C^["M.0TVC MJ(K81"DRI\-@3&TE*&R=2D1Z.49KL13)T_T+ZHDPT#.+K 4,_8]H_3053Z

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end